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Abstract 
Introduction: Ependymoma is the second most common malignant brain tumour 
of childhood. 50% of children with primary disease recur; three-quarters of these 
do not achieve long term survival. In the ‘molecular era’ of cancer research, 
diagnosis combines advanced molecular profiling with histopathological 
assessment. Whilst primary ependymomas can be classified based on epigenetic 
and transcriptomic features, there is little information on molecular signatures at 
recurrence. However, some small studies have implicated cancer immunity. Trials 
of novel therapies at recurrence have been disappointing. This study undertook 
molecular profiling of recurrent ependymoma, combined with contemporary 
clinical data, to better understand recurrence biology and potential therapy 
options. Methods: Clinical outcomes for 188 children with recurrent 
ependymoma were analysed. Cases with primary and matched recurrent samples 
were included in DNA methylation (n=56), RNA sequencing (n=52) and 
immunohistochemical (IHC) (n=56) analyses. RNA sequencing from FFPE tissue 
was validated to expand the cohort. Results: Recurrence was the strongest 
predictor of long term survival. Treatment approach at primary diagnosis was not 
associated with survival, but radiotherapy at first recurrence was associated with 
better short-term outcomes. Children with the commonest DNA methylation 
based diagnoses, EPN_PFA and EPN_RELA, had equally poor outcomes. RNA 
sequencing from FFPE tissue was effective, therefore tumours sequenced from 
FFPE and FF tissue were included in paired gene expression analyses. 
Transcriptomic and DNA methylation analyses identified three similar subgroups 
in FFPE and FF cohorts (PF1, PF2 and ST). At first recurrence, PF1 was associated 
with downregulated immune and inflammatory ontologies, which may indicate 
tumour immune escape. PF2 and ST subgroups demonstrated upregulation of 
ontologies associated with adaptive immunity. Despite this, there was little 
evidence of change in either immunogenicity or T-cell effector activity at first 
recurrence. IHC analysis identified a fall in inflammatory cells in posterior fossa 
tumours at recurrence and indicated that ependymoma is an immune excluded 
tumour. Conclusions: This study highlights both the abysmal prognosis for this 
disease, and the need for a better understanding of tumour biology to improve 
outcomes. This study has contributed novel data on changes at recurrence across 
molecular subgroups, and identified the immune excluded nature of 
ependymoma, which may be important in guiding therapy. The validation of RNA-
seq from FFPE in childhood brain tumours has facilitated access to a large set of 
previously uninvestigated samples. 
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 1 
1 Introduction 
1.1  Childhood cancer 
1.1.1 Epidemiology 
Cancer is a leading cause of death in young people in the developed world. In the 
UK, it is the leading cause of death in 5-14 year olds, and second only to injuries 
and poisonings in under four year olds. In 15-19 year olds it is superseded by 
death related to risks and behaviours (Royal College of Paediatrics and Child 
Health and National Children’s Bureau, 2014). 
 
In the UK, around 1600 children are diagnosed with, and 250 die from, cancer 
annually. By age 14, 1 in 500 children develop cancer (Cancer Research UK, 
2015a). The overall incidence for paediatric cancer in Europe is 130.9 per million 
(0-14 years) and 157 per million (0-19 years) (Steliarova-Foucher et al., 2004). 
Other reported incidences vary from 122.1 per million (England and Wales) to 
160.6 per million (American Hispanics in Los Angeles) (Kaatsch, 2010). Boys 
develop malignancy more frequently than girls (Kaatsch, 2010). 
 
The epidemiology of childhood cancer has been well studied through large 
national and international registries including SEER (Surveillance, Epidemiology 
and End Results programme), ACCIS (Automated Childhood Cancer Information 
System) and EUROCARE (European Cancer Registry based study on survival and 
care of cancer patients). Since the early 1970s the incidence of childhood cancer 
of all types has increased (Howlader N et. al., 2013; Steliarova-Foucher et al., 
2004). Whilst this may be accounted for, in part, by improved diagnostic and 
reporting methods, the lack of uniformity across all cancer types suggests a 
genuine increase (Kaatsch et al., 2006). 
 
In Europe, five-year survival has improved from 50% in the 1970s (Steliarova-
Foucher et al., 2004) to 77.9% between 1999 and 2007 (Gatta et al., 2014). 
Whilst survival is improving, implications for long-term health are dire and 
attention must be paid to ameliorating late effects. In children who have a life 
expectancy of 70-80 years, simply reporting the risk of death to five years is 
inadequate to assess the true impact of the disease. 
 
A disparity in survival has been noticed between the developed and developing 
world. Even comparing outcomes within Europe, survival is better in the West. 
 2 
Factors suggested for this difference include variable diagnostic techniques and 
the availability of specialist centres and medications (Gatta et al., 2014). 
1.1.2 Classification 
Whilst adult malignancies are classified by site, cancer in childhood is less 
anatomically defined. Many adult malignancies are of epithelial tissue whilst in 
children this does not hold true (Birch and Marsden, 1987). Childhood cancer is a 
disease of development arising from early progenitor cells, with few or no 
apparent genetic mutations (Scotting et. al., 2005). As a consequence, these 
neoplasms may not be restricted to a specific location. With this in mind, a 
classification of childhood cancer, first described in 1987, was based on 
morphology rather than anatomy. More recently, authors have suggested that 
morphological classifications should be superseded by molecular classifications 
(Pajtler et al., 2015; Schwalbe et al., 2017; Sturm et al., 2016). 
 
The International Classification of Childhood Cancer (ICCC-3) is based on the 
morphological codes outlined in the International Classification of Diseases for 
Oncology (ICD-O). The ICCC-3 was intended for international adoption by the 
large cancer registries (Steliarova-Foucher et. al., 2005). 12 main diagnostic 
groups were identified (Table 1-1). 
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Major Diagnostic Groups of 
Childhood Cancer 
Incidence (/million) Relative % 
0-14yrs 0-19yrs 0-14yrs 0-19yrs 
(1) Leukaemias, myeloproliferative 
and myelodysplastic diseases 42.4 37.3 32.3 25.8 
(2) Lymphomas and 
reticuloendothelial neoplasms 14.3 21.0 10.9 14.5 
(3) CNS and miscellaneous 
intracranial and intraspinal 
neoplasms 
28.1 29.5 21.5 20.4 
(4) Neuroblastoma and other 
peripheral nervous cell tumours 9.8 7.1 7.5 4.9 
(5) Retinoblastoma 3.8 3.3 2.9 2.3 
(6) Renal tumours 8.5 7.1 6.5 4.9 
(7) Hepatic tumours 1.4 1.4 1.1 1.0 
(8) Malignant bone tumours 5.4 7.6 4.1 5.3 
(9) Soft tissue and other extra 
osseous sarcomas 8.3 9.4 6.3 6.5 
(10) Germ cell tumours, 
trophoblastic tumours, and 
neoplasms of gonads 
4.0 8.0 3.1 5.5 
(11) Other malignant epithelial 
neoplasms and malignant 
melanomas 
3.4 9.9 2.6 6.8 
(12) Other malignant neoplasms 1.2 2.9 0.9 2.0 
Total: 130.9 144.6 100 100 
Table 1-1: The classification of childhood cancer into 12 subgroups. Incidence and 
percentage contributions of each type according to age. CNS malignancies are the second 
most common type overall. Adapted from Howlader N et.al., 2013; Kaatsch, 2010. 
1.2 Paediatric brain tumours 
Tumours of the central nervous system (CNS) are the second most common 
neoplasm in children, accounting for 26% of the total (Cancer Research UK, 
2015a), and the most common type of solid tumour (Kaatsch, 2010). They grow 
in a rapidly developing anatomical compartment, associated with eloquent 
structures. This has implications for all stages in care including diagnosis, 
investigation, treatment and follow up. 
1.2.1  Classification 
CNS tumours may be classified according to: 
(1) Cell origin and relationship to the brain; 
(2) Location within the CNS; 
(3) Histological grade; 
(4) The World Health Organisation (WHO) classification, including molecular 
features for specific tumours. 
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Tumours arising from glial, neural or choroid plexus cells are intrinsic to the brain 
parenchyma, whilst tumours arising from Rathke’s pouch and germ cells are 
extrinsic to the brain parenchyma. Tumours can then be further subdivided by 
cell of origin (Table 1-2) (Kieran et al., 2015). 
 
Relationship to brain Cell Type Tumour Type 
Extrinsic 
Rathke’s Pouch Epithelium Craniopharyngioma 
Germ cell Germinoma 
Intrinsic 
Glial 
Astrocytoma 
Ependymoma 
Oligodendroglioma 
Neural 
Medulloblastoma 
PNET* 
Choroid Plexus Choroid Plexus Carcinoma 
Table 1-2: Cellular origin and relationship to brain of paediatric brain tumours. *Primitive 
Neuroectodermal tumours (PNETs) are increasingly recognised as a group of distinct 
entities (Sturm et al., 2016) and have recently been removed from the WHO classification. 
 
Figure 1-1: Location of supratentorial (ST) and posterior fossa (PF, infratentorial) regions. 
The supratentorium contains the cerebrum and the posterior fossa contains the cerebellum 
and brain stem. The dashed black line indicates the boundary between the two areas. 
Image modified from stock.adobe.com/#93141325. 
Tumours defined by cell of origin may occur in more than one anatomical 
location. For brain intrinsic tumours, location can be divided between the 
posterior fossa and supratentorium. The posterior fossa encompasses the region 
Supratentorium 
Posterior Fossa 
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below the tentorium cerebelli and above the foramen magnum, containing the 
cerebellum and brainstem. The supratentorium includes the remainder of the 
cranial cavity above the tentorium cerebelli and contains the cerebrum. Paediatric 
tumours may also occur in the spine (Figure 1-1). 
 
Histological grade differs across tumour types, but in general: 
• Grade 1: Low proliferative potential and possible surgical cure; 
• Grade 2: Infiltrative with low level proliferative activity and often recur; 
• Grade 3: Evidence of malignancy (may include nuclear atypia and 
increased mitotic activity); 
• Grade 4: Malignant, cytologically active, necrotic tumours which rapidly 
progress and result in death (Louis et al., 2007). 
 
The WHO classification has previously been based upon histological appearance, 
taking into account tumour grade (Louis et al., 2007). The 2016 revision of the 
classification included, for the first time, the addition of molecular stratification. 
New molecularly defined entities include IDH-mutant glioblastomas, H3-K27M 
mutated diffuse midline gliomas, SHH- and WNT-activated medulloblastomas and 
RELA fusion-positive ependymomas (Louis et al., 2016) (Table 1-3). The inclusion 
of molecular features as part of this classification is likely to expand over time as 
more evidence of the biological differences between tumour types emerges. 
 
 
Table 1-3: Selected features of the WHO classification of the tumours of the central 
nervous system and possible grades for each tumour. Reproduced from Louis et. al. 2016. 
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1.3 Paediatric ependymoma 
Ependymoma is the second most common malignant brain tumour of childhood 
(Peris-Bonet et al., 2006). Morphologically, it mimics the ependymal lining of the 
central nervous system (Lehman, 2008). It can arise anywhere in the neuraxis 
and presents in children and adults, with a median age of diagnosis of around five 
years (Perilongo et al., 1997). Childhood tumours arise most commonly in the 
supratentorial (ST) or posterior fossa (PF) regions of the brain, and adult tumours 
in the spine. Diagnosis is based upon clinical presentation, imaging and 
histopathology. Symptoms of a developing tumour depend upon location of the 
lesion, but commonly include headaches, vomiting and ataxia. 
 
With the advent of molecular biology, new subtypes of ependymoma are being 
proposed, but the implications of these for clinical outcome and treatment 
strategy are not yet clear (Hoffman et al., 2014a; Pajtler et al., 2015; Wani et 
al., 2012; Witt et al., 2011). In the future, DNA methylation profiling may have a 
role (Pajtler et al., 2015) and is being introduced into clinical trials. 
1.3.1 Epidemiology 
Ependymoma constitutes approximately 10% of all paediatric brain tumours. 
Incidences have been reported as 4 per million in 0-14 year olds and 3.7 per 
million in 0-19 year olds, between 2007 and 2011, in the USA (Howlader N at. al. 
2013). In Europe between 1978 and 1997, incidences of 3.4 per million in 0-14 
year olds were reported (Peris-Bonet et al., 2006). It is most common in the first 
three years of life (Peris-Bonet et al., 2006; Rickert and Paulus, 2001), and it has 
been suggested that these younger children have the worst outcomes (Agaoglu et 
al., 2005; Jaing et al., 2004; Messahel et al., 2009; Pollack et al., 1995).  
 
Reported overall survival (OS) and event free survival (EFS) rates vary in 
published clinical trials (Evans et al., 1996; Grill et al., 2001; Grundy et al., 2007; 
Robertson et al., 1998; Venkatramani et al., 2013). Some studies indicate very 
poor outcomes with two year OS and EFS of 40% and 23% respectively (Duffner 
et al., 1998), whilst others found better outcomes with five-year OS and EFS of 
71% and 57% (Garvin et al., 2012). These studies have been conducted over 
long time periods and now represent relatively old case series; it is therefore 
possible that outcomes have improved over time. This hypothesis is supported by 
survival data from more recent series published after 2010. A large study of 146 
patients found a five-year OS and EFS of 82.6% and 68.9% respectively 
(Godfraind et al., 2012). Another indicated three year OS of 100% and 73% for 
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ST and PF tumours respectively (Venkatramani et al., 2013). A third study found 
five-year OS and EFS of 81.1% and 65.4% in a series of 160 patients with mixed 
tumour locations (Massimino et al., 2016).  
 
A key factor in ependymoma survival is recurrence. The recurrence rate 
approaches 50% at five years and only 24-27% of children survive five years 
after the first recurrence (Messahel et al., 2009).  
 
The only other consistently reported clinical factor associated with improved EFS 
is extent of surgical resection (Agaoglu et al., 2005; Grill et al., 2001; Jaing et 
al., 2004; Massimino et al., 2004; Perilongo et al., 1997; Robertson et al., 1998), 
however this is not a universal finding (Grundy et al., 2007). Achieving a gross 
total resection (GTR) is difficult due to the delicate nature of the surrounding 
structures and has been reported to only be attainable in 50-60% of cases 
(Bouffet et al., 1998; Perilongo et al., 1997). However, some centres report rates 
of up to 81.7% (Merchant et al., 2009). Resection rates can be improved by 
second-look surgery (Vinchon et al., 2005).  
 
One study found that duration of symptoms before diagnosis was an independent 
risk factor for poor outcome in both univariate and multivariate analyses (Pollack 
et al., 1995). This finding supports the recent drives for earlier diagnosis of 
paediatric brain tumours by HeadSmart, a UK campaign that has reduced the 
time from first symptoms to diagnosis (Shanmugavadivel et al., 2015; Wilne et 
al., 2010).  
1.3.2 Current approaches to treatment 
The main accepted treatment strategies in ependymoma management include 
surgery, radiotherapy and chemotherapy. 
 
Surgery is used in all patients, with an aim to achieve GTR (Jaing et al., 2004; 
Paulino et al., 2002). Adjuvant radiotherapy is often given to older children at 
diagnosis, and radiotherapy is recommended for all at recurrence (Grundy et al., 
2007; Messahel et al., 2009; Perilongo et al., 1997). Despite evidence of its 
efficacy (Koshy et al., 2011; Merchant et al., 2009; Snider et al., 2017), children 
under three generally do not receive radiotherapy in view of concerns about late 
effects; more recently it has been suggested that this age cut off should be 
lowered to 12-18 months (Rudà et al., 2017). There is an increasing role for 
proton beam radiotherapy (Indelicato et al., 2017). Instead of radiotherapy, the 
youngest children often receive chemotherapy (Grill et al., 2001; Grundy et al., 
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2007; Rudà et al., 2017). Some argue that the use of chemotherapy in younger 
children has been a relatively successful approach, with studies demonstrating 
that radiotherapy may be delayed in around 40% of infants with non-metastatic 
disease (Duffner et al., 1993; Geyer et al., 2005; Grill et al., 2001; Grundy et al., 
2007; Strother et al., 2014). Others have suggested that chemotherapy is only 
beneficial in supratentorial disease (Venkatramani et al., 2013), or not at all 
(Evans et al., 1996).  
 
Long-term effects of cancer therapy must be balanced against the risk of disease 
progression. A recognised dilemma in many paediatric cancers, including acute 
lymphoblastic leukaemia and optic pathway glioma (Taylor et al., 2008; Vora et 
al., 2013). Radiotherapy has significant neurocognitive impact and is associated 
with declines in memory, processing speed, attention, visual, motor and 
intellectual and executive functioning (Shortman et al., 2014; Spiegler et al., 
2004).  
 
A cohort of 26 patients from 12 Canadian centres provided evidence that, in 
children aged over two years with low proliferative markers and in whom GTR had 
been achieved, radiotherapy might be avoided completely (Ailon et al., 2014). 
This supports other research describing a group of PF ependymomas (EPN_PFB) 
with a markedly improved prognosis (over 90% EFS and OS), that may be 
amenable to more conservative treatment (Pajtler et al., 2015; Ramaswamy et 
al., 2016; Witt et al., 2011). This finding needs to be verified in an adequately 
powered, prospective trial before introduction into the clinical environment. 
 
The development of evidence based treatment strategies requires large 
prospective cohorts and prospectively designed, randomised, trials rather than 
small cohorts from single centres (Bouffet et al., 1998). Some progress has been 
made in this respect through multi-centre co-operation and a summary table of 
prospective clinical trials of different combinations of conventional therapies in 
ependymoma is presented (Table 1-4). Despite this progress, of the 11 studies 
considered, only one included in excess of 100 patients (Massimino et al., 2016). 
A further difficulty in interpreting these studies is that whilst all used the 
conventionally accepted approaches of surgery, with or without chemotherapy 
and radiotherapy, the clinical cohorts and experimental protocols varied, 
generating a heterogeneous dataset. 
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Study Patients OS EFS Intervention Main Outcome 
(Evans et al., 1996) 42 39% 
(10yr) 
36% 
(10yr) 
Surgery and RT +/- CT. CT not effective in improving outcome. 
(Duffner et al., 1998) 48 40-50% 
(2yr) 
23% 
(2yr) 
2 year delayed RT in children <2 years, 1 
year delayed in children >2 years. CT until 
RT delivered. 
Youngest children had worse outcomes. 
Attributed to longer RT delay. 
(Robertson et al., 1998) 32 64% 
(5yr) 
50% 
(5yr) 
Surgery and RT plus one of two possible CT 
regimens. 
Outcome not affected by either CT regimen. 
(Grill et al., 2001) 73 59% 
(4yr) 
22% 
(4yr) 
CT to avoid RT in children <5 years. RT avoided or delayed in substantial 
proportion of <5 year olds. 
(Geyer et al., 2005) 74 59% 
(5yr) 
32% 
(5yr) 
Children <3 years randomised to one of 
two CT arms. RT for progression. 
No difference in outcomes between the two 
CT arms. 
(Grundy et al., 2007) 89 63% 
(5yr) 
42% 
(5yr) 
CT to avoid RT in children <3 years. RT avoided or delayed in substantial 
proportion of under 3 year olds. 
(Massimino et al., 2011) 41 37% 
(5yr) 
26% 
(5yr) 
Upfront CT to avoid RT in young children. High failure rates demonstrated. 
Neurocognitive outcomes not improved for 
those who did not receive RT. 
(Garvin et al., 2012) 84 71% 
(5yr) 
57% 
(5yr) 
CT pre-RT in children with STR. Those with near total resection had 
equivalent outcomes to GTR. Those with STR 
had suboptimal outcomes. 
(Venkatramani et al., 2013) 19 73% 
(3yr) 
27% 
(3yr) 
Intensive induction and consolidation CT 
prior to RT.  
Potential to improve outcomes in children 
with ST disease. Appeared ineffective in PF 
disease. 
(Strother et al., 2014) 82 29% 
(10yr) 
18% 
(10yr) 
DI versus standard CT in children <3 years. 
RT for progression. 
Treatment with DI resulted in better EFS but 
not OS. 
(Massimino et al., 2016) 160 65% 
(5yr) 
81% 
(5yr) 
3 arms stratified by extent of resection and 
grade:  
(1) STR: CT + RT  
(2) GTR+grade II: RT 
(3) GTR+grade III: CT+RT 
Worst outcomes seen in children with STR 
followed by GTR and grade III. Best 
outcomes in GTR and grade II disease. 
Table 1-4: Summary of multicentre prospective clinical trials using conventional therapies in paediatric ependymoma. CT: Chemotherapy. RT: 
Radiotherapy. DI: Dose intensification.
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1.3.3 Clinical and molecular features associated with outcome 
Numerous clinical and molecular features have been associated with clinical 
outcome in ependymoma. The level of evidence for each feature is variable. 
1.3.3.1 Tumour grade 
The World Health Organisation (WHO) classification describes four histological 
types of ependymoma (Louis et al., 2007): 
• Myxopapillary ependymoma (WHO grade I); 
• Subependymoma (WHO grade I); 
• Ependymoma (WHO grade II); 
• Anaplastic ependymoma (WHO grade III). 
 
Morphologically, ependymomas vary from highly differentiated tumours with 
densely cellular areas and perivascular rosettes, to anaplastic types with areas of 
necrosis, chaotic vascularity and calcification (Kilday et al., 2009; Louis et al., 
2007). The level of heterogeneity seen in assessment of tumour histology is 
summarised in the grading scheme proposed by Ellison (Table 1-5). 
 
 
Table 1-5: New criteria for histological assessment based on the tumour samples collected 
from patients involved in 4 European ependymoma trials. Reproduced from Ellison et. al. 
2011. 
The results of multiple studies of tumour grade as a marker of prognostic 
significance are mixed. Some studies provide no evidence that tumour grade at 
presentation correlates with either OS or EFS (Agaoglu et al., 2005; Bouffet et 
al., 1998; Ellison et al., 2011; Li et al., 2015; Paulino et al., 2002; Ridley et al., 
2008; Robertson et al., 1998; Snider et al., 2017; Tabori et al., 2008). This may 
be due to small study size. However others, including a recent large prospective 
study, identified significant differences in outcome for children with different 
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tumour grades (Massimino et al., 2016; Tihan et al., 2008). A further explanation 
for the conflicting evidence may be that accurate, reproducible grading is 
challenging (Ellison et al., 2011). 
1.3.3.2  Resection status 
It has been consistently reported that GTR is the most important and 
reproducible predictor of long-term survival (Agaoglu et al., 2005; Aizer et al., 
2013; Amirian et al., 2012; Cage et al., 2013; Godfraind et al., 2012; Grill et al., 
2001; Jaing et al., 2004; Mendrzyk et al., 2006; Perilongo et al., 1997; Pollack et 
al., 1995; Robertson et al., 1998; Snider et al., 2017; Tabori et al., 2008). 
However, achieving this can be challenging (Bouffet et al., 1998; Perilongo et al., 
1997). In some cases STR may need to be followed up with second look surgery 
to obtain GTR (Foreman et al., 1997; Godfraind et al., 2012; Vinchon et al., 
2005). In one example the GTR rate was improved to 80% using this approach 
(Godfraind et al., 2012). 
1.3.3.3  Location 
Paediatric ependymomas make up 6-12% of all childhood intracranial tumours 
and 30% of spinal tumours. 90% of cases are intracranial and around 70% of 
these arise in the PF (Jaing et al., 2004; Vinchon et al., 2005). Spinal tumours 
have a better prognosis (McGuire et al., 2009). There is conflicting evidence 
about the implications of intracranial tumour location on outcome. Some studies 
report no difference between PF and ST tumours (Agaoglu et al., 2005; Jaing et 
al., 2004; Paulino et al., 2002; Perilongo et al., 1997; Pollack et al., 1995; 
Robertson et al., 1998; Snider et al., 2017). Some report that ST tumours have 
worse survival outcomes (Cage et al., 2013; Mansur et al., 2005; Nambirajan et 
al., 2014) and some report that PF tumours have worse outcomes (Grill et al., 
2001; Ridley et al., 2008; Venkatramani et al., 2013). This data is difficult to 
interpret in view of the heterogeneity of the study designs and lack of knowledge 
about the molecular subgroup of the tumours included in the studies.  
 
Figarella-Branger and colleagues reported that PF tumours located laterally had 
worse outcomes than those located centrally (Figarella-Branger et al., 2000). This 
might account for some of the discrepancies in results for outcomes of PF versus 
ST tumours. Consequently various studies have looked at further sub-
classification of tumours in one anatomical location; in particular the posterior 
fossa (Hoffman et al., 2014a; Wani et al., 2012; Witt et al., 2011). DNA 
methylation classification, which will be introduced later, supports the concept of 
midline and lateral PF tumours being different entities (Pajtler et al., 2015). 
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1.3.3.4  Age at diagnosis 
Young children have the poorest outcomes (Agaoglu et al., 2005; Amirian et al., 
2012; Bouffet et al., 1998; Figarella-Branger et al., 2000; Jaing et al., 2004; 
McGuire et al., 2009; Perilongo et al., 1997; Snider et al., 2017; Tabori et al., 
2008). It has taken time for age to emerge as a clear prognostic factor because 
studies have used different age bands and included adult patients in their case 
series (Bouffet et al., 1998). Additionally, younger children are more difficult to 
clinically assess and there is appropriate reluctance to use radiotherapy on the 
developing brain (Agaoglu et al., 2005; Gilbertson et al., 2002; Jaing et al., 
2004; Massimino et al., 2004). Despite this, it would be erroneous to conclude 
that the differing therapeutic approaches due to age are the only cause for poorer 
outcomes, as it is now emerging that younger children may have more 
biologically aggressive tumours, irrespective of treatment (Carter et al., 2002; 
Hirose et al., 2001; Pajtler et al., 2015; Ramaswamy et al., 2016; Wani et al., 
2012; Witt et al., 2011). 
1.3.3.5  Genomic profiles 
Ependymoma has been described as ‘genetically bland’ and ‘enigmatic’ (Kilday et 
al., 2009; Mack et al., 2013; Robertson et al., 1998). Whilst there are multiple 
examples of DNA copy number change (Bouffet et al., 1998; Dyer et al., 2002; 
Hirose et al., 2001; Kilday et al., 2012; Witt et al., 2011b) there are few genetic 
mutations (Mack et al., 2013). Reasons cited for this include: 
(1) heterogeneous nature of the tumour resulting in missing important and 
focal genetic changes;  
(2) presence of epigenetic, but not genetic, drivers; 
(3) insufficient depth of analysis (Mack & Taylor, 2009). 
 
Despite this, a number of genomic abnormalities have been linked with 
ependymoma and these present an area for investigation. 
 
Associations have been described between chromosome 1q gain, disease 
progression and higher tumour grade. This copy number change has gained a 
great deal of prominence regarding its association with tumour prognosis and has 
been repeatedly associated with outcome in multiple studies (Carter et al., 2002; 
Dyer et al., 2002; Godfraind et al., 2012; Hirose et al., 2001; Kilday et al., 2012; 
Mendrzyk et al., 2006; Rousseau et al., 2010). 
 
Loss of chromosome 22 has been associated with sporadic ependymoma and is 
present in 17-75% of tumours (Carter et al., 2002; Jeuken et al., 2002; Reardon 
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et al., 1999; Zheng et al., 2000). It was initially thought that the NF2 gene was 
the candidate gene associated with this chromosomal loss, however it emerged 
that this was only the case in spinal ependymoma (Mack & Taylor, 2009).  
 
Ependymomas in different CNS locations appeared to have different chromosomal 
constitutions in some studies. Spinal tumours were associated with gains of 
chromosomes 7, 9, 11, 18 and 20 and loss of 1, 2 and 10 whilst intracranial 
ependymomas showed gain of chromosome 1q and loss of 22, 3, 9p and 13q 
(Mack & Taylor, 2009; Rousseau et al., 2010).  
 
In 2002 Dyer and colleagues analysed 42 primary and 11 recurrent 
ependymomas by array-CGH. They clustered tumours into three groups based on 
levels of genomic imbalance: 
(1) Numerical: 13 or more imbalances (12%); 
(2) Structural: 1-6 imbalances and high ratio of partial to whole 
chromosome imbalances (45%); 
(3) Balanced (43%). 
 
When these groups were analysed in relation to their clinical behaviour, children 
under three years had mainly balanced profiles whilst older children fell into 
numerical or structural groups. Multivariate analysis demonstrated that children 
with tumours in the structural group had the worst outcomes when controlled for 
tumour location, histology, extent of resection, adjuvant therapy and age at 
diagnosis. The study also found that tumours exhibiting 1q gain had a trend 
towards poorer five-year OS (15% versus 50%). In analysing their small cohort 
of recurrent tumours, 10 out of 11 of the specimens showed a structural profile. 
Gain of 1q was identified in eight cases. The authors concluded that tumours in 
the structural group are clinically more aggressive. A larger study of 292 cases 
confirmed similar genomic subgroups (Korshunov et al., 2010). 
 
One study reported that the presence of chromosomal imbalance was more likely 
to be associated with recurrent disease, in particular gains of chromosome 9q33 
and 9q34 (Puget et al., 2009). 
 
Researchers in the USA demonstrated that copy number aberrations (CNAs) were 
affecting oncogenes and tumour suppressor genes (TSGs) resulting in 
upregulated and downregulated gene expression. CNAs were characterised for a 
set of 204 ependymomas from which the authors identified 84 and 39 candidate 
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oncogenes and TSGs. They transduced the genes in radial-glial cells which were 
then injected in pools into immunocompromised mice. PCR analysis from the 
subsequent mouse tumours determined which oncogenes or TSGs had driven 
tumour formation. These genes were again transduced, one per pool, into cells of 
origin and injected into 209 different mice. 53% developed tumours histologically 
consistent with ependymoma, validating ten tumour suppressor genes and eight 
oncogenes (Johnson et al., 2010; Mohankumar et al., 2015). The genes that 
emerged from this analysis are outlined in Table 1-6 and Table 1-7. 
 
Tumour Suppressor Gene Function 
ALDH3A1 Aldehyde dehydrogenase activity 
ACTR1A Regulates vesicle trafficking 
SNX6 Regulates vesicle trafficking 
ULK2 Regulates vesicle trafficking 
PCMT1 Protein repair/degradation 
DNA2 DNA modification and repair 
SUFU Negative regulator in Hedgehog signalling pathway 
STAG1 DNA modification and repair 
TET1 DNA modification and repair 
ST13 Protein binding 
Table 1-6: Tumour suppressor genes from Mohankumar et. al. 2015. Function from 
www.genecards.org. 
Oncogene Function 
ZNF688 Links chromatin relaxation state to DNA repair 
BCL7C Member of the SWI/SNF chromatin regulatory complex 
RAB3A Late-stage vesicle trafficking and exocytosis in neuronal cells 
PRDX2 Regulates oxidation induced apoptosis 
RTBDN Belongs to folate receptor family 
AKT2 Mediator of cell survival 
TMEM129 Mediates HLA class I protein degradation 
MRPS17 Mitochondrial ribosomal protein 
Table 1-7: Oncogenes from Mohankumar et. al. 2015. Function from www.genecards.org. 
1.3.3.6  Gene expression profiles 
Through the use of gene expression arrays, numerous authors have correlated 
transcriptional profiles of ependymoma with clinicopathological features, including 
age, grade, gender and tumour location. Researchers have also attempted to look 
for associations between transcriptional profiles and clinical outcomes. Specific 
gene expression profiles have been linked most frequently to location within the 
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CNS with large numbers of differentially expressed genes between spinal, 
posterior fossa and supratentorial locations. However, associations have also 
been suggested with tumour grade (Korshunov et al., 2003; Palm et al., 2009), 
gender (Pajtler et al., 2015) and patient age (Korshunov et al., 2003; Pajtler et 
al., 2015; Wani et al., 2012; Witt et al., 2011) (Table 1-8). 
 
Initial studies undertook supervised approaches to these investigations, 
performing differential expression analysis on groups of tumours with particular 
clinical characteristics (Korshunov et al., 2003; Lukashova-v.Zangen I. et al., 
2007; Modena et al., 2006; Taylor et al., 2005). One of the drawbacks of this 
approach was the tendency to be able to find expression profiles based on 
predefined ideas about the disease, risking biased conclusions. More recently, 
studies have undertaken unsupervised clustering approaches. This has resulted in 
the delineation of numerous subgroups which were annotated clinically to identify 
numerous associations with specific locations, epidemiological features and 
clinical outcomes. Some of the proposed subgroups were complex and not 
validated in the literature (Johnson et al., 2010). 
 
A key development was the description of two PF based gene expression 
subgroups, initially named A and B. Group A was found to be associated with a 
particularly aggressive phenotype with poor outcomes, a balanced genome (apart 
from isolated 1q gain) and younger age. Group B was associated with better 
outcomes, a more unbalanced genome, midline location, and an older age profile 
(Wani et al., 2012; Witt et al., 2011). Biomarkers were identified which were 
representative of these two gene expression groups: Laminin-alpha-2 (LAMA2) 
selected to represent group A, and Neural Epidermal Growth Factor Like 2 
(NELL2) selected to represent group B. Each group was also associated with 
specific gene ontology terms, including wound healing and the inflammatory 
response for group A, and terms related to cilia and motility for group B. 
Interestingly, given that A and B gene expression groups were found to have 
specific associations with clinical features, it is unsurprising that authors prior to 
2011 had also found clinical associations with gene expression. However, the 
definition of A and B subgroups allowed the knowledge of the associations to be 
linked with well-defined molecular phenotypes.
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Table 1-8: Summary of gene expression array studies investigating transcriptomic profiles of ependymoma. Location refers to spinal and intracranial 
(All), intracranial only (IC) or posterior fossa only (PF). Approach reflects whether the studies tested for differences between predefined clinical factors 
(supervised) or used hierarchical clustering to generate clusters before comparing the clinical features of each cluster (unsupervised). Columns relating 
to age, location, grade, relapse/outcome and gender indicate whether the study in question made an association between gene expression profile and 
each characteristic. The molecular subgroup column indicates whether accepted gene expression subgroups were defined or discussed in the study. 
Study Patients  
(Location) 
Approach Age Location Grade Relapse/ 
Outcome 
Gender Molecular 
Subgroup 
(Korshunov et al., 2003) 39 (All) Supervised Yes Yes Yes No No No 
(Taylor et al., 2005) 32 (All) Supervised No Yes No No No No 
(Modena et al., 2006) 24 (IC) Supervised No Yes No Yes No No 
(Lukashova-v.Zangen I. et al., 2007) 47 (All) Supervised No Yes No Yes No No 
(Palm et al., 2009) 34 (All) Supervised and unsupervised No Yes Yes No No No 
(Donson et al., 2009) 19 (IC) Supervised No No No Yes No No 
(Johnson et al., 2010) 83 (All) Unsupervised No Yes No No No No 
(Witt et al., 2011) 177 (PF) Unsupervised Yes N/A No Yes No PFA, PFB 
(Wani et al., 2012) 67 (PF) Unsupervised Yes N/A No Yes No PFA, PFB 
(Hoffman et al., 2014a) 44 (All) Unsupervised No Yes No Yes No PFA, PFB 
(Pajtler et al., 2015) 209 (All) Unsupervised Yes Yes No Yes Yes Multiple 
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1.3.3.7 DNA methylation profiles 
DNA methylation is an epigenetic mark which can alter gene expression and 
biological function. DNA methylation patterns vary between tissue types, tumour 
types and age. Given their relative stability, DNA methylation patterns can be 
used as part of the diagnostic process. This approach is now being used 
extensively in childhood brain tumours (Pajtler et al., 2015; Schwalbe et al., 
2017; Sturm et al., 2016). 
 
In 2014 Mack and colleagues reported a study of 47 PF ependymomas and found 
that whilst these tumours were unremarkable when assessed by whole-genome 
and whole-exome sequencing, they demonstrated heterogeneous DNA 
methylation profiles. They reported that the EPN_PFA and EPN_PFB groups were 
replicated when clustered by DNA methylation profile. EPN_PFA ependymomas 
demonstrated a CpG island methylator or ‘CIMP’ phenotype (Mack et al., 2014). 
The authors hypothesised that the reason for the aggressive behaviour of the 
EPN_PFA tumours could be due to epigenetic silencing of genes promoting cellular 
differentiation. They found that some of the hypermethylated genes were those 
silenced by the Polycomb Repressive Complex 2 (PRC2) in embryonic stem cells. 
EZH2 expression, a component of the PRC complex, has subsequently been 
associated with poorer five-year OS in childhood ependymoma (Li et al., 2015). 
 
An international collaboration led by researchers in Heidelberg has since identified 
nine groupings based on DNA methylation status. The DNA methylation profiles of 
500 adult and paediatric ependymal tumours were established with Infinium 
HumanMethylation450 BeadChip Arrays (Illumina). Results were clustered to 
reveal three subgroups for each of the three tumour locations (Pajtler et al., 
2015) (Figure 1-2). 
 
There were no children in the SP-SE, PF-SE and ST-SE groups. Children under the 
age of 18 years constituted 99% of the EPN_PFA group, 92% of the EPN_YAP 
group and 76% of the EPN_RELA group but only 19% of the EPN_PFB group. This 
is important given that different transcriptional profiles have also been attributed 
to different age groups (Korshunov et al., 2003). The DNA methylation defined 
groups also correlated perfectly with the transcriptionally defined groups. 
EPN_PFA and EPN_PFB were reflective of the gene expression patterns of group A 
and group B described in section 1.3.3.6. 
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Figure 1-2: The nine proposed subgroups of ependymoma. Note that this classification 
includes both adults and children. Groups most relevant to paediatric cohorts include ST-
EPN-YAP1, ST-EPN-RELA, PF-EPN-A and PF-EPN-B. Classification with poor outcomes are 
marked with a red dot. Modified with permission from Pajtler et al. 2015. 
 
The DNA methylation defined subgroups were associated with disparate 
outcomes. Children with EPN_PFA and EPN_RELA tumours had poorer outcomes 
in contrast to those with EPN_PFB and EPN_YAP tumours. Given that EPN_PFB is 
more commonly seen in older children and adults, the finding that younger 
children have poorer outcomes may actually be related to the molecular 
composition of the tumours experienced by younger children. 
 
Pajtler and colleagues also reported that no tumour changed subgroup at 
recurrence, however this contradicts gene expression findings (Hoffman et al., 
2014a). One explanation for this discrepancy is that DNA methylation profiles are 
set very early in foetal development and are then relatively permanent. However, 
other genetic and epigenetic changes could still occur that affect gene expression 
profiles. 
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Evidence is emerging that the EPN_PFA tumours can be further subdivided into 
nine groups, with two major subgroups; PFA-1 and PFA-2. This data has been 
presented internationally and has been submitted for publication (Pajtler et al., 
2017). 
1.3.3.8  Fusion genes 
Fusion genes form from two genes which were previously spatially separated. 
They can form through localised genomic rearrangements (deletions, inversions 
or translocations) or by more widespread rearrangements resulting from 
chromothripsis; a mechanism first described in the context of chronic lymphocytic 
leukaemia (Forment et al., 2012). In the process of chromothripsis it is thought 
that chromosomes are shattered by an extreme insult, followed by incorrect 
rearrangement resulting in deletions, inversions and translocations. It has been 
suggested that cancerous cells which develop following chromothripsis are more 
susceptible to novel targeted cancer therapies as a result of their genomic 
instability (Forment et al., 2012). 
 
Fusion genes may contribute to ST ependymoma development (Parker et al., 
2014; Pietsch et al., 2014). Parker and colleagues performed whole genome and 
RNA sequencing of 41 and 77 ependymomas respectively from both ST and PF 
locations, identifying and validating 27 novel fusion genes involving chromosome 
11q. These fusions occurred exclusively in ST tumours. Of particular interest were 
fusions with the RELA gene, an important component of NF-kB signalling. A form 
of the C11orf95-RelA fusion was found in 70% of paediatric ST ependymomas, 
with seven different molecular variants identified. 
 
The C11orf95-RelA fusion gene resulted in the upregulation of the NF-kB cellular 
signalling pathway by the transportation of RELAFUS1 protein into the nucleus. 
Some upregulation is also seen with wild type RELA protein (RELAWT) which is 
probably involved in normal cellular homeostasis. RELAFUS1 seemed to induce the 
NF-kB pathway with more potency and resulted in increased ependymoma 
formation in mouse models (Parker et al., 2014). Mouse tumours were also 
induced by another gene fusion, C11orf95-YAP1, indicating that multiple fusions 
are potentially capable of ependymoma oncogenesis. 
 
The work on DNA methylation profiles by Pajtler and colleagues subsequently 
identified that specific DNA methylation based subgroups were associated with 
RELA and YAP1 fusions (EPN_RELA and EPN_YAP), associating the presence of 
different fusion genes with clinical outcomes, epidemiological characteristics and 
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gene expression patterns. Pajtler and colleagues also reported that whilst RELA 
fusions were associated with chromothripsis and a disordered genomic profile, 
YAP1 fusions were associated with balanced profiles but specific copy number 
aberrations around the YAP1 locus (Pajtler et al., 2015). 
1.3.4 A cancer stem cell origin for ependymoma 
Cancer stem cells (CSCs) form a small proportion of the overall cancer burden 
and have the capacity for self-renewal and tumour maintenance (Clarke et al., 
2006). Their existence was first indicated in 1937 by a study demonstrating that 
large numbers of cells needed to be injected into mice to initiate cancer thus 
inferring that not every cancer cell can propagate malignancy (Furth and Kahn, 
1937). It has been theorised that this subpopulation of tumour initiating and 
propagating cells are relatively refractory to conventional therapies. As a result, 
their presence may make for tumours that are difficult to eradicate with 
conventional approaches (Clarke et al., 2006).  
 
CSCs may play a role in cancer recurrence (Esmatabadi et al., 2016). One theory 
is that, in view of their general resistance to therapy, they are not completely 
eradicated during initial treatment. Consequently, a proportion lie dormant and 
recapitulate the tumour when environmental factors permit. Importantly, these 
cells may lie dormant for many years, resulting in recurrence of the same tumour 
long after the patient and physician believe it has been eradicated. This suggests 
that recurrence might develop from asymptomatic residual disease (Aguirre-
Ghiso, 2007). It is not clear what maintains CSCs in their dormant state, but one 
review suggests considering mechanisms antagonising the expansion of the 
dividing tumour cell population and mechanisms resulting in cessation of tumour 
growth. The review describes three types of dormancy;  
(1) Cellular dormancy: results in dormant cells having entered a G0-G1 
arrest, potentially allowing them to evade immune recognition; 
(2) Angiogenic dormancy: Maintained by the balance of factors promoting 
and opposing angiogenesis; 
(3) Immunosurveillance: Components of the immune system recognise 
and suppress proliferating cancer cells (Aguirre-Ghiso, 2007). 
Not only does this indicate a role for CSCs in recurrence, but also the importance 
of an appropriate microenvironment for tumours to develop from a dormant state 
(Aguirre-Ghiso, 2007; Jandial et al., 2008). 
 
Cancer stem cells (CSCs) can be identified by the expression of cluster of 
differentiation molecule 133 (CD133) (Li, 2013). Approximately 1% of CD133 
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positive ependymoma cells display a radial glia-like phenotype, compared to none 
of the CD133 negative cells. It has been demonstrated that these CD133 positive 
cells with a radial-glia like phenotype form neurospheres under in vitro 
conditions, favourable to stem cell growth. Consequently, CD133 expressing 
radial-glia like neural stem cells (NSCs) have been proposed as a CSC origin for 
ependymoma. Not only this, but by also using gene expression profiling, Taylor 
showed that location specific ependymoma gene expression profiles correlated 
with regionally specified radial-glia-like cells, suggesting that ependymomas in 
different locations may have distinct origins (Taylor et al. 2005). 
 
It has also been postulated that NSCs arising from different parts of the CNS give 
rise to biologically distinct tumours. In support of this hypothesis, modified NSCs 
from different parts of the CNS produced location specific ependymomas in 
mouse models (Johnson et al., 2010). The studies by Taylor and Johnson marked 
a shift to considering the developmental biology underpinning ependymoma and 
help to provide an explanation for a mechanism by which ependymoma may 
recur. 
1.4 Ependymoma recurrence 
1.4.1 Epidemiology 
Paediatric ependymoma is an aggressive disease in which relapse is common, 
recurrent, and often fatal. Ependymoma tends to recur at its original site, with 
metastasis in around 25% of cases (Antony et al., 2014; Jaing et al., 2004; 
Messahel et al., 2009). In a study of 108 children with recurrence in the United 
Kingdom five-year OS was 24% for children under three years and 27% for older 
children (Messahel et al., 2009). Earlier studies have reported even worse 
outcomes, with five-year OS of 12.3% (Jaing et al., 2004), three-year OS of 0% 
(Pollack et al., 1995) and two-year OS of 39% (Goldwein et al., 1990). Available 
studies of recurrence are based on historical patient cohorts. However, given that 
cancer survival outcomes have improved over the decades (Cancer Research UK, 
2015a), it is possible that in more contemporaneous cohorts outcomes are better. 
 
Despite the development of DNA methylation classification, conferring 
dramatically different prognoses between ependymoma subgroups (Pajtler et al., 
2015; Ramaswamy et al., 2016), there has been no detailed study of the clinical 
features of recurrent disease supported by DNA methylation profiling. 
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1.4.2 Prognostic factors 
Independent prognostic factors impacting OS at recurrence include: extent of 
repeat surgery; use of radiotherapy; and the presence of metastatic disease 
(Bouffet et al., 2012; Merchant et al., 2008; Messahel et al., 2009; Tsang et al., 
2018; Zacharoulis et al., 2010). Despite this, approaches to the treatment of 
recurrent disease have not been standardised. Whilst the treatments mentioned 
have been shown to improve short term prognosis, the long term prognosis of 
recurrence remains poor for all patients (Messahel et al., 2009; Zacharoulis et al., 
2010). 
 
Achieving a GTR can be even more challenging than at first presentation due to 
tumour infiltration, with resultant high morbidity (Vinchon et. al., 2005). GTR 
may also be more difficult to achieve in children with multi-site disease. 
 
Children with metastatic disease at recurrence have demonstrated worse 
outcomes in multivariate analyses in more than one study. In one case median 
OS was 13 months in the metastatic patients compared to 30 months in those 
with local disease (Messahel et al., 2009). In another study median OS was not 
reported, but hazard ratios for patients with metastatic recurrence were 
significantly increased (Zacharoulis et al., 2010). 
 
Re-irradiation has been suggested to significantly improve survival duration, 
albeit with the risk of increased neurotoxicity (Bouffet et al., 2012; Lobón et al., 
2016; Merchant et al., 2008; Tsang et al., 2018), although this is not a universal 
finding (Zacharoulis et al., 2010). However, children who received radiotherapy 
during treatment of their primary tumour had worse OS at recurrence than those 
who did not (Messahel et al., 2009).  
 
There was no improvement with chemotherapy in recurrent disease in one study, 
whilst another associated chemotherapy with poorer outcomes after first relapse 
(Messahel et al., 2009; Zacharoulis et al., 2010). 
 
On the basis of previous research into recurrent ependymoma, European 
guidelines suggest that therapy at relapse should include repeat surgery and/or 
radiotherapy, consideration of chemotherapy and consideration of inclusion in a 
clinical trial (Rudà et al., 2017). 
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1.4.3 Future therapies 
Novel therapies have been investigated in phase I and II clinical trials in patients 
with recurrence with minimal success. Possible reasons for this include small 
study numbers, inclusion of multiple types of recurrent brain tumour, and a lack 
of understanding about the underlying biology of recurrent disease. Novel agents 
tested include Perifosine (Phase I) (Becher et al., 2017), 5-Fluorouracil (Phase I) 
(Wright et al., 2015), Erlotinib (Phase II) (Jakacki et al., 2016), Sunitinib (Phase 
II) (Wetmore et al., 2016), Bevacizumab and Lapatinib (Phase II) (DeWire et al., 
2015), Bevacizumab and Irinotecan (Phase II) (Gururangan et al., 2012), 
interferon (IFN) beta (Phase I-II) (Allen et al., 1991) and Paclitaxel (Phase II) 
(Hurwitz et al., 2001). Unfortunately, none of these phase II studies showed 
promise in recurrent ependymoma. 
 
Immunotherapy is not an evidenced based treatment in recurrent ependymoma 
although it has been a therapy of interest in many other malignancies, including 
melanoma (Hodi et al., 2010). However, a search of www.clinicaltrials.gov for 
‘ependymoma’ and ‘immunotherapy’ highlighted eight trials investigating the role 
of various immunotherapy techniques in brain tumours including ependymoma. 
In order to assess whether immunotherapeutic interventions stand any chance of 
being effective, a better understanding of the biological basis of ependymoma 
recurrence is essential. 
1.4.4 Studies of ependymoma biology at recurrence 
Minimising the risk of recurrence is a crucial consideration in the management of 
primary disease. Given that recurrence is so common, a better understanding of 
its biology is a research priority. 
 
The investigation of recurrent paediatric ependymoma has been hampered by the 
rarity of the disease and the difficulty in obtaining adequate numbers of matched 
primary and recurrent pairs. Eight studies investigating tumour biology at 
recurrence have been published (Table 1-9). These were largely 
immunohistochemistry based, investigating specific molecular markers (Ridley et 
al., 2008; Tabori et al., 2008) or comparative genomic hybridisation (CGH), 
investigating genomic imbalances (Dyer et al., 2002; Puget et al., 2009). Only 
two studies used array base gene expression profiling. Both were performed 
before current, DNA methylation defined, molecular subgroups were identified 
(Mack and Taylor, 2017). 
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Peyre et al. (2010), investigated 17 matched pairs from all intracranial locations, 
implicating kinetochore proteins and metallothioneins in tumour behaviour at 
relapse. Peyre also identified immune related genes in a recurrence signature, 
with downregulation of chemokines CXCL5 and CX3CL1 amongst others. Hoffman 
et. al. (2014), investigated only PF ependymomas. They suggested that EPN_PFA 
and EPN_PFB subgroups displayed different patterns of immune response at 
recurrence. However, subgroups were only defined using gene expression 
profiling, which recent research has suggested could be misleading (Pajtler et al., 
2017). Follow-up suggested that primary tumours with EPN_PFA phenotypes 
display evidence of immune suppression (Hoffman et al., 2014a).  
 
In addition to studies investigating biology at recurrence, a study by Donson and 
colleagues in 2009 investigated the differences between primary ependymomas 
that subsequently relapsed and those that did not. Based on gene expression 
profiling and immunohistochemistry, they suggested that non-recurrent primaries 
were associated with enrichment of immune related genes, and that tumours with 
immune gene enrichment demonstrated a longer time to progression when they 
did recur. They also correlated increased tumour infiltration with CD4+ T-cells 
with improved outcomes. Unfortunately this study was based on a small sample 
size of nine non-recurrent tumours and ten recurrent tumours, making robust 
conclusions difficult (Donson et al., 2009). There is no evidence that either this 
work, or the Hoffman paper from 2014, has been validated by other authors or 
investigated in more detail in the published literature. 
 
In view of the association of relapse with the immune system in two published 
articles, a search of PubMed for ‘ependymoma’ and ‘immune’ across all time 
periods was undertaken. 46 results were generated, only three of which were 
specific studies of the immune response in ependymoma, all from the same group 
(Donson et al., 2009; Griesinger et al., 2017; Hoffman et al., 2014a). The 2009 
and 2014 studies have already been described. The 2017 study investigated the 
upregulation of NF-kB signalling being associated with the epigenetic silencing of 
the gene LDOC1 in EPN_PFA tumours. 
 
Following the completion of the literature search, one further study was published 
relating to the immune environment in ependymoma, again by the same research 
group (Witt et al., 2018). This study investigated levels of PD-L1 expression in 
EPN_RELA disease. The authors suggested that EPN_RELA tumours expressed 
more PD-L1 and had higher levels of CD4+ and CD8+ infiltration than other 
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tumour subtypes and concluded that EPN_RELA tumours should be considered for 
checkpoint inhibitor clinical trial inclusion. Interestingly, the authors did not use 
DNA methylation classifications to define the subgroups, instead using 
transcriptomic and protein based approaches. Comparisons between this and 
other studies where DNA methylation was used for classification should therefore 
be made with this in mind. 
 
Overall, the lack of published literature on the immune system in ependymoma is 
surprisingly limited and represents a gap that needs to be addressed.  
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Study Number of tumours Technique Key findings Comments 
Primary Recurrent Matched Pairs 
(Dyer et al., 2002) 42 11 7 Array CGH Subtyped ependymoma by chromosomal 
aberrations: 
(1) Structural; (2) Numerical;(3) Balanced.  
At recurrence 91% of tumours were unbalanced. 
Few recurrent 
tumours and 
few pairs. 
(Sowar et. al., 
2006) 
10 3 1 Gene 
expression 
array 
Minimum subset required to classify all tumours by 
recurrence status included 3 genes; PLEK, NF-kB2 
and LOC374491. 
Small sample 
size. 
(Ridley et al., 2008) 74 23 17 IHC, TRAP Low nucleolin expression associated with better 5-
year EFS. Telomerase reactivation and maintenance 
appear necessary for tumour progression. 
IHC study. 
TRAP on small 
cohort. 
(Tabori et al., 2008) 83 50 31 IHC, TRAP hTERT correlated with proliferation markers (MIB-1 
and mitotic indices and overall tumour grade). No 
correlation between telomere length and survival. 
IHC study. 
TRAP on small 
cohort. 
(Puget et al., 2009) 33 26 15 Array CGH Subtypes similar to Dyer 2002. Greater incidence at 
recurrence of gain of 9q34, 1q and loss of 6q. In 
the paired patients 3 profiles remained balanced, 
one showed loss of chromosome 22, 6 showed new 
abnormalities and 5 showed fewer imbalances. Gain 
on 9q33 and 9q34 were associated with recurrence 
(p=0.003 and 0.009), age over 3 (p=0.019 for 
9q34) and PF location (p=0.002 and 0.015) 
 
Small overall 
sample size 
and few pairs. 
 27 
Study Number of tumours Technique Key findings Comments 
 Primary Recurrent Matched Pairs 
(Peyre et al., 2010) 17 27 17 Array CGH, 
gene 
expression 
array 
Kinetochore proteins and genes involved in neural 
development (Wnt, CD133 and Notch) upregulated, 
metallothioneins downregulated. Metallothionein 
expression had epigenetic control and was restored 
by histone deacetylase inhibitors. No change in 
copy number between presentation and recurrence. 
Small sample 
size. 
(Hoffman et al., 
2014a) 
44 14 14 Gene 
expression 
array, SNP 
microarray 
Confirmed previously described PF subgroups (Witt 
et al., 2011) and defined 2 further subgroups 
(PFA1, PFA2, PFB1, PFB2) based on gene 
ontologies. 4 tumours changed group at recurrence. 
Small sample 
size. 
(Pajtler et al., 2015) 452 48 45 450K 
Methylation 
array, gene 
expression 
array 
Tumours divided into 9 DNA methylation based 
subgroups. Matched recurrences clustered closely 
with primary tumours suggesting DNA methylation 
classification can be applied to recurrent as well as 
primary disease – tumours did not change group. 
Mixed adults 
and children. 
Table 1-9: Summary of studies including matched primary and recurrent paediatric ependymoma cases to date. 
PFA: Posterior Fossa Group A, PFB: Posterior Fossa Group B, hTERT: human telomerase reverse transcriptase, IHC: Immunohistochemistry, TRAP: 
Telomeric Repeat Amplification Protocol, CGH: Comparative Genomic Hybridisation, PF: Posterior Fossa, EFS: Event Free Survival. 
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1.5 Cancer immunity and recurrence 
Given the association of ependymoma, particularly in relation to recurrence, with 
the immune system, this section considers the role of the immune system in 
cancer progression in general. 
1.5.1 The tumour microenvironment 
The National Cancer Institute defines the tumour microenvironment as: 
 
“The normal cells, molecules, and blood vessels that surround and feed a tumour 
cell” (NCI Dictionary of Cancer Terms). 
 
The tumour microenvironment contains elements which may support or 
antagonise cancer growth. These include extracellular matrix, immune cells and 
fibroblasts. The microenvironment is shaped by cancer cells through interactions 
with the host (Whiteside, 2008). One way in which cancer cells can interact 
through the microenvironment is via cell signalling, in particular by modulating 
cytokine expression. Cytokines are small proteins, which are secreted by and act 
upon immune, tumour and other microenvironment cells. They are able to alter 
cellular functions such as taxis (movement), cellular proliferation and growth. 
 
Cancers can be considered as ‘wounds that do not heal’ (Dvorak, 1986). Pro-
inflammatory signals, precipitating the wound healing response, do not originate 
from immune cells as originally predicted, but from cells undergoing apoptotic cell 
death. Consequently, one postulated microenvironmental mechanism for cancer 
recurrence is the ‘Phoenix rising’ pathway, in which apoptotic tumour cell death 
promotes wound healing and tissue regeneration pathways (Esmatabadi et al., 
2016; Li et al., 2010). It is hypothesised that when cancer cells undergo 
apoptosis as a result of therapy, pro-inflammatory mediators stimulate the 
surviving cancer stem cells. This may produce a mechanism by which the cancer 
can recur or progress (Esmatabadi et al., 2016).  
1.5.2 The innate and adaptive immune response 
The innate immune response is involved in the immediate recognition of 
pathogens in a non-specific fashion. It includes neutrophils, macrophages and 
natural killer (NK) cells and, in the brain, microglia. It is based on the recognition 
of chemical signals produced by pathogens and has no capacity for immunological 
memory (Reeves and Todd, 2004).  
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The adaptive immune response is based upon the actions of effector T- and B-
cells which are able to develop an immunological memory and therefore 
recognise specific antigens. Immunological memory is developed through 
exposure of T- and B- cells to target antigens, which are usually proteins, by 
antigen presenting cells (Reeves and Todd, 2004). A summary of the key effector 
cells involved in innate and adaptive immunity is found in Table 1-10. 
 
Cell Type Function Markers Immune 
Response 
Neutrophil Phagocytic cell. Immediately migrate to 
affected tissues. Produce cytokines and 
prostaglandins. Internalise and kill pathogens. 
CD16, 
CD66b 
Innate 
Macrophage Phagocytic cell. Accumulate at sites of 
infection. Secrete products including lysozyme, 
cytokines and complement proteins. 
Internalise and kill pathogens.  
CD14, 
CD33 
Innate 
Natural killer Kill target cells without antigen-specific 
activation. Killing functions are enhanced by 
the presence of interferons. 
CD56 Innate 
Microglia Function as the macrophages of the brain. CD68 Innate 
T lymphocyte Divided into helper T-cells (CD4+) and 
cytotoxic/effector T-cells (CD8+). Require 
antigen specific activation. CD4+ cells activate 
other cells to recognise antigen. CD8+ cells 
execute the final steps in cell killing by 
secreting perforins and granzymes onto the 
surface of target cells.  
CD3, 
CD4, CD8 
Adaptive 
B 
lymphocyte 
Secrete antibody to opsonise the surface of 
target cells. Mediate humoral immunity 
through body fluids. 
CD19, 
CD20 
Adaptive 
Table 1-10: Summary of key immune cells in innate and adaptive immunity. Modified from 
(Reeves and Todd, 2004). CD Marker identification modified from (BDBiosciences, 2016). 
All cells also express the leucocyte common antigen (CD45) which serves as a marker of 
inflammation. 
Both innate and adaptive immune responses have been implicated in cancer. 
Innate responses are mediated through NK cells and adaptive responses through 
lymphocytes, such as T- and B-cells (Woo et al., 2015). Immune responses can 
be pro- or anti-cancer, and mechanisms by which cancer can subvert the immune 
system and lead to tumour progression have been widely described (Kim and 
Chen, 2016; Spranger, 2016; Zitvogel et al., 2006). 
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1.5.3 The immune environment 
The immune system has long been postulated to play a role in cancer; physicians 
were attempting to develop cancer vaccines by inoculation with malignant tissue 
as early as 1777 (Ichim et al., 2005). There is emerging evidence that loss of 
immune control of a malignancy may contribute to tumour recurrence. 
 
The immune system is involved in discriminating ‘self’ from ‘non-self’ (Blair and 
Cook, 2008) in the process of immunosurveillance (Zitvogel et al., 2006). Whilst 
cancer originates from ‘self’ molecules, subtle changes such as the development 
of new mutations forming neoantigens or altered DNA methylation patterns, 
induce the host immune system to target it as ‘non-self’, enabling tumour 
destruction (Rooney et al., 2015). Such targets are known as tumour antigens 
(Table 1-11). However, in some cases the microenvironment induced by the 
cancer may harness the immune response and either evade, or modify, it to 
become pro-tumour (Raman et al., 2007; Spranger, 2016). Additionally, immune 
cell infiltration into the tumour microenvironment may be immune suppressive, 
aiding in tumour survival (Whiteside, 2008). 
 
Molecule Description 
Neoantigens An antigen arising in a tumour due to a new genetic mutation  
Oncoviral proteins Proteins produced following viral induction of a malignancy. 
Glycolipids Human tumours often express high levels of surface 
glycoproteins and glycolipids which may be targeted by the 
immune system. 
Cancer-Testis 
antigens (CTAs) 
Preferentially expressed in cells normally sheltered from the 
immune system, including testes and placenta. Some tumours 
re-express these markers, inducing an immune response. A 
database of CTAs was presented by Almeida in 2009. 
Hypomethylated DNA  Double stranded DNA is immunogenic and hypomethylated DNA 
even more so. 
Table 1-11: Antigens in human tumours associated with the induction of an anti-tumour 
immune response. Summary derived from Rooney et al. 2015; Charoentong et al. 2017; 
Almeida et al. 2009; Serrano et al. 2011. 
 
There is an ongoing balance between the tumour and the immune system which 
was illustrated by Zitvogel and colleagues in 2006 (Figure 1-3). Pre-malignant 
lesions are maintained by intact cancer immunosurveillance, in which immune 
cells detect and destroy malignant cells. As the tumour progresses the presence 
of an immune response selects for malignant phenotypes which are less 
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immunogenic in the process of immunoselection (which may also be referred to 
as immunoediting). This may include downregulation of some of the tumour 
antigens described in Table 1-11. Eventually tumours undergo immune escape by 
actively suppressing the immune response, allowing for more rapid growth. This 
is referred to as immunosubversion (Zitvogel et al., 2006). Tumour immune 
escape through the process of immunosubversion can take place through a 
number of mechanisms:  
(1) interference with the anti-tumour response; 
(2) suppression of effector T- cell function; 
(3) downregulation of immune recognition signals; 
(4) selection of immunoresistant phenotypes (Whiteside, 2008). 
 
 
Figure 1-3: The balance between immune surveillance and tumour growth. Intact 
immunosurveillance results in failure of progression of a pre-malignant to a malignant 
lesion. Once control is lost, oncogenesis occurs encouraging immunoselection resulting in 
tumour growth and, as the tumour escapes immune control, immunosubversion. Figure 
reproduced from (Zitvogel et al., 2006) with permission of the Nature Publishing Group. 
The role of the immune system is considered so critical to cancer development 
and progression that “evading the immune response” has recently been added as 
one of the new emerging hallmarks to the original six ‘Hallmarks of Cancer’ 
(Hanahan and Weinberg, 2011, 2000): 
• Sustaining proliferative signalling; 
• Evading growth suppression; 
• Activating invasion and metastasis; 
• Enabling replicative immortality; 
• Inducing angiogenesis; 
• Resisting cell death. 
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These hallmarks were designed to provide a framework to help understand the 
complexity of cancer. Each of the original six hallmarks have links to various 
components of the immune system (Zitvogel et al., 2006), thus emphasising the 
critical role of the immune system in cancer development. The other new 
emerging hallmark is ‘deregulating cellular energetics’. 
1.5.4 Immunotherapy in cancer 
Researchers are now trying to harness the immune response in cancer therapy 
(Farkona et al., 2016). Attempts thus far have focussed on modifying the 
adaptive immune response.  
 
Immune checkpoint blockade has become a well-known approach, arguably due 
to the dramatic, but often transient, responses sometimes generated. For 
example, ipilimumab in melanoma (Addeo and Rinaldi, 2013; Hodi et al., 2010). 
Checkpoint inhibition works by blocking inhibitory immune checkpoints, 
preventing immune cell inhibition by malignant cells, and theoretically stimulating 
an increased immune response. Malignant cells are known to express ligands 
which can interact with these inhibitory checkpoint receptors; suppressing the 
immune activity of cells they interact with. However, immunotherapy 
encompasses a multitude of modalities, with checkpoint blockade only beneficial 
in a relatively small subset of patients (Charoentong et al., 2017).  
 
Examples of other approaches include: 
• Monoclonal antibodies: bind specific receptors to induce cell killing, for 
example, trastuzumab in HER2 positive breast cancer (Nahta and Esteva, 
2003); 
• Cytokines: stimulate the host immune response by acting on cellular 
receptors. Two adjuvant cytokine therapies have been approved in the 
USA for metastatic melanoma (IL-2 and IFN-a) and renal cell carcinoma 
(IL-2) (Lee and Margolin, 2011; Sharma et al., 2011); 
• Cancer vaccines: induce an immune response against specific tumour 
antigens and have shown promise in some malignancies, including 
prostate cancer (Yaddanapudi et al., 2013); 
• Chimeric Antigen Receptor T-cell therapy: reprogrammes the patients’ 
own T-cells to recognise and eliminate tumour cells based on the 
identification of specific tumour antigens (Perica et al., 2015; Yu et al., 
2017).  
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Whilst immunotherapies have shown some promise in solid tumours, progress 
has been hampered by the development of drug resistance (Sharma et al., 
2017). 
 
Within the brain the situation is more challenging. Historically, the brain has been 
considered an ‘immune privileged site’ because of the widely held belief that the 
systemic immune system was prevented from reaching the parenchyma by the 
blood brain barrier. However, there is emerging evidence that activated T-cells 
are able to pass through (Ransohoff et al., 2003). A better understanding of how 
therapeutic interventions might reach the tumour parenchyma is warranted. 
 
In addition to the role of the blood brain barrier, the brain is regulated by its own 
immune system. Microglia are the resident macrophages whilst astrocytes are 
able to release pro- and anti-inflammatory mediators which may supress T-cell 
functioning (Gimsa et al., 2013; Perry and Teeling, 2013). Given this distinct 
immune environment, cancer therapies that may be effective elsewhere in the 
body need independent consideration within the brain.   
 
Treatment regimens often include steroids and there is a risk that this could 
dampen down any induced immune response. Conversely there is also concern 
that inflammation induced by the immune response may cause significant 
neurological deficits. Additionally, in paediatric cohorts, there are few approved 
agents (Sayour and Mitchell, 2017). 
1.6  The role and methods of next generation sequencing 
RNA sequencing (RNA-seq) can potentially allow a more detailed analysis of gene 
expression profiles than array based techniques. It is a type of Next Generation 
Sequencing (NGS); a term used to describe modern, high-throughput, 
sequencing technologies.  
 
It has been argued that the field of paediatric brain tumours has shown the 
greatest advance of any scientific field during the ‘Next Generation Sequencing 
era’ (Northcott et al., 2015). 
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1.6.1 The development of next generation sequencing 
NGS allows deep sequencing of whole genomes and transcriptomes in a short 
space of time but at huge computational cost. It has replaced non-automated 
techniques, leading the cost of sequencing to fall precipitously (Wetterstrand, 
2015) (Figure 1-4).  
 
 
 
 
 
 
A method for sequencing DNA was first described by Frederick Sanger in 1975. 
This ‘Plus and Minus method’ was based on the principle of exposing known 
nucleotides, in the presence of DNA polymerase, to an expanding DNA fragment 
to determine which base was the next in the sequence. Fragments of different 
lengths were then separated on acrylamide gels and the position of each base in 
the fragment was inferred (Sanger and Coulson, 1975).  
 
Subsequently the chain-termination method was proposed (Sanger et al., 1977). 
DNA fragments were assembled onto a complementary strand of DNA. The 
reaction occurred in the presence of DNA polymerase I, dTTP and ddTTP plus the 
other three nucleotides. The ddTTP contained no 3’ hydroxyl group meaning that 
once the initial nucleotide was incorporated into the extending DNA strand, no 
further additions could take place (chain-termination). The reaction took place 
Figure 1-4: Data from the National Human Genome Research Institute 
demonstrating the rapid fall in whole genome sequencing costs in dollars 
since the beginning of the millennium. Moore's law refers to the rapid 
improvement in technology and cost. Reproduced with permission. 
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concurrently in three other tubes to allow ddATP, ddCTP and ddGTP to act as 
terminating nucleotides. The resulting fragments then underwent electrophoresis, 
allowing quantification by autoradiography (Sanger et al., 1977). Modifications of 
this method included the use of ‘Shotgun’ sequencing, in which the DNA is 
fragmented and then amplified in bacterial vectors before sequencing and re-
assembly (Franca et al., 2002; Venter et al., 1996). This approach has high 
redundancy (the same DNA is sequenced multiple times) with a huge data yield 
requiring complex computational approaches and was used by Celera in the initial 
sequencing of the human genome (Franca et al., 2002; Venter et al., 2001).  
 
The study of biology, medicine and the life sciences has increased demand for 
rapid, reliable and cheap techniques for generating the sequence of a genome, 
transcriptome or epigenome. Developments such as the use of tiny capillaries 
rather than polyacrylamide gels for separation of the DNA fragments have 
allowed the rapid miniaturisation of this technology (Ansorge, 2009). In 1991 an 
application was made to patent ‘Sequencing by Synthesis’, an approach in which 
fluorescently labelled base terminators were annealed to the end of a developing 
DNA strand (Ansorge, 1991). Once the base annealed it would be detected by a 
camera before sequencing continued. Rather than being run on gels this would 
occur on miniature beads (Margulies et al., 2005). This development allowed 
parallel sequencing of many millions of DNA strands, vastly increasing 
throughput. Commercial organisations, such as Illumina (formerly Solexa), have 
developed this technique for extensive use. This approach can be applied to RNA 
as readily as to DNA, by converting RNA strands into a complementary DNA 
(cDNA) template prior to sequencing (Ansorge, 2009). This process is known as 
RNA sequencing. 
1.6.2 The method of sequencing by synthesis 
Sequencing by synthesis has been claimed to account for 90% of the world’s 
sequencing data (Data calculation on file. Illumina, Inc 2015). A basic outline of 
the process divides it into four steps and is summarised here from information 
provided in Illumina documentation (Illumina, 2015): 
(1) Library preparation (Figure 1-5A): 
DNA (for genome or exome sequencing) or cDNA (for RNA sequencing) is 
fragmented to create very short sequences called fragments. 
Oligonucleotide sequences called adapters are attached to the 3’ and 5’ 
ends of each fragment to create a sequencing library; 
(2) Cluster amplification (Figure 1-5B): 
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The adapters are complementary to a lawn of oligonucleotides present on 
the surface of a glass slide (a flow cell). The sequencing library is applied 
to the flow cell and the adapter sequences attach the cDNA fragments to 
its surface. Once the fragments are attached they undergo polymerase 
chain reaction amplification to create tens of thousands of clusters. The 
co-ordinates of each cluster on the flow cell is known in order to perform 
downstream quality control assessments; 
(3) Sequencing (Figure 1-5C): 
Fluorescently labelled nucleotides are added to the sequencer and bind to 
the complementary base in the fragment, starting at the first base. Once 
this base has attached, a fluorescent image is taken of the flow cell and 
the colour determines the identity of the base. The action of identifying a 
nucleotide is termed a base call. The reaction repeats with the next base n 
times. n is set by the user, called the read length, and often ranges from 
20-100 bases. This generates a sequence of base calls termed a read. 
Reads can be single end or paired-end. For single end reads, one read is 
generated from one end of the fragment, for paired-end reads two reads 
are generated, one from each end of the fragment. Millions of individual 
reads are generated for each sample under investigation; 
(4) Alignment and data analysis (Figure 1-5D): 
Once reads have been generated, they are combined into a fastq file 
which contains information on the base sequence and quality of each read. 
Fastq files can then be manipulated bioinformatically, firstly, by being 
subjected to quality control procedures and then by aligning to the 
genome and transcriptome. Alignment is the process by which the base 
sequence in each read is matched to the complementary sequence or 
sequences in the genome. This then allows for the determination of 
expressed genes or genetic mutations depending. Details on the nature of 
file formats used in sequencing analysis are included in Appendix 2. 
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Figure 1-5: The four basic steps of Illumina sequencing by synthesis. Reproduced from 
(Illumina, 2015). (A) The sequencing library is generated by fragmenting DNA or cDNA 
before the addition of adapter sequences to the end of each fragment. (B) The fragments 
in the library are added to the sequencer by attaching the adapter sequence to 
complementary oligos distributed across a flow cell. Each fragment is then amplified to 
generate tens of thousands of clusters of fragments. (C) Complementary bases bind to the 
fragment and as they are fluorescently labelled the identity of the added base can be 
confirmed by imaging. After each base is confirmed the next base is incorporated and this 
is repeated for the length of the read (usually 25-100 bases). (D) The data from the reads 
is incorporated into a fastq file for downstream analysis, including alignment of reads to 
the genome. 
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1.6.3 Structure of a cDNA fragment after library preparation 
Fragment length refers to the length of the cDNA strand being sequenced and is 
composed of:  
• the adapter sequences at either end of the fragment; 
• the paired-end reads; 
• the nucleotide bases between the reads.  
Insert length refers to the distance between the two adapter sequences.  
Inner mate distance refers to the distance between the paired-end reads.  
The length of the sequencing adapters and the length of the read are constant, 
therefore the insert length and inner mate distance are directly affected by the 
overall length of the fragment (Figure 1-6). A negative inner mate distance 
indicates that reads overlap. The value of the inner mate distance is required by 
genome alignment software. Inner mate distance may be calculated by 
measuring average fragment length on a Bioanalyser or by estimation directly 
from BAM files. 
 
Figure 1-6: A graphical representation of the meanings of fragment length, insert length 
and inner mate distance. Each circle represents one sequenced base. Red circles represent 
the adapter attaching the fragment to the sequencing tile. Green circles represent bases 
actually ‘read’ by the sequencer. Blue circles represent the bases between the paired-end 
sequencing reads. The combination of red, green and blue circles represents the entire 
cDNA fragment. 
1.6.4 Transcriptome arrays versus RNA-seq 
Array based technologies are used to profile the transcriptomes of various cells 
and tissues. They can yield a wealth of information but are limited to predefined 
sequences, requiring a priori knowledge of the genome (Schuster, 2008; Wang et 
al., 2009). There is also risk of cross-hybridisation of the probe, resulting in high 
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levels of background noise (Ansorge, 2009; Wang et al., 2009). Arrays are unable 
to achieve transcriptome comprehensiveness; that is complete coverage of all 
genes and detection of all RNAs (Mortazavi et al., 2008; Wang et al., 2014, 
2009).  
 
In contrast, RNA-seq is able to identify novel transcripts; genes expressed at very 
high and low levels; small insertions and deletions (Indels); single nucleotide 
polymorphisms (SNPs); and splice variants (Fang and Cui, 2011; Kratz and 
Carninci, 2014; Wang et al., 2014, 2009). RNA-seq can produce higher resolution 
outputs, to the level of individual nucleotides, and requires relatively little input 
RNA (Wang et al., 2009). Drawbacks to RNA-seq include its relative expense and 
potential for bias and background noise complicating analysis. It is important to 
design a rigorous experiment, paying attention to sequencing depth and number 
of replicates (Fang and Cui, 2011; Kratz and Carninci, 2014). 
 
Errors in RNA sequencing can occur at multiple stages, particularly in library 
preparation, sequencing and data analysis. When billions of bases are examined, 
even small inaccuracies can result in significant numbers of incorrect calls, with 
potential for incorrect genome assembly. The Illumina sequencing platform 
incorporates information about the reliability of base calls into its fastq output 
files as the Phred score (Ewing and Green, 1998; Ewing et al., 1998). Phred 
scores indicate the probability of errors in the sequencing process and are 
represented using a logarithmic scale (Table 1-12). The Phred score (q) 
generated by Illumina RNA sequencing protocols ranges between 0 (0% accurate) 
and 40 (99.99% accurate), and is calculated using the formula: 
 
q = -10 x log10(p) 
 
Where p is the probability of the base call being correct (Ewing and Green, 1998). 
 
Phred scores often deteriorate as a run progresses, therefore adequate data 
quality control before trimming of poor quality bases is important. 
Phred Score Probability call is wrong Accuracy of call 
10 1/10 90% 
20 1/100 99% 
30 1/1000 99.9% 
40 1/10000 99.99% 
50 1/100000 99.999% 
Table 1-12: Illustration of how accuracy of base call changes with Phred score. Modified 
from http://www.phrap.com/phred/ 
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1.6.5 RNA sequencing of degraded Samples, including FFPE 
There is increasing use of RNA-seq for degraded samples. Of particular interest 
are those samples that have been fixed in formalin and embedded in paraffin 
(FFPE) shortly after collection. Formalin fixation has been taking place since the 
late 19th century (Fox et al., 1985), resulting in over one billion FFPE archival 
specimens worldwide (Blow, 2007). The ability to use these in retrospective 
biological studies would therefore be of huge potential benefit. 
 
There are several reasons for the degradation of RNA quality in FFPE tissue: 
• Formalin forms reversible cross-links between protein (histones) and 
nucleic acids (Chalkley and Hunter, 1975) and is associated with the 
addition of mono-methylol groups to nucleotides (Masuda et al., 1999). 
Both processes can inhibit the polymerase chain reaction during 
sequencing (Williams et al., 1999); 
• Prolonged time between ligation of blood supply and fixation, allows 
degradation to occur and this process is likely to vary from sample to 
sample (Blow, 2007); 
• Exposure to light and variable temperatures after tissue fixation (von 
Ahlfen et al., 2007); 
• The size of the specimen: formalin penetrates thicker tissue sections 
more slowly, leaving tissue at the centre unfixed for variable periods (von 
Ahlfen et al., 2007).  
 
Messenger RNA (mRNA) constitutes 4% of the total RNA, with the majority of the 
remainder being ribosomal RNA (rRNA). mRNA contains transcripts of expressed 
genes and is therefore the main molecule of interest for RNA-seq. If libraries 
made from total RNA are used there will be extensive sequencing of rRNA at the 
expense of mRNA. Therefore, in order to measure gene expression via RNA 
sequencing there must be a process of mRNA enrichment.  
 
One technique is to capture mRNA via the polyadenylated 3’ end of the molecule, 
however this region is lost in degraded material. An alternative approach in such 
a situation is to remove the rRNA via the use of magnetic beads (ribodepletion) 
prior to cDNA synthesis.  
 
The extent of RNA degradation is indicated by measurement of the RNA Integrity 
(RIN) score on a Bioanalyzer (Schroeder et al., 2006) and can help to determine 
the best approach to mRNA enrichment (Figure 1-7).  
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One way of overcoming some of the difficulties related to degradation is to 
increase the depth of sequencing (the overall number of reads) (Robasky et al., 
2014). Greater depth also allows better assessment of infrequently expressed 
transcripts in RNA-seq experiments (Marioni et al., 2008). However, one must be 
cautious; increased depth can lead to increased false positive base calls and 
analysis of the results must take this into account (Tarazona et al., 2011). In 
addition to this a number of studies have found that beyond a certain number of 
reads, increasing depth adds very little power to expression analysis and 
increasing the number of biological replicates becomes more important (Ching et 
al., 2014; Yuwen Liu et al., 2014). 
 
Using kits designed specifically for extracting nucleic acids from degraded 
material, studies are beginning to show success in RNA-seq of FFPE tissue. These 
kits digest surrounding materials with proteinase K and attempt to reverse the 
additions of mono-methylol groups with heat treatment (Masuda et al., 1999). A 
few studies sequencing matched FFPE and frozen specimens to compare obtained 
transcriptomic profiles have now been reported (Graw et al., 2015; Hedegaard et 
al., 2014; Li et al., 2014; Yu Liu et al., 2014; Mittempergher et al., 2011; Morlan 
et al., 2012). These studies found high correlation coefficients for expressed 
genes, ranging from 0.7 to greater than 0.9. Most excitingly, the RNA from FFPE 
tissue from a victim of the 1918 flu pandemic was sequenced and compared with 
that of a 2009 flu victim. The 1918 and 2009 samples both demonstrated 
expression of genes related to cellular defence and immune and inflammatory 
responses. The sequencing of this sample of nearly 100 years of age showed that 
RNA-seq is applicable to FFPE specimens. However, caution is required in 
experimental design to maximise the utility of the results (Xiao et al., 2013).  
 
Figure 1-7: Bioanalyser traces for low quality, degraded RNA with a RIN score of 2.60 
(left) and high quality RNA with a RIN of 9.70 (right). The high quality RNA exhibits 
distinct peaks at 40-45s and 50s which represent intact ribosomal RNA. These peaks 
are not present in the low quality sample indicating that the rRNA is heavily degraded. 
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Whilst data from initial studies using FFPE derived RNA is promising, literature 
searches suggest that there have been no large profiling studies undertaken 
using FFPE brain material for RNA sequencing. This is important because the 
composition of RNA in the brain may differ from other tissues, with increased 
levels of nascent (partially processed) RNA which may make the sequencing 
process more challenging (Ameur et al., 2011). 
1.7 Aims 
Using a large clinical cohort, this study aimed to undertake molecular profiling of 
recurrent ependymoma, combined with contemporary clinical data, to better 
understand recurrence biology and potential therapies. In particular, improved 
knowledge of how tumours change from primary to recurrence in the same 
patient was sought. It was hoped that any new understanding of ependymoma 
recurrence may provide new insights into future therapies or management 
strategies.  
 
In planning to achieve the above goals a number of specific aims were developed 
which included: 
(1) Collating and analysing a cohort of recurrent paediatric ependymoma 
cases to determine: 
a. Patterns of relapse in the entire cohort and location determined 
subgroups; 
b. Factors impacting upon time to first relapse and OS in a relapsed 
cohort; 
c. Factors influencing progression and OS after first relapse; 
d. Factors affecting risk of relapse; 
(2) Supporting the results of the clinical analysis by generating DNA 
methylation profiles for samples with tissue availability; 
(3) Undertaking RNA sequencing of a cohort of FFPE tumour specimens in 
order to expand the cohort for primary and recurrence analysis.  
(4) Validation of the use of FFPE RNA-Seq against a cohort of fresh frozen 
specimens in order to make recommendations for future research; 
(5) Performing gene expression analysis of matched primary and 
recurrent pairs to determine changes in expression patterns at relapse 
and correlate with molecular classifications where DNA methylation 
data is available; 
(6) Establishing, in an independent cohort, whether the immune response 
is implicated in ependymoma recurrence; 
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(7) Validating key expression changes using immunohistochemical 
approaches. 
1.8 Thesis structure and navigation 
In order to achieve the aims the project was divided into: 
Chapters 3 and 4: A clinical analysis of a cohort of 188 children with recurrent 
ependymoma, supported by DNA methylation profiling; 
Chapter 5: Validation of FFPE RNA-Seq on a cohort of 106 FFPE paediatric 
ependymoma specimens; 
Chapter 6: Gene expression RNA-seq analysis of matched primary and recurrent 
ependymomas from 29 fresh frozen cases and 27 FFPE cases; 
Chapter 7: Follow up of gene expression findings and investigation of the level of 
immune cell markers in recurrent ependymoma. 
 
Methods relevant to the entire project are included in Chapter 2. Methods specific 
to individual chapters are included in the methods section of that chapter. 
Chapter locations of the different methods are indicated in Table 1-13.   
 
Chapter Methods 
2 Pathology assessment 
Nucleic acid extraction 
Haematoxylin and Eosin staining 
Basic data analysis protocols 
3 Survival analysis 
4 Generation of DNA methylation profiles 
Ependymoma subgroup classification 
5 RNA sequencing bioinformatic pipeline 
Differential expression analysis 
Hierarchical clustering 
Gene ontology analysis 
6 Quantitative PCR 
Generation of immunophenotypes 
7 Immunohistochemistry 
Table 1-13: Summary and location of the methods used in the research.
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2 Materials and Methods 
2.1  Sample identification 
A cohort of primary and recurrent ependymomas was generated by interrogating 
the Children’s Brain Tumour Research Centre’s (CBTRC) master database. Tissue 
for only 20 -30 primary and recurrent pairs were available through this route. 
Additional requests were sent via the Children’s Cancer and Leukaemia Group 
(CCLG) Biobank to centres across the UK. Collaborations were developed with a 
centre in Denver, Colorado Great Ormond Street Children’s Hospital (GOSH), UK. 
The final study cohort contained 95 primary and recurrent tumour pairs with a 
total of 243 individual tumour samples (Appendix 1). Specimens were a mixture 
of fresh frozen (FF) and FFPE material.  
 
Clinical data was available for a cohort of 208 patients who suffered at least one 
recurrence. Data included age, gender, number of recurrences, timing of 
recurrences, treatment protocols, trial inclusion, tumour location, extent of 
resection and dates of surgery. When unavailable, data was requested from 
primary treating centres via the Children’s Cancer and Leukaemia group. 
Individual centres were also asked to identify cases that were not accessible 
through the CBTRC archives in order to increase the size of the cohort. 
2.2 Ethics and consent 
Ethical approval came from the local research ethics committee. The study was 
also approved by the CCLG to allow specimens to be obtained from their biobank. 
Consent had been obtained from all patients or their families where relevant. 
Where consent was not in place but the samples formed part of existing holdings 
(obtained before 1st September 2006), data and tissue samples were handled in 
accordance with the guidelines of the Human Tissue Act. Data was handled with 
due respect to patient anonymity and held on a secure database within the 
university. 
2.3 Definition of tumour recurrence 
Recurrence was defined as the return of a tumour that had been completely 
resected (GTR) or, for those children who had received a subtotal resection 
(STR), a clinical or radiological progression of tumour requiring further 
therapeutic intervention or palliation. Where available, a pathology specimen was 
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analysed to confirm that the recurrent tumour represented ependymoma rather 
than another tumour. 
2.4 Preparing frozen samples for nucleic acid extraction 
Samples were identified and removed from the minus 80ºC freezer and placed 
onto dry ice in a category two hood. Tissue samples were taken from their tubes 
one at a time and replaced before the next sample was removed. Each sample 
was placed on an open petri dish on a shallow bed of dry ice to reduce the risk of 
nucleic acid degradation. Using a sterile blade (Swann-Morton, UK) and forceps 
(John Weiss International, UK), approximately 10 mg of tissue was removed and 
placed into a 1.5 ml vial (Eppendorf, UK). A small amount of tissue was also fixed 
onto an uncoated glass slide in preparation for pathology assessment by placing it 
into a Coplin jar of Carnoy solution before staining.  
2.5 Haematoxylin and Eosin staining 
Haematoxylin and Eosin (H&E) staining was performed for pathology review. The 
protocols for FFPE sections and frozen smears are outlined below. 
 
FFPE Sections 
5 µm wax sections were rehydrated through xylene for 10 minutes, 100% ethanol 
for 10 minutes and 95% ethanol for 10 minutes before being washed in tap 
water. The sections were then placed into Gills-3 haematoxylin for five minutes 
before a further wash with tap water. Next, slides were placed into 1% lithium 
carbonate, 1% acid alcohol and 1% lithium carbonate again for a few seconds 
each, with tap water washes between each step. The final stain was performed 
with 1% eosin for five minutes before a wash with tap water. Sections were 
dehydrated, for ten seconds each, through 95% ethanol, 100% ethanol and 
xylene. Slides were mounted using DPX (distyrene, plasticiser, xylene) mountant 
(Sigma-Aldrich, UK) and left to dry overnight on a heated rack. 
 
Frozen Smears 
Slides were removed from Carnoy solution and agitated in haematoxylin for 10 
seconds and then placed under running tap water until it cleared. Following this 
they were agitated in 1% lithium carbonate for 10 seconds and then in 1% eosin 
for 20 seconds, with tap water washes in between. Following staining the slides 
were dehydrated in 95% ethanol, 100% ethanol and xylene for 10 seconds each, 
mounted in DPX and left to dry. 
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2.6 Pathology review 
Cases were reviewed within their originating centres for diagnosis of 
ependymoma. Those patients who had been included on a clinical trial had 
undergone central pathology review to confirm diagnosis.  
 
Additionally, H&E stained sections were reviewed by a neuropathologist (Dr 
Simon Paine) at the CBTRC who confirmed that the sample was consistent with 
ependymoma and was predominantly tumour. Samples were excluded for lacking 
sufficient viable tumour or for not being consistent with a diagnosis of 
ependymoma. 
 
The samples extracted from frozen RNA contributed by collaborators in Denver 
underwent tissue assessment and nucleic acid extraction in the USA before being 
shipped to the UK. 
2.7  Nucleic acid extraction 
To minimise the risk of contamination, gloves were worn at all times and RNA 
specific pipettes and tips were maintained. The workbench was cleaned prior to 
commencement of the protocol. RNAse- and DNAse-free tubes (Eppendorf, UK) 
were purchased to minimise the risk of contamination post extraction. 
2.7.1 RNA extraction from frozen tissue 
The mirVanaTM miRNA isolation kit (ThermoFisher Scientific, UK, AM1560) was 
used to extract RNA from frozen tissue. Sections were placed into lysis buffer 
equivalent to 10 times the volume of the tissue in a flat-bottomed vial and 
homogenised (Stuart, UK). 1/10th the volume of miRNA homogenate additive was 
added to the tissue lysate and mixed by vortexing, before being left on ice for 10 
minutes. The equivalent of one volume of tissue mass of acid-phenol:chloroform 
mixture was then added to the vial and mixed by vortexing for 30 seconds. The 
vial was subsequently centrifuged at 10000 x g for five minutes. The resultant 
aqueous (upper) phase was transferred to a new vial without disturbing the lower 
phase which was discarded. 1.25 volumes of room temperature absolute ethanol 
were added. A filter column was inserted into a pre-supplied collection tube and 
700 µl lysate/ethanol mixture was pipetted onto it and centrifuged at 10000 x g 
for 15 seconds. The flow through was discarded. Up to a further 700 µl 
lysate/ethanol mixture was added again to the filter until depleted. The filter 
column was kept in the same collection tube for wash steps which involved: 
• 700 µl miRNA wash solution 1 followed by 10 second centrifuge; 
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• 500 µl wash solution 2/3 followed by 10 second centrifuge, repeated once. 
Following the wash steps the flow through was discarded and the filter column 
centrifuged for one minute to remove residual fluid. The filter column was 
transferred into a fresh collection tube before the addition of 100 µl of preheated 
(95ºC) nuclease free water. This was spun for 30 seconds to elute the final RNA. 
Eluted RNA was stored at -80ºC.  
2.7.2 RNA extraction from cell lines for qPCR 
Cell pellets were harvested from a 70% confluent T75 flask (Eppendorf, UK) and 
snap frozen. RNA was extracted from cell lines using RNA STAT-60TM Extraction 
Reagent (Amsbio, UK). 500 µl RNA STAT-60TM was added to each cell pellet. 100 
µl chloroform was added in a fume hood before covering and vortexing for 15 
seconds. Samples were then incubated at room temperature for two minutes 
before being centrifuged at 12000 x g for 15 minutes. The aqueous phase was 
transferred to a new plastic vial and incubated at room temperature for 10 
minutes after the addition of 250 µl isopropanol. The sample was centrifuged 
again at 12000 x g for 15 minutes. The supernatant was discarded and the pellet 
was washed with 200 µl 75% ethanol before vortexing. The solution was 
centrifuged at 7500 x g for five minutes, before removal of the supernatant and 
air drying of the pellet at room temperature for 10 minutes. Finally, the pellet 
was dissolved in 25 µl RNAse-free water and vortexed before a further incubation 
at 55ºC for 10 minutes on a hot block (Eppendorf, UK). RNA was stored at -80ºC. 
2.7.3  DNA extraction from frozen tissue 
The QIamp DNA Mini Kit (Qiagen, Germany) was used to extract DNA from frozen 
specimens. 10 mg of tissue was disrupted with a homogeniser in 80 µl phosphate 
buffered saline (PBS). Following this, 100 µl buffer ATL and 20 µl proteinase K 
was added. The solution was incubated at 56ºC for three hours with occasional 
vortexing until the tissue had lysed. Subsequently, 200 µl buffer AL was added 
before a 10 minute incubation at 70ºC on a hot block. 200 µl absolute ethanol 
was added and vortexed before applying the mixture to a QIAmp Mini Spin 
Column placed in a 2ml collection tube. The tube was centrifuged at 6000 x g for 
one minute and the filtrate discarded. The following washes were then 
performed: 
• 500 µl buffer AW1 followed by centrifugation at 6000 x g for one minute; 
• 500 µl buffer AW2 followed by centrifugation at 6000 x g for three 
minutes. 
The column was then placed into a new tube and centrifuged at full speed for one 
minute to dry the membrane. The column was then transferred to a new 
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collection tube before being incubated for five minutes with 100 µl buffer AE 
(elution buffer) and spun at 6000 x g for one minute. The elution step was 
repeated twice to maximise DNA yield. DNA was stored at -20ºC.  
2.7.4  RNA and DNA extraction from FFPE tissue 
RNA and DNA from FFPE samples were extracted with the AllPrep DNA/RNA FFPE 
Kit (Qiagen, Germany). Starting material was either eight 10 µm scrolls (where 
collaborating centres were unable to provide original blocks) or ten 5 µm cores 
taken from tumour representative areas. The samples were placed into 1.5 ml 
vials (Eppendorf, UK) until ready for processing. RNA and DNA were extracted 
from the same piece of tissue, preserving tumour material and theoretically 
giving better comparability between RNA and DNA studies. 
 
Extraction was carried out according to the recommended three step protocol:  
(1) Sample preparation: Specimens were deparaffinised by adding 1 ml xylene to 
a vial of crushed cores or scrolls and incubated for 10 minutes on a hot block at 
50ºC. The vial was spun at maximum speed on a centrifuge for three to five 
minutes until a pellet had formed. The xylene was removed using a pipette and 1 
ml absolute ethanol was added before further centrifugation to reform a pellet. 
The ethanol step was repeated once. After deparaffinisation, 150 µl buffer PKD 
and 10 µl proteinase K were added to the tube. This mixture was incubated for 15 
minutes at 56ºC and then placed on ice for three minutes. Following a further 15 
minute centrifugation at 20000 x g, the supernatant was transferred to a 2 ml 
vial whilst the pellet was kept for DNA extraction; 
 
(2) RNA extraction: The supernatant from step one was incubated for 15 minutes 
at 80ºC before the addition of 320 µl buffer RLT and 1120 µl absolute ethanol. 
700 µl of this sample was pipetted into an RNeasy MinElute spin column placed in 
a 2 ml collection tube (supplied with the kit). The spin column was centrifuged for 
15 seconds and the step repeated until all of the lysate had been used. Next, 350 
µl buffer FRN was added to the column and centrifuged for 15 seconds. 80 µl 
DNase stock solution, mixed in a 1:7 ratio with buffer RDD, was added to the spin 
column and incubated at room temperature. After 15 minutes 500 µl buffer FRN 
was added to the spin column and centrifuged for 15 seconds. The flow through 
was transferred back into the spin column which was placed in a new collection 
tube. 500 µl buffer RPE was added to the column and centrifuged. This step was 
repeated once before placing the column in a new collection tube and centrifuging 
at full speed for five minutes with an open lid to dry the membrane. Finally, the 
 49 
spin column was placed in a new collection tube and RNA was eluted in 30 µl 
RNase-free water by centrifuging for one minute following a one minute 
incubation. The eluted RNA was stored at -80ºC; 
 
(3) DNA extraction: The pellet resulting from step one was resuspended in 180 µl 
buffer ATL before the addition of 40 µl proteinase K. After vortexing, the sample 
was incubated for one hour at 56ºC and then for 2 hours at 90ºC. After a short 
centrifugation, 200 µl buffer AL was added with 200 µl absolute ethanol. This 
mixture was added to a QIAmp MinElute spin column and centrifuged for one 
minute. The spin column was placed in a new collection tube before addition of: 
(a) 700 µl buffer AW1 with 15 second centrifuge; 
(b) 700 µl buffer AW2 with 15 second centrifuge; 
(c) 700 µl absolute ethanol with 15 second centrifuge. 
On each occasion, the flow through was discarded. The column was then spun for 
five minutes to dry the membrane before being placed in a new collection tube 
for DNA elution. 100 µl of buffer ATE was added to the membrane before a one 
minute incubation and one minute centrifugation to elute the DNA. The eluted 
DNA was stored at -20ºC.  
2.8  Nucleic acid quality control 
Following extraction, RNA and DNA purity and quantity was measured by adding 
1 µl of nucleic acid to the Nanodrop spectrophotometer (ThermoFisher Scientific, 
UK). Nucleic acids with 260/280 and 260/230 ratios close to two were considered 
to be of high purity. 
2.9  RNA sequencing 
RNA sequencing was performed by Exiqon (Denmark). RNA library preparation 
was carried out using a ribodepletion technique with Ribo-Zero (Illumina, USA), 
and libraries were sequenced on an Illumina HiSeq machine with 100 base pair, 
paired-end sequencing, targeting 50 million reads per sample. The input amount 
of RNA for the FF and FFPE samples was 100 ng and 600 ng respectively. 
Sequencing of the FF and FFPE samples was conducted as separate projects, as 
including RNA of substantially different qualities on the same sequencing run can 
interfere with the final results (Personal communication, L Klitten). Each RNA-seq 
sample generated two fastq files (Appendix 2) containing the raw reads, one file 
with forward reads and one file with reverse reads, representing the paired-end 
sequencing. Full details of the analysis are included in the methods section of 
Chapter 5. 
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2.10  DNA methylation profiling 
DNA methylation profiling was performed by UCL Genomics (UK). DNA was 
hybridised to 450k Illumina methylation arrays following bisulphite conversion. 
Full details are included in the methods section of Chapter 4. 
2.11  Cluster computing and data storage 
To conduct the more computationally intense parts of the analysis, access was 
gained to the High Performance Computing Cluster (HPC) at the University of 
Nottingham. The cluster was accessed remotely using a login node, but 
operations were conducted on one (or more) of the compute nodes and 
submitted as Shell scripts using the ‘qsub’ command. This approach allowed the 
bioinformatic pipelines to be run in parallel for different samples on shorter 
timescales, meaning that each run took several weeks rather than months or 
longer. 
 
Data was stored securely across a research drive and cloud based facility ‘UoN 
BOX’. Files were also backed up onto encrypted hard drives to protect against 
data loss. 
2.12  Data analysis 
Statistical analyses were performed using R (R Core Team, 2014) running in 
RStudio (version 0.99.489). The code for the underlying analyses is reproduced in 
Appendix 3. For all statistical tests a p-value of <0.05 was considered significant.
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3 A Clinical Analysis of 188 Recurrent 
Ependymomas 
3.1 Introduction 
Epidemiological and clinical studies of paediatric ependymoma have tended to be 
small (less than 100 patients) (Antony et al., 2014; Zacharoulis et al., 2010) or 
confined to few centres (Antony et al., 2014) or geographical locations (Messahel 
et al., 2009). A number of studies investigated specific treatment options at 
recurrence but did not analyse the whole spectrum of relapsed disease (Lobón et 
al., 2016; Hoffman et al., 2014a; Tsang et al., 2017). Other studies are old and 
assessment of their relevance to current practice, particularly in view of the 
development of molecular classification and survival improvements, is required 
(Goldwein et al., 1990). Consequently, the heterogeneity of the available 
literature can make general application of the results to recurrent paediatric 
ependymoma difficult.  
 
50% of paediatric ependymomas relapse and subsequent survival is poor 
(Messahel et al., 2009; Zacharoulis et al., 2010). It is surprising that there are no 
recent, large reviews focussing on the features of relapse across multiple centres 
and geographic locations. This may be in part due to the relative rarity of the 
disease; a problem that has been highlighted with a plea for more transnational 
co-operation (Bouffet et al., 1998). 
 
In identifying clinical cases for inclusion in biological studies of matched primary 
and recurrent ependymoma, a retrospective analysis of clinical data was 
undertaken. This aimed to assess the features of recurrent ependymoma in an 
exclusively paediatric cohort, from multiple centres. During data collection, a 
cohort of patients with non-recurrent ependymoma was established to provide a 
direct comparison. However, the primary aim was a description of the 
epidemiology and outcomes of relapsed disease. 
 
The research questions were: 
• What is the natural history of relapsed paediatric ependymoma? 
• Which, if any, factors confer a higher risk of relapse in paediatric 
ependymoma? 
• What, if any, factors impact upon OS in the relapse cohort? 
• What, if any, factors impact upon time to first relapse? 
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• What is the impact of therapy at relapse? 
3.2 Materials and methods 
3.2.1 Definition of patient outcomes 
Outcomes of interest were overall survival (OS), event free survival (EFS) and 
time to progression (TTP). OS was defined as the duration from diagnosis of 
primary ependymoma to death. EFS was defined as the duration from diagnosis 
of primary ependymoma until progression or death. For OS and EFS, patients 
who had not progressed or died by the end of the follow up period were right 
censored at the date of last follow up. TTP was defined as the duration from 
diagnosis of primary ependymoma to disease recurrence or progression. TTP 
allowed the assessment of patients who recurred, whilst excluding those who 
died; providing a quantitatively different result to EFS. 
3.2.2  Survival analyses 
Univariate analyses 
Survival analysis employs techniques for interrogating data where the outcome of 
interest is the time to occurrence of a pre-specified event. Survival curves and 
Cox Proportional Hazards (CPH) models were used to undertake this analysis 
through the R packages ‘survival’, ‘survminer’ and ‘survMisc’ (Dardis, 2016; 
Kassambara and Kosinski, 2017; Therneau, 2015).  
 
Survival analysis using the ‘survival’ package was based on the creation of a 
survival object, which took the format: 
 
> SurvObject = Surv(Time, Event) 
 
‘Time’ was a vector containing the time for each patient to reach the outcome and 
‘Event’ was a vector of information about whether the patient experienced the 
event of interest or was right censored.  
 
A statistical comparison between two or more curves was created using the 
‘Survdiff’ function, which took the format: 
 
> Survdiff(SurvObject ~ X, rho=Y) 
 
‘X’ represented the factor by which data was stratified for the statistical 
comparison, for example a vector of data containing the gender of the patient or 
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whether they received a certain type of therapy. ‘rho’ specified the statistical test. 
Rho=0 used the log-rank test, which required the assumption of proportional 
hazards to be met. If the curves crossed, the log-rank test was considered 
insufficiently powered; consequently, all curves were visually inspected. When 
curves crossed, the supremum (Renyi) set of tests (Fleming et al., 1987) were 
implemented using the survMisc package. 
 
In the absence of censoring, the Wilcoxon rank-sum test was used to compare 
the medians of the two groups. 
 
Multivariate analyses 
CPH models were used for multivariate analyses by incorporating factors that 
were statistically significant in univariate analyses.  
 
CPH models were generated in ‘survival’ using the generic code: 
 
> coxph = coxph(Surv(Time, Event) ~ Z) 
 
Where ‘Z’ represented a vector comprised of all of the variables under 
investigation used to stratify the cohort. 
 
The assumptions of the CPH model are firstly, that censoring is non-informative 
and secondly, that hazards are proportional over time. The proportionality of 
hazards was evaluated with a Schoenfeld test using the following code in the 
‘survival’ package: 
 
> cox.zph(coxph, transform=”rank”, global=TRUE) 
 
A result suggestive of non-proportional hazards had a global p-value below 0.05. 
3.2.3  The non-recurrent cohort 
The data for the non-recurrent cohort was collected by a colleague, Dr Hazel 
Rogers. Patients were included who had a primary diagnosis of ependymoma but 
had not recurred. Competing risks regression (Fine and Gray, 1999) was used to 
test for the association with risk of recurrence using STATA (Statcorp, Texas, 
USA), including death before first recurrence as a competing risk.  
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3.3 Results 
3.3.1 Defining the recurrent and non-recurrent cohorts 
438 cases of primary disease were identified from the CBTRC archives. 88 cases 
were excluded based on having either inadequate clinical data, or a non-WHO 
grade II or III ependymoma. After excluding cases there was a cohort of 350 
children (Figure 3-1A). 
 
 
 
 
Figure 3-1: (A) Patient flow through the study. Recurrent and non-recurrent cohorts 
included patients with grade II or III ependymoma, diagnosed after 1989, with sufficient 
clinical data for analysis. (B) Children diagnosed after 1989 had significantly improved OS 
compared with those diagnosed earlier. Children diagnosed in the 1960s had the worst 
outcomes. 
A 
B 
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Children diagnosed before the 1990s had worse outcomes than those diagnosed 
later (p<0.001). In particular, a high proportion died prior to recurrence (Figure 
3-1B). There was no difference in OS for those diagnosed between 1990 and 
2000 compared with after the year 2000 (p=0.415). The cohort was therefore 
restricted to diagnoses from 1990 onwards, giving a total of 307 children, 
including 188 recurrences. 
3.3.2 Baseline characteristics of the recurrent cohort 
The recurrent cohort included 188 patients who recurred at least once between 
1990 and 2015. 65 patients were treated on the International Society of 
Paediatric Oncology (SIOP) 1992 ‘Baby Brain’ protocol (Grundy et al., 2007) and 
47 on the SIOP 1999 protocol (unpublished). The remaining 76 were treated 
outside the confines of a clinical trial. 157 patients were treated in the UK across 
16 centres, 16 in the USA, 9 in Holland, 5 in Dublin, 2 in Denmark and 2 in Spain. 
 
114 (60%) patients had died and 70 (37%) were alive at last follow up. Median 
OS for the group was 61 months (95% confidence interval 48-71 months). 5 and 
10-year OS was 50% and 33% respectively (Figure 3-4A). Median follow up 
duration was 50 months for all patients (range 1-260 months) and 97 months for 
patients still alive at the end of the study (range 13-260 months). 
 
136 (72%) tumours occurred in the posterior fossa, 44 (23%) in the 
supratentorium and 7 (4%) in the spine. Location was unknown for one patient. 
There was a 1.3:1 male:female ratio, with boys accounting for 56% of the cohort 
(n=105) and girls for 41% (n=77) (p=0.050). Gender was unknown in 6 cases 
(3%) (Table 3-1). 
 
Median age of diagnosis of primary ependymoma was 35 months (3 to 199 
months) and exhibited a unimodal distribution (Figure 3-2A). PF, ST and spinal 
tumours presented at median ages of 30, 67 and 136 months respectively. There 
were significant differences for all tumour locations. PF versus ST p=0.014; PF 
versus spinal p<0.001; ST versus spinal p=0.03 (Figure 3-2B). 
 
85 (52%) primary tumours were WHO grade II, 78 (48%) WHO grade III and 25 
had no information about grade. 76 (45%) patients had GTR, whilst 93 (55%) 
had STR. Extent of resection was unavailable for 19 patients. 77 (43%) patients 
received radiotherapy. Radiotherapy data was unavailable in 10 cases. 125 (73%) 
patients received chemotherapy. Chemotherapy data was unavailable for 17 
(Table 3-1). 
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Parameter 
Recurrent Cohort 
(n=188) 
Non-recurrent 
Cohort (n=119) 
Chi-Square 
P Value 
Number % Number % 
Age 
<3 years 94 51 47 40 
0.076 3+ years 91 49 71 60 
NK 3 - 1 - 
Gender 
Male 105 58 65 55 
0.817 Female 77 42 53 45 
NK 6 - 1 - 
Extent of 
Resection 
GTR 76 45 65 59 
0.028 STR 93 55 46 41 
NK 19 - 8 - 
Location 
PF 136 73 75 64 
0.405 
ST 44 23 31 27 
SP 7 4 10 9 
NK 1 - 2 - 
Grade 
WHO II 85 52 58 62 
0.153 WHO III 78 48 36 38 
NK 25 - 25 - 
Radiotherapy 
at diagnosis 
Yes 77 43 32 50 
0.382 No 101 57 32 50 
NK 10 - 55 - 
Chemotherapy 
at diagnosis 
Yes 125 73 67 58 
0.008 No 46 27 49 42 
NK 17 - 3 - 
Table 3-1: Baseline characteristics of the recurrent and non-recurrent cohorts. Patients in 
the recurrent cohort were significantly less likely to have received GTR but significantly 
more likely to have received chemotherapy. NK: Not Known. Percentages calculated as the 
proportion of those with data available. 
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Figure 3-2: (A) Age at presentation for all ependymomas had a unimodal distribution. This 
is consistent with expectations for paediatric ependymomas. n=185. (B) Median age at 
presentation compared between tumour locations. Boxes represent 25th centile, median 
and 75th centiles. *: p<0.05, **: p<0.001. 
3.3.3 Baseline characteristics of the non-recurrent cohort 
Median OS for the non-recurrent cohort was not calculable as only seven (6%) 
patients had died. Median follow up duration for all patients was 82 months (0-
182 months) (Figure 3-4A).  
 
75 (64%) tumours occurred in the posterior fossa, 31 (27%) in the 
supratentorium and 10 (9%) in the spine. Location was unknown for two 
patients. Boys accounted for 55% of the cohort (n=65) and girls for 45% (n=45) 
(p=0.07). Gender was known for all patients (Table 3-1). Median age of diagnosis 
was 50 months (0 to 225 months), which was significantly older than the 
recurrent cohort (p=0.002).  
 
58 (62%) primary tumours were WHO grade II, 36 (38%) WHO grade III and 25 
had no information about grade. 65 (59%) of patients had GTR whilst 46 (41%) 
had STR. Extent of resection was unavailable for eight patients. 32 (50%) 
patients received radiotherapy. Radiotherapy data was unavailable in 55 cases. 
67 patients received chemotherapy (58%). Chemotherapy data was unavailable 
for three children (Table 3-1). 
 
Comparing baseline characteristics between the recurrent and non-recurrent 
cohorts, the recurrent group more likely to have STR (p=0.028) and 
chemotherapy (p=0.008) (Table 3-1). 
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3.3.4  Factors predicting risk of recurrence 
To establish whether any factors were associated with risk of recurrence, a 
competing risks analysis was performed. In a univariate analysis WHO grade III 
ependymomas were associated with increased risk of recurrence when compared 
to grade II ependymomas (p=0.003), whilst older age at first diagnosis was 
associated with a decreased risk (p=0.026). Gender and tumour location were 
not associated with risk of recurrence.  
 
GTR was associated with a lower recurrence risk (p=0.004) as was receipt of 
radiotherapy (p=0.020). Chemotherapy was associated with a significantly 
increased risk (p=0.001).  
 
When all significant factors were included in a multivariate analysis only resection 
status remained significant (Subhazard Ratio = 0.636, p=0.013) (Table 3-2). 
Whilst GTR was associated with a decreased risk of recurrence, it did not 
completely prevent it. Of the 213 patients with GTR in the multivariate analysis, 
115 (54%) experienced at least one recurrence. 
 
 Sub Hazard Ratio 95% CI P Value 
Grade (III v II) 1.78 1.238-2.548 0.058 
Age (continuous) 1 0.995-1.004 0.917 
Resection (GTR Vs STR) 0.636 0.445-0.910 0.013 
Radiotherapy (yes vs no) 0.670 0.409-1.097 0.111 
Chemotherapy (yes vs no) 1.307 0.784-2.179 0.304 
Table 3-2: Multivariate competing risks analysis for risk of recurrence. Death included as a 
competing risk. Only resection remained significantly associated with increased recurrence 
risk. n=213.  
3.3.5 Patterns of recurrence 
There was a median of two recurrences (range 1-8). Following first recurrence, 
96 (51%) had further relapses, 45 (24%) died and 44 (23%) survived with no 
disease progression. Following each subsequent recurrence, the proportion of 
patients who recurred again was around 50%; this figure was fairly constant even 
at fifth, sixth and seventh recurrence (Figure 3-3). 89 (47%) patients had only 
one recurrence, 46 (24%) two, 22 (12%) three, 14 (7%) four, 7 (4%) five, 3 
(2%) six, 1 (0.5%) seven and 1 (0.5%) eight (Figure 3-3). For some children, 
ependymoma became a chronically relapsing disease with 26 (14%) having in 
excess of three recurrences.  
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Data on metastasis was available for 82 patients at first recurrence, of these 20 
(24%) had metastatic disease and 62 had isolated local disease (76%). Of those 
with metastatic disease, 10 had isolated distant disease and 10 had local and 
distant disease. The proportions of patients with metastatic disease were fairly 
constant for relapses two (31%), three (22%) and four (25%). 
 
Patients who received radiotherapy after initial diagnosis had a median of one 
recurrence, compared with two recurrences for those who did not (p=0.04). 
There were no significant differences in number of recurrences for other baseline 
characteristics (Table 3-3). 
 
Parameter Median recurrences P Value 
Age 
<3 years 2 
0.07 
3+ years 1 
Gender 
Male 2 
0.10 
Female 1 
Extent of Resection 
GTR 2 
0.22 
STR 1 
Location 
PF 1 
0.80 
ST 1 
Grade 
WHO II 2 
0.06 
WHO III 1 
Radiotherapy at diagnosis 
Yes 1 
0.04 
No 2 
Table 3-3: Number of recurrences experienced for patients with different baseline 
characteristics. Only radiotherapy was associated with fewer recurrences. N=188. 
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Figure 3-3: Flow diagram illustrating all recurrences for patients with tumours in any 
location. Between 40% and 50% of patients experienced further relapses after each 
relapse. 60% of the cohort were not alive at the end of the follow up period. N=188. Five 
patients were lost to follow up; three after recurrence 1 and two after recurrence 2. One 
patient was known to be alive and had at least one recurrence but with an unknown final 
number of recurrences. This patient was included in the total number of surviving patients. 
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3.3.6 Recurrence and overall survival 
Survival analysis, stratified by recurrence status, demonstrated that recurrence 
was a key factor associated with OS. In the non-recurrent cohort only seven 
(6%) patients died. In the recurrent cohort 114 (60%) died (p<0.001) (Figure 
3-4A). However, OS, from primary diagnosis, did not differ with increasing 
numbers of recurrences (p=0.066) (Figure 3-4B). 
 
Figure 3-4: (A) Patients who experienced recurrence had worse OS than those who did not 
(p<0.001). (B) When stratified by number of recurrences, there were no significant 
differences in OS between those experiencing 1, 2, 3 or 4 episodes (p=0.066). 
 
A 
B 
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3.3.7 Overall survival in the recurrent cohort 
3.3.7.1 At primary diagnosis 
Age, gender, extent of resection, tumour location, grade and therapy were not 
associated with OS (Table 3-4). Following each recurrence, OS shortened (Table 
3-5), falling to 5 months after the fifth recurrence. 
Parameter 
Cases 
tested 
Median 
survival 
(months) 
5-year 
survival 
(%) 
10-year 
survival 
(%) 
Supremum 
P Value 
Age 
<3yr 93 53 46 29 
0.896 
>3yr 91 63 55 37 
Gender 
M 103 53 48 29 
0.548 
F 76 64 55 38 
Extent of 
Resection 
STR 93 47 43 33 
0.157 
GTR 76 67 59 31 
Location 
PF 136 51 46 27 
0.143 ST 40 68 56 44 
SP 7 - 100 67 
Grade 
II 84 68 57 38 
0.181 
III 76 48 44 23 
Radiotherapy 
at diagnosis 
Yes 77 63 52 32 
0.343 
No 101 53 48 31 
Chemotherapy 
at diagnosis 
Yes 125 54 47 31 
0.515 
No 46 63 59 34 
Table 3-4: OS from primary diagnosis stratified by epidemiological and treatment variables 
for the recurrent cohort. No factors were significantly associated with outcome. 
Tumour 
Episode 
Number of 
patients 
Median OS 
(months) 
95% CI 
(months) 
5-year 
OS (%) 
10-year  
OS (%) 
P 184 61 48-71 50 33 
R1 182 31 24-38 34 30 
R2 92 17 13-25 19 18 
R3 45 14 9-27 18 - 
R4 24 11 4-20 14 - 
R5 11 8 - 23 - 
R6 4 7 - 0 - 
R7 2 3.5 - 0 - 
R8 1 4.0 - 0 - 
Table 3-5: Median, 5- and 10-year OS following each recurrence. P: Primary, R: 
Recurrence. 
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3.3.7.2 At first recurrence 
At first recurrence, 133 (95%) patients underwent further resection, data was 
unavailable for 48. This left only seven patients in the non-surgery group, limiting 
statistical power. There was no difference in OS for those who underwent further 
surgery compared to those who did not (p=0.059). No difference in OS was 
identified for extent of resection at first recurrence (p=0.126).  
 
95 (66%) patients received radiotherapy, with data unavailable for 45. Those 
who received radiotherapy had a better OS (33 months vs 10 months, p=0.001). 
However, this survival benefit only lasted for the first six years following 
recurrence, raising the question as to whether radiotherapy at recurrence can 
lead to a sustained remission (Figure 3-5A). When patterns of radiotherapy were 
compared, there was no difference in OS depending on whether patients received 
reirradiation or first irradiation at recurrence (p=0.091) (Figure 3-5B). Treatment 
with chemotherapy was not associated with OS (p=0.829). 
 
OS after first recurrence was associated with metastatic status and relapse 
location. 20/83 patients suffered a metastatic recurrence and had significantly 
worse median OS than those with local recurrence (20 months versus 44 months 
p=0.025) (Figure 3-5C). Those with just local disease fared best (median OS 44 
months), those with distant and local disease had intermediate survival (median 
OS 20 months) and those with isolated distant disease had the worst outcomes 
(median OS 9 months) (p=0.013) (Figure 3-5D).  
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Figure 3-5: (Previous page). (A) OS after first relapse was significantly associated with 
treatment with radiotherapy at relapse (p=0.001) (B) but not with whether this was first 
irradiation or reirradiation (p=0.091). (C) The presence of metastases was associated with 
poorer OS (p=0.025) (D) and patients with distant metastases had worse outcomes than 
those with isolated local disease (p=0.013). 
 
 
3.3.8  Progression in the recurrent cohort  
3.3.8.1 Time to first and subsequent recurrences 
The median time to first recurrence was 17 months (0-149 months). The data 
was skewed towards early recurrence with 66% of tumours recurring less than 
two years after diagnosis. Within five years, 93% had recurred, rising to 98% by 
10 years. Four recurrences occurred beyond 10 years after diagnosis, with the 
latest at 12.5 years (Figure 3-6A). Of these four, two were subsequently 
confirmed as ependymoma at recurrence by molecular profiling. The other two 
did not undergo molecular profiling but were confirmed by histopathological 
analysis (Chapter 4). 
 
Following the first relapse subsequent recurrences occurred more rapidly, with a 
shortened median time to the next relapse (Figure 3-6B). Median time to first 
relapse was 17 months compared to 11, 7, 5, 11, 4, 2 and 1 for relapses 2, 3, 4, 
5, 6, 7 and 8 respectively (p<0.001). 
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Figure 3-6: (A) Median time to first recurrence for the relapsed cohort was 17 months with 
a long tail of late recurrences. Dotted lines represent the median. (B) Median time to 
progression for recurrences 1, 2, 3 and 4 significantly shortened for each subsequent 
relapse (p<0.001). Recurrences beyond the fourth were not included in the statistical 
analysis in view of the small numbers available.
A 
B 
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3.3.8.2 Factors associated with time to first recurrence 
To further delineate the behaviour of recurrent ependymoma, time to progression 
data was stratified based on age, gender, extent of resection, receipt of 
radiotherapy or chemotherapy, tumour location and grade (Table 3-6, Figure 
3-7). 
 
Factors associated with a more rapid first recurrence were: tumour grade (WHO 
II 21 months versus WHO III 16 months, p=0.002) (Figure 3-7A), tumour 
location (PF 18 months versus ST 14 months, p=0.010) (Figure 3-7B), extent of 
initial resection (STR 15 months versus GTR 19 months, p=0.002) (Figure 3-7C), 
no radiotherapy at primary diagnosis (radiotherapy 20 months versus no 
radiotherapy 16 months, p=0.025) (Figure 3-7D) and chemotherapy at primary 
diagnosis (chemotherapy 16 months, no chemotherapy 22 months, p=0.049) 
(Figure 3-7E). 
 
Parameter 
Median time to 
recurrence 
(months) 
Median 
Difference 
(months) 
95% CI 
(months) 
P 
Value 
Age 
<3yr 17 
1 -3 to +5 0.658 
>3yr 17 
Gender 
M 17 
0 -3 to +5 0.862 
F 17 
Extent of 
Resection 
STR 15 
6 +2 to +10 0.002 
GTR 19 
Location 
PF 18 
6 +1 to +10 0.010 ST 14 
SP 11 
Grade 
II 21 
6 +2 to +11 0.002 
III 16 
Radiotherapy 
at diagnosis 
Yes 20 
5 +1 to +9 0.025 
No 16 
Chemotherapy 
at diagnosis 
Yes 16 
5 -10 to 0 0.049 
No 22 
Table 3-6: Univariate analysis of median difference in time to first recurrence for patients 
categorised by epidemiological features and therapy. Median differences compared by 
Mann-Whitney U test. Number of patients included in each comparison is indicated in the 
life tables in Figure 3-7.  
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Figure 3-7: (A) Grade III ependymomas relapsed significantly faster than grade II tumours 
(p=0.002). (B) PF tumours relapsed significantly more slowly than ST tumours (p=0.010). 
(C) GTR was associated with a significantly lower relapse compared to STR (p=0.002). (D) 
Patients who received radiotherapy relapsed significantly more slowly than those who did 
not (p=0.025). (E) Patients who received chemotherapy relapsed significantly more 
quickly than those who did not (p=0.049). 
 
Factors showing significance in the univariate analyses were included in a 
multivariate analysis using the CPH model. The assumption of proportional 
hazards was fulfilled (global Schoenfeld test, p=0.368). 
 
The factors that remained associated with a faster time to first recurrence were 
grade III versus grade II tumour (p=0.002) and not receiving radiotherapy 
following initial diagnosis (p=0.048). Extent of resection, tumour location and 
receipt of chemotherapy all lost significance (Table 3-7). 
A B 
C D 
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Factor Hazard Ratio 95% CI P Value 
Extent of resection 
GTR 1.000 
0.981-2.241 0.062 
STR 1.482 
Location 
PF 1.000 
0.867-2.037 0.192 
ST 1.328 
Tumour grade 
II 1.000 
1.328-1.258 0.002 
III 1.780 
Radiotherapy at 
primary diagnosis 
Yes 0.598 
0.358-0.996 0.048 
No 1.000 
Chemotherapy at 
primary diagnosis 
Yes 1.000 
0.472-1.658 0.701 
No 0.884 
Table 3-7: Multivariate analysis of risk factors associated with a more rapid time to first 
recurrence. Only tumour higher tumour grade and lack of treatment with radiotherapy 
remained significant. 132 cases included. 
 
3.3.8.3  Event free survival after first recurrence 
GTR and receipt of radiotherapy were associated with better EFS following first 
recurrence (GTR vs STR, median 21 versus 9.5 months, p=0.009 and 
radiotherapy versus none, median 19 versus 7 months, p<0.001) (Figure 3-8A 
and B). Chemotherapy was not associated with any difference (p=0.652). 
 
The absence of metastatic disease was associated with a longer median EFS of 20 
versus 12 months, p=0.008 (Figure 3-8C). Isolated distant disease had worse 
median EFS than either combined local and distant, or isolated local disease (20 
vs 18 vs 5 months, p<0.001) (Figure 3-8D). 
 70 
 
A 
B 
C 
D 
 71 
Figure 3-8: (Previous page). EFS after first relapse was significantly associated with extent 
of resection (p=0.009) (A) and radiotherapy (p<0.001) (B). The presence of metastases 
was associated with poorer EFS (p=0.011) (C) and patients with distant metastases had 
worse outcomes than those with isolated local disease (p=0.002) (D).  
 
3.3.9  Outcomes stratified by tumour location in the recurrent cohort 
3.3.9.1 Baseline characteristics and relapse patterns 
 
Figure 3-9: Flow diagram of patient outcomes for (A) posterior fossa (N=136) and (B) 
supratentorial ependymomas (N=44). 
Different outcomes have been ascribed to tumours appearing in differing CNS 
locations (Pajtler et al., 2015; Ramaswamy et al., 2016), hence the need to 
consider tumours in different locations as separate cohorts. Flow diagrams were 
generated for those patients with PF (N=136) and ST (N=44) tumours (Figure 
3-9). Numbers were insufficient to provide illustrations for spinal tumours. PF 
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tumours had a maximum of six recurrences compared to eight for ST tumours. 
The median number of recurrences for the PF cohort was two compared to one 
for the ST cohort (p=0.493). For initial recurrences, both groups demonstrated an 
approximately 50% recurrence rate after each relapse, consistent with the data 
presented for the overall cohort. 
 
Recurrent tumours in the posterior fossa compared to the supratentorium had 
different baseline characteristics at primary diagnosis, which may have been 
masked in the analysis of the combined cohort. PF tumours that recurred were 
more likely to be from younger children than ST tumours (p<0.001). The 
recurrent ST tumours were less completely resected than the PF tumours 
(p=0.027) and were more likely to be of a higher grade (p=0.041). There was no 
difference in whether patients received chemotherapy or radiotherapy, or in the 
gender mix of the groups (Table 3-8). 
 
Parameter 
Posterior Fossa 
(n=136) 
Supratentorial 
(n=44) 
Chi-Square 
P Value 
Number % Number % 
Age 
<3 years 82 60 12 29 
<0.001 3+ years 54 40 29 71 
NK 0 - 3 - 
Gender 
Male 81 61 20 48 
0.151 Female 51 39 22 52 
NK 4 - 2 - 
Extent of 
Resection 
GTR 59 49 11 28 
0.027 STR 62 51 29 72 
NK 15 - 4 - 
Grade 
WHO II 66 56 14 36 
0.041 WHO III 51 44 25 64 
NK 19 - 5 - 
Radiotherapy 
at diagnosis 
Yes 52 40 21 53 
0.201 No 79 60 19 47 
NK 5 - 4 - 
Chemotherapy 
at diagnosis 
Yes 96 76 28 74 
0.830 No 30 24 10 26 
NK 10 - 6 - 
Table 3-8: A comparison of the recurrent posterior fossa cohort with the recurrent 
supratentorial cohort. Significant differences were identified in the age, extent of resection 
achieved and tumour grade. 
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3.3.9.2 Risk of recurrence 
Using both recurrent and non-recurrent cohorts the risk of recurrence was 
established for intracranial tumour locations. In the PF cohort, all variables 
associated with recurrence risk within the whole cohort remained significant, 
except for resection status and radiotherapy. For ST tumours, only the extent of 
resection remained significant (p=0.011) (Table 3-9).  
 
 
Sub Hazard 
Ratio 
95% CI 
P 
Value 
Cases 
tested 
PF 
Age (continuous) 0.996 0.992-1.000 0.050 203 
Gender (female vs male) 0.846 0.597-1.198 0.347 200 
Grade (III vs II) 1.767 1.207-2.584 0.003 165 
Resection (GTR vs STR) 0.702 0.491-1.002 0.051 187 
Radiotherapy (yes vs no) 0.723 0.513-1.016 0.062 199 
Chemotherapy (yes vs no) 2.224 1.391-3.557 0.001 182 
ST 
Age (continuous) 0.998 0.993-1.003 0.450 74 
Gender (female vs male) 1.107 0.591-1.941 0.821 74 
Grade (III vs II) 1.295 0.690-2.432 0.421 62 
Resection (GTR vs STR) 0.424 0.218-0.824 0.011 72 
Radiotherapy (yes vs no) 0.633 0.346-1.158 0.138 72 
Chemotherapy (yes vs no) 1.542 0.751-3.166 0.238 67 
Table 3-9: Univariate competing risks analysis for tumours based on intracranial location. 
Comparison between relapsed and non-recurrent cases with death before relapse as a 
competing risk. 
3.3.9.3 Progression and survival 
For the PF tumours, low tumour grade (p=0.044) (Figure 3-10A); GTR (p=0.001) 
(Figure 3-10B); receipt of radiotherapy (p=0.026) (Figure 3-10C); and non-
receipt of chemotherapy (p=0.016) (Figure 3-10D), all remained significantly 
associated with a slower time to first recurrence. Age and gender were not 
significantly associated with time to first recurrence (p=0.806 and 0.278 
respectively). For the ST group, only lower tumour grade was significantly 
associated with a slower time to first relapse (p=0.047) (Figure 3-11A). 
 
No factors were associated with OS in the PF cohort. In the ST cohort, children 
under three years of age had significantly better OS (p=0.036) (Figure 3-11B). 
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Figure 3-10: Factors associated with more rapid time to first relapse in posterior fossa 
tumours. (A) WHO grade III (p=0.044). (B) STR (p=0.001). (C) No radiotherapy 
(p=0.026). (D) Chemotherapy (p=0.016). 
 
 
Figure 3-11: (A) Faster time to first relapse was significantly associated with higher grade 
in the supratentorial cohort. (B) OS for the supratentorial cohort stratified by age at 
diagnosis. Younger children had better survival (p=0.036). 
3.4 Discussion and conclusions 
This chapter presents a large analysis of recurrent paediatric ependymoma in 
order to better understand the natural history of the disease and the impact of 
various therapies. The large cohort, coupled with long follow up, has permitted a 
more comprehensive assessment of outcomes than previous studies. The cohort 
size has also allowed the investigation of the pattern of relapse stratified by 
tumour location and, as will be demonstrated in Chapter 4, molecular subgroup. 
The data highlights the dismal prognosis for children who recur and that lack of 
A B 
C D 
A B 
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early recurrence does not guarantee long-term disease-free survival. A number of 
epidemiological and disease factors were associated with risk and speed of 
recurrence; in particular, tumour grade and treatment with radiotherapy. 
However, once a relapse occurred, only radiotherapy significantly impacted OS in 
the short term. The poor overall outcomes shown and the lack of sustained 
therapeutic response to current interventions support a call for a better 
understanding of the underlying biology driving recurrent disease, hopefully 
leading to the development of new treatments. 
 
In order to investigate a contemporaneous cohort, outcomes were initially 
analysed by decade of diagnosis. It was found that children treated after 1989 
had better OS than those treated earlier. This allowed the cohort to be refined to 
take into account improvements in healthcare over time, including the 
development of intensive care techniques. It was encouraging that outcomes had 
improved and this was consistent with both recent cancer statistics (Cancer 
Research UK, 2015a) and another study that analysed outcomes by treatment 
decade (Snider et al., 2017).  This highlights that epidemiological studies must be 
updated over time and that the conclusions of older studies, whilst scientifically 
valid when published, should not be relied upon indefinitely. 
 
The survival data for children with recurrent ependymoma was sobering; 
recurrence was the key feature conferring poor prognosis. Only 34% and 30% of 
children were alive five and ten years after their first recurrence, in comparison 
with 94% in the non-recurrent cohort. These figures are consistent with other 
published work (Antony et al., 2014; Messahel et al., 2009; Zacharoulis et al., 
2010). Given that the median age of diagnosis of first recurrence was under three 
years, with the OS described above, many children with recurrence will not reach 
adulthood. In view of this poor outlook, it is perhaps surprising that such little 
research has investigated recurrent paediatric ependymoma.  
Previously published studies have usually focussed on the first, second and 
occasionally third relapse (Messahel et al., 2009; Vinchon et al., 2005). Within 
the recurrent cohort, children had a median of two, with a maximum of eight, 
recurrences. For this small proportion of children, ependymoma became a 
chronically relapsing disease. The risk of further recurrence remained high, 
following each relapse, at around half. Whilst a 50% relapse rate has previously 
been described for the primary to first recurrence (Messahel et al., 2009), this 
data has shown that it also applies to later relapses. Interestingly, there was no 
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significant difference in OS between children who relapsed only once and those 
that recurred multiple times, suggesting that recurrent disease itself confers a 
poorer prognosis rather than the number of episodes. 
Whilst the majority of recurrences occurred within two years, a lack of early 
recurrence does not provide reassurance about long term prognosis; 34% of 
patients in the recurrent cohort relapsed after two years and four children 
relapsed beyond ten years after initial diagnosis. This finding has important 
implications for the duration of follow up for these children, including transition to 
adult services.  
The time interval between relapse decreased with each recurrence. This was 
particularly significant for the time from first to second recurrence compared to 
primary to first recurrence, which was in direct contrast to a previously reported 
smaller case series (Hoffman et al., 2014b). There could be a number of reasons 
for this including: increasing biological aggressiveness; increased resistance of 
the tumour to therapy; decreasing host physiological reserve; or a lack of 
effective, evidence based therapy at recurrence.  
GTR and radiotherapy at diagnosis were both significantly associated with 
decreased recurrence risk and delayed time to first recurrence. Although 
radiotherapy lost its association with risk of recurrence in multivariate analysis. 
However, neither treatment prevented recurrence. In fact, approximately half of 
patients who received GTR or radiotherapy still recurred, suggesting that close 
monitoring of these patients is required. This was consistent with another 
published study (Marinoff et al., 2017). Additionally, neither GTR nor radiotherapy 
were associated with improved OS from diagnosis in the recurrent cohort. 
However, when used at first recurrence, there was evidence that both 
radiotherapy and GTR were associated with better EFS, and radiotherapy with 
better OS. This supports other authors who have suggested improved outcomes 
with these interventions at relapse (Messahel et al., 2009; Vinchon et al., 2005).  
Studies have suggested that reirradiation at recurrence may be of benefit 
(Bouffet et al., 2012; Lobón et al., 2016; Merchant et al., 2008). This study 
showed the importance of radiotherapy at first recurrence, irrespective of 
whether this was reirradiation or first irradiation, which differed from previously 
reported research (Zacharoulis et al., 2010). Disappointingly, none of these 
survival benefits persisted beyond the first few years post therapy. It is well 
described that radiotherapy can have significant adverse neurocognitive effects 
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on the developing brain (Spiegler et al., 2004; Yock et al., 2014). Its use must 
therefore be cautiously considered. 
Unsurprisingly, the presence of metastatic disease at first relapse was associated 
with significantly worse outcomes than with local disease only. However, it is of 
interest that children with only metastatic disease had slightly worse outcomes 
than those with local and metastatic disease. This may suggest a difference in the 
biology of local versus distant disease and warrants further consideration. 
There were associations between receipt of chemotherapy, recurrence risk and 
reduced time to progression, although this was lost in multivariate analyses. It is 
unlikely that chemotherapy directly caused tumour progression but more 
probable that it was given to children at higher risk of poor outcomes, for 
example those ineligible for radiotherapy or not achieving GTR. This finding was 
similar to that identified in another study (Zacharoulis et al., 2010). 
Tumour grade was also associated with both risk of, and time to first, recurrence. 
Grade III tumours had an increased chance of recurrence and relapsed more 
quickly compared to grade II tumours. This is in agreement with one study 
(Goldwein et al., 1990), but in disagreement with another, where grade made no 
difference in time to first relapse (Messahel et al., 2009). There is much discord 
in the literature as to the reliability of histological grading and its association with 
outcome (Ellison et al., 2011). However, this study suggests that grade is 
associated with outcome, and is likely to be more reliable in view of the large 
number of samples included. 
In univariate analysis, younger age was associated with increased recurrence 
risk. This could have been influenced by the different treatments given to 
younger children, or by the molecular composition of tumours in different age 
groups. The majority of children were treated in Europe, where radiotherapy is 
generally only given at primary diagnosis to children over three years of age. The 
younger children often receive chemotherapy (Grill et al., 2001; Grundy et al., 
2007; Massimino et al., 2011). This was reflected in the loss of significance for 
age and treatment with chemotherapy in multivariate analysis which included 
treatment with radiotherapy. 
In contrast, age at diagnosis did not affect time to first recurrence. This is 
surprising given that young children have been previously thought to have poorer 
outcomes (Jaing et al., 2004; Perilongo et al., 1997). This may be in part 
explained by the recurrent cohort having poorer outcomes thus masking any 
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difference between age groups. Even more surprising was the association 
between younger age and better outcome in ST ependymomas. This may be 
explained, to some extent, by the molecular subgroups present in the 
supratentorium. EPN_YAP tumours have been described as occurring in younger 
children and are associated with better outcomes (Pajtler et al., 2015). 
Previous research has suggested ependymomas arising within different CNS 
compartments should be considered as biologically distinct groups (Johnson et 
al., 2010; Pajtler et al., 2015; Taylor et al., 2005). When PF and ST 
ependymomas were considered as separate cohorts, increased risk of recurrence 
was associated with higher grade and chemotherapy for PF tumours, and extent 
of resection for ST tumours. The location based cohorts did not have significantly 
different survival outcomes or recurrence risk. However, tumours arising in the 
posterior fossa relapsed at a slower rate than those occurring in the 
supratentorium. This is in disagreement with a study which identified no 
difference in time to first relapse based on tumour location (Messahel et al., 
2009). The present study is based on a significantly larger dataset which may 
account for this discrepancy. 
The strengths of this chapter of work were the large size of the dataset, not only 
of the cohort as a whole, but also when sub-classified by tumour location. It 
supported a number of previously published studies, and some of the differing 
findings may be related to increased statistical power from a larger cohort. Novel 
contributions included the recurrence patterns for tumour locations and the 
consistent 50% risk of relapse beyond first and second recurrences. 
At recurrence, paediatric ependymoma is a highly aggressive disease with 
extremely poor outcomes. Many children who recur will not reach adulthood. 
Current treatments fail to provide sustained control of this tumour and cause 
significant morbidity. Given the developing knowledge of location-based 
subgroups, a better understanding of the biological basis of recurrent 
ependymoma is needed to guide targeted therapies.
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4 DNA Methylation Analysis of the Recurrent 
Clinical Cohort 
4.1 Introduction 
The understanding of paediatric brain tumours is benefitting from the advent of a 
‘molecular era’ of cancer research (Louis et al., 2016). Molecular profiling 
techniques are playing an enhanced role in discovery and definition of tumour 
biology as demonstrated by recent descriptions of seven medulloblastoma 
subgroups, BRAF fusions in pilocytic astrocytomas, and distinct molecular 
phenotypes of CNS primitive neuroectodermal tumours (CNS PNETs) (Jones et 
al., 2008; Schwalbe et al., 2017; Sturm et al., 2016; Taylor et al., 2012).  
 
When this study began, in February 2015, ependymoma was defined by tumour 
location and grade. Subgroups had been proposed based on genomic imbalances 
(Dyer et al., 2002), and the concept of two PF groups had been introduced (Wani 
et al., 2012; Witt et al., 2011). In May 2015, Kristian Pajtler and colleagues 
published work on the molecular classification of paediatric ependymoma using 
DNA methylation profiling, including the profiling of nearly 50 matched primary 
and recurrent ependymomas (Pajtler et al., 2015). On the basis of this, the 
experimental protocol was adapted to include the generation of a molecular 
profile of the cohort, by extracting DNA from FFPE and FF tissue, from a subset of 
the primary and recurrent cohorts described in Chapter 3.  
 
This chapter presents the DNA methylation profiling data from an independent 
cohort of matched primary and recurrent ependymomas. The aims of this chapter 
were to: 
(1) Profile a subset of the recurrent paediatric ependymoma clinical cohort; 
(2) Provide clinical annotation to a group of DNA methylation confirmed, 
recurrent paediatric ependymomas; 
(3) Investigate the hypothesis that ependymomas do not change molecular 
subgroup at recurrence; 
(4) Investigate whether tumours cluster by molecular profile or recurrence 
status. 
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4.2 Materials and methods 
4.2.1 Generation of DNA methylation IDAT files 
Processing of samples for DNA methylation profiling was conducted by 
collaborators at UCL genomics (London, UK). FFPE samples underwent a 
restoration process to repair fragmented ends of DNA sequences, before all 
samples were bisulfite converted. Samples were then run on Illumina Infinium 
450k DNA methylation arrays (Illumina Inc, San Diego, USA), according to the 
UCL genomics summary protocol, as summarised below: 
 
In a deep well plate, 500 ng of high quality bisulphite converted DNA was whole 
genome amplified overnight (37°C for 20-24 hours), then fragmented (37°C for 
one hour and fifteen minutes in a hybridisation oven), precipitated and 
resuspended in hybridisation buffer. Samples were hybridised onto BeadChips 
using a liquid handling robot (Freedom Evo, Tecan Ltd, Switzerland) and 
incubated at 48°C for 16-24 hours. The amplified and fragmented DNA samples 
anneal to locus specific 50mers (covalently linked to one of over 500,000 bead 
types) during hybridisation. Unhybridised and non-specifically hybridised DNA 
was washed away and the BeadChip was prepared for staining and extension. 
Single-base extension of the oligos on the BeadChip, using the captured DNA as a 
template, incorporated detectable labels on the BeadChip and determined the 
DNA methylation level of the query CpG sites. The process of single base 
extension and staining was carried out using the liquid handling robot. The 
staining procedure itself involved signal amplification by multi-layer 
immunohistochemical staining. Finally, the BeadChips were scanned using the 
iScan scanner with autoloader (Illumina Inc, San Diego, USA). Data was saved in 
the IDAT file format. 
4.2.2  The DKFZ brain tumour classifier 
The IDAT files generated by the 450k DNA methylation arrays were processed 
through the German Cancer Research Centre (DKFZ) brain tumour classifier 
version 11b2 (accessed at www.molecularneuropathology.org). Samples were 
compared to a reference cohort of brain tumour entities and a subgroup 
prediction was generated. The confidence of the prediction was indicated by a 
score between 0 and 1. DKFZ use a cut off of 0.9 to call a subgroup classification. 
However, this is very stringent and as this was a study aimed at generating new 
hypotheses, rather than making clinical diagnoses, a lower score of 0.5 was 
accepted. 
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4.2.3  The Chip Analysis Methylation Pipeline (ChAMP) 
The Chip Analysis Methylation Pipeline (ChAMP) (Morris et al., 2014) was 
implemented from within the R statistical environment to cluster the data. Data 
was loaded into R using the Champ.load function (Aryee et al., 2014; Fortin et 
al., 2017), followed by quality control analysis using champ.QC (Morris et al., 
2014). Data was then normalised with beta-mixture quantile normalisation 
(BMIQ) using the champ.norm function (Teschendorff et al., 2013). R base 
functions were then used to produce multi-dimensional scaling plots (R Core 
Team, 2014). The script used for this analysis can be found in Appendix 3. 
4.3 Results 
4.3.1  The recurrent methylation cohort 
DNA methylation profiles were generated for 253 tissue samples in the recurrent 
clinical cohort; 120 primary tumours (64%) and 133 recurrences (80 first, 31 
second, 13 third, 5 fourth, 2 fifth recurrences plus 1 sixth and 1 seventh 
recurrence). This represented 64% of all the primary tumours and 45% of all the 
tumours (primary or recurrent) in the recurrent clinical cohort (Chapter 3). The 
patients in the methylation cohort showed no significant baseline differences with 
respect to age (p=0.813), gender (p=0.905), extent of resection (p=0.460), 
tumour location (p=0.587), grade (0.627), treatment with radiotherapy 
(p=0.903) or chemotherapy (p=1.000) when compared to the recurrent clinical 
cohort at primary diagnosis.  
4.3.2  Classifier scores 
The median classifier score for all of the samples was 0.990 (range 0.05-1.00). 
There was a difference in median scores between the primary and recurrent 
samples, with the primary samples generally exhibiting higher scores (median 
1.00 versus 0.980, p=0.025).  
 
A score of 0.5 was used as a cut off for defining a subgroup prediction; excluding 
14 primary and 23 recurrent tumours from further analysis. 
4.3.3  DNA methylation subgroup predictions 
After excluding samples with low classifier scores, the primary tumours consisted 
of 77 (73%) EPN_PFA tumours; 13 (12%) EPN_RELA tumours; 2 (2%) EPN_PFB 
tumours, 4 (4%) EPN_YAP tumours and 3 (3%) EPN_MPE tumours. There were 7 
(7%) non-ependymoma molecular diagnoses (Figure 4-1A and B). The recurrent 
tumours showed a similar distribution of DNA methylation profiles. The proportion 
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of non-ependymoma entities rose towards the higher recurrence numbers; this 
was likely biased by one case of HGNET_MN1 in which the same patient 
experienced multiple relapses (Figure 4-1B).   
 
 
Figure 4-1: (A) Table illustrating the DNA methylation subgroup predictions at each 
episode of relapse (R). ‘Other’ includes all non-ependymoma entities and those samples 
which were predicted to be normal brain. (B) Distribution of DNA methylation subgroup 
predictions for the 106 primary paediatric ependymomas with adequate classifier scores 
(>0.5) in the dataset profiled by Illumina Infinium 450k methylation arrays. EPN_PFA was 
the most common tumour in this cohort. 
4.3.4  Clinical correlates of the DNA methylation subgroups 
DNA methylation subgroups have been associated with specific clinical features 
including location, age and gender (Pajtler et al., 2015). In order to validate the 
DNA methylation dataset described here and to describe the behaviour of the 
A 
B 
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DNA methylation subgroups when they recur, these clinical aspects were 
examined. 
 
74 of the 77 (96%) EPN_PFA were located in the posterior fossa with the 
remaining three (4%) in the supratentorium. All 13 EPN_RELA tumours were in 
the supratentorium. EPN_PFA tumours were significantly more likely to occur in 
the posterior fossa and EPN_RELA tumours were significantly more likely to occur 
in the supratentorium (p<0.001). All four of the EPN_YAP tumours were in the 
supratentorium and both EPN_PFB tumours were located in the posterior fossa. 
All three EPN_MPE tumours were found in the spine. 
 
 
Figure 4-2: Age distributions for the tumours with DNA methylation subgroup predictions. 
Children with EPN_YAP tumours were the youngest, with increasing age for the other 
tumour types. Numbers indicate p values. NS: Not significant. 
 
The median age for the EPN_PFA patients was 30 months, EPN_RELA 75 months, 
EPN_YAP 6 months, EPN_PFB 148 months and EPN_MPE 136 months. The 
children with EPN_YAP tumours were significantly younger than those with 
EPN_PFA tumours (p=0.002). The children with EPN_PFA tumours were 
significantly younger than those with EPN_RELA tumours (p=0.020). There were 
no significant differences between the ages of the children with EPN_RELA 
tumours and EPN_PFB or EPN_MPE tumours, but the numbers for this analysis 
were small (Figure 4-2). 
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There were no significant differences in the gender distribution of the DNA 
methylation subgroups. 42 (59%, p=0.211) of the EPN_PFA patients were male 
as were 8 (53%, p=0.290) of the EPN_RELA patients, 0 (0%, p=0.067) of the 
EPN_YAP patients and 1 (50%, p=0.500) of the EPN_PFB patients.  
4.3.5 Outcomes for subgroups in the recurrent methylation cohort 
Curves were generated to illustrate differences in OS between DNA methylation 
subgroups. Numbers were small for the EPN_PFB, EPN_MPE and EPN_YAP 
tumours and therefore, for these groups, statistics were not performed. However, 
the curves demonstrated that patients with EPN_PFB and EPN_YAP tumours 
appeared to have the best OS; EPN_MPE tumours had intermediate OS; and 
EPN_PFA and EPN_RELA tumours had very poor OS (Figure 4-3).  
 
 
Figure 4-3: Overall survival of the ependymoma DNA methylation subgroups in the 
recurrent cohort. EPN_PFA and EPN_RELA were associated with poor outcomes, EPN_MPE 
with intermediate outcomes and EPN_YAP and EPN_PFB with better outcomes. Statistics 
not performed in view of the low numbers in three of the five groups. 
 
Further analysis was performed on the two most common paediatric subgroups, 
EPN_PFA and EPN_RELA.  
 
Median OS for EPN_PFA was 67 months, compared with 110 months for 
EPN_RELA. However, there was no statistically significant difference in OS 
between the two groups (p=0.763) (Figure 4-4A). 
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Figure 4-4: (A) Overall survival for the relapsed EPN_PFA and EPN_RELA groups was not 
significantly different (p=0.763). (B) Time to first relapse for the EPN_PFA and EPN_RELA 
groups demonstrated that EPN_RELA tumours recurred significantly more quickly 
(p=0.008). 
  
EPN_RELA tumours recurred significantly more quickly than EPN_PFA tumours 
(median EPN_PFA 21 months versus median EPN_RELA 15 months, p=0.008) 
(Figure 4-4B). 
 
EPN_PFA and EPN_RELA subgroups were analysed to determine whether grade, 
extent of resection, receipt of radiotherapy or chemotherapy, age or gender were 
associated with TTP or OS at primary diagnosis. The only positive association was 
seen between tumour grade and time to recurrence in EPN_PFA (median 17.5 
months for grade III and 27 months for grade II tumours, p=0.043) (Table 4-1). 
 
A 
B 
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Parameter 
EPN_PFA EPN_RELA 
Cases 
TTP 
(months) 
P-
value 
Cases 
TTP 
(months) 
P-
value 
Age 
<3yr 43 23 
0.562 
2 4 
0.239 
>3yr 34 21 8 16 
Gender 
M 45 21 
0.783 
6 18 
0.325 
F 31 25 5 5 
Extent of 
Resection 
GTR 38 25 
0.117 
4 18 
0.521 
STR 31 20 6 9 
Grade 
II 38 27 
0.043 
4 19 
0.424 
III 34 18 9 12 
Radiotherapy 
at diagnosis 
Yes 32 26 
0.637 
5 15 
1.000 
No 41 19 5 12 
Chemotherapy 
at diagnosis 
Yes 51 21 
0.900 
5 5 
0.623 
No 18 25 4 17 
Table 4-1: Factors associated with time to first progression for the EPN_PFA and EPN_RELA 
cohort. The only factor significant association was between higher grade and a more rapid 
first relapse in EPN_PFA tumours (p=0.043). 
 
EPN_PFA and EPN_RELA tumours were next analysed to determine whether, 
consistent with data for the recurrent clinical cohort, surgery and radiotherapy 
were associated with better outcomes after first relapse. Using tumours with an 
EPN_PFA or EPN_RELA diagnosis at primary and available clinical information 
(n=60 for EPN_PFA and n=10 for EPN_RELA), it was found that radiotherapy at 
recurrence for EPN_PFA tumours was associated with better OS (median 10.5 vs 
32 months, p=0.036) and EFS (median 10 vs 37 months, p= 0.013) (Figure 4-5). 
Extent of surgery was not associated with outcome in either subgroup and 
radiotherapy was not associated with outcome in the EPN_RELA group. 
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Figure 4-5: Survival outcomes at first recurrence for patients with EPN_PFA. OS (A) and 
EFS (B) were significantly worse for patients who did not receive radiotherapy at first 
recurrence 
4.3.6 Recurrence in ‘good prognosis’ subgroups 
Studies have indicated that EPN_PFA and EPN_RELA have worse outcomes than 
EPN_PFB, EPN_YAP and EPN_MPE (Pajtler et al., 2015; Ramaswamy et al., 2016). 
In the recurrent cohort, all three of these better prognosis subgroups were 
represented: two EPN_PFB; three EPN_MPE; and four EPN_YAP. The clinical 
histories of these cases were reviewed (Table 4-2). Despite recurring, only two 
out of the nine patients had died by the end of follow up. Median follow up for the 
living patients was relatively long at 114 months. Six of the patients had STR, 
three had GTR and two were treated with radiotherapy. OS appeared to be better 
for these subgroups than EPN_PFA and EPN_RELA (5-year survival for EPN_PFB, 
EPN_MPE and EPN_YAP 100%, 50% and 75% respectively) but this was not 
tested for significance in view of the low numbers.
A 
B 
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ID 
Methylation 
Prediction 
Gender 
Age 
(months) 
Relapses Location Grade Resection Radiotherapy Chemotherapy Outcome 
Follow 
up 
(months) 
Epend223 EPN_PFB F 97 1 PF II STR Yes Yes A 104 
Epend316 EPN_PFB M 199 1 PF II STR Yes Yes A 188 
Epend094 EPN_MPE F 136 1 SP III GTR No No A 181 
Epend129 EPN_MPE F 72 3 SP II GTR No No D 63 
Epend152 EPN_MPE M 171 1 SP II GTR No No A 14 
Epend017 EPN_YAP F 7 1 ST III STR No Yes D 7 
Epend103 EPN_YAP F 17 1 ST III STR No Yes A 260 
Epend124 EPN_YAP F 3 2 ST III STR No Yes A 62 
Epend171 EPN_YAP F 4 1 ST II STR No Yes A 114 
Table 4-2: Summary of the clinical outcomes of the better prognosis DNA methylation subgroups. All but two patients were alive at the end of follow up 
despite all patients suffering from at least one recurrence. SP: Spinal, A: Alive, D: Dead.
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4.3.7 DNA methylation predictions in matched primary and recurrent 
cases 
Matched primary and first recurrent pairs were available for 56 cases, with DNA 
methylation subgroup matching in 54 (98%) (Appendix 1). Using the genotypes 
generated by the DKFZ classifier, it was confirmed that all paired samples were 
from the same patient. 39 cases were EPN_PFA, 9 EPN_RELA, 1 EPN_PFB, 2 
EPN_YAP and 1 EPN_MPE. Two of the matching cases were non-ependymoma 
entities. In the two cases where the DNA methylation group changed, one 
switched from EPN_PFA to DNET and one from DNET to EPN_RELA. Paired results 
were available for two of the four cases that first recurred more than 10 years 
after initial diagnosis. In both cases the tumours were classified as EPN_PFA at 
primary and recurrence, consistent with ependymoma recurrence rather than a 
treatment induced second malignancy.  
4.3.8 Clustering DNA methylation data 
Given the lack of evidence of a change in DNA methylation subgroup at first 
recurrence in this and a previous study (Pajtler et al., 2015), it was hypothesised 
that samples would cluster according to DNA methylation subgroup assignment. 
This was confirmed by performing multidimensional scaling of all primary and first 
recurrent tumours (Figure 4-6). It was clearly demonstrated that, with the 
exception of one EPN_PFB tumour, samples clustered according to their DNA 
methylation subgroup prediction rather than recurrence status, thus supporting 
the hypothesis.  
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Figure 4-6: Multidimensional scaling plot based on the 1000 most variable DNA 
methylation probes of all primary and first recurrent ependymoma samples demonstrating 
clustering by subgroup rather than recurrence status. P:Primary. R1: Recurrence 1. 
 
EPN_PFA represented the largest group of DNA methylation samples and formed 
the majority of the PF samples. Evidence for multiple EPN_PFA subgroups has 
been recently presented at an international conference (Pajtler et al., 2017). In 
order to investigate for evidence of EPN_PFA subgroups within this dataset, 
multidimensional scaling of the EPN_PFA samples was undertaken. Two clusters 
of samples were identified which may represent the two major PFA subgroups 
(EPN_PFA1 and EPN_PFA2) (Figure 4-7). Clustering into one of the two groups 
occurred irrespective of whether the tumour was primary or recurrent. Further 
investigation into these groups was not undertaken as it did not represent one of 
the main aims of the study; however extensive investigation of this dataset has 
been undertaken elsewhere (Pajtler et al., 2017). 
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Figure 4-7: Multidimensional scaling based on 1000 most variable DNA methylation probes 
of all EPN_PFA primary (P - green) and first recurrent (R1 - orange) samples indicating two 
potential subgroups of EPN_PFA ependymoma. 
4.4 Discussion and conclusions 
Molecular subgrouping in ependymoma has advanced rapidly over the last few 
years and a shared understanding of how these subgroups behave clinically is 
required. Whilst one study has investigated a cohort with matched primary and 
recurrent DNA methylation profiles in both adults and children, this was limited to 
comparing subgroup assignment at recurrence with no additional clinical analysis 
specific to the relapsed group (Pajtler et al., 2015). This chapter is believed to be 
the first piece of work in which a substantial cohort of purely recurrent paediatric 
ependymomas have both clinical data and DNA methylation annotations. 
 
The primary tumours for 56% (n=106) of the original clinical cohort were 
annotated with a DNA methylation prediction with adequate classifier score. This 
cohort was highly representative of the clinical recurrent cohort (Chapter 3) in 
terms of baseline characteristics. This cohort was also consistent with current 
knowledge of the DNA methylation subgroups, namely: age, location and gender, 
suggesting that the DNA methylation profiling was robust (Pajtler et al., 2015). 
The only exception to this was the finding that three (4%) EPN_PFA tumours 
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were reported to have occurred in the supratentorium. Possible explanations for 
this are that these tumours did arise supratentorially, perhaps originating close to 
the edge of the infratentorium or that these tumours were misclassified at the 
time of diagnosis. Because of the multicentre nature of the study and the access 
to imaging available it was not possible to perform further review on these cases.  
 
The majority (98%) of ependymomas remained in the same subgroup from 
primary diagnosis to first recurrence, consistent with Pajtler et al. 2015. 
Importantly, tumours recurring after long time intervals did not change 
subgroup; late recurrences were still classified as ependymoma rather than 
treatment induced secondary malignancies. One possible reason for the 2% that 
changed subgroup is contamination of the sample with normal brain tissue, 
making accurate classification more difficult. Unfortunately, there was insufficient 
remaining tumour tissue for repeat analysis. Another explanation is that as the 
DKFZ classifier is a research tool not yet proven in a clinical setting, it is possible 
that misclassification could occur. 
 
There was a small but significant decrease in classifier scores of recurrent 
tumours compared to primaries (median 1.000 in the primaries and 0.980 in the 
recurrences, p=0.025). The classifier was developed from primary tumours taken 
from patients who had received neither chemotherapy nor radiotherapy at the 
time of resection (www.molecularneuropathology.org - not yet published). It is 
possible that there were subtle therapy induced changes that affected the DNA 
methylation profile at recurrence. This hypothesis merits further consideration. 
 
An analysis of the two major paediatric DNA methylation subgroups, EPN_PFA 
and EPN_RELA, demonstrated a significant difference in time to first recurrence. 
EPN_RELA recurred more rapidly than EPN_PFA, with all of the EPN_RELA cases 
relapsing within two years of primary diagnosis, and EPN_PFA cases taking up to 
12.5 years. This finding may have implications for how the follow up of children 
with different DNA methylation subgroups is undertaken. Children with EPN_RELA 
may need more regular follow up immediately after diagnosis, whereas children 
with EPN_PFA may need longer term follow up. 
 
EPN_PFA and EPN_RELA demonstrated no statistical difference in OS for children 
experiencing at least one recurrence. OS for the tumours previously associated 
with improved outcomes (EPN_PFB, EPN_MPE and EPN_YAP) appeared to be 
better than for EPN_PFA and EPN_RELA. However, numbers were inadequate to 
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confirm this statistically, reflecting their relative rarity. Whilst these tumours do 
still show evidence of a propensity for relapse, their OS was still generally good. 
This was supported by seven out of nine of these patients being alive at the end 
of follow up, but needs further investigation with substantially increased 
numbers. 
 
A more detailed analysis of the EPN_RELA and EPN_PFA subgroups failed to 
demonstrate any association for factors previously thought to impact OS at 
primary diagnosis, including: treatment with radiotherapy or chemotherapy; 
extent of resection; tumour grade; and age at diagnosis. A positive association 
was seen between grade and EPN_PFA tumours for time to first progression; 
tumours with a higher grade recurred more quickly. This cohort contained only 
recurrent tumours and therefore some of the lack of survival associations may 
relate to the selection of a group with inherently poor outcomes. Alternatively, 
there may have been a lack of power to detect associations and therefore further 
research, with greater numbers, is needed to determine the effects of these 
factors in primary tumours that go on to recur. 
 
Radiotherapy was associated with better OS and EFS in EPN_PFA tumours at first 
recurrence. Surgery was not associated with any benefit in either group and 
radiotherapy was not associated with outcome in the EPN_RELA group. Given that 
the EPN_RELA group was very small it is difficult to draw firm conclusions from 
this finding. However, the radiotherapy findings for EPN_PFA were consistent with 
the results of the overall clinical cohort. Future research needs to generate 
cohorts with larger numbers to be able to determine the true behaviour of these 
molecular subgroups after therapy. 
 
The multidimensional scaling demonstrated that samples clustered by their DNA 
methylation subgroup rather than primary or recurrence status, suggesting 
minimal change in DNA methylation profiles from primary to recurrence. This 
indicates that DNA methylation subgroup is the most important factor in 
determining how these tumours relate to one another. This may also suggest that 
DNA methylation modifying therapies that have failed on primary tumours are 
unlikely to be successful at recurrence. However, an analysis of differentially 
methylated regions at primary versus recurrence may help to identify any subtle 
changes in more detail and will form part of the ongoing work following this 
doctoral research. 
 
 94 
Whilst it was not the primary aim of the study to perform in-depth analysis of 
ependymoma DNA methylation profiles, this data provided an opportunity to look, 
for the first time, at the clinical outcomes of a recurrent ependymoma cohort with 
confirmed DNA methylation subgroups. The data also provided an additional 
validation tool for the RNA sequencing performed in subsequent chapters.
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5 RNA Sequencing of 106 FFPE Ependymomas  
5.1 Introduction 
Given that paediatric ependymoma is relatively rare, with an incidence in the 
United Kingdom of 2-10 cases per million for children aged 0-14 years (Cancer 
Research UK, 2015b), obtaining access to high quality tissue samples is 
challenging. In the UK, the CCLG tissue bank (CCLG, 2017) provides a resource 
from which to identify archival tumour specimens, particularly those collected 
from uncommon malignancies. The difficulty of accessing sufficient tissue 
specimens was compounded by the fact that this study required matched primary 
and recurrent samples to perform a paired analysis. Given that only two, single 
institution studies have conducted paired analysis of gene expression patterns in 
recurrent paediatric ependymoma (Hoffman et al. 2014a; Peyre et al. 2010), it is 
likely that this is not a unique problem. It therefore required an innovative 
solution. 
 
A number of approaches were taken to increase the number of available samples. 
Firstly, collaborations were developed with the research group of Dr Nicholas 
Foreman in Denver, USA and with Dr Thomas Jacques at the UCL Institute of 
Child Health in London. In addition to utilising samples provided through the 
CCLG biobank, these collaborations increased the number of samples available for 
profiling. Secondly, the spectrum of potential samples available for use was 
widened by investigating the use of RNA sequencing of FFPE tissue. Presently, 
gene expression profiling tends to be limited to high quality fresh frozen (FF) 
tissue specimens. There is emerging evidence that it is feasible to perform whole 
transcriptome RNA sequencing on archival FFPE tissue specimens. In order to 
identify the level of evidence available with regards to FFPE RNA-seq, a PubMed 
search was undertaken with the terms “FFPE”, “RNA” and “Sequencing”.  
 
221 results were returned and abstracts reviewed. Only studies of whole 
transcriptome RNA-seq on archival FFPE specimens were retained, resulting in 19 
studies, 16 on human and three on animal tissue (Table 5-1). Of the human 
studies; 13 were based on cancer samples. None of these investigated any type 
of paediatric brain tumour. The only study using brain tissue was a study of 
glioblastoma multiformae (GBM) in adults, which consisted of just four samples 
(Esteve-Codina et al., 2017). This is important as gene expression patterns have 
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been reported to be different in the brain compared to other tissues, in particular 
due to the presence of nascent RNAs (Ameur et al., 2011).  
 
This study provided the opportunity to (1) validate the use of FFPE RNA-seq in 
paediatric brain tumours and (2) add a substantial amount of data to developing 
knowledge about the benefits and pitfalls of this approach. 
 
This chapter describes the FFPE RNA-Seq analysis of a cohort of primary and 
recurrent ependymomas, from tissue with storage times of up to 30 years. The 
validity of this approach was assessed by comparing the results to: previously 
published datasets; the DNA methylation profiles generated in Chapter 4; and 
matched fresh frozen (FF) specimens sequenced using the same library 
preparation techniques. In addition to the matched FF specimens, a larger, 
unmatched FF cohort of 67 samples was sequenced to make more general 
comparisons between sequencing outcomes for FFPE and FF brain tumour 
samples. Recommendations were also made to assist further research in this field 
and beyond.  
 
The primary aims were to establish: 
(1) Is RNA-seq, from FFPE tissue, feasible on a large scale? 
(2) How does the quality of the data compare to FF samples? 
(3) Is the data of adequate quality to include when investigating other 
research questions? 
(4) What are the potential pitfalls of this approach and can 
recommendations be generated to advise future research? 
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(A) Human Studies          
Reference PubMed ID Species 
Read 
Type 
Read 
Length 
Read 
Depth Samples 
Matched 
FF/FFPE 
Sample 
Age Sample Origin 
Cancer 
Study 
(French et al., 2017) 28818508 Human SE 50 NK 3 0 NK Liver No 
(Haile et al., 2017) 28570594 Human PE 75 20M 4 0 4 yrs Lymphoma Yes 
(Jovanović et al., 2017) 28376728 Human NK NK 13M-80M 21 21 4 >10 yrs, 17 < 10 yrs Breast Yes 
(Esteve-Codina et al., 
2017) 28122052 Human PE 76 54M-65M 4 4 NK GBM Yes 
(Vukmirovic et al., 2017) 28081703 Human PE 50 50M 12 0 6 yrs Lung No 
(Guo et al., 2016) 27774452 Human PE 90 20M 4 0 8 yrs Breast Yes 
(Just et al., 2016) 26998913 Human SE 80 42M 1 0 <2 yrs Kidney Yes 
(Graw et al., 2015) 26202458 Human NK NK 50M 6 6 <1.5 yrs Ovarian Yes 
(Li et al., 2014) 25495041 Human SE 35 10M 2 2 2 yrs Kidney Yes 
(Zhao et al., 2014) 24888378 Human PE 48 200M 17 17 NK Breast Yes 
(Hedegaard et al. 2014) 24878701 Human PE 100 20M-50M 73 38 < 20 yrs Bladder, Prostate, Colon, Tonsil Yes 
(Morton et al., 2014) 24735754 Human PE 100 198M 18 0 3yrs Lung Yes 
(Norton et al., 2013) 24278466 Human PE 50 NK 9 9 4 yrs Breast Yes 
(Xiao et al., 2013) 23180419 Human SE 76 235M 2 0 94 yrs Lung No 
(Morlan et al., 2012) 22900061 Human SE 50 20-50M 4 0 NK Breast Yes 
(Sinicropi et al., 2012) 22808097 Human SE 50 43M 136 0 8.5 yrs Breast Yes 
           (B) Animal Studies          
Reference PubMed ID Species 
Read 
Type 
Read 
Length 
Read 
Depth Samples 
Matched 
FF/FFPE 
Sample 
Age Sample origin 
Cancer 
Study 
(Amini et al., 2017) 28835206 Canine SE 125 NK 4 0 NK Breast Yes 
(Hester et al., 2016) 27562560 Mouse PE 50 30-70M 40 40 <2 vs >20yrs Liver No 
(Auerbach et al., 2015) 25378103 Rat PE 100 100M 8 8 4 yrs Liver No 
 
Table 5-1: Summary of previously published studies investigating whole transcriptome RNA sequencing from archival FFPE tissues. (A) Studies using 
human tissue. (B) Studies using animal tissue. NK: Not Known. BP: Base pairs. M: Million.
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5.2 Materials and methods 
FF and FFPE cohorts were formed from a subset of the clinical recurrent cohort 
described in Chapter 3 based on tumour tissue availability. RNA sequencing was 
performed by Exiqon (Denmark), as described in section 2.9. Following the 
generation of the raw data, all analysis was conducted by the author. The file 
formats encountered in the analysis (fastq, SAM and BAM) are described in 
Appendix 2. The theory underpinning RNA-seq methodology and the key 
terminology is outlined in section 1.6. 
5.2.1 RNA sequencing data analysis pipeline 
An analytical pipeline was developed to ensure a uniform approach to all samples. 
This consisted of: 
• FastQC data quality control (Andrews, 2010) (section 5.2.1.1); 
• Read trimming of adapter sequences and low quality bases using 
Trimmomatic (Bolger et al., 2014) (section 5.2.1.2); 
• Removal of abundant sequences, particularly rRNA, by alignment with 
TopHat2 (Kim et al., 2013) (section 5.2.1.3); 
• Aligning remaining reads to the transcriptome and genome using TopHat2 
(section 5.2.1.4); 
• Counting reads and assigning to exons using FeatureCounts from the 
RSubRead package (Liao et al., 2014) (section 5.2.1.5). 
The output of the pipeline was a matrix of raw gene expression levels which was 
then normalised before downstream analysis. The computer scripts used to 
perform the analysis can be found in Appendix 3. The results generated from the 
data analysis pipeline can be found in Appendix 4. 
5.2.1.1 FastQC data quality control 
FastQC is a tool written in JavaScript to perform basic quality control of high 
throughput sequencing data (Andrews, 2010). It was designed for DNA 
sequencing, but provides insight into RNA-seq data quality. It can assist with 
decisions about quality control interventions prior to downstream analysis, but 
does not have specific cut-offs for poorly performing samples in RNA-Seq. 
 
Paired fastq files were run through the FastQC tool using the desktop module. 
Details of the parameters analysed and summaries of their interpretation for 
RNA-seq, as derived from the FastQC documentation (Andrews, 2010), follow: 
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• Basic Statistics (Figure 5-1A): 
This module provided details of the input file, number of reads generated 
and sequence length. It was used to check the basic parameters of the 
sequencing run. 
 
• Per base sequence quality (Figure 5-1B): 
This module detailed the Phred quality score for each base position in the 
read across each sample. Reads on a green background were good 
quality; amber, an acceptable quality; and red, poor quality. The blue line 
indicated the mean quality score; the yellow box, the interquartile range; 
and the whiskers, the top and bottom 10% of scores. 
 
• Per base sequence content (Figure 5-1C): 
For DNA sequencing, the relative composition of the four nucleotides 
should be the same at each base position in the read. This assumption 
does not hold true for RNA-seq, as library preparation begins with random 
hexamer priming that introduces a technical bias. This explains the erratic 
lines to the left of the illustrated plot and is why the module generates a 
warning in many RNA-seq libraries. It is not thought to impact 
downstream analyses (Andrews, 2010). 
 
• Per tile sequence quality (Figure 5-1D): 
This module detailed the Phred quality of the reads at different positions 
on the Illumina flow cell. It can identify losses in quality in a particular 
area of the flow cell. The plot should be blue; other colours signify 
problems with the sequencing run. 
 
• Per base N content (Figure 5-1E): 
When the sequencer is unable to accurately call a base, it replaces it with 
an ‘N’ in the output fastq file. This plot demonstrated the average 
proportion of ‘Ns’ at each base position in the read. An increase in ‘Ns’ can 
occur towards the end of sequencing runs if reads are short, or as 
chemicals used in the process deteriorate. 
 
• Per sequence quality scores (Figure 5-1F): 
This module showed the number of reads per Phred score for each sample. 
Normally, most reads have high scores generating a unimodal distribution, 
peaking at the right of the graph (Andrews, 2010). 
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• Per sequence GC content (Figure 5-1G): 
The Guanine-Cytosine (GC) content from each sample should follow an 
approximately normal distribution to indicate a lack of bias or 
contamination within the data. A total RNA library would be expected to 
have a shifted distribution to an mRNA enriched library as RNA species 
have differing GC content (Aissani and Bernardi, 1991). Additionally, as 
every organism has a unique GC composition profile, the analysis can 
highlight evidence of contamination with non-human RNA. 
 
• Sequence length distribution (Figure 5-1H): 
This module plotted the length of each read and could be affected by 
library preparation methods and read trimming. 
 
• Sequence duplication levels (Figure 5-1I): 
This module estimated the level of duplication of reads within each fastq 
file. Less complex libraries produce less information about expressed 
genes, and have high levels of duplicated sequences. High levels of 
duplicated sequences can be caused by rRNA contamination and excessive 
PCR amplification during library preparation, and are indicated by a rise in 
the line at the right of the graph illustrated. 
 
• Adapter content (Figure 5-1J): 
This module detects adapter sequences in the fastq files which can be 
removed by trimming to prevent negative impact on downstream 
analyses. Adapter sequences are bound to both ends of each cDNA 
fragment, with the proximal adapter attached to the flow cell. The 
sequencer reads along the fragment, proximally to distally. As the read 
length is fixed, if the fragment is short then the sequencer will begin to 
read into the adapter sequence attached to its distal end. This results in 
adapter sequence read-through in the raw read. 
 
Following FastQC processing, results from individual samples were inspected, 
normalised and then combined within the R statistical environment (R Core Team, 
2014), in order to assess quality differences between FFPE and FF cohorts.
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Figure 5-1: Summary of FastQC modules used in quality control of the FF and FFPE raw data (Andrews, 2010). Results from fastq file 4589-072 
(Forward sequences) used as an example. (A) Basic statistics. (B) Per base sequence quality. (C) Per base sequence content. (D) Per tile 
sequence quality. (E) Per base N content. (F) Per sequence quality scores. (G) Per sequence GC content. (H) Sequence length distribution. (I) 
Sequence duplication levels. (J) Adapter content. 
J I 
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5.2.1.2 Read trimming of adapter sequences and low-quality bases 
Reads were trimmed to remove adapter sequences and low-quality bases. There 
is debate about the benefits of trimming but there is some evidence that light 
trimming improves alignment rates (Del Fabbro et al., 2013; Williams et al., 
2016). 
 
Adapter sequences were removed using the ILLUMINACLIP command in 
Trimmomatic (Bolger et al., 2014) and paired-end adapter sequences provided by 
Illumina. Low quality bases were removed from the beginning and end of reads 
based on Phred scores below five. The SLIDINGWINDOW command was used to 
scan the full lengths of reads to remove sections where the mean Phred score fell 
below 15 over four bases. If read length fell below 30 base pairs the read was 
discarded; excessive numbers of short reads can result in changes in differential 
expression due to ambiguous mapping (Williams et al., 2016). 
5.2.1.3  Removal of abundant sequences 
All samples were filtered to remove abundant sequences (predominantly 
ribosomal RNA but also transfer RNA and mitochondrial RNA), by aligning all 
reads in each sample to an abundant sequences index file and retaining the 
unaligned reads.  
 
The abundant sequences were obtained from the UCSC genome browser in FASTA 
format (www.genome.ucsc.edu) and a Bowtie 2 index file was generated. A 
Bowtie 2 index is a way of rearranging the genomic sequence, in order to 
minimise the amount of computer memory used to perform the alignment. 
 
Alignment was then performed using Tophat 2. This required two fastq files of 
raw reads (forward and reverse) and a Bowtie 2 index as input. The output of the 
alignment was a BAM file of reads aligned to abundant sequences (discarded) and 
a BAM file of unaligned reads (retained).  
 
The default parameters of TopHat 2 were modified to take into account the inner 
mate distance for the paired-end reads (Figure 1-6). Fragment length was 
estimated by the sequencing provider (Exiqon, Denmark) on the basis of 
Bioanalyser analysis of the sequencing libraries. The estimated average fragment 
length was 300 bases, from which adapter lengths were subtracted, leaving a 
median insert length of 155 base pairs. From the insert length, the inner mate 
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distance was calculated by subtracting the read lengths (2*100). This calculation 
gave a median inner mate distance of -45.  
 
The calculated inner mate distance was confirmed by examining the BAM files 
using Picard tools (Accessed at: http://broadinstitute.github.io/picard, December 
2015), which indicated that the median insert length was 156 base pairs. 
Subtracting the read lengths from this (2*100) indicated an inner mate distance 
of -44, which was consistent with the value predicted by the Bioanalyser. 
5.2.1.4 Alignment to transcriptome and genome 
The unaligned BAM files were first converted back to fastq files, using the 
bam2fastx converter within the TopHat 2 package. They were then aligned, by 
TopHat 2, to the human transcriptome (Gencode GrCh37 Version 11, obtained 
from www.genecodegenes.org) and genome (version Hg19). The output of the 
genome/transcriptome alignment was a BAM file of reads aligned to human 
sequences and a BAM file of unaligned reads for each sample. The BAM files of 
aligned reads were used to count reads overlapping with exons and genes. 
5.2.1.5  Counting reads using FeatureCounts 
FeatureCounts, a programme within RSubRead (Shi, 2014), summarises aligned 
reads within a BAM file (Liao et al., 2014), and was used to count aligned 
fragments overlapping with exons or genes. This resulted in a counts matrix 
indicating the number of reads aligning to each exon or gene. 
 
Inputs were a BAM file for each sample and the transcriptome reference sequence 
(Gencode GrCh37 Version 11). The commands for the algorithm were changed 
from default, to: 
• facilitate paired-end reads; 
• only count a fragment when both reads were mapped;  
• specify a minimum mapping quality score of 10.  
 
In order to summarise the read counts and make comparisons between FF and 
FFPE cohorts, metrics were generated for proportions of reads falling on exons; 
introns; intergenic regions; or reads not assigned to any feature. The proportion 
of reads falling on exons was calculated by working out the overall percentage of 
reads assigned to exons. The proportion of intronic reads was calculated by 
subtracting the number of reads assigned to exons from the number of reads 
assigned to genes. Intergenic reads were assumed to be those which could not be 
assigned to any features in the GTF file. Those reads which were either from 
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chimeric fragments, were ambiguous or unassigned for any other reason were 
included in the ‘technical’ category. 
5.2.2  Differential expression analysis 
EdgeR (Empirical Analysis of Digital Gene Expression Data in R) (Robinson et al., 
2010) was selected to perform differential expression analysis in view of its 
extensive documentation, widespread use and ability to perform a paired 
analysis.  
 
Raw, untransformed, data was loaded into the R statistical environment as a 
table of counts, one column per sample and one gene per row, with a sample 
sheet to identify the correct column for each sample. Gene names were converted 
from Ensembl gene IDs to Entrez gene IDs and official gene symbols using the R 
packages org.Hs.eg.db v3.4.1 (Carlson, 2017) and AnnotationDbi v1.3.82 (Pages 
et al., 2017).  
 
In order to maximise the utility of the False Discovery Rate (FDR) corrections, 
data was filtered to remove genes with a count of less than two fragments per 
million amongst half of the dataset. This approach aimed to remove genes that 
would be unlikely to show differential expression, over and above the noise of 
lowly expressed genes in the data. 
 
Following filtering, EdgeR corrected for varying library size between the samples 
and estimated the dispersion of the data using common, trended and tagwise 
approaches (Robinson et al., 2010). Differential expression analysis was then 
performed, generating lists of differentially expressed genes. 
5.2.3  Clustering and data visualisation 
For comparison of FFPE and FF cohorts, data was normalised and transformed 
using the R-log transformation in DESeq2 (Love et al., 2014). The R-log 
transformation normalises samples based on the number of reads generated, but 
also takes into account the distribution of lowly and highly expressed genes to 
prevent them from distorting the final results (Love et al., 2014). 
 
Following transformation, samples underwent unsupervised hierarchical clustering 
using the HClust package in R (R Core Team, 2014). Clustering was performed 
using all of the genes and subsets of the most highly expressed and variable 
genes; these approaches were compared to assess the clustering stability. For all 
clustering, Euclidean distance measures were used and Ward’s algorithm was 
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implemented. Additionally, clusters identified as possible PF subgroups were 
subjected to supervised hierarchical clustering using published signature genes of 
the PF subgroups (Pajtler et al., 2015; Witt et al., 2011), to check for overlap 
with the unsupervised approach. 
5.2.4 The hypergeometric test 
To compare the similarity of FFPE, FF and previously published datasets, 
hypergeometric tests were used to assess whether the level of overlap of 
significantly differentially expressed genes was likely to have occurred by chance. 
This test used the principle of random sampling, without replacement, from a 
population of known size. When comparing two sets of genes (sets A and B) the 
calculation in the R statistical environment took the format: 
 
phyper(q, m, n, k, lower.tail=FALSE) 
 
where: 
q = number of significant genes appearing in set A and in set B; 
m = number of significant genes in total in set A; 
n = Total number of genes in set A minus number of significant genes in set A; 
k = Number of significant genes in total in set B; 
lower.tail=FALSE represents a need to look at the upper tail of the distribution. 
 
The calculation was performed using the R base statistics package and the 
example above is derived from its associated documentation (R Core Team, 
2014). A p-value of <0.05 was considered significant. 
5.2.5  Gene ontology and enrichment analyses 
Changes in related groups of genes can infer change in biological function. In 
order to investigate this, gene ontology and enrichment analyses were 
performed. 
 
A threshold free approach was used by implementing the Gene Ontology 
enRichment anaLysis and visuaLizAtion tool (GOrilla) (Eden et al., 2009). This 
approach meant that groups of significant genes did not need to be arbitrarily 
specified by selecting a cut-off p-value, but that the enrichment algorithm 
identified groups of genes over-represented at the top compared to the bottom of 
ranked lists. There is evidence that gene ontology analyses are more sensitive to 
underlying biological changes if up- and down-regulated genes are considered 
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separately (Hong et al., 2013), therefore lists were ranked based both on fold 
change direction and statistical significance of all of the expressed genes.  
 
In order to corroborate the GOrilla analyses, gene set enrichment analyses were 
performed using Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 
2005). This approach used a modified Kolmogorov-Smirnov statistic as opposed 
to the multiple Hypergeometric test (mHG) test performed by GOrilla. Whilst 
GOrilla tested many more ontology terms than GSEA (14212 versus 4436 at the 
time of analysis), using both approaches meant that the analysis would be 
strengthened if two different statistical methods supported similar conclusions. 
 
The GOrilla package was implemented through the web based interface 
(accessible at http://cbl-gorilla.cs.technion.ac.il). The entire ranked gene list was 
entered into the software. The GSEA package (version 3.0) was downloaded from 
the Gene Set Enrichment Analysis website (www.gsea-msigdb.org) as a java 
package. The enrichment analyses were run using the GSEA Preranked option. 
This allowed for the direct input of the gene lists generated by EdgeR. GSEA was 
run in ‘classic’ mode for the enrichment statistic, selected from the basic fields 
options, with otherwise default parameters. 
 
The Database for Annotation, Visualisation and Integrated Discovery v6.7 
(DAVID) (Huang et al., 2009a, 2009b) was used to compare the results with 
previous studies (Hoffman et al., 2014a; Wani et al., 2012). Genes with FDR 
<0.05 and fold change >2 were used as the target set. DAVID was not used for 
analyses other than validating the results in the context of these previous 
studies, and for comparing differential expression between matched FF and FFPE 
samples, where a statistical cut-off was desirable for an effective comparison. 
5.3 Results 
5.3.1 Generation of sequencing libraries 
132 FFPE samples had RNA extracted, following which 26 were excluded for 
having an inadequate quantity of total RNA, leaving 106 samples for sequencing.  
The median input RNA concentration was 102.3 ng/µl (21.3 ng/µl to 877.5 ng/µl). 
Satisfactory libraries were created from all samples. The median age of the FFPE 
blocks was 11.7 years (0.54-27.85 years). All 67 FF samples had a sufficient 
quantity of RNA for sequencing with a concentration of greater than 100 ng/µl. 
Satisfactory libraries were created from all samples. 14 individual tumour 
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samples, including one matched primary and recurrent pair, appeared in both FF 
and FFPE cohorts. 
5.3.2 Clinical summary of FFPE and FF tumours undergoing RNA-seq 
FFPE cohort 
106 samples from 50 (24%) patients in the clinical recurrent cohort were 
analysed; including 25 matched primary and first recurrences. The samples that 
were not part of matched pairs were either primary or recurrent samples from 
tumours which had recurred. There were no differences in parameters for the 
FFPE cohort versus the clinical recurrent cohort (Table 5-2). 
 
Parameter 
Clinical Cohort 
(n=188) 
FFPE Cohort 
(n=50) P Value 
Number % Number % 
Age 
<3 years 94 51 27 55 
0.521 3+ years 91 49 21 45 
NK 3 - 2 - 
Gender 
Male 105 58 28 57 
1.000 Female 77 42 21 43 
NK 6 - 1 - 
Extent of 
Resection 
GTR 76 45 24 52 
0.409 STR 93 55 22 48 
NK 19 - 4 - 
Location 
PF 136 73 35 70 
0.710 
ST 44 23 13 26 
SP 7 4 2 4 
NK 1 - 0 - 
Grade 
WHO II 85 52 23 46 
0.519 WHO III 78 48 27 54 
NK 25 - 0 - 
Radiotherapy at 
diagnosis 
Yes 104 59 30 64 
0.617 No 73 41 17 36 
NK 11 - 3 - 
Median age 35 months 30 months 0.687 
Median TTP 17 months 18 months 0.311 
Median OS 61 months 106 months 0.087 
Table 5-2: Comparison of key parameters between clinical and FFPE cohorts. NK: Not 
Known. P-values for clinical parameters by Chi-square test, for times by Wilcoxon and 
Supremum tests. 
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FF Cohort 
67 samples from 30 (16%) patients in the clinical recurrent cohort were 
analysed. 29 had matched primary and recurrent pairs; two had only second 
recurrences available, leaving 27 primary and first recurrent pairs. There were no 
significant differences in clinical parameters for the FF cohort, compared to the 
clinical recurrent cohort (Table 5-3). 
 
Parameter 
Clinical Cohort 
(n=188) 
FF Cohort (n=30) 
P Value 
Number % Number % 
Age 
<3 years 94 51 13 43 
0.556 3+ years 91 49 17 57 
NK 3 - - - 
Gender 
Male 105 58 16 55 
0.841 Female 77 42 13 45 
NK 6 - 1 - 
Extent of 
Resection 
GTR 76 45 11 50 
0.658 STR 93 55 11 50 
NK 19 - 8 - 
Location 
PF 136 73 23 77 
0.632 
ST 44 23 5 17 
SP 7 4 2 7 
NK 1 -  - 
Grade 
WHO II 85 52 7 33 
0.163 WHO III 78 48 14 67 
NK 25 - 9 - 
Radiotherapy 
at diagnosis 
Yes 104 59 19 68 
0.412 No 73 41 9 32 
NK 11 - 2 - 
Median age 35 months 40 months 0.936 
Median TTP 17 months 17 months 0.718 
Median OS 61 months 77 months 0.191 
 
Table 5-3: Summary of the clinical features of the FF compared to the overall clinical 
cohort. NK: Not Known. P-values for clinical parameters by Chi-square test. P-values for 
times by Wilcoxon and Supremum tests. 
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5.3.3 Generation of raw reads 
Libraries were sequenced with a target depth of 50 million paired-end reads. The 
mean number of raw reads generated by the FFPE samples was 45.9 million 
(median 46.3 million) with a range of 2.2 to 93.2 million. In comparison, the FF 
samples generated a mean of 54 million reads (median 53.4 million) with a range 
of 22 to 78.5 million (Figure 5-2A). There was a statistically significant difference 
between the median number of reads generated for the FF compared to FFPE 
group (p<0.001). The FF samples also had a smaller range of reads (91 million 
for FFPE, 56.5 million for FF). Seven of the libraries in the FFPE group generated 
particularly low numbers of reads with less than 20 million. 
 
There was no correlation between the age of the FFPE block and the number of 
raw reads generated (r=+0.06, p=0.546). For the FFPE samples there was a 
weak positive correlation between the number of raw reads generated and the 
concentration of the input RNA (r=+0.21, p=0.030). The 260/280 and 260/230 
spectrophotometer purity measurements had no association with the generation 
of raw reads (r=+0.14, p=0.167 and r=+0.08, p=0.398 respectively). 
5.3.4  Read trimming 
The median proportion of reads removed by trimming was 3.0% in the FFPE 
group and 4.7% in the FF group (p<0.001). The difference in distribution 
between the two groups was distinct; seven FFPE samples had in excess of 10% 
of reads removed, compared to none of the FF samples (Figure 5-2B). 
5.3.5  Filtering abundant sequences 
A median of 4.1% of reads were filtered from the FFPE samples, compared to 
3.2% of FF reads. This did not represent a statistically significant difference 
(p=0.099). Both cohorts had a small minority of samples with significant rRNA 
contamination, eight FFPE and seven FF samples had in excess of 10% rRNA 
content (Figure 5-2C). 
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Figure 5-2: Basic mapping statistics for the FF and FFPE datasets. Numbers indicate p-
values. Graphs demonstrate the variability of the FFPE cohort with wider boxes than the FF 
samples for every parameter investigated. (A) Number of raw reads generated by 
sequencer. (B) Levels of read trimming in each dataset. (C) Proportion of reads mapping 
to rRNA/abundant sequences. (D) Raw reads aligning to the human genome. 
5.3.6  Reads aligning to the human genome 
The median proportion of reads aligning to the human genome in the FFPE group 
was 72.1%, compared with 83.9% in the FF group (p<0.001). The FFPE reads 
exhibited a wider interquartile range of 46.2% compared with 5.1% in the FF 
group (Figure 5-2D).  
 
FF samples with low human genome alignment were also noted to have higher 
levels of reads filtered out at the abundant sequences step, indicating rRNA 
contamination. This was not the case for FFPE, suggesting that in this cohort, the 
low alignment was not associated with rRNA contamination.  
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5.3.7  Bacterial sequence alignment in FFPE samples 
To investigate the reason for low levels of alignment in some of the FFPE 
samples, reads were extracted at random from the BAM files of unaligned reads 
in samples with the lowest human alignment levels, and entered into the National 
Center for Biotechnology Information’s Basic Local Alignment Search Tool (NCBI-
BLAST). The search returned perfect alignment with numerous bacterial 
sequences, in particular the rRNA sequences of the Enterobacteriaceae family. As 
a result of this finding, the unaligned reads were realigned to the bacterial 
genome of e-coli, using TopHat 2, to establish the level of bacterial reads 
contained within the FFPE samples. 
 
The proportion of reads aligning to bacterial sequences varied from 0.4% to 
91.4% with a median of 7.9%. When the proportion of FFPE reads aligning to 
bacterial sequences was added to the proportion of reads aligning to human 
sequences, the overall alignment rate reached figures close to the overall 
alignment rate for the FF samples. The median proportion of aligned reads to any 
organism for the FFPE samples was 87.6% compared to 88.0% for the FFPE 
samples (p=0.078). There was a strong negative correlation between human and 
bacterial sequence alignment (r=-0.95, p<0.001) (Figure 5-3). 
 
 
Figure 5-3: Proportion of reads aligning to human sequences plotted against the proportion 
of reads aligning to bacterial sequences for all the FFPE samples. The strong correlation 
indicates that as bacterial reads increased the proportion of reads aligning to the human 
genome fell.  
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5.3.8  FastQC analysis 
The FastQC files were reviewed to look for differences in quality between the FFPE 
and FF cohorts, including evidence of contamination, which may have accounted 
for variability in alignment statistics. 
5.3.8.1 FASTQC: Per sequence PHRED 
The median number of reads with each Phred score were similar for both FFPE 
and FF cohorts, however there was a higher proportion of FFPE reads with the 
maximum Phred score (67% versus 58%) (Figure 5-4). FFPE samples had 0.14% 
of reads with low Phred scores (2 to 14), whereas the FF samples had no reads 
with a score less than 15. FFPE samples had more variable scoring than the FF 
samples but both cohorts still had a majority of reads with high scores. 
 
 
Figure 5-4: Illustration of the proportion of reads for each tissue type with Phred scores 
between 2 and 36. Each point represents the median percentage of reads at each score.  
5.3.8.2 FastQC: GC content analysis 
Combined GC profiles from the FFPE samples contained two peaks; one smooth 
peak at 35-42%, and one spike at 54% (Figure 5-5A). The FF data generated a 
similar smooth peak at 35-42% and a number of ‘shoulders’ at higher 
percentages. Given its similar nature in both cohorts, the smooth peak was 
thought to represent human mRNA (Figure 5-5B). 
 
The sharp spike seen at 54% in the FFPE data correlated strongly with the 
samples that had very low (<20%) human genome, but high bacterial, 
alignment. Whilst many samples demonstrated evidence of reads contributing to 
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the bacterial spike, the worst affected had very few reads contributing to the 
human mRNA peak (Figure 5-5A). 
 
Three FF samples generated large ‘shoulders’ vertically away from the normal 
distribution, at 47-63% (Figure 5-5B). These ‘shoulders’ had different morphology 
to the spike seen in the FFPE samples, and therefore represented a different 
source of contamination.  The samples with ‘shoulders’ also demonstrated a lower 
percentage of reads contributing to the human mRNA peak. The alignment 
statistics for these three samples demonstrated significantly more rRNA than the 
other FF specimens (p=0.011), indicating rRNA contamination.  
 
 
Figure 5-5: GC content curves. (A) FFPE samples demonstrating a smooth peak at 35-42% 
and a spike at 54%. The spike is formed by samples with high bacterial RNA and low 
human RNA (blue). (B) FF samples demonstrating a smooth peak at 35-42% and several 
‘shoulders’ at 47-63%. The shoulders are formed by samples with high rRNA and low 
human RNA (blue). 
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5.3.8.3 FastQC: ‘N’ content analysis 
The median proportions of ‘Ns’ increased along the read length in the FFPE 
samples, from 0.11% at the first base to 26.5% by base 100. In the FF samples 
the N content remained very low throughout (<0.08%) and showed no tendency 
to increase along the read length. At every base position, the N content in the 
FFPE reads was higher than N content in the FF reads (p<0.001) (Figure 5-6). 
 
Figure 5-6: Median N content (% of total reads) by position of the base in read. FF tissue 
in red, FFPE tissue in blue. 
5.3.8.4 FastQC: duplication levels 
The FFPE samples had a significantly lower proportion of unique reads (median 
9.6%, range 0.5% to 67.0%, p<0.001) than the FF samples (median 44.6%, 
range 13.1-70.3%) (Figure 5-7). The largest category of reads in the FF samples 
was formed from reads with no duplication (unique sequences) whereas the 
largest category in the FFPE samples was formed by those samples with a single 
duplicate.  
 
In both cohorts, there was a small spike for sequences that were duplicated 10-
50 times (FFPE: median 4.5%, range 1.9-64.8%; FF: median 7.1%, range 2.3-
18.2%). This was largely consistent with that expected from an RNA sequencing 
library. 
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Figure 5-7: Median sequence duplication levels indicated by proportions of raw reads with 
different duplication levels across all samples. Sequences with no duplication (sequence 
duplication level = 1, unique sequences) were the most common finding in the FF cohort 
(44%). The FFPE samples demonstrated a significantly higher proportion of very highly 
duplicated sequences (sequence duplication level >10k) than the FF samples, p<0.001. 
 
When examining sequences with extremely high duplication (greater than 
10,000) the FFPE samples were more affected than the FF samples (FFPE median 
5.4%, range 0.1-70.8% and FF median 3.3%, range 0.4%-47.2%) (Figure 5-7). 
The FF samples with these extremely high levels were those that had also 
demonstrated high levels of rRNA contamination in both the alignment and GC 
content analysis steps (Figure 5-8). Removal of rRNA during the alignment 
process removed this duplication. 
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Figure 5-8: Sequence duplication levels for FF samples with high levels of rRNA 
contamination. FF053 – 47% rRNA alignment, FF054 – 62% rRNA alignment, FF055 – 68% 
rRNA alignment. High levels of rRNA sequence duplication identified by the rise in 
sequence duplication levels >10k. 
 
The FFPE samples demonstrated a logarithmic relationship between low levels of 
unique reads (high duplication) and high levels of bacterial reads (Figure 5-9). 
The lack of library complexity arose from bacterial contamination, with many 
duplicated reads being contributed by bacterial rRNA. 
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Figure 5-9: (A) Alignment of sequences to bacterial reads plotted against the proportion of 
unique reads. Each data point represents one FFPE sample. (B) Alignment of sequences to 
bacterial reads plotted against the proportion of unique reads following logarithmic 
transformation. 
  
FastQC also generated data for the consequences of deduplication of the repeated 
sequences (Figure 5-10). This showed that once the repetitive sequences 
introduced by rRNA and bacterial RNA were removed, the duplication profiles 
were much improved for libraries of both tissue types.  
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Figure 5-10: Median sequence duplication levels following FastQC deduplication. The graph 
demonstrates the proportion of raw reads at each sequence duplication level. This plot 
demonstrates that, after removal of duplicate sequences, the proportion of unique reads 
(sequence duplication level=1) was very high (50% for FFPE and 80% for FF samples). 
5.3.8.5 FastQC: Adapter read-through and insert length 
Adapter content increased towards the end of each read in both FFPE and FF 
samples. This was more evident in the FFPE than the FF samples, reaching 
statistical significance at every read position beyond the sixteenth base. By base 
position 100, the FFPE samples had a median of 6.7% reads containing adapter 
sequence compared to 4.3% in the FF samples (p<0.001) (Figure 5-11). 
 
Figure 5-11: Median adapter content for FFPE and FF cohorts at each position in the read. 
As base position in the read increased, so did the median adapter content for both cohorts 
(p<0.001). 
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It was hypothesised that increased adapter content was seen more in the FFPE 
samples because the input RNA fragments were shorter. To test this, the insert 
length for each read was calculated using Picard tools. The median insert length 
for the FFPE samples was significantly shorter at 128 bases (111-146 bases) 
versus 155 bases (142-190 bases) (p<0.001) (Figure 5-12). 
  
Figure 5-12: Box and whisker plot demonstrating the distribution of insert sizes for the FF 
versus FFPE samples. The FF cohort had significantly longer inserts (p<0.001), suggesting 
longer RNA fragments as input into the FF sequencing. 
5.3.8.6 Other FastQC parameters 
The other FastQC parameters tested were: per base sequence quality, per tile 
sequence quality, per base sequence content and sequence length; giving an 
indication of the quality of the sequencing run. All were acceptable, for all 
samples, showing no differences between FFPE and FF cohorts. This suggested 
that the sequencing runs were satisfactory and unaffected by RNA origin. 
5.3.9  FFPE input material: scrolls versus cores 
FFPE nucleic acids were extracted from a mixture of scrolls and cores. Scrolls of 
tissue were obtained for 44 (41.5%) samples and cores for 62 (58.5%). Samples 
extracted from scrolls and cores were compared to identify any key differences 
between these methods and to test the hypothesis that the level of bacterial read 
contamination could be affected by the input type. 
 
There were no differences between scrolls and cores for the number of raw reads 
(p=0.94) (Figure 5-13A), input concentration of RNA (p=0.95) (Figure 5-13C) or 
age of FFPE block (p=0.053) (Figure 5-13B). There was a significant difference in 
proportion of bacterial reads between scrolls and cores (median 32.1% vs 4.12%, 
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p<0.001) (Figure 5-13D). Confirming the hypothesis that scrolls, taken from the 
surface of the block, were more likely than cores to be contaminated with 
bacteria. 
 
Figure 5-13: FFPE tissue parameters compared between samples extracted from cores 
versus scrolls of tissue with p-values indicated. (A) Number of raw reads generated. (B) 
Age of FFPE block. (C) Input RNA concentration. (D) Proportion of reads mapping to the 
bacterial genome. Scrolls were associated with significantly higher levels of bacterial read 
mapping compared to cores. No other significant differences were identified. 
5.3.10 Counting aligned reads 
The median proportion of aligned reads, for FFPE compared to FF samples, 
mapping to exons was 23.2% versus 43.7% (p<0.001); to introns, 51.6% versus 
34.2% (p<0.001); and to intergenic regions, 12.4% versus 9.0% (p<0.001). 
There was no significant difference in the proportion of reads that were excluded 
for being chimeric, ambiguous or unmapped between the two tissue types (FFPE 
11.3%, FF 11.4%, p=0.60). By only using reads that aligned to the human 
genome, bacterial reads and rRNA contamination were excluded.  
 
 123 
5.3.11 Number of genes identified per sample  
When counting genes identified by the presence of at least one RNA-Seq read, 
the FFPE samples identified a significantly lower median number of genes per 
sample than the FF cohort (24450 versus 28690, p<0.001). FFPE samples also 
had a much wider range of numbers of identified genes, suggesting greater 
sample to sample variability (FFPE range 1651-31270, FF range 22800-34460) 
(Figure 5-14).  
 
A significant logarithmic relationship between number of genes and number of 
reads aligned to the human genome was evident in both cohorts, but much 
stronger for FFPE (r=+0.94, p<0.001) (Figure 5-15) than for FF samples 
(r=+0.52, p<0.001).  
 
For the FFPE samples, greater RNA input concentration was weakly associated 
with the detection of more genes (r=+0.29, p=0.002). There was no correlation 
between the number of genes detected and the age of the sample (r=-0.16, 
p=0.13). 
 
 
Figure 5-14: Distribution of numbers of identified genes with at least one read, compared 
between the fresh frozen (FF) and FFPE cohorts. Genes were identified more frequently 
and more reliably across samples in the FF cohort. 
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Figure 5-15: Relationship between number of genes identified with at least one read and 
number of reads aligned to the human genome for the FFPE samples. Each black dot 
represents one FFPE sample. A: Untransformed data. B: log transformed numbers of 
aligned reads demonstrating a linear relationship. 
5.3.12 Correlations between biological replicates 
The ENCODE RNA sequencing guidelines (ENCODE, 2016) recommend standards 
for correlation coefficients for biological replicates. The correlation is measured by 
comparing the expression levels for each gene with levels for other samples in 
the dataset. Correlation coefficients were calculated between all FFPE samples 
and between all FF samples to assess the reliability of the biological replicates. 
 
The raw FFPE data had inter-sample correlation coefficients varying between 0.13 
and 1.00, with a median of 0.85. The raw FF data, in contrast, had a narrower 
range of coefficients (0.51 – 1.00 with a median of 0.88). Both cohorts were 
skewed towards higher values. This suggested that the raw FFPE data 
demonstrated more variability between biological replicates than the FF samples 
(Figure 5-16). 
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Figure 5-16: Histograms of inter-sample gene expression correlation coefficients for raw 
RNA-seq data for (A) FFPE samples and (B) FF samples. 
 
When assessing the normalised and transformed data generated by the DESeq2 
R-log transformation, the correlation coefficients were less variable in both 
sample types when compared with the raw data. The FFPE tissue again showed 
more variability than the FF samples, with the range of correlation coefficients 
being 0.57 – 1.00 (median 0.95) for FFPE and 0.91 – 1.00 (median 0.99) for FF. 
For both cohorts, the coefficients were skewed towards higher values (Figure 
5-17).  
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Figure 5-17: Histograms of inter-sample gene expression correlation coefficients for 
DESeq2 RLD transformed RNA-seq data for (A) FFPE samples and (B) FF samples. 
5.3.13 Correlations between technical replicates 
14 of the samples had matched FFPE and FF tissue and were used as technical 
replicates. These samples were compared using raw data and the DESeq2 R-log 
transformation. Overall the mean correlation coefficient for the raw data was 
relatively high at 0.85 (range 0.6 – 0.98). Once data had been normalised, in 
DESeq2, it improved to 0.98 (range 0.96-0.99); meaning that final correlations 
were very strong between matched FFPE and FF samples (Figure 5-18). 
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Figure 5-18: Representative examples of correlations between FF and FFPE technical 
replicates. (A) Raw counts from sample 26A FF (26AF) versus FFPE (26AP). (B) Normalised 
counts from sample 26A FF (26AF) versus FFPE (26AP). (C) Raw counts from sample 26B 
FF (26BF) versus FFPE (26BP). (D) Normalised counts from samples 26B FF (26BF) versus 
FFPE (26BP). 
5.3.14 Differential expression between technical replicates 
EdgeR was used to perform differential expression analysis between paired FFPE 
and FF samples. 1188 genes were differentially expressed at FDR <0.05 and fold 
change >2 level; this represented 6.4% of all the genes tested. 
 
The differentially expressed genes were processed through the DAVID Gene 
Ontology database. For genes upregulated in the FFPE versus FF samples, the 
significant ontologies were “positive regulation of transcription from RNA 
polymerase II promoter” (FDR <0.001) and “transcription, DNA-templated’ (FDR 
A B 
C D 
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0.048). For the genes downregulated in the FFPE versus FF samples, the 
significant ontologies were “ion membrane transport” (FDR <0.001), “chemical 
synaptic transmission” (FDR <0.001), “cell adhesion” (FDR <0.001), “potassium 
ion transmembrane transport” (FDR 0.002), “long-term synaptic potentiation” 
(FDR 0.006), “potassium ion transport” (FDR 0.011) and “homophilic cell 
adhesion via plasma membrane adhesion molecules” (FDR 0.024). 
5.3.15 Hierarchical clustering 
In view of the quality control differences described, unsupervised hierarchical 
clustering was performed separately on the FFPE and FF cohorts using R-log 
transformed data (Figure 5-19 and Figure 5-20). 
 
FFPE Cohort Clustering 
Three distinct groups were visible within the FFPE dendrogram (Figure 5-19).  
 
The largest group contained 58 samples; 51 (88%) in the posterior fossa, 6 
(10%) in the supratentorium, and 1 (2%) in the spine. The next largest group 
contained 27 samples; 23 (85%) in the supratentorium, 3 (11%) in the posterior 
fossa and 1 (4%) in the spine. These two groups were named PF and ST 
respectively, on the basis of the statistically significant difference in the locations 
of the tumours in each group (p<0.001, chi-square test). The age at diagnosis of 
primary disease for patients in the PF group was significantly lower than in the ST 
group (median 26.5 versus 73 months, p=0.026). The PF group was also noted to 
divide into two subclusters; which were named PF1 and PF2. 
 
The third group contained 21 samples, 6 (29%) in the supratentorium and 15 
(71%) in the posterior fossa. These were exclusively poor-quality RNA-seq 
samples, as judged by the proportions of reads aligned to the human and 
bacterial genomes. This was therefore called the Quality Control (QC) Fail group. 
The median number of human aligned reads was 35,913,105 in the PF group, 
34,310,500 in the ST group, and 663,115 in the QC Fail group. This represented 
a significant difference between the PF and QC Fail group (p<0.001), ST and QC 
Fail group (p<0.001), but not the PF and ST group (p=0.660). The median 
percentage of reads aligned to the bacterial genome was 5.32% in the PF group, 
4.48% in the ST group, and 77.79% in the QC Fail group (PF versus QC Fail 
group p<0.001, ST versus QC Fail group p<0.001, and PF versus ST group 
p=0.679). 
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Adequate DNA methylation class predictions were available for 54/58 (93%) 
tumours in the PF group, 22/27 (81%) tumours in the ST group and 14/21 
(66.7%) in the QC fail group.  
 
The PF group consisted of: 
• 46 (85%) EPN_PFA;  
• 4 (7%) EPN_YAP;  
• 2 (4%) EPN_PFB;  
• 1 (2%) EPN_MPE; 
• 1 (2%) GBM_RTK_MYCN.  
The ST group consisted of:  
• 13 (59%) EPN_RELA;  
• 7 (32%) HGNET_MN1;  
• 1 (5%) HGNET_BCOR;  
• 1 (5%) DIG1.  
The QC Fail group consisted of:  
• 10 (71%) EPN_PFA;  
• 4 (29%) EPN_RELA. 
 
The QC fail group was significantly less likely to produce an adequate class 
prediction compared to the PF and ST groups (p=0.001). Samples in the QC Fail 
group were subsequently removed from further analysis. 
 
FF Cohort Clustering 
Three distinct groups were evident within the FF dendrogram (Figure 5-20).  
 
The first group contained 30 samples; 25 (83%) posterior fossa tumours, 2 (7%) 
supratentorial tumours, and 3 (10%) spinal tumours. The second group contained 
28 samples; 24 (85%) posterior fossa tumours, 3 (11%) supratentorial tumours, 
and 1 (4%) spinal tumour. The third group contained 7 samples; 5 (71%) 
supratentorial and 2 (29%) posterior fossa tumours. There were statistically 
significant differences in tumour location between the first and third groups 
(p=0.001), second and third groups (p=0.004), but not between first and second 
groups (p=1.000). On the basis of the predominant tumour locations and 
statistical testing, groups one, two and three were named PF1, PF2 and ST 
respectively. 
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Two supratentorial samples (1C and 25C) clustered away from the rest of the 
samples and were removed from further analysis.  
 
The two PF groups collectively contained DNA methylation predictions for 43/58 
(74%) of tumours and consisted of:  
• 37 (86%) EPN_PFA;  
• 2 EPN_MPE (5%);  
• 2 EPN_YAP (5%); 
• 2 HGNET_MN1 (5%).  
The ST group had few samples with DNA methylation predictions (3/7) but 
contained: 
• 2 EPN_PFA; 
• 1 EPN_RELA.  
The only tumour with an EPN_RELA prediction clustered into the ST group. There 
were no EPN_PFB tumours in the dataset. 
 
Comparisons between the FFPE and FF clusters 
Both cohorts contained an ST group and two PF groups. No significant differences 
were identified when comparing the composition of tumour locations between the 
FF and FFPE PF groups (p=1.000, chi-square test) or between the FF and FFPE ST 
groups (p=0.268, chi-square test). Additionally, the FFPE cohort demonstrated a 
cluster of poor quality samples, which was not identified in the FF cohort. 
 
When a comparison was made between the samples sequenced from both FFPE 
and FF material; 9/13 samples that clustered within one of the three main groups 
(PF1, PF2 or ST) clustered in the same group in FF and FFPE cohorts. This was 
unlikely to have occurred by chance (p=0.007). 
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Figure 5-19: Unsupervised hierarchical clustering of all (mixed primary and recurrent) FFPE samples based on Euclidean distances, Ward’s algorithm and 
all expressed genes. Three subgroups were initially identified; PF which subdivided into PF1 and PF2 containing significantly more PF location samples 
than the other groups; ST which contained predominantly ST samples and QC fail which contained samples with significantly lower human genome 
alignment than the other samples. PF1 contained exclusively EPN_PFA DNA methylation profiles and PF2 contained predominantly EPN_PFA profiles.  
PF1 PF2 ST QC Fail 
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Figure 5-20: Unsupervised hierarchical clustering of all (mixed primary and recurrent) FF samples based on Euclidean distances, Ward’s algorithm and 
all expressed genes. Three subgroups were initially identified; PF1 and PF2 containing significantly more PF location samples than the other groups; ST 
which contained predominantly ST samples. PF1 contained almost exclusively EPN_PFA DNA methylation profiles and PF2 contained predominantly 
EPN_PFA profiles. The groups reflected those seen in the FFPE sample clustering. 
PF1 PF2 ST 
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It was hypothesised that the two PF groups in both cohorts may demonstrate the 
EPN_PFA and EPN_PFB gene expression patterns described by previous authors 
(Pajtler et al., 2015; Wani et al., 2012; Witt et al., 2011). Further analysis of 
gene expression and DNA methylation patterns was therefore undertaken. 
5.3.16 PF group features 
DNA Methylation Profiles 
Across both datasets PF1 contained almost exclusively EPN_PFA predictions, 
whilst PF2 contained EPN_PFA as the most common prediction (Table 5-4). On 
this basis it was evident that, PF1 and PF2 represented two mainly EPN_PFA 
groups, rather than separate EPN_PFA and EPN_PFB groups. 
 
EPN_YAP tumours arise in the supratentorium (Pajtler et al., 2015). However, in 
both datasets, all of the EPN_YAP tumours clustered into the PF2 group rather 
than the ST group. 
 
Methylation 
Prediction 
PF1 PF2 
FF Cohort (%) FFPE Cohort (%) FF Cohort (%) FFPE Cohort (%) 
EPN_PFA 17 (94) 36 (100) 20 (80) 10 (57) 
EPN_RELA - - - - 
EPN_PFB - - - 2 (11) 
EPN_YAP - - 2 (8) 4 (22) 
EPN_MPE - - 2 (8) 1 (6) 
Other 1 (6%) - 1 (4) 1 (6) 
Table 5-4: Illustration of composition by DNA methylation group of the PF1 and PF2 
subgroups in the FF and FFPE datasets. Percentage calculated as a proportion of samples 
in each group with available DNA methylation data. DNA methylation data unavailable for 
10 samples in FF PF1, five samples in FF PF2, three samples in FFPE PF1 and one sample 
in FFPE PF2. 
Survival 
OS was compared between the PF1 and PF2 groups across both datasets. The 
median OS for PF1 was 77 months versus 114 months for the PF2 group 
(p=0.115, log-rank test). There was no difference in time to first recurrence 
(p=0.486). 
 
Differential Expression Analysis 
Differential expression and gene ontology analyses were performed, comparing 
tumours with PF location in PF1 to those with PF location in PF2. In the FFPE 
dataset 4606 genes were differentially expressed at FDR <0.05 between the two 
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groups, representing 30.7% of all genes tested. In the FF dataset, 5518 genes 
were found to be differentially expressed at FDR <0.05 between the two groups, 
representing 27% of all genes tested. These results suggest major transcriptional 
differences between PF1 and PF2 in both datasets.  
 
The 39 signature genes of EPN_PFA and EPN_PFB subgroups were then 
investigated. This confirmed that PF1 in both FFPE and FF cohorts overlapped 
with 15/20 (75%) of the EPN_PFA signature genes. PF2 in both FFPE and FF 
cohorts overlapped with 19/19 (100%) of the EPN_PFB signature genes 
(p<0.001, hypergeometric test) (Table 5-5). Supervised hierarchical clustering, 
using these 39 genes, recapitulated the PF gene expression subgroup assignment 
in both datasets. 
 
Signature Gene 
(PF Group) 
FF Cohort FFPE Cohort 
LFC (PF2 vs PF1) FDR LFC (PF2 vs PF1) FDR 
CYP1B1 (PFA) -2.12 <0.001 -2.88 <0.001 
SERPINA5 (PFA) -1.87 <0.001 -1.78 0.011 
TGFBI (PFA) -1.64 <0.001 -2.21 <0.001 
COL4A1 (PFA) -1.11 0.002 -1.49 <0.001 
COL4A2 (PFA) -0.98 0.005 -1.55 <0.001 
VEGFA (PFA) -1.49 <0.001 -2.56 <0.001 
HILPDA (PFA) -1.07 0.002 -1.29 <0.001 
PRSS23 (PFA) -1.43 <0.001 +0.60 0.163 
TIMP1 (PFA) -2.66 <0.001 -0.72 0.139 
NNMT (PFA) -2.80 <0.001 -2.28 <0.001 
C1S (PFA) -1.91 <0.001 -1.43 <0.001 
CFB (PFA) -1.22 0.013 -2.32 <0.001 
SERPINA3 (PFA) -1.46 0.002 -1.65 0.007 
TAGLN (PFA) -2.21 <0.001 -0.94 0.008 
CXCL2 (PFA) -1.69 <0.001 -1.76 <0.001 
OLFML1 (PFA) -0.85 0.074 -2.23 <0.001 
CHODL (PFA) +0.45 0.419 -0.89 0.171 
NSG1 (PFA) -0.29 0.520 -0.37 0.518 
BMP5 (PFA) +0.43 0.532 -1.29 0.107 
LAMA2 (PFA) -0.30 0.513 -1.34 0.001 
IQCA1 (PFB) +1.67 <0.001 +1.88 <0.001 
CCDC170 (PFB) +1.58 <0.001 +2.02 <0.001 
FHOD3 (PFB) +1.10 <0.001 +1.59 <0.001 
ATP4B (PFB) +3.00 <0.001 +3.35 <0.001 
CDS1 (PFB) +1.72 <0.001 +2.23 <0.001 
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SHANK2 (PFB) +2.33 <0.001 +2.47 <0.001 
DNAI2 (PFB) +3.25 <0.001 +3.51 <0.001 
SPEF1 (PFB) +1.84 <0.001 +2.00 <0.001 
DNAH6 (PFB) +1.76 <0.001 +1.64 <0.001 
SPAG8 (PFB) +2.24 <0.001 +1.94 <0.001 
AGBL2 (PFB) +2.04 <0.001 +2.29 <0.001 
ZBBX (PFB) +2.08 <0.001 +2.13 <0.001 
ADGB (PFB) +2.39 <0.001 +2.52 <0.001 
CFAP69 (PFB) +1.61 <0.001 +1.71 <0.001 
DNAI1 (PFB) +2.07 <0.001 +1.77 <0.001 
CCDC81 (PFB) +1.52 <0.001 +1.66 <0.001 
RIBC2 (PFB) +1.57 <0.001 +1.33 <0.001 
TUBA4B (PFB) +3.10 <0.001 +3.81 <0.001 
SH3GL3 (PFB) +0.95 0.005 +1.70 <0.001 
Table 5-5: Signature genes of the PFA and PFB molecular subgroups as defined by Witt et. 
al., compared to differentially expressed genes in groups PF1 and PF2 in the FFPE and FF 
cohorts. LFC: Log2 Fold Change. FDR: False Discovery Rate. 
To further investigate the overlap of PF1 and PF2 with the expression patterns of 
EPN_PFA and EPN_PFB, more comprehensive lists of differentially expressed 
genes associated with the nine ependymoma subgroups were obtained (Pajtler et 
al., 2015). The Pajtler dataset contained 715 EPN_PFA associated genes, 696 of 
which could be evaluated in both FFPE and FF cohorts; and 1267 EPN_PFB 
associated genes, 1221 of which could be evaluated in both FFPE and FF cohorts. 
The overlap between the Pajtler genes and FFPE and FF cohorts were evaluated 
using the hypergeometric test. 
 
In the FFPE cohort, 396 (56.8%) EPN_PFA genes were significantly upregulated in 
the PF1 compared to the PF2 group (p<0.001), and 633 (90.9%) genes exhibited 
the same direction of fold change as seen in EPN_PFA (p<0.001). 706 (57.8%) 
EPN_PFB genes were significantly upregulated in the PF2 compared to the PF1 
group (p<0.001), and 1060 (86.8%) exhibited the same direction of fold change 
as seen in EPN_PFB (p<0.001) (Figure 5-21). 
 
In the FF cohort, 320 (46.0%) EPN_PFA genes were significantly upregulated in 
the PF1 compared to the PF2 group (p<0.001), and 544 (78.2%) exhibited the 
same direction of fold change as seen in EPN_PFA (p<0.001). 657 (53.8%) 
EPN_PFB genes were significantly upregulated in the PF2 compared to PF1 group 
(p<0.001), and 1059 (86.7%) exhibited the same direction of fold change as 
seen in EPN_PFB (p<0.001) (Figure 5-21). 
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Figure 5-21: Summary of the overlap between PF1 and PF2 groups with PFA and PFB gene 
expression profiles (Pajtler et. al. 2015). PF1 and PFA overlap in (A) the FFPE dataset and 
(B) the FF dataset. PF2 and PFB overlap in (C) the FFPE dataset and (D) the FF dataset. All 
overlaps were highly significant as determined by the hypergeometric test, p<0.001. 
Datasets generated by this study appear in red, the Pajtler dataset genes appear in green. 
 
To further validate the two PF subgroups, gene level comparisons were made 
between the FFPE and FF cohorts. The PF1 compared to the PF2 subgroup had 
1062 shared genes significantly upregulated in both FFPE and FF datasets 
(p<0.001). The PF2 compared to the PF1 subgroup had 1585 shared genes 
significantly upregulated in both FFPE and FF datasets (p<0.001) (Figure 5-22). 
 
A 
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Hypergeometric 
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B 
C D 
Hypergeometric 
test P<0.001 
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PFB Genes 
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FFPE PF1 FF PF1 
PFA Genes 
FF PF2 
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Figure 5-22: Venn diagrams illustrating the overlap between significantly differentially 
expressed genes in the two posterior fossa subgroups in the FFPE and FF datasets. (A) The 
PF1 (EPN_PFA like) subgroup demonstrated 1062 overlapping differentially expressed 
genes between FFPE and FF datasets plus 2471 that were exclusive to the FF samples and 
1300 that were exclusive to the FFPE samples. (B) The PF2 subgroup demonstrated 1585 
overlapping differentially expressed genes between the FFPE and FF datasets plus 1200 
that were exclusive to the FF samples and 1249 that were exclusive to the FFPE samples.  
 
Ontology of PF1 and PF2 subgroups 
Gene ontology analyses were performed on group PF1 and PF2 genes using 
DAVID. Analyses was performed separately on the FFPE and FF datasets and 
shared terms were identified. 
 
52 statistically significant gene ontologies, in the category of biological process, 
were identified for group PF1; including the immune and inflammatory response, 
organisation of the extracellular matrix, and cell adhesion (Table 5-6). Group PF2 
was associated with 15 statistically significant ontologies which were less diverse, 
being mainly related to cilia and microtubule function (Table 5-7).  
A 
B 
Hypergeometric test 
P=<0.001 
Hypergeometric test 
P=<0.001 
PF1 FF PF1 FFPE 
PF2 FF PF2 FFPE 
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GO Term: PF1 FF FDR FFPE FDR 
GO:0006952~defense response <0.001 0.003 
GO:0006954~inflammatory response <0.001 <0.001 
GO:0006955~immune response <0.001 0.020 
GO:0007267~cell-cell signaling <0.001 0.004 
GO:0009611~response to wounding <0.001 <0.001 
GO:0007610~behavior <0.001 0.003 
GO:0055082~cellular chemical homeostasis <0.001 0.041 
GO:0055066~di-, tri-valent inorganic cation homeostasis <0.001 0.044 
GO:0006873~cellular ion homeostasis <0.001 0.049 
GO:0048545~response to steroid hormone stimulus <0.001 0.015 
GO:0042127~regulation of cell proliferation <0.001 <0.001 
GO:0022610~biological adhesion <0.001 <0.001 
GO:0007155~cell adhesion <0.001 <0.001 
GO:0007626~locomotory behavior <0.001 0.003 
GO:0019932~second-messenger-mediated signaling <0.001 <0.001 
GO:0032101~regulation of response to external stimulus <0.001 0.007 
GO:0030198~extracellular matrix organization <0.001 <0.001 
GO:0043062~extracellular structure organization <0.001 <0.001 
GO:0044057~regulation of system process <0.001 <0.001 
GO:0003013~circulatory system process <0.001 0.002 
Table 5-6: List of 20 most significant biological process gene ontology terms upregulated 
in group PF1 compared to PF2 in both FFPE and FF datasets. 
GO Term: PF2 FF FDR FFPE FDR 
GO:0000003~reproduction <0.001 0.002 
GO:0001539~ciliary or flagellar motility <0.001 <0.001 
GO:0022414~reproductive process <0.001 0.002 
GO:0007018~microtubule-based movement <0.001 <0.001 
GO:0019953~sexual reproduction <0.001 0.003 
GO:0007276~gamete generation <0.001 0.009 
GO:0007017~microtubule-based process <0.001 0.006 
GO:0032501~multicellular organismal process <0.001 <0.001 
GO:0032504~multicellular organism reproduction <0.001 0.016 
GO:0048609~reproductive process in a multicellular organism <0.001 0.016 
GO:0006811~ion transport <0.001 <0.001 
GO:0006813~potassium ion transport 0.002 0.005 
GO:0015672~monovalent inorganic cation transport 0.006 0.004 
GO:0030001~metal ion transport 0.034 <0.001 
GO:0006812~cation transport 0.049 0.009 
Table 5-7: List of all 15 significant biological process gene ontology terms upregulated in 
group PF2 compared to PF1 in FFPE and FF datasets. 
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5.3.17 Summary of FFPE and FF clustering 
• Significant levels of overlap were confirmed between FFPE and FF cohorts 
for both PF subgroups (PF1 and PF2); 
• PF1 was a predominantly posterior fossa group consisting of up to 100% 
EPN_PFA tumours. There was significant overlap with EPN_PFA gene 
expression patterns and ontologies; 
• PF2 was a predominantly posterior fossa group consisting of up to 80% 
EPN_PFA tumours, but also a number of non-EPN_PFA entities, including 
EPN_YAP and EPN_PFB tumours. There was significant overlap with 
EPN_PFB gene expression patterns and ontologies; 
• ST was a predominantly supratentorial group containing all of the 
EPN_RELA tumours, and tumours of older children. 
5.4 Discussion and conclusions 
The primary aims of this chapter were to establish: 
(1) Is RNA-seq, from FFPE tissue, feasible on a large scale? 
(2) How does the quality of the data compare to FF samples? 
(3) Is the data of adequate quality to include in investigating other 
research questions? 
(4) What are the potential pitfalls of this approach and can 
recommendations be made to advise future research? 
 
This chapter has demonstrated that paediatric brain tumour samples, fixed in 
formalin and embedded in paraffin for up to 30 years, can be profiled by RNA 
sequencing to produce robust data that reflect known findings. Analysis of this 
large cohort of 106 samples provided adequate data to be able to identify poorly 
performing samples. The key challenge in working with this type of material was 
the risk of bacterial contamination of the RNA, particularly when extracting from 
scrolls instead of tissue cores. 
 
Parameters used for previously published FFPE RNA sequencing studies were 
heterogeneous (Table 5-1), with varying read lengths; read depths; age 
distributions; and a mixture of single- and paired-end sequencing. The findings of 
this chapter therefore contribute to the technical knowledge of FFPE RNA 
sequencing and describe the largest cohort ever presented using brain material. 
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5.4.1 Is RNA-seq from FFPE feasible on a large scale? 
Many of the previous FFPE RNA-seq studies have been limited in size, and 
therefore unable to answer questions about its scalability. The median size of 
previous studies was just five samples, with only three presenting more than 20 
cases (Table 5-1).  This study represents the second largest RNA sequencing 
study from human FFPE tissue found in the literature search and increases the 
overall number of samples from 316 to 422. 
 
19 (18%) FFPE samples clustered into the QC Fail group. Loss of one fifth of 
samples is substantial, and could create difficulties for research investigating 
large cohorts. This is an issue which may not have been detected in smaller 
studies and is therefore an important finding. Despite sample loss, the study 
resulted in the successful sequencing of over 80 FFPE libraries, demonstrating 
that a large-scale approach is feasible.  
 
The library preparation and sequencing on a large scale was a significant 
undertaking. It was critical that these stages of the research were performed by a 
service provider with experience and expertise in this type of project. 
5.4.2 How does FFPE data quality compare to FF data quality? 
The gold standard for assessing the quality of FFPE RNA-seq is to compare with 
FF samples prepared in the same way. Previous attempts to do this have been 
limited by differing methods of library preparation, resulting in exaggerated 
differences between the two sample types. In one study, where FF libraries 
underwent the poly-A tail selection method of RNA enrichment, and the FFPE 
samples underwent ribodepletion, there were over 11,000 differentially expressed 
genes, many of which were related to non-coding sequences (Jovanović et al., 
2017). In fact, there was only a single study in the literature review where library 
preparation had been the same for both FF and FFPE samples (Hedegaard et al. 
2014). The number of differentially expressed genes ranged from 2000-7000, 
which is more consistent with the 1188 genes identified in this chapter. One 
advantage of the present approach, therefore, is that both FF and FFPE samples 
underwent whole transcriptome RNA-seq library preparation following 
ribodepletion. 
 
RIN values were measured for all FF samples to ensure that they were above 
seven. RIN values were not measured for the FFPE samples as they are known to 
be low in this type of material. A recent study of nucleic acid extraction from 108 
FFPE samples demonstrated that 99% had a RIN score below three (Yakovleva et 
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al., 2017). Therefore, knowledge of the exact values would not have changed the 
approach to sequencing. 
 
The input requirements for the cDNA synthesis for the FFPE RNA-Seq was 600-
1000 ng. This is in line with previous publications using whole transcriptome RNA-
seq on FFPE (Esteve-Codina et al., 2017; French et al., 2017; Guo et al., 2016; 
Haile et al., 2017; Just et al., 2016; Li et al., 2014; Norton et al., 2013; Sinicropi 
et al., 2012; Vukmirovic et al., 2017). This was much higher than the 
requirement for FF tissue (100 ng). The nature of this higher requirement meant 
that 20% of samples were excluded on the basis of RNA yield. There is hope that 
this requirement may reduce in the future as biotechnology companies produce 
alternative library preparation kits and sequencing approaches. An example of 
this is Illumina’s RNA access kit, which claims to only need 20 ng of input RNA 
from FFPE material (Illumina, USA). However, this kit is focussed on capturing 
regions of coding RNA, meaning that it cannot assess the whole transcriptome.  
 
This study identified an association between the concentration of the input RNA 
and sequencing outcomes; samples with higher concentrations appeared to 
perform better when judged by read alignment statistics. Higher quality RNA may 
be more highly concentrated, or RNA at very low concentrations may be 
measured less accurately by the spectrophotometer. No association was found 
between measures of RNA purity (260/280 and 260/230 values) and alignment 
quality, despite many of the 260/230 values being suboptimal.  
 
A discrepancy was identified in the number of reads generated by each sample 
type. Whilst both sequencing runs generated a median value of reads close to the 
target (50 million per sample), the FFPE cohort had a much wider range of values 
than the FF cohort. This was believed to be due to the more degraded nature of 
the RNA from the FFPE blocks, making it a more challenging material to sequence 
(personal communication, L Klitten, Exiqon). The increased variability in the FFPE 
cohort makes planning future experiments challenging, because it cannot be 
guaranteed that the target number of reads will be obtained for any specific 
sample. 
 
The FF samples had marginally more reads removed through trimming than the 
FFPE samples (4.7% versus 3%). Whilst this was statistically significant, the 
magnitude was small and is likely to have a negligible effect on downstream 
processes. Only one study of whole transcriptome RNA-seq reported on the level 
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of read trimming in FFPE compared to FF samples, and found that in two of their 
three datasets there was more trimming in the FFPE reads, and in the third 
dataset there was more trimming in the FF reads (Hedegaard et al. 2014). It is 
probable that the level of read trimming is affected by the RNA extraction 
processes and the parameters of each sequencing run, and not necessarily 
directly by the nature of FF versus FFPE tissue. Despite the small difference in 
medians, the distribution between the two groups was very different. The FF 
samples had a small range of reads removed, whereas in the FFPE dataset, seven 
percent of samples lost over 10% of reads, again highlighting the greater 
variability of the FFPE cohort. 
 
There was no difference in the levels of ribosomal reads between the two cohorts. 
Overall, 3-4% of reads were removed during the abundant sequences filtering, 
which is consistent with some studies (Hedegaard et al., 2014; Zhao et al., 2014) 
but higher than others (Haile et al., 2017; Jovanović et al., 2017; Li et al., 2014; 
Sinicropi et al., 2012) and is likely a product of the specific protocol used for 
ribodepletion. Both had some libraries with greater than 10% rRNA content and, 
interestingly, these were consecutively processed samples. It is likely that for 
these samples that the ribodepletion efficiency fell for technical reasons. Overall, 
ribodepletion seemed to be equally effective in both FF and FFPE tissue. 
 
Whilst the FFPE cohort was associated with a significantly lower rate of alignment 
to the human genome than the FF cohort (83.9% versus 72.1%), the level of 
alignment was still consistent with previously published data (Haile et al. 2017; 
Jovanović et al. 2017; Esteve-Codina et al. 2017; Vukmirovic et al. 2017; Guo et 
al. 2016; Just et al. 2016; Li et al. 2014; Hedegaard et al. 2014; Morton et al. 
2014; Norton et al. 2013; Xiao et al. 2013; Sinicropi et al. 2012). Some studies 
reported rates of alignment up to 95% (Esteve-Codina et al., 2017; Haile et al., 
2017; Jovanović et al., 2017), however, these used small datasets. The only 
other large study generated an average read alignment of 69.45% (Sinicropi et 
al., 2012). This lower rate of alignment is consistent with the values described for 
the current study, leading to the conclusion that an alignment rate above 90% 
may not be realistic across a larger, more diverse sample set. 
 
There was a strong negative correlation between reads aligning to the human and 
bacterial genomes (r=-0.95), suggesting that the limiting factor in human 
genome alignment was contamination with bacteria, rather than RNA 
degradation. This was emphasised by the finding that when all FFPE samples with 
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less than 10% bacterial reads were analysed, median human genome alignment 
was 78.3%; in keeping with levels seen in FF tissue. There is no evidence to 
suggest that this has been identified in other published datasets, even in those 
with low levels of read alignment, where this was generally attributed to poor 
RNA quality (Guo et al., 2016; Morton et al., 2014; Vukmirovic et al., 2017; Xiao 
et al., 2013).  
 
FastQC analysis (Andrews, 2010) was performed to investigate the possible 
causes for differences between FF and FFPE samples. Surprisingly, few studies 
provided a detailed report of their FastQC or equivalent analysis. The only 
exceptions being three studies which provided information on GC content 
(Esteve-Codina et al., 2017; Graw et al., 2015; Guo et al., 2016). Unfortunately, 
all of these studies were small with a combined total of 14 samples. The key 
differences between FF and FFPE samples were found to be the Phred quality 
scores, GC content, ‘N’ content, duplication levels and levels of adapter read-
through. 
 
The distribution of Phred scores was different between the two cohorts, with FFPE 
samples exhibiting some Phred scores under 15. However, both cohorts 
demonstrated acceptable scores overall, confirming that the technical quality of 
the sequencing was good.  
 
When assessing GC distribution, both cohorts had a smooth peak at 35-42%. This 
was consistent with the GC content of the human genome (39.3%), although 
below that of protein coding sequences (48.9%) (Guo et al., 2016). The inclusion 
of numerous non-coding sequences in whole transcriptome RNA-seq may explain 
why the values are more consistent with the human genome content rather than 
just the protein coding sequences. It is highly probable that the 35-42% peak 
represented human RNA. 
 
The two cohorts had differing additional GC peaks. The FFPE cohort demonstrated 
a further ‘spike’ at 54%. Interestingly, Graw and colleagues also reported a 
similar peak at 56% in their FFPE dataset of six samples. They attributed this to 
increased levels of intronic sequences (Graw et al., 2015). However, in the 
present study this peak was strongly associated with those samples that had high 
alignment to the bacterial genome. This GC peak is therefore more likely to 
represent bacterial, rather than intronic, sequences. The FF samples 
demonstrated several ‘shoulders’ at 47-63% which were associated with rRNA 
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contamination. These samples had been randomised to the library preparation 
process consecutively, suggesting a partial failure of the ribodepletion step. This 
was therefore not specific to sample type. 
 
This study used a read length of 100 bases, which was longer than most reported 
research (Table 5-1). As FFPE material is known to be more degraded, it was 
hypothesised that the fragments being sequenced would be shorter than the FF 
equivalents. This was supported by a significantly shorter insert length, increased 
‘N’ content and increased adapter read-through towards the end of each read in 
the FFPE cohort. With shorter sequences, by the time the sequencer reaches 
higher base positons in the read, it is reading either into the adapter sequence or 
beyond the end of the fragment. This results in either high levels of adapter 
content or insertion of ‘Ns’ in the output. This is unlikely to have any impact on 
downstream analysis, as adapter and ‘N’ sequences are removed by trimming. 
Only two previous FFPE studies used a read length beyond 75 bases (Hedegaard 
et al., 2014; Morton et al., 2014) but neither reported on the adapter or ‘N’ 
content at higher base positions. It may be better to use a shorter read length to 
prevent this ‘wasted’ sequencing. 
 
Consistent with a previous study (Esteve-Codina et al., 2017), FFPE 
demonstrated less library complexity than FF samples. Samples with the highest 
duplication levels in the FFPE cohort were also those that had very high levels of 
bacterial reads. This reduction in complexity therefore resulted from repeated 
sequencing of high levels of bacterial rRNA. These reads were removed during the 
filtering steps, but again represented ‘wasted’ sequencing.   
 
To quantify gene expression, only reads mapped to exons were counted. There 
was a large difference between the FFPE and FF cohorts, with exon mapping of 
23.2% and 43.7% respectively. The numbers for both datasets were lower than 
for poly-A enriched libraries, as ribodepletion does not remove unspliced and 
nascent RNAs, which may subsequently align to introns. It has been reported that 
brain tissue is enriched for nascent RNAs and it would therefore be anticipated 
that a greater proportion of reads align to introns, irrespective of library 
preparation methods (Ameur et al., 2011). The fact that the FFPE samples had 
even lower exonic fragments than FF supports the findings of previous FFPE, non-
brain, studies where exonic fragments have been reported to be as low as 10-
13% of total mapped reads (Hedegaard et al., 2014; Sinicropi et al., 2012). The 
reasons for this are unclear. One way to overcome this problem would be to 
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increase the number of reads sequenced, to counter this large loss of reads at the 
exon mapping step, thus increasing the absolute number of reads aligning to 
exons. 
 
FFPE samples had significantly fewer genes identified than FF. This is likely due to 
the fact that there were fewer reads, and a lesser proportion of reads mapping to 
exons in the FFPE cohort. No evidence was found to suggest that this was due to 
a lesser quality of FFPE RNA. The number of genes identified per FFPE sample 
was consistent with that reported by some FFPE studies (Haile et al., 2017; 
Morton et al., 2014) but much higher than others (Li et al., 2014; Sinicropi et al., 
2012; Vukmirovic et al., 2017). However, it was evident in the FFPE cohort that 
the variation was high (1651 genes for the worst performing sample to 31270 for 
the best) and this must be taken into consideration when assessing the quality of 
an FFPE RNA sequencing run.  
 
For both FFPE and FF cohorts the level of correlation between biological replicates 
was high, even prior to normalisation, with median correlation coefficients of 0.85 
and 0.88 respectively. Differences between FFPE and FF cohorts were apparent in 
the variability of the FFPE; following normalisation, the range of coefficients for 
the FFPE cohort was 0.57-1.00 compared to 0.91-1.00 in the FF cohort. This 
again emphasises the need for removal of poor quality samples.  
 
The level of correlation between paired FFPE and FF technical replicates was high; 
the mean correlation coefficient was 0.85, increasing to 0.98 with normalisation. 
This suggests that despite some technical differences between the two cohorts, 
the FFPE and FF sequencing results were highly similar for matched pairs. This is 
encouraging in terms of the technical reliability of the FFPE RNA-seq. It would be 
surprising if technical replicates reached 100% similarity, given that samples 
would have been obtained from different areas of the same tumour. Little is 
known about the level of intra-tumour heterogeneity in ependymoma, but at the 
microscopic level there is variation across tumour samples. 
5.4.2.1 Challenges specific to FFPE samples 
This study was unique in obtaining FFPE tissue samples from a mixture of scrolls 
and cores. This provided an opportunity to compare the impact of these 
approaches on alignment to the human genome. The difference in tissue 
sampling appeared to be the largest factor in determining the level of bacterial 
contamination of the samples, with cores demonstrating a significantly higher 
median number of reads aligning to the human genome compared with scrolls 
 146 
(77% versus 42%, p<0.001). A search of the literature was unable to find any 
other study that had attempted to investigate this question. Therefore, this is 
both a critical and novel finding, leading to the recommendation that samples 
sequenced from FFPE should be taken from cores where possible. Should use of 
scrolls be unavoidable, they should not be taken from the block surface.  
 
Based on the theory that older blocks would contain more degraded RNA, it was 
hypothesised that the age of the block may have an impact on sequencing 
outcomes. The findings of this study were not consistent with this hypothesis. In 
fact, some of the best performing runs actually resulted from the oldest blocks. 
The oldest sample in the analysis had been in storage for almost 28 years, yet 
still had a human genome alignment rate of 77.8% and identified 26864 genes. 
Blocks in storage for more than 20 years did not have a significantly different 
alignment rate to those in storage for less than 20 years (p=0.79). This finding 
contradicts the work of other authors who have suggested that older blocks result 
in poorer sequencing runs (Hester et al., 2016; Jovanović et al., 2017).  
 
In comparison to previous publications, this study investigated older blocks (eight 
blocks in excess of 20 years, median 11.7 years). The age of the blocks was 
unreported in five, less than 10 years in nine and 10-20 years in two studies. One 
study sequenced a single sample of 94 years storage time, however no other 
human study included samples exceeding 20 years in age (Xiao et al., 2013). 
Consequently, a possible explanation for the lack of age related differences in this 
research, is that nucleic acid deterioration occurs early on in the storage process 
and, therefore, samples beyond a certain age do not show measurable differences 
in quality. Given that the effect of storage time on nucleic acids has been the 
subject of some debate it was surprising that 6 of the 19 relevant investigations 
did not clearly report the age of the blocks used (Table 5-1). 
5.4.3 Is the data of adequate quality to use in answering other research 
questions? 
The finding that RNA sequencing of FFPE is technically possible on a large scale is 
positive for researchers who wish to perform molecular profiling on historical 
cohorts of patients with rare disease. However, despite demonstrating the 
technical feasibility of this approach, it still needed to be shown that the data was 
adequate to analyse a clinical cohort. One of the challenges was that a lack of 
research in this area has meant that there are no clear quality control parameters 
guiding which samples should be removed from downstream analysis. Therefore, 
the FFPE was directly compared with the FF cohort and previously published work 
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to check its performance in a clinical analysis. 
 
Unsupervised hierarchical clustering of the FFPE cohort generated distinct 
subgroups relating to tumour location, which were supported by DNA methylation 
class predictions. Crucially, clustering identified an additional group of poor 
quality samples, with very low human genomic reads as a result of enrichment of 
bacterial sequences. It was of interest that this poor-quality group was also 
significantly less likely to produce DNA methylation class predictions, suggesting 
there may be global problems with the samples, preventing molecular profiling.  
 
In both cohorts, the gene expression and ontology analyses of the two PF groups 
(PF1 and PF2) were highly consistent with previously described EPN_PFA and 
EPN_PFB tumours (Pajtler et al. 2015, Hoffman et al. 2014a; Pajtler et al. 2015; 
Witt et al. 2011). Interestingly, most of the DNA methylation class predictions in 
both PF1 and PF2 groups were for EPN_PFA. In fact, only two EPN_PFB specimens 
were identified across both datasets. Consequently, the PF clustering was 
suggestive of two EPN_PFA molecular subgroups, supporting the analysis of the 
DNA methylation profiles in Chapter 4. This data indicated that EPN_PFA and 
EPN_PFB expression patterns are not always suggestive of EPN_PFA and EPN_PFB 
tumours, but may be seen in subtypes of EPN_PFA. This needs to be corroborated 
by further research, but has the implication that using gene expression profiling 
alone may result in misleading interpretations of ependymoma clustering.  
 
In both cohorts, the PF2 group consisted of tumours with a number of DNA 
methylation profiles, the majority of which were EPN_PFA. However, the PF1 
group consisted almost exclusively of DNA methylation defined EPN_PFA tumours. 
This suggested that one subgroup of EPN_PFA (PF1) has very distinct gene 
expression patterns, whilst the other (PF2) may have patterns similar to other 
ependymoma types. This may also have arisen as a result of the relatively low 
numbers of non-EPN_PFA tumours being unable to form a separate cluster. It 
also explains why a number of ST tumours, particularly EPN_YAP, clustered into 
the PF2 group. 
 
In view of the ability of the FFPE RNA-seq to reflect previously described 
clustering, gene expression and ontology patterns, and to correlate strongly with 
the patterns in the FF cohort, it was decided that it was appropriate to continue to 
use these results in the analysis of matched primary and recurrent ependymoma 
in the remainder of the thesis.  
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5.4.4 What recommendations can be given to future researchers? 
The recommendations that should be applied to future FFPE RNA sequencing 
studies are: 
(1) Minimising bacterial contamination: 
a. Specimens should be taken from cores of blocks rather than scrolls. 
If scrolls are necessary, they should not be from the surface of the 
block but the first few sections should be discarded; 
b. Consideration should be given to performing PCR to identify 
bacterial ribosomal sequences in the extracted RNA prior to 
sequencing. Removal of contaminated samples at this stage may 
minimise costs of wasted sequencing. 
(2) Dealing with shorter RNA fragments: 
a. RIN measurements may not be helpful for FFPE RNA-seq in view of 
known high levels of degradation. However, it is unnecessary to 
sequence with long read lengths due to the high number of 
uninformative calls towards the end of reads. 25-50 base pairs may 
be more appropriate than 100 but further research is needed to 
confirm the exact number. 
(3) Number of reads: 
a. A higher read target (in excess of 50 million) should be generated 
for each sample in view of the variability of FFPE samples. This 
would ensure a higher minimum number of reads and increase the 
absolute number of reads mapping to exons.  
(4) Identifying poorly performing samples: 
a. An unsupervised clustering approach to quality control may be 
appropriate for investigators using large sample sets. For those 
with smaller numbers further work is needed to identify quality 
control cut-offs for excluding samples. In this study samples with 
human genome aligning reads of <20% clustered into the QC fail 
group. 
(5) Planning for sample loss: 
a. Up to 20% of samples may be lost due to quality inadequacies. 
This needs to be taken into account when planning projects;  
b. On the basis of this study, sample age should not be a barrier to 
inclusion. 
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5.4.5 Summary 
The decision to undertake RNA-seq of FFPE samples was made in an attempt to 
improve the power of the primary and recurrent ependymoma study, and 
represented a novel approach to addressing this problem.  
 
Few studies have published FFPE RNA-seq data and of those that have, only two 
included more than 25 samples, making the understanding of the utility of this 
approach in larger datasets relatively unknown. Additionally, no other studies 
have yet been conducted using paediatric brain tumour samples. 
 
This chapter has demonstrated that NGS of RNA from large sets of archival tissue 
specimens is feasible and can produce results which replicate known patterns. 
Challenges of FFPE RNA sequencing were: obtaining adequate RNA yields; 
increased variability in data; shorter fragment lengths; and contamination with 
bacterial reads. These problems could be overcome in the future with the 
potential of new RNA extraction kits, modifying read parameters, and clustering 
approaches to identify poorly performing samples. 
 
Data from the FFPE cohort reflected the findings of the FF cohort and previously 
published studies with regards to molecular subgrouping. It has also provided 
supporting evidence for the presence of more than one EPN_PFA molecular 
subgroup, which has previously been proposed by an international collaboration 
which included DNA methylation profiles from this study. 
 
The FFPE samples that performed well in this analysis were taken forward to the 
analysis of matched primary and recurrent ependymoma described in the 
remainder of the thesis.
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6 RNA Sequencing of Matched Primary and 
Recurrent Ependymoma Pairs 
6.1 Introduction 
Despite much research into the underlying biology of primary paediatric 
ependymoma, with the exception of two studies, little is known about tumour 
biology at recurrence (Peyre et al., 2010; Hoffman et al., 2014a). Given that 
there are no specific treatments for recurrence after radiotherapy (Peyre et al., 
2010), a better understanding of the biological behaviour of these tumours is 
warranted to provide further insights into possible therapeutic interventions. By 
using paired samples, a clearer picture can be obtained of changes at recurrence 
by minimising the impact of inter-individual variation on the study design (Peyre 
et al., 2010). 
 
Previous authors (Hoffman et al., 2014a; Peyre et al., 2010) have investigated 
matched primary and recurrent ependymomas, but neither used RNA sequencing. 
Using gene expression arrays, Hoffman and colleagues identified immune system 
changes as being important in the posterior fossa molecular subgroups; whilst 
Peyre identified increases in kinetochore proteins alongside downregulation of 
metallothioneins at recurrence (Chapter 1.4.4). Peyre also identified the 
downregulation of a number of immune related genes. On the basis of these 
overlapping findings, further consideration of the immune system in recurrent 
ependymoma was warranted. 
 
Recent research on cancer and the immune response has defined ways to 
investigate immune activity in tumours, based on gene expression data from 
whole tumour samples. 
 
A report by a group at the University of Innsbruck described the creation of the 
Cancer Immunome Atlas (TCIA), based on patient samples derived from the 
Cancer Genome Atlas (TCGA) (Charoentong et al., 2017). This report introduced 
the concept of the immunophenoscore, based on RNA sequencing of whole tissue 
samples from tumour specimens. The immunophenoscore is a marker of tumour 
immunogenicity and was developed from a panel of immune related genes, 
divided into subcategories, based on function: 
(1) Effector cells; 
 151 
(2) Immunosuppressive cells; 
(3) Major histocompatibility (MHC) molecules; 
(4) Immunomodulators.   
Increased cancer mutational load was associated with a higher 
immunophenoscore (Charoentong et al., 2017). The immunophenoscore was also 
found to be a predictor of response to immune checkpoint blockade in patients 
with melanoma.  
 
Rooney and colleagues investigated properties associated with local cytolytic 
(CYT) activity (Rooney et al., 2015). CYT is a measure of T-cell effector activity is 
considered important because it is the final step in tumour cell killing. CYT was 
scored based on expression levels of Perforin (PRF1) and Granzyme A (GZMA), 
which assessed the level of CD8+ T-cell effector activity within tumour. (Rooney 
et al., 2015). 
 
Another suggested mechanism by which tumours can up- and downregulate their 
immune profile is the expression or suppression of CTAs (Almeida et al., 2009). 
These are genes with restricted expression in normal tissue, being expressed only 
in the human germ line and numerous cancers (Simpson et al., 2005). They are 
immunogenic and have been identified as potential therapeutic targets for cancer 
vaccines; phase I and II trials have been conducted (Krishnadas et al., 2015). 
Whilst there are some reports of studies of specific CTAs in mixed cohorts of 
glioma (Grizzi et al., 2006; He et al., 2014; Li et al., 2017) there was no evidence 
of published data on CTA expression in cohorts of recurrent paediatric 
ependymoma. 
 
Chapter Aims 
This chapter aimed to: 
• Compare gene expression at primary diagnosis compared to matched 
recurrence across FF and FFPE datasets based on: 
o All tumours combined; 
o Location; 
o Molecular designation. 
• Consider the impact of therapy on differential expression at recurrence; 
• Assess the role of the immune system in primary and recurrent 
ependymoma using predefined scoring systems (immunophenoscore and 
cytolytic activity score) plus consideration of CTAs. 
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6.2 Materials and methods 
The RNA-seq data of FFPE and FF cohorts validated in Chapter 5 were used for 
the analysis of matched primary and recurrent ependymoma pairs. 
6.2.1 Differential expression analysis 
Raw gene expression data was analysed using EdgeR for differential expression 
analyses as described in Chapter 5.2.2. All analyses in this chapter were paired 
tests. 
6.2.2 The hypergeometric test 
As described in Chapter 5.2.4, the hypergeometric test was performed to 
compare the significance of the overlap of differentially expressed genes, 
between FF and FFPE cohorts. It was based on the number of matching genes, 
with an unadjusted p-value of <0.05, in each cohort. 
6.2.3  RNA-seq meta-analysis 
RNA-seq meta-analysis was performed using the R package ‘metaRNASeq’ (Rau 
et al., 2014). This generated lists of shared differentially expressed genes across 
FFPE and FF datasets, and created ‘signature sets’ of differentially expressed 
genes for recurrence. Not only did this approach allow p-values to be combined, 
using Fisher’s combined probability test (Fisher, 1925; Fisher and Mosteller, 
1948), but it also allowed the application of an FDR correction to resultant gene 
sets.  
6.2.4 Gene enrichment analysis 
Details of the methodology for gene enrichment analyses are provided in section 
5.2.5. As the GOrilla analyses tended to produce very long lists of terms, ‘Reduce 
and Visualise Gene ontology’ (REVIGO) (Supek et al., 2011) was used in an 
attempt to develop a better understanding of these lists. This software removed 
redundant terms from long lists of ontologies and then displayed the remaining 
terms in semantic scatterplots based on their similarity to each other. 
 
Enriched gene lists were entered into the REVIGO web based platform 
(revigo.irb.hr) after extracting them from GOrilla (Eden et al., 2009), and 
scatterplots were modified in the R statistical environment for visualisation.  
6.2.5 Normalisation and transformation of counted reads 
Transcript per million (TPM) normalised data was used for immunophenoscore, 
CYT and CTA analyses as they were unable to manage raw data (Charoentong et 
al., 2017; Rooney et al., 2015). Samples were TPM normalised by correcting for 
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the number of reads (number of counts per million mapped reads) and gene 
length (number of counts per kilobase). TPM was calculated within the R 
statistical environment using the GenomicFeatures and R base packages 
(Lawrence et al., 2013; R Core Team, 2014) (Appendix 3). TPM values were then 
transformed by a log2 conversion to account for the high variance of lowly 
sampled genes (Love et al., 2014).  
6.2.6  Generation of ependymoma immunophenoscores 
Immunophenoscores were calculated from log2 normalised TPM values. The 
results were generated in the R statistical environment using the published 
immunophenoscore script (Charoentong et. al., 2017). Results were also 
generated for the four individual components of the immunophenoscore: antigen 
presentation (MHC); effector immune cells (EC); suppressor immune cells (SC); 
and checkpoint inhibitors or stimulators (CP).  
6.2.7 Calculation of immune cytolytic activity (CYT) 
CYT was measured by calculating the geometric mean of the TPM for Perforin 
(PRF1) and Granzyme A (GZMA), for each sample, as outlined in a previous study 
(Rooney et al., 2015). 
 
The formula used was: 
 
Immune Cytolic Activity = Ö(PRF1 * GZMA) 
 
6.2.8  Cancer-Testis antigen analysis 
A list of verified CTAs was obtained from the CTDatabase (cta.Incc.br). CTAs with 
low expression across both FFPE and FF datasets (TPM less than one) were 
removed. The remaining CTAs were compared to the differentially expressed 
gene lists for primary and recurrent samples to identify CTAs that changed at 
recurrence. 
6.2.9 Cell culture and cell lines 
BJ hTERT + SV40 Large T+ (BJLE) (Weinberg et al., 1999) were used in this 
study, which were kindly provided by Professor Robert Weinberg (Professor for 
Cancer Research at the Massachusetts Institute of Technology). 
 
Cells were cultured in a medium consisting of Knockout DMEM (Thermo Fisher 
Scientific, USA), 14.5% Fetal Bovine Serum (Thermo Fisher Scientific, USA), 
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16.5% Medium 199 (Thermo Fisher Scientific, USA), 1.76 mM L-Glutamine 
(Sigma, UK) and 0.88% penicillin-streptomycin (Sigma, UK). 
 
To recover cells, cryovials were thawed quickly, in a 37oC water bath, before 
being transferred to a T25 flask (Eppendorf AG, Hamburg, Germany, Catalogue 
No. 0030710118) in 5 ml of culture medium. Flasks were placed in a standard 
5% CO2-air incubator (Panasonic, UK) at 37ºC. After 24 hours, the flasks were 
inspected under a microscope (Olympus, UK) to ensure that cells had adhered, 
before the culture medium was replaced. 
 
Cells were grown in T75 flasks (Eppendorf AG, Hamburg, Germany, Catalogue 
No. 0030711122) and passaged when they reached approximately 70% 
confluence (48-72 hours). At each passage, cells were washed with 10 ml Hank’s 
Balanced Salt Solution (HBSS) (Thermo Fisher Scientific, UK) before incubation at 
37ºC with 2ml of 1X Trypsin-EDTA (Sigma, UK) for five minutes, until the cells 
had detached. 10 ml of media were added to inhibit the trypsin and the resultant 
solution was split into new flasks in a ratio of 1:2 to 1:5. The flasks were then 
placed in the incubator for cells to adhere and grow. 
6.2.10 cDNA synthesis for qPCR 
For the purposes of the validation experiments, all of the cDNA was synthesised 
simultaneously to minimise the impact of varying conversion efficiencies. It was 
not possible to use the same cDNA created for the sequencing libraries. 
 
RNA was treated with DNase to reduce genomic contamination. For each sample, 
1 µg of RNA was incubated with 2 µl of DNase (Promega, USA) and 2 µl of DNase 
buffer (Promega, USA), then made up to a total volume of 20 µl with double 
distilled water. The mixture was incubated at 37oC for 30 minutes before the 
addition of 2 µl stop buffer and incubation at 65oC for 15 minutes. 
 
Next, half of the RNA was transferred to a second vial. One vial was labelled RT 
(reverse transcriptase) and the other NRT (no reverse transcriptase). Two master 
mixes were created (RT mastermix and NRT mastermix) (Table 6-1). 10 µl of RT 
and NRT master mixes were added to each RT and NRT vial respectively. Samples 
were then incubated on a thermal cycler (Techne, UK) for ten minutes at 25oC, 
one hour at 42oC and five minutes at 70oC. 40 µl of nuclease free water was 
added to each sample before storage at -20ºC. 
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Reagent Amount per sample Manufacturer 
5x Revertaid buffer 4 µl 
Thermo Scientific, UK RNAse inhibitor 0.5 µl 
dNTP mix 2 µl 
Oligo dTs 1 µl Eurofins genomics, Germany 
Random primers 50 ng Thermo Scientific, UK 
Double distilled water 1.5 µl - 
Reverse transcriptase 1 µl* Thermo Scientific, UK 
Table 6-1: Table of reagents for the RT and NRT mastermixes. *For the NRT mastermix 
the reverse transcriptase was replaced with an additional one microlitre of water. 
6.2.11 qPCR primer design 
Transcripts for selected genes were identified using Ensembl 
(http://www.ensembl.org). Primers were designed based on these transcripts 
using the NCBI Primer Blast software 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer Blast settings were 
modified to: identify PCR products of 50-200 base pairs; include introns (to 
prevent amplification of genomic DNA); and allow amplification of splice variants.  
 
Primer Blast results were analysed to identify primers of 20-25 base pairs with 
balanced GC composition, and no guanine at the five-prime end. The selected 
primers were pasted into NCBI Nucleotide BLAST (Basic Local Alignment Search 
Tool) (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and compared to human 
sequences to ensure specificity to the gene of interest.  
 
Primers were supplied in lypophilised format by Eurofins Genomics (Ebersberg, 
Germany) and diluted to a concentration of 100 pmol/µl with nuclease free water 
to make a stock solution. 
 
The genes of interest were C-X-C motif chemokine ligand 12 (CXCL12), 2’-5’ 
Oligoadenylate synthetase 1 (OAS1), 2’-5’ Oligoadenylate synthetase 2 (OAS2), 
2’-5’ Oligoadenylate synthetase 3 (OAS3), Bone marrow stromal cell antigen 2 
(BST2) and Radical S-adenosyl methionine domain contain 2 (RSAD2). Primers 
were also generated for glyceraldehyde-3-phopshate dehydrogenase (GAPDH) as 
a normalising gene (Table 6-2).  
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Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
OAS1 CGAGGTAGCTCCTACCCTGT TCTCCCCGGCGATTTAACTG 
OAS2 CAGGAACCCGAACAGTTCCC GGACAAGGGTACCATCGGAG 
OAS3 CGCGGAAGGAGTTCGTAGAG AAGCAGTCGAGGAAGATGACAA 
BST2 GCGTCCTGAAGCTTATGGTTT TTCAGGATGTGGAGGCCCA 
RSAD2 GCAAAGTAGAGTTGCGGCTG CCACGGCCAATAAGGACATTG 
CXCL12 TGAGCTACAGATGCCCATGC CTTCAGCCGGGCTACAATCT 
MX1 ATCTGGAGTGAAGAACGCCG CAGCTGGATCAGCTTTTGCG 
GAPDH TCTGGCCCCCTCTGCTGATGC GGTGGCAGTGATGGCATGGAC 
Table 6-2: Summary of primer sequences used for the qPCR validation of the RNA 
sequencing data. 
6.2.12 Polymerase chain reactions (PCR) 
PCR involves the amplification of few copies of cDNA to a detectable level, 
through the generation of a complementary strand to a DNA template. The 
reaction consists of three main steps:   
(1) Denaturation: Breaking apart the complementary cDNA strands; 
(2) Annealing: The attachment of forward and reverse primers to denatured 
cDNA; 
(3) Extension: Synthesis of the remainder of the complementary strand by 
extending the primer sequences under the activity of DNA polymerases. 
The steps are repeated 40 times with a doubling of the amount of cDNA each 
time. 
 
The contents of each reaction are outlined in Table 6-3. For each PCR experiment, 
a mastermix was made up by calculating the volume for the number of reactions 
required and adding 10%. 24 µl of mastermix was then added to each well of an 
unskirted 96-well plate (Bio-Rad, UK) before the addition of either cDNA 
template, no template control or negative control (RNAse free water).  
 
Reagent Amount per well (µl) Manufacturer 
SYBR Green 12.5 Bio-Rad, UK 
Double distilled water 2.5 - 
Forward Primer 2.5 Eurofins Genomics, 
Germany Reverse Primer 6.5 
Table 6-3: Contents of each PCR reaction. 
PCR reactions were performed on a C1000 thermal cycler within the CFX96 Real-
Time System (Bio-Rad, UK). The thermal cycler protocol involved:  
• Initial activation: five minutes at 95oC; 
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• 39 cycles of: 
o Denaturation: 30 seconds at 95oC;  
o Annealing: one minute at the temperature determined during 
primer optimisation;  
o Extension: one minute at 72oC. 
• Final extension: ten minutes at 72oC.  
 
For each reaction, melt curves were generated to ensure that only one product 
was amplified. A read of the fluorescence level was taken after each denaturation, 
annealing, and extension cycle; to determine when the level of fluorescence rose 
above background (the C(t) value). C(t) values were used for calculation of 
primer efficiencies and relative expression levels. 
6.2.13 Primer optimisation and efficiency calculations 
Primers were optimised by temperature gradient end-point PCR and 
electrophoresis, on a 2% (w/v) agarose gel (50 ml TAE, 1 g agar, 1 µl ethidium 
bromide). The brightest bands identified the optimal temperatures. For all 
primers 58oC was adequate.   
 
Primer efficiencies were calculated using the BJLE cells as input cDNA. A serial 
1:2 dilution was made from the neat cDNA and five different known 
concentrations were run on the same 96-well plate. Each reaction was performed 
in triplicate and C(t) values were taken as the mean. The Bio-Rad CFX software 
was used to calculate the primer efficiencies using a regression equation based on 
the mean C(t) values on the y-axis and the log concentration of the input cDNA 
concentration on the x-axis: 
 
y= mx + c 
 
The value of m was the gradient of the slope and was used to calculate the 
efficiency of the primer pair with a standardised equation (Pfaffl, 2001): 
 
E = (10(-1/Gradient))  
Efficiency = E - 1 
 
Target efficiencies were 90-110% for each primer pair. All but one primer pairs 
(MX1, efficiency 154%) achieved this. 
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6.2.14 qPCR comparison of genes in primary and matched recurrences 
One 96 well PCR plate was used per gene validation. On each the BJLE cell line 
was used as the control sample and four primary and matched recurrent tumours 
were investigated. Each sample was run in triplicate and mean C(t) values were 
calculated. Negative and NRT controls were also run for each sample. 
 
Relative gene expression was calculated based on the Pfaffl equation (Pfaffl, 
2001): 
 
Relative Ratio = EtargetDC(t)(control-sample)/EreferenceDC(t)(control-sample) 
 
Where E was the efficiency of the primer pair, control was the mean C(t) value of 
the BJLE cells, sample was the mean C(t) value of the ependymoma specimen in 
question, target was the gene of interest and reference was the reference gene 
(GAPDH). 
 
The relative ratio was the expression level of the gene of interest relative to the 
reference gene, and was used to compare samples to calculate the relative fold 
change of expressed transcripts. Fold change at recurrence was calculated by: 
 
Relative Ratio Recurrent Sample  / Relative Ratio Primary Sample 
 
The fold changes were then compared with those produced by RNA-seq to 
confirm that the genes had a similar direction of fold change at recurrence 
compared to primary disease.  
6.3 Results 
Descriptions of the overall FFPE and FF cohorts, as compared to the clinical 
recurrent cohort, are found in Chapter 5, Table 5-2 and Table 5-3. 
 
For each location and molecular subgroup based comparison between primary 
and first recurrence, Table 6-4 and Table 6-5 outline the number of samples 
included, differentially expressed genes and enriched ontologies. Unless otherwise 
specified, the results quoted for ontology analyses were derived from GOrilla. 
6.3.1 Recurrence across all tumour types 
In order to obtain a global overview of the differences between primary and first 
recurrence across the entire dataset, a differential expression analysis was 
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conducted. This was irrespective of tumour location, molecular subtype or 
therapeutic intervention.  
 
The FFPE and FF cohorts included 25 and 27 matched pairs respectively. The two 
sets were largely independent with overlap between two pairs (25A and B, 26A 
and B). After filtering, 14315 genes were tested in both cohorts.  
 
In the FFPE cohort 652 genes were differentially expressed at first recurrence at 
p<0.05. None met the FDR<0.05 threshold. In the FF cohort 794 genes were 
differentially expressed at first recurrence with p<0.05. Two genes remained 
after FDR correction (RASL10A and ASIC4). Across both cohorts 65 overlapping 
genes were differentially expressed, in the same direction of fold change. This 
was highly statistically significant (p<0.001, hypergeometric test). 
 
When combining the two cohorts in RNA-seq meta-analysis, three genes were 
downregulated at first recurrence with FDR<0.05. These were Elastin microfibril 
interfacer 3 (EMILIN3) (Fold change -3.4, FDR<0.001), Acid sensing ion channel 
subunit family member 4 (ASIC4) (Fold change -2.7, FDR=0.001) and Lipoma 
HMGIC fusion partner-like 3 (LHFPL3) (Fold change -3.8, FDR=0.025).  
 
GOrilla was used to assess whether there was enrichment of comparable gene 
ontologies between FFPE and FF cohorts (Eden et al., 2009). 
 
Across both cohorts, 22 overlapping terms were upregulated at first recurrence 
(p<0.001, hypergeometric test) (Appendix 5). After removal of redundant terms 
with REVIGO (Supek et al., 2011), the remaining terms were related to 
multicellular organismal catabolism, oxygen transport, regulation of response to 
external stimulus, extracellular matrix organisation, regulation of lymphocyte 
proliferation and the immune response (Figure 6-1). 
 
Across both cohorts, 122 overlapping terms were downregulated at first 
recurrence (p<0.001, hypergeometric) (Appendix 5). Terms relating to biological 
adhesion, cell-cell adhesion, cell communication and signalling pathways were 
identified. No immune related ontologies were downregulated (Figure 6-2). 
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Comparison 
Pairs included Genes 
tested 
Genes with p-
value <0.05 
Genes with 
FDR<0.05 
Overlapping 
genes 
(p<0.05) 
Hypergeometric 
p-value (FF vs 
FFPE) 
No. Genes in 
meta-
analysis FFPE FF FFPE FF FFPE FF 
All cases 25 27 14315 652 794 0 2 65 <0.001 3 
Location 
ST 8 - 15330 560 - 0 - - - - 
PF 16 20 14485 475 1217 3 5 40 0.452 8 
Molecular 
groups 
EPN_RELA 5 - 13742 411 - 0 - - - - 
PF1 9 13 14108 569 1759 3 323 102 <0.001 113 
PF2 3 11 14289 499 1219 39 22 55 0.029 47 
Table 6-4: Summary of differential expression analyses of primary compared to first recurrent tumours for location and molecular subgroups. Genes 
tested include number of genes tested after filtering to remove lowly expressed genes. Hypergeometric tests were performed comparing FF and FFPE 
datasets to establish whether the number of significant genes appearing in both cohorts are likely to have occurred by chance (p>0.05) or represent 
significant overlap between the two cohorts (p<0.05). 
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Comparison 
Downregulated terms at first 
recurrence with FDR<0.05 
Hypergeometric p-
value (FF vs FFPE) 
Upregulated terms at first 
recurrence with FDR<0.05 
Hypergeometric p-
value (FF vs FFPE) 
FFPE FF Overlap FFPE FF Overlap 
All cases 171 327 122 <0.001 32 456 22 <0.001 
Location 
ST 30 - - - 459 - - - 
PF 193 168 9 <0.001 191 529 0 1.000 
Molecular 
groups 
EPN_RELA 0 - - - 178 - - - 
PF1 348 496 179 <0.001 6 138 1 0.056 
PF2 306 119 2 0.723 195 684 51 <0.001 
Table 6-5: Summary of GOrilla gene set enrichment analysis of primary compared to first recurrent tumours for location and molecular subgroups. 
14412 biological process gene ontology terms were tested for each comparison. Hypergeometric tests were performed comparing FF and FFPE datasets 
to establish whether the number of significant ontologies appearing in both cohorts are likely to have occurred by chance (p>0.05) or represent 
significant overlap between the two cohorts (p<0.05).  
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Figure 6-1: A scatterplot of non-redundant significantly upregulated gene ontology terms 
at first recurrence across the entire primary and recurrence dataset. The colour of the 
circles represents the p-value and the size of the circle represents the specificity of the 
term (more general terms appear as larger circles). 
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Figure 6-2: A scatterplot of none-redundant significantly downregulated gene ontology 
terms at first recurrence across the entire primary and recurrence dataset. The colour of 
the circles represents the p value and the size of the circle represents the specificity of the 
term (more general terms appear as larger circles). 
 
When considering upregulated ontology terms that did not overlap between the 
two cohorts, the FFPE cohort generated fewer terms than the FF cohort. Of the 10 
gene ontology terms exclusively upregulated at recurrence in the FFPE dataset, 
three (30%) were related to the immune response (GO:0002250 – Adaptive 
immune response, GO:0046641 – Positive regulation of alpha-beta T-cell 
proliferation, GO:0050701 – Interleukin-1 secretion). Of the 434 terms 
exclusively upregulated at recurrence in the FF dataset, 145 (33%) were related 
to the immune response.  
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When considering downregulated ontology terms that did not overlap between 
the two cohorts, the FFPE cohort generated fewer terms than the FF. Of the 49 
terms exclusively downregulated in the FFPE dataset, none were related to the 
immune response. Of the 205 terms exclusively downregulated at recurrence in 
the FF dataset, only one was related to the immune response (GO:0009611 – 
Response to wounding).  
6.3.2  Recurrence in tumours clustering in supratentorial groups 
There were insufficient numbers of primary and matched recurrences clustering 
into the FF ST group for analysis. Therefore, ST location and DNA methylation 
subgroup analyses were based on the FFPE cohort. All eight matched primary and 
first recurrent ST ependymomas were included; five of which were in the 
EPN_RELA DNA methylation subgroup, one in the EPN_YAP subgroup and two 
with HGNET class predictions.  
 
After filtering, 15330 genes were tested. 560 genes were differentially expressed 
at first recurrence with p<0.05 and none with FDR<0.05.  
 
GOrilla analysis identified 459 terms upregulated at first recurrence, mainly 
related to the innate and adaptive immune responses and the production of 
cytokines (Table 6-6) (Appendix 5). REVIGO further classified these terms, of 
which three subheadings were particularly prominent; ‘Regulation of cytokine 
production’ encompassed 64 terms, ‘immune response’ encompassed 63 and 
‘response to external biotic stimulus’ encompassed 20 terms (Figure 6-3). 
 
Under the ‘regulation of cytokine production’ subheading, the interleukins were 
heavily represented, with ontologies identified for regulation of interleukin 1, 2, 6, 
8, 10 and 12 and positive regulation of interleukin 1, 2, 6 and 12. The GSEA 
analysis supported these findings, identifying positive regulation of interleukin 4 
production as a significant term (Figure 6-4).  
 
Under the ‘immune response’ subheading there were terms related to T-cell and 
B-cell activation and taxis. Interestingly, there were two terms related to NF-kB 
signalling; GO:0051092 – ‘Positive regulation of NF-kappaB transcription factor 
activity’ and GO:0042346 – ‘Positive regulation of NF-kappaB import into 
nucleus’. This is relevant given that five out of the eight profiled tumours were 
from the DNA methylation class prediction EPN_RELA, a subgroup associated with 
aberrant NF-kB signalling (Parker et al., 2014). The ‘immune response’ 
subheading also included a number of terms related to the type I interferon (IFN) 
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response including GO:0060337 – ‘Type I interferon signalling pathway’, 
GO:0032481 – ‘Positive regulation of type I interferon production’ and 
GO:0032479 – ‘Regulation of type I interferon production’. 
 
Under the ‘response to external biotic stimulus’ subheadings there were 20 terms, 
all directly related to inflammatory and immune responses. 
 
GO Term Description P-value FDR value 
GO:0006955 immune response <0.001 <0.001 
GO:0002376 immune system process <0.001 <0.001 
GO:0006952 defense response <0.001 <0.001 
GO:0002682 regulation of immune system process <0.001 <0.001 
GO:0050776 regulation of immune response <0.001 <0.001 
GO:0002684 positive regulation of immune system process <0.001 <0.001 
GO:0070665 positive regulation of leukocyte proliferation <0.001 <0.001 
GO:0043207 response to external biotic stimulus <0.001 <0.001 
GO:0001817 regulation of cytokine production <0.001 <0.001 
GO:0042102 positive regulation of T cell proliferation <0.001 <0.001 
Table 6-6: Top ten most significantly enriched ontology terms at first recurrence in the ST 
FFPE cohort. 
 166 
 
Figure 6-3: REVIGO plot of the ontologies significantly enriched at first recurrence in the 
supratentorial cohort. Redundant terms are removed. Plot size represents specificity of the 
term and colour represents the p value. Note the large number of circles representing 
terms overlapping with immune response and regulation of cytokine production categories, 
representing 63 and 64 sub terms respectively. 
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Figure 6-4: A-F: Enrichment plots of interleukin related terms significantly enriched at first 
recurrence in the FFPE supratentorial dataset. FDR: False discovery rate significance level.  
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GOrilla identified 30 significantly downregulated terms at first recurrence 
(Appendix 5). None of these were related to the immune response. Nine terms 
(30%) were associated with the glycolytic process and energy metabolism (Table 
6-7). When the process was repeated with GSEA, no significant ontologies were 
identified.  
 
Gene Ontology Terms P-Value FDR 
GO:0006735 - NADH regeneration <0.001 0.006 
GO:0061718 – Glucose catabolic process to pyruvate <0.001 0.005 
GO:0061621 – Canonical glycolysis <0.001 0.005 
GO:0061620 – Glycolytic process through glucose-6-phosphate <0.001 0.006 
GO:0061615 – Glycolytic process through fructose-6-phosphate <0.001 0.005 
GO:0006007 – Glucose catabolic process <0.001 0.015 
GO:0006096 – Glycolytic process <0.001 0.018 
GO:0006757 – ATP generation from ADP <0.001 0.024 
GO:0019320 – Hexose catabolic process <0.001 0.044 
Table 6-7: List of terms downregulated in ST ependymoma at relapse and associated with 
energy metabolism or glycolysis. 
6.3.3 Recurrence in the EPN_RELA molecular group 
EPN_RELA tumours formed the largest molecular subgroup within the ST location 
and were re-analysed independently to identify whether they exhibited features 
differentiating them from the remainder of the cohort. 
 
Five FFPE EPN_RELA samples were analysed; after filtering, 13742 genes were 
tested. This generated 411 genes differentially expressed at p<0.05 at first 
recurrence but none at FDR<0.05. 
 
138 of the terms identified as upregulated in the ST location cohort were also 
identified as upregulated in the EPN_RELA specific analysis (p<0.001, 
hypergeometric test) (Appendix 5). Over 50% of these were related to the 
immune or inflammatory responses, including terms related to interleukin 
upregulation and cytokine production (Appendix 5). No terms downregulated at 
first recurrence in the overall ST cohort reached statistical significance in the 
EPN_RELA only cohort. 
 
40 terms were upregulated at first recurrence in the EPN_RELA cohort but not in 
the overall ST cohort. Only one of these terms was related to the immune 
response, ‘GO:00771347: Cellular response to interleukin-1’. The remaining 
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terms were heterogeneous but a number were related to transport, including 
transport of lipids, organic anions, carboxylic acids, phospholipids and organic 
acids (Table 6-8). 
 
GO Term Description P-value FDR value 
GO:0043087 regulation of GTPase activity <0.001 <0.001 
GO:0009653 anatomical structure morphogenesis <0.001 0.002 
GO:0006869 lipid transport <0.001 0.003 
GO:0048646 
anatomical structure formation involved in 
morphogenesis 
<0.001 0.005 
GO:0043085 positive regulation of catalytic activity <0.001 0.005 
GO:0003073 regulation of systemic arterial blood pressure <0.001 0.005 
GO:0051056 
regulation of small GTPase mediated signal 
transduction 
<0.001 0.006 
GO:0015711 organic anion transport <0.001 0.007 
GO:0014910 regulation of smooth muscle cell migration <0.001 0.009 
GO:0006820 anion transport <0.001 0.009 
GO:0032502 developmental process <0.001 0.011 
GO:0035023 regulation of Rho protein signal transduction <0.001 0.011 
GO:0098609 cell-cell adhesion <0.001 0.012 
GO:0006811 ion transport <0.001 0.013 
GO:0046942 carboxylic acid transport <0.001 0.019 
GO:0015849 organic acid transport <0.001 0.019 
GO:0015914 phospholipid transport <0.001 0.019 
GO:0035850 
epithelial cell differentiation involved in kidney 
development 
<0.001 0.020 
GO:0007154 cell communication <0.001 0.020 
GO:0042908 xenobiotic transport <0.001 0.023 
Table 6-8: Top 20 terms upregulated at first recurrence in the FFPE EPN_RELA tumours 
but not the ST tumours. 
6.3.4 Recurrence in posterior fossa tumours 
The FFPE and FF cohorts included 16 and 20 matched primary and first 
recurrences respectively, in which the primary tumours had both PF location and 
clustered into a PF gene expression group. DNA methylation class predictions 
were available for 15 (94%) FFPE and 13 (65%) FF primary samples. All 
predictions for both groups were EPN_PFA, apart from one FFPE prediction which 
was EPN_PFB. 
 
In order to interpret any differences in expression changes at recurrence between 
FFPE and FF PF cohorts, clinical parameters were compared between the two 
groups. There was no difference in extent of initial resection or tumour grade 
(63% GTR in the FFPE groups Vs 62% GTR in the FF group, p=1.000, 50% WHO 
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Grade II in the FFPE group versus 38% WHO Grade II in the FF group, p=0.718). 
In the FFPE cohort, 10 (63%) children had not received radiotherapy between 
primary diagnosis and first recurrence, whereas in the FF cohort 4 (24%) had not 
received radiotherapy (p=0.037). 
 
After filtering, 14485 genes were tested in both FFPE and FF cohorts. In the FFPE 
cohort, 475 genes were differentially expressed at first recurrence at p<0.05 and 
three genes remained after FDR correction. In the FF cohort, 1217 genes were 
differentially expressed at first recurrence at p<0.05 and five genes remained 
after FDR correction. Across both cohorts, 40 overlapping genes were 
differentially expressed with the same fold change direction. This was not 
statistically significant (p=0.452, hypergeometric test), suggesting that there was 
not a strong overlap in change at first recurrence between these two cohorts. 
 
RNA-Seq meta-analysis of the FFPE and FF datasets identified three genes that 
were significantly upregulated (KCNE1, LOC388820, COL15A1), and five genes 
that were significantly downregulated, at first recurrence (PDGFRA, ASIC4, 
EMILIN3, LHFPL3 and NKD1) (Table 6-9). 
 
Genes upregulated at first posterior fossa recurrence 
Gene 
Fold 
Change 
FDR 
Value 
Potassium Voltage-gated Channel Subfamily E Regulatory 
Subunit 1 (KCNE1) 
+2.42 0.007 
Putative Uncharacterized Protein LOC388820 (LOC388820) +3.30 0.008 
Collagen Type XV Alpha 1 Chain (COL15A1) +2.43 0.044 
Genes downregulated at first posterior fossa recurrence 
Gene 
Fold 
Change 
FDR 
Value 
Platelet Derived Growth Factor Receptor Alpha (PDGFRA) -2.55 0.005 
Acid Sensing Ion Channel Subunit Family Member 4 (ASIC4) -2.68 0.007 
Elastin Microfibril Interfacer 3 (EMILIN3) -3.27 0.008 
Lipoma HMGIC Fusion Partner-Like 3 Protein (LHFPL3) -3.25 0.008 
Naked Cuticle Homolog 1 (NKD1) -1.48 0.044 
Table 6-9: List of genes significantly up and down regulated at first recurrence in all PF 
tumours based on meta-analysis of FFPE and FF datasets. 
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In the GOrilla analysis, between FFPE and FF cohorts, there were no shared gene 
ontology terms upregulated at first recurrence. There were nine, non-specific, 
shared terms downregulated at first recurrence. These were: 
• GO:0048519 – Negative regulation of biological process; 
• GO:0030154 – Cell differentiation; 
• GO:0032502 – Developmental process;  
• GO:0048731 – System development;  
• GO:0048856 – Anatomical structure development;  
• GO:0048869 – Cellular developmental process;  
• GO:0009887 – Animal organ morphogenesis;  
• GO:0007399 – Nervous system development;  
• GO:0045664 – Regulation of neuron differentiation.  
 
It became apparent that FFPE and FF datasets exhibited opposing patterns of 
gene expression at first recurrence. 98 of the 193 upregulated ontologies in the 
FFPE dataset overlapped with 98 of the 529 downregulated ontologies in the FF 
dataset. This was highly statistically significant (p<0.001, hypergeometric test) 
(Appendix 5). These terms were almost exclusively related to the immune and 
inflammatory responses.  
 
Immune ontologies were also seen in the terms that did not overlap, but were 
related to different mechanisms; the adaptive immune response was upregulated 
at first recurrence in the FF cohort, with 50 related terms, including those 
pertaining to both T-cell stimulation and B-cell activation. The innate immune 
response was downregulated at first recurrence in the FFPE cohort with the 
identification of no B- or T-cell specific terms. This pattern was recapitulated 
during the GSEA analysis (Figure 6-5). 
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Figure 6-5: A-F: Significantly enriched lymphocyte and adaptive immunity related terms 
upregulated at first recurrence in the FF posterior fossa dataset and not upregulated in the 
response in the FFPE posterior fossa dataset. FDR: False discovery rate significance. NES: 
Normalised enrichment score. 
 
 
A B 
C D 
E F 
NES: 2.81 
FDR: 0.001 
NES: 2.91 
FDR: 0.000 
NES: 2.49 
FDR: 0.002 
NES: 2.66 
FDR: 0.001 
NES: 3.32 
FDR: 0.000 
NES: 2.69 
FDR: 0.001 
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GOrilla and GSEA also identified a particular immune ontology of interest, in 
which the FFPE and FF datasets diverged; ‘GO:0034340 - Response to Type I 
interferon’. In the FF dataset, the term was significantly upregulated in the 
recurrent tumours, with 41 out of a possible 50 genes being associated with the 
ontology (ES 4.40, FDR=0.000), whereas in the FFPE dataset the term was 
downregulated in the recurrent tumours, with 32 out of a possible 50 genes being 
associated (ES -3.36, FDR=0.000) (Figure 6-6). 26 genes were in the core list for 
the Response to type I IFN ontology in both datasets, demonstrating opposing 
directions of fold change (Table 6-10). 
 
 
Figure 6-6: Enrichment plots for GO:0034340 - Response to type I IFN at first recurrence 
compared to primary presentation in (A) the FF posterior fossa cohort and (B) the FFPE 
posterior fossa cohort. FDR: False discovery rate significance level, NES: Normalised 
enrichment score. 
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Guanylate binding protein 2 (GBP2) 
2’-5’-oligoadenylate synthetase 2 (OAS2) 
2’-5’-oligoadenylate synthetase 3 (OAS3) 
SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 
(SAMHD1) 
Major histocompatibility complex, class I, C (HLA-C) 
Interferon stimulated exonuclease (ISG20) 
Signal transducer and activator of transcription 2 (STAT2) 
Major histocompatibility complex, Class I, B (HLA-B) 
Interferon regulatory factor 8 (IRF8) 
Interferon alpha inducible protein (IFI27) 
Interferon induced protein with tetratricopeptide repeats 2 (IFIT2) 
Chromosome 19 open reading frame 66 (C19orf66) 
Signal transducer and activator of transcription 1 (STAT1) 
XIAP associated factor 1 (XAF1) 
Tripartite motif containing 56 (TRIM56) 
2’-5’-oligoadenylate synthetase 1 (OAS1) 
Major histocompatibility complex, class I, F (HLA-F) 
Major histocompatibility complex, class I, E (HLA-E) 
MX dynamin like GTPase 1 (MX1) 
ISG15 ubiquitin-like modifier (ISG15) 
SP100 nuclear antigen (SP100) 
Interferon induced protein with tetratricopeptide repeats 3 (IFIT3) 
Interferon regulatory factor 2 (IRF2) 
Bone marrow stromal cell antigen 2 (BST2) 
Interferon regulatory factor 1 (IRF1) 
Interferon induced transmembrane protein 1 (IFITM1) 
Table 6-10: Core list of genes for term GO:0034340 - Response to type I IFN expressed in 
opposing directions in FFPE (downregulated at recurrence) and FF (upregulated at 
recurrence) posterior fossa location datasets when analysed by GSEA. 
 
When looking at the composition of the FFPE and FF posterior fossa cohorts by 
molecular subgroup; the FFPE posterior fossa group contained 82% PF1 and 18% 
PF2 primary tumours, compared to the FF posterior fossa group which contained 
45% PF1 and 55% PF2 primary tumours (p=0.011, chi-square test). It was 
therefore hypothesised that the divergent pattern of immune enrichment 
described in the FFPE and FF posterior fossa location cohorts was due to a 
different distribution of molecular subgroups. Therefore, recurrence patterns 
within PF1 and PF2 molecular subgroups were investigated. 
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6.3.5 Recurrence in the PF1 subgroup 
The FFPE and FF PF1 groups contained 9 and 13 primary and recurrent pairs 
respectively. Other than receipt of radiotherapy, there were no differences 
between the two cohorts. In the FFPE dataset only 4 of 13 (30%) patients 
received radiotherapy between initial diagnosis and first recurrence, whilst in the 
FF dataset 7 of 9 (78%) patients received radiotherapy (p=0.030). 
 
After filtering, 14108 genes were tested across both datasets. In the FFPE cohort, 
569 genes were differentially expressed at first recurrence with p<0.05 and three 
at FDR<0.05. In the FF cohort, 1759 genes were differentially expressed at first 
recurrence with p<0.05 and 323 at FDR<0.05. A total of 102 statistically 
significant genes with matching fold change direction appeared in both datasets. 
This represented a statistically significant association between FFPE and FF 
datasets (p<0.001, hypergeometric test). 
 
Genes significantly downregulated in both datasets included a number of 
cytokines and their receptors: Interleukin 1 receptor type 2 (IL1R2); C-X-C motif 
chemokine ligand 1 (CXCL1); C-X-C motif chemokine ligand 8 (CXCL8); C-C motif 
chemokine ligand 2 (CCL2); C-X-C motif chemokine ligand 3 (CXCL3); interleukin 
1 receptor type 1 (IL1R1); and interleukin 11 receptor subunit alpha (IL11RA). 
 
RNA-seq meta-analysis of the FF and FFPE datasets identified 133 differentially 
expressed genes, 37 of which were upregulated (Table 6-11) and 96 which were 
downregulated at first recurrence (Table 6-12). 
 
Gene Symbol FDR Gene Symbol FDR Gene Symbol FDR 
DLEC1 <0.001 PLCXD3 0.004 CTNNA2 0.029 
SLCO3A1 <0.001 DCHS2 0.007 C14orf180 0.030 
PER3 <0.001 CXCL12 0.007 TMPRSS7 0.033 
FGF1 <0.001 NR1D2 0.007 PAMR1 0.034 
CLSTN2 0.001 LINC01354 0.008 PNMAL1 0.035 
KIAA1217 0.001 LOC153684 0.008 CD200 0.036 
MYO5C 0.001 ANKRD45 0.010 EPHX1 0.036 
AGT 0.001 USH1C 0.014 RASGRF2 0.036 
CDS1 0.001 EFHB 0.015 MATN2 0.039 
NWD1 0.002 CNGA3 0.016 GRID1 0.040 
LGR6 0.003 CACNA1D 0.017 FHOD3 0.043 
C5orf64 0.003 NAV3 0.017   
COL15A1 0.003 IFIT1 0.024   
Table 6-11: Upregulated genes in PF1 recurrence from RNA-seq meta-analysis of FFPE and 
FF datasets. 
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Gene Symbol FDR Gene Symbol FDR Gene Symbol FDR 
LHFPL3 <0.001 HMCN1 0.008 SCNN1B 0.030 
EMILIN3 <0.001 PLEKHG4 0.008 HAPLN4 0.030 
C1QL4 <0.001 MDFI 0.010 NAMPT 0.030 
GRK5 <0.001 CHI3L2 0.010 PPAT 0.032 
MEG3 <0.001 ASIC4 0.010 ANKRD36BP2 0.033 
MME <0.001 OLFM2 0.010 CDC42EP3 0.033 
CXCL1 <0.001 C1QL1 0.010 TMEM158 0.033 
TGFBI <0.001 WNT7A 0.011 PRPH 0.033 
BMP2 0.001 ARC 0.012 IRX2 0.034 
SLC26A7 0.001 CACNA1I 0.012 AQP9 0.035 
SLC6A11 0.001 SEMA5B 0.012 CA10 0.035 
ITGA5 0.001 IL1R2 0.013 FGF7 0.035 
HSD11B2 0.001 CDCP1 0.013 FKBP10 0.035 
MEG8 0.001 CRTAC1 0.013 CHPF 0.036 
SERPINA3 0.002 OBSCN 0.014 FERMT1 0.036 
FNDC4 0.002 LGR5 0.014 IQGAP2 0.036 
IL1RL1 0.002 IL1R1 0.015 TIPARP 0.036 
MET 0.002 SCNN1G 0.015 GLIPR2 0.036 
NRK 0.002 HSPB1 0.015 MEIS3 0.036 
CDH15 0.002 CSPG4 0.016 RARA 0.037 
WEE1 0.003 TSPAN18 0.016 TNFRSF12A 0.037 
STAC 0.003 ANGPTL4 0.016 PTX3 0.037 
GLRX 0.004 ADGRG1 0.020 ALDH1L1 0.040 
NFIL3 0.004 GRIK3 0.021 DCHS1 0.041 
PLIN2 0.004 TRIM47 0.022 CD163 0.043 
EMP1 0.005 CXCL6 0.024 LDHA 0.043 
NNMT 0.006 H19 0.024 FAM20C 0.043 
PRRG3 0.007 COL6A2 0.024 PEG10 0.045 
CADPS 0.007 C1R 0.027 ERBB3 0.045 
STC2 0.008 SERPINH1 0.027 PHLDA1 0.049 
DIO3 0.008 CACNG4 0.029 SOCS3 0.049 
FAM46B 0.008 TMEM97 0.030 GABRA5 0.050 
Table 6-12: Downregulated signature genes of PF1 recurrence generated from RNA-seq 
meta-analysis combining FFPE and FF datasets. 
 
FFPE and FF cohorts generated 179 significantly downregulated overlapping 
ontologies at first recurrence (p<0.001, hypergeometric test) (Appendix 5). This 
included 52 ontologies related to the immune and inflammatory responses, 
including neutrophil chemotaxis and cytokine mediated signalling pathways 
(Table 6-13, Figure 6-7).  
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GO Term Description 
GO:0006954 inflammatory response 
GO:0002526 acute inflammatory response 
GO:0006952 defense response 
GO:0006935 chemotaxis 
GO:0042330 taxis 
GO:0043408 regulation of MAPK cascade 
GO:0060326 cell chemotaxis 
GO:0043410 positive regulation of MAPK cascade 
GO:0050900 leukocyte migration 
GO:0006953 acute-phase response 
GO:0030595 leukocyte chemotaxis 
GO:0050920 regulation of chemotaxis 
GO:0050727 regulation of inflammatory response 
GO:0030334 regulation of cell migration 
GO:0002687 positive regulation of leukocyte migration 
GO:0002690 positive regulation of leukocyte chemotaxis 
GO:0071621 granulocyte chemotaxis 
GO:0050921 positive regulation of chemotaxis 
GO:0030593 neutrophil chemotaxis 
GO:0002685 regulation of leukocyte migration 
GO:0009617 response to bacterium 
GO:2000145 regulation of cell motility 
GO:0002688 regulation of leukocyte chemotaxis 
GO:0006959 humoral immune response 
GO:0097529 myeloid leukocyte migration 
GO:0097530 granulocyte migration 
GO:1990266 neutrophil migration 
GO:0016477 cell migration 
GO:0034097 response to cytokine 
GO:0002237 response to molecule of bacterial origin 
GO:0042742 defense response to bacterium 
GO:0043406 positive regulation of MAP kinase activity 
GO:0043207 response to external biotic stimulus 
GO:0019221 cytokine-mediated signaling pathway 
GO:0006955 immune response 
GO:0048870 cell motility 
GO:0050729 positive regulation of inflammatory response 
GO:0070098 chemokine-mediated signaling pathway 
GO:0009607 response to biotic stimulus 
GO:0001819 positive regulation of cytokine production 
Table 6-13: Top 40 significantly downregulated gene ontology terms, related to immune 
and inflammatory responses, at first relapse in both PF1 gene expression groups. Terms in 
this table are shared between the FFPE and FF datasets. Full list of all terms alongside 
significance values can be found in Appendix 5. 
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Figure 6-7: A scatterplot of none-redundant significantly downregulated gene ontology 
terms at first recurrence in the PF1 subgroup, generated from genes that were statistically 
significant in both the FFPE and FF cohorts. The colour of the circles represents the p-value 
and the size of the circle represents the specificity of the term (more general terms appear 
as larger circles). 
 
The GSEA analysis supported these findings with downregulation of the eight 
following overlapping terms at recurrence: GO:0006954 - Inflammatory 
response; GO:0030155 – regulation of cell adhesion; GO:0001817 – regulation of 
cytokine production; GO:0043410 – Positive regulation of MAPK cascade; 
GO:0050727 – Regulation of inflammatory response; GO:0043408 – Regulation 
of MAPK cascade; GO:0040017 – Positive regulation of locomotion; GO:0045596 
– Negative regulation of cell differentiation. 
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The FFPE cohort demonstrated fewer ontology terms upregulated at first 
recurrence than the FF cohort (6 and 138 respectively). Only one significantly 
upregulated ontology overlapped in both datasets (‘GO:0006813: Potassium ion 
transport’) (p=0.056, hypergeometric test). 
 
Key upregulated ontologies exclusive to the FF dataset were related to: 
(1) the IFN I pathway and defense response to virus;  
(2) cell-cell signalling and adhesion;  
(3) ion transport.  
GSEA also identified GO:0051607 – ‘Defense response to virus’ with FDR 0.013. 
 
A number of individual genes, differentially expressed at the FDR level in the FF 
dataset, also featured in the Type I IFN pathway related ontologies. These were 
OAS1 (LFC 1.88, FDR 0.002), OAS2 (LFC 1.34, FDR 0.013), RSAD2 (LFC 1.44, 
FDR 0.028), MX1 (LFC 1.23, FDR 0.050), IFI27 (LFC 1.78, FDR 0.018). 
 
The equivalent type I IFN pathway related terms were not significantly 
upregulated in the FFPE dataset.  
6.3.5.1 PF1 relapse profile and radiotherapy 
Patients in the FFPE PF1 subgroup were less likely to have been treated with 
radiotherapy between primary and first recurrence than in the FF PF1 subgroup 
(p=0.030). It was hypothesised that the upregulated immune response, in 
particular the type I IFN pathway, seen in the FF dataset may be associated with 
treatment with radiotherapy. To investigate this further, the FFPE cohort was 
divided into those treated with radiotherapy and those who were not.  
 
In the non-irradiated FFPE group, there were no significantly upregulated terms 
at first recurrence. In the four patients who received radiotherapy there were 227 
terms significantly upregulated at FDR<0.05 at first recurrence. 32 (14%) of 
these terms were related to the immune response (Table 6-14) and 8 (3.5%) 
were related to cell death (Table 6-15). The type I IFN pathway was not 
upregulated in this analysis, therefore only partially supporting the hypothesis. 
Consistent with the FF cohort, in both irradiated and non-irradiated FFPE groups, 
the downregulated ontology terms reflected a decreased inflammatory and 
immune response. 
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GO Term Description FDR 
GO:0045055 regulated	exocytosis <0.001 
GO:0043299 leukocyte	degranulation <0.001 
GO:0002275 myeloid	cell	activation	involved	in	immune	response <0.001 
GO:0043312 neutrophil	degranulation <0.001 
GO:0002283 neutrophil	activation	involved	in	immune	response <0.001 
GO:0008284 positive	regulation	of	cell	proliferation <0.001 
GO:0036230 granulocyte	activation <0.001 
GO:0002366 leukocyte	activation	involved	in	immune	response <0.001 
GO:0001775 cell	activation <0.001 
GO:0002274 myeloid	leukocyte	activation <0.001 
GO:0002263 cell	activation	involved	in	immune	response <0.001 
GO:0042119 neutrophil	activation <0.001 
GO:0006887 exocytosis <0.001 
GO:0045321 leukocyte	activation <0.001 
GO:0002376 immune	system	process <0.001 
GO:0030334 regulation	of	cell	migration <0.001 
GO:0002252 immune	effector	process 0.006 
GO:0016477 cell	migration 0.020 
GO:1902105 regulation	of	leukocyte	differentiation 0.022 
GO:0040011 locomotion 0.027 
GO:0048870 cell	motility 0.028 
GO:0050863 regulation	of	T	cell	activation 0.032 
GO:0030335 positive	regulation	of	cell	migration 0.032 
GO:0071496 cellular	response	to	external	stimulus 0.032 
GO:0034097 response	to	cytokine 0.035 
GO:0050900 leukocyte	migration 0.038 
GO:0006950 response	to	stress 0.038 
GO:0006954 inflammatory	response 0.040 
GO:0009611 response	to	wounding 0.046 
GO:1903037 regulation	of	leukocyte	cell-cell	adhesion 0.046 
GO:0071345 cellular	response	to	cytokine	stimulus 0.047 
GO:0002694 regulation	of	leukocyte	activation 0.048 
Table 6-14: Significantly enriched immune related terms at first recurrence in irradiated 
FFPE PF1 tumours (n=4). 
GO Term Description FDR 
GO:0010941 regulation	of	cell	death <0.001 
GO:0060548 negative	regulation	of	cell	death <0.001 
GO:0043069 negative	regulation	of	programmed	cell	death <0.001 
GO:0043067 regulation	of	programmed	cell	death <0.001 
GO:0042981 regulation	of	apoptotic	process <0.001 
GO:0012501 programmed	cell	death 0.009 
GO:0008219 cell	death 0.012 
GO:0043068 positive	regulation	of	programmed	cell	death 0.046 
Table 6-15: Significantly enriched cell death related terms at first recurrence in irradiated 
FFPE PF1 tumours (n=4). 
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6.3.5.2 RT-qPCR validation of upregulated type I IFN related genes in the 
FF PF1 dataset 
Whilst radiotherapy treated tumours were associated with upregulation of 
immune ontologies in both FFPE and FF cohorts, the upregulation of the type I 
IFN pathway was only identified in the FF, and not the FFPE, dataset. Therefore, 
in order to provide a technical validation of this finding in the FF dataset, real 
time quantitative PCR was performed for a subset of significantly differentially 
expressed type I IFN related genes.   
 
RNA was only available to perform this for four cases. An a priori decision was 
made not to perform statistical analysis on this sample set in view of low 
statistical power, but to confirm that the direction of fold change matched for the 
qPCR and RNA-seq samples. The genes tested were CXCL12, OAS3, BST2, 
RSAD2, OAS2, OAS1 and MX1. 
 
Every gene tested expressed a direction of fold change consistent with that seen 
in the RNA-seq dataset (upregulated at first recurrence). The values calculated 
for log2 fold change for each gene for the qPCR analysis were: CXCL12 +1.57, 
OAS3 +2.71, BST2 +1.08, RSAD2 +4.10, OAS2 +3.11, OAS1 +3.32, MX1 +2.70. 
For the RNA-seq data the log2 fold changes were: CXCL12 +3.22, OAS3 +0.94, 
BST2 +1.44, RSAD2 +2.33, OAS2 +1.86, OAS1 +3.78, MX1 +2.69. The lower 
point of the error bar, based on standard error of the mean, still remained 
positive for all samples. For most genes, there was a greater than two-fold 
increase in gene expression at first recurrence, measured by both RNA-seq and 
RT-qPCR (Figure 6-8); providing technical confirmation of the FF cohort RNA-seq 
findings. 
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Figure 6-8: Bar plots demonstrating log2 of the fold change for genes chosen for the 
technical validation in the posterior fossa group PF1 of the FF dataset (n=4). All genes 
demonstrated upregulation at first recurrence and this is represented by a fold change 
greater than zero. The dashed lines represent a fold change of two (positive and negative). 
The solid line represents zero-fold change. Error bars are based on standard error of the 
biological replicates. 
6.3.6  Recurrence in the PF2 subgroup 
The FFPE and FF PF2 subgroups contained 3 and 11 matched pairs respectively. 
Tumours with ST location were excluded.  
 
Due to small sample size in the FFPE dataset, clinical variables were compared 
using a Fisher’s exact test. No statistically significant differences were 
demonstrated for patient demographics or treatment approaches between the 
FFPE and FF datasets. Nine of the 14 patients in this group received radiotherapy 
between primary and first recurrence (2/3 FFPE patients, 7/11 FF patients, 
p=1.000).  
 
After filtering, 14289 genes were tested across both datasets. In the FFPE dataset 
499 genes were differentially expressed at first recurrence with p<0.05 and 22 
with FDR<0.05. In the FF dataset 1219 genes were differentially expressed at 
first recurrence with p<0.05 and 39 with FDR<0.05. There were 55 overlapping 
significant genes with the same direction of fold change between FF and FFPE 
cohorts (p=0.029, hypergeometric test). 
 
RNA-Seq meta-analysis identified 47 genes below the FDR<0.05 cut off, 7 
downregulated (Table 6-16) and 40 upregulated (Table 6-17). 
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Gene Symbol FDR 
PCDH15 0.001 
RNY1 0.003 
ACSS1 0.012 
DSCAM 0.031 
SLC16A4 0.032 
NKAIN4 0.035 
LHFPL3 0.036 
Table 6-16: Downregulated genes generated from RNA-Seq meta-analysis of FF and FFPE 
datasets in PF2 group relapses. 
 
Gene Symbol FDR Gene Symbol FDR Gene Symbol FDR 
MOBP <0.001 LTBP2 0.003 PLVAP 0.035 
POSTN <0.001 CORO2A 0.010 ANK3 0.036 
UNC5C <0.001 SPTB 0.010 COL1A1 0.036 
HHIP <0.001 SVIL 0.010 DOCK5 0.036 
LUM <0.001 HBA1 0.013 ENPP2 0.036 
ALDH1A1 <0.001 ARSJ 0.013 GCNT1 0.036 
THBS1 <0.001 SLC7A14 0.022 MBP 0.036 
CLDN11 0.001 SLC6A6 0.023 SELL 0.036 
LYZ 0.001 LAMB1 0.027 UBASH3B 0.036 
MICAL2 0.002 RYR2 0.028 RASGEF1B 0.039 
COL1A2 0.003 ESM1 0.030 SLAMF8 0.049 
HBB 0.003 HMOX1 0.033 KIAA1324L 0.049 
ST18 0.003 C7 0.033   
CADPS2 0.003 GPNMB 0.035   
Table 6-17: Upregulated genes generated from RNA-Seq meta-analysis of FF and FFPE 
datasets in PF2 group relapses. 
 
In FFPE and FF PF2 datasets, 51 overlapping gene ontology terms were 
upregulated at first recurrence (Figure 6-9) (Appendix 5). Five were related to 
cell adhesion and 18 were related to either the immune or inflammatory 
response, cytokine release or chemotaxis. Four terms were related to changes in 
the extracellular matrix and its organisation. 18 immune related terms were not 
visible in the REVIGO plot as they were classified under the subheading ‘immune 
system process’; they are presented separately (Table 6-18). 
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GO Term Description 
GO:0006955 immune response 
GO:0006952 defense response 
GO:0001819 positive regulation of cytokine production 
GO:0006935 chemotaxis 
GO:0042330 taxis 
GO:0050900 leukocyte migration 
GO:0001817 regulation of cytokine production 
GO:0006954 inflammatory response 
GO:0002376 immune system process 
GO:2000145 regulation of cell motility 
GO:0045087 innate immune response 
GO:0001775 cell activation 
GO:0040011 locomotion 
GO:0060326 cell chemotaxis 
GO:0030334 regulation of cell migration 
GO:0040012 regulation of locomotion 
GO:0050707 regulation of cytokine secretion 
GO:0002697 regulation of immune effector process 
Table 6-18: List of upregulated gene ontology terms related to immune function 
significantly enriched (FDR<0.05) in FFPE and FF PF2 datasets. 
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Figure 6-9: A scatterplot of non-redundant significantly upregulated gene ontology terms 
in FFPE and FF PF2 tumours at first recurrence generated from GOrilla enrichment 
analysis. The colour of the circles represents the p-value and the size of the circles 
represents the specificity of the term. 
 
There were two overlapping downregulated terms: GO:0044282 – ‘Small 
molecule catabolic process’ and GO:0032787 – ‘Monocarboxylic acid metabolic 
process’. 
 
The FFPE cohort had fewer upregulated immune related terms than the FF cohort. 
The additional FF terms were particularly related to lymphocyte activation 
including GO:0050870 – ‘Positive regulation of T cell activation’ and GO:0050864 
– ‘Regulation of B cell activation’. Of interest for potential therapy was the 
upregulation of several ontologies related to programmed cell death, for example 
GO:0043067 – ‘Regulation of programmed cell death’. The FF dataset also 
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demonstrated significant upregulation at first recurrence of multiple IFN related 
pathways, including GO:0034341 – ‘Response to interferon gamma’ and 
GO:0060337 – ‘Type I interferon signalling’ which was represented by the genes 
IFITM1, HLA-A, RSAD2, HLA-C, HLA-B, OAS3, HLA-F, MYD88, IFI35, ISG20, 
IFITM2, GBP2, EGR1, XAF1, BST2, IRF1, RNASEL, MX2, MX1, OAS1, OAS2, 
IFNAR2, SP100 and IFI6 (Figure 6-10). 
 
 
Figure 6-10: Significantly enriched IFN (A, B) and adaptive immunity (C, D) related terms 
at first recurrence in the FF PF2 dataset. FDR: False discovery rate significance. NES: 
Normalised enrichment score. 
6.3.7 Immunophenoscores 
The differential expression and enrichment analyses for the molecular subgroups 
provided evidence of changes to the immune response at first recurrence in 
paediatric ependymoma. In order to investigate for evidence of a functional 
change in gene expression, and therefore to provide an indication of any change 
in the susceptibility to checkpoint blockade therapy, the immunophenoscore of 
A B 
C D 
NES: 1.91 
FDR: 0.007 
NES: 1.83 
FDR: 0.012 
NES: 1.75  
FDR: 0.019 
NES: 1.85 
FDR: 0.010 
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each tumour was assessed (Charoentong et al., 2017). As immunophenoscores 
are based on reference datasets and normalised, once generated they are 
comparable between datasets. Therefore, for this analysis, FFPE and FF cohorts 
were combined. 
 
The immunophenoscore cohort included all 151 tumour samples, consisting of 67 
primary tumours, 60 first recurrences, 12 second recurrences, 4 third 
recurrences, 5 fourth recurrences and 1 fifth, sixth and seventh recurrence. Of 
those with DNA methylation profiles, 86 were EPN_PFA, 13 EPN_RELA, 7 
EPN_YAP, 3 EPN_PFB, 3 EPN_MPE and 11 non-ependymoma designations. DNA 
methylation profiles were unavailable for 28 of the samples. There were 53 
matched primary and recurrent pairs. 
 
The mean immunophenoscore was 5.31 (range 3-8) for all samples and 5.28 for 
primaries alone. There was no difference between the primary and recurrent 
tumours as two separate groups, so they were then analysed together 
(p=0.662). There were significant differences between scores for tumours in 
different locations; ST mean score 4.70 versus PF mean score 5.53 (p<0.001). 
Additionally, EPN_RELA had a significantly lower score than EPN_PFA (4.78 versus 
5.48, p=0.015).  
 
Categories contributing to the immunophenoscore (MHC, effector cells, 
suppressor cells, checkpoints and immunomodulators) were then compared 
between locations. In the MHC category, a significant difference was identified 
between the PF and ST cohort in the MHC category, indicating differing antigen 
presenting potential (PF mean 1.35, versus ST mean 1.12, p=0.002). There were 
no differences in effector cells, suppressor cells or checkpoint genes (Figure 
6-11).  
 
When comparing the two PF gene expression subgroups there were no significant 
differences between the overall immunophenoscores (PF1 mean 5.60 versus PF2 
mean 5.45), however when comparing the categories, the PF1 tumours were 
enriched for MHC molecules and effector cells (p=0.040 and p<0.001 
respectively), whilst the PF2 tumours were enriched for suppressor cells 
(p=0.001). There was no significant difference between the two PF subgroups for 
checkpoint scores (p=0.080). When including just the primary tumour specimens 
from PF subgroups, only effector cells maintained significance; with PF1 being 
more enriched than PF2 tumours (p=0.041). 
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Figure 6-11: Immunophenoscores demonstrating (A) an ST sample (Score 3) and (B) a PF 
sample (Score 7). The main difference is identified in the Major Histocompatibility Complex 
(MHC) score, which is enriched in the PF sample. Both samples had low levels of 
checkpoint molecule expression. 
 
When comparing all paired primary and first recurrent tumours there was no 
significant difference in overall immunophenoscore. However, effector cells 
significantly increased at recurrence (p=0.032). When subdividing this analysis 
into PF1, PF2 and ST tumours, no significant differences were identified between 
paired primary and first recurrence in either the overall immunophenoscore or in 
any of the four categories.  
 
For all tumours, the levels of checkpoint associated genes were low, including 
checkpoint blockade targets PD1 and CTLA-4. In many comparisons, the level of 
expression was so low that the gene did not pass the filters to be included in the 
A 
B 
EC: Effector Cells 
SC: Suppressor Cells 
CP: Checkpoints 
MHC: Major Histocompatibility 
Complex 
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analysis. The median number of transcripts per million for PD1 was 0. The 
median number of transcripts per million for CTLA-4 was 0.39. 
6.3.8  Levels of immune checkpoint gene expression in ependymoma 
The identification of low levels of checkpoint genes in the immunophenoscores 
stimulated further analysis of a wider spectrum of checkpoint genes in 
ependymoma. Based on immunoinhibitory markers associated with T-cell anergy, 
discussed in a recent review (Catakovic et al., 2017), the gene expression data 
from both FF and FFPE datasets were re-reviewed. Data was separated into 
receptors (the immune checkpoints expressed on immune cells), consisting of: 
PD1, CTLA-4, LAG3, TIM3, TIGIT, BTLA, CD96 and CD244; and ligands (the 
antigens expressed by cancer cells and presented to immune cells by antigen 
presenting cells), consisting of: CD80, PDL1, PDL2, GAL9, CD112, CD155, HVEM, 
CD48 and CD2 (Figure 6-12). Levels of receptors, apart from TIM3, were 
extremely low, with median values below one count per million. The ligand 
molecules were expressed at higher levels than the receptors, but only two genes 
were above the median expression level for all genes in the dataset. The only 
receptor with matched ligand that was expressed at reliably detectable levels was 
TIM3 (receptor)/GAL9 (ligand) (Figure 6-12). 
 
 190 
 
Figure 6-12: Bar plots of levels of immune checkpoint receptors and ligands across all 
samples in both ependymoma datasets (n=151). (A) Receptor molecules expressed by 
immune cells. (B) Ligands/antigens expressed by tumour cells. Red hashed line: Median 
gene expression level for all genes with median expression above 0 TPM in the dataset 
(n=26038). Blue hashed line: One count per million mapped reads; the level considered to 
represent expression of the gene. 
 
In light of a recent study indicating that EPN_RELA tumours may be enriched for 
PDL1 (Witt et al., 2018), further analysis was conducted to see whether there 
were differences in immune checkpoint ligand and receptor expression between 
tumours in PF versus ST locations or for tumours with EPN_PFA versus EPN_RELA 
DNA methylation classifications. In view of the almost absent nature of EPN_RELA 
class predictions in the FF samples this analysis was based on the FFPE tumour 
set only. 12 EPN_RELA tumours and 45 EPN_PFA tumours were included. 
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One receptor, TIM3, was significantly enriched in PF compared to the ST tumours 
and in EPN_PFA compared to EPN_RELA tumours (Fold change 1.8, p<0.001 and 
fold change 1.7, p=0.036 respectively). One ligand, CD112, was significantly 
enriched in PF compared to the ST tumours and in EPN_PFA compared to 
EPN_RELA tumours (Fold change 1.5, p=0.001 and fold change 1.6, p=0.008 
respectively). Notably, there were no other significant differences based on 
location or DNA methylation group. In particular, no differences were seen for 
PD1 (p=0.090 and p=0.775 respectively), PDL1 (p=0.460 and p=0.352 
respectively) or PDL2 (p=0.934 and p=0.194 respectively). 
6.3.9 Cytolytic activity (CYT) 
A CYT score was generated for each of the 151 tumour samples. The median 
score was 0.40 TPM (range 0-3.25). There was no significant difference in the 
level of cytolytic activity between molecular subtypes, all primary and recurrent 
pairs, or primary and recurrent pairs stratified by molecular subgroup (PF1, PF2, 
ST).  
6.3.10 CT antigens 
In assessing CTA expression across all tumours, PF1 and PF2 molecular 
subgroups were noted to exhibit different profiles. The PF2 tumours significantly 
overexpressed a greater number of CTAs compared to PF1 (22/276 versus 8/276, 
p=0.013). In order to establish whether the differentially expressed CTAs 
identified in PF1 and PF2 were associated with evidence of being able to generate 
an immune response, the CT-database was consulted. 18/30 of the CTAs 
identified had been associated with an immune response in at least one cancer 
type (Table 6-19) (Almeida et al., 2009).  
 
In the PF1 group, two CTAs were significantly upregulated at recurrence in both 
FF and FFPE datasets; ANKRD45 and CTNNA2. Neither of these genes have ever 
been experimentally associated with the ability to generate an immune response 
(Almeida et al., 2009). In the PF2 groups no CTAs were upregulated at 
recurrence. Additionally, no CTAs underwent significant changes at recurrence in 
the ST group. 
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CT-Antigen Expression PF Group Immune Response 
SPAG8 Testis 2 Humoral 
SPEF2 Testis-Brain 2 No 
TSGA10 Testis 2 Humoral 
ARMC3 Testis 2 Humoral 
TMEM108 Testis-Brain 2 No 
ANKRD45 Testis 2 No 
RGS22 Unknown 2 No 
SPA17 Testis-Brain 2 Cellular 
CCDC33 Testis 2 No 
SPAG17 Unknown 2 Humoral 
PTPN20 Unknown 2 No 
SPAG1 Unknown 2 Humoral 
ODF2 Unknown 2 Humoral 
CCDC110 Testis 2 Humoral, Cellular 
SPAG6 Testis 2 Humoral 
CTNNA2 Testis-Brain 2 No 
CCNA1 Unknown 2 Cellular 
CEP290 Testis 2 Humoral 
ZNF165 Testis 2 Humoral 
KIF20B Testis 1 Cellular, Induced 
IGSF11 Testis-Brain 2 Cellular 
TTK Testis 1 Cellular, Induced 
MAEL Testis 2 No 
AKAP3 Testis 2 No 
CEP55 Testis 1 Cellular 
KIF2C Unknown 1 Cellular 
OIP5 Testis 1 No 
NUF2 Testis 1 Cellular 
ATAD2 Unknown 1 No 
PBK Testis 1 No 
Table 6-19: Table of CTAs expressed in Posterior Fossa Ependymoma. Expression refers to 
whether the expression is restricted to testis, testis and brain or unknown. PF group (PF1 
or PF2) indicates which group the gene is significantly enriched in when comparing the two 
groups. Expression and immune response data derived from (Almeida et al., 2009). 
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6.4 Discussion 
6.4.1 Aims 
This chapter aimed to: 
• Compare gene expression at primary diagnosis compared to matched 
recurrence across FF and FFPE datasets based on: 
o All tumours combined; 
o Location; 
o Molecular classification. 
• Consider the impact of therapy on differential expression at recurrence; 
• Assess the role of the immune system in primary and recurrent 
ependymoma using predefined scoring systems (immunophenoscore and 
cytolytic activity score) plus consideration of CTA expression. 
6.4.2 Merits of the study design 
By using RNA sequencing, more biological replicates than previous authors, and a 
paired study design; this study attempted to provide an in-depth analysis of 
biological functioning in recurrent paediatric ependymoma. RNA sequencing 
profiles low abundance transcripts with greater accuracy than microarray studies 
(Wang et al., 2014), potentially making this investigation more detailed than 
previous research. However, some argue that the most effective way to increase 
the power of a study is to use more biological replicates (Yuwen Liu et al., 2014), 
which was achieved by including FFPE samples. Paired analysis not only increases 
statistical power, but also minimises variation between individuals to give a 
clearer indication of genuine biological change (Peyre et al., 2010). This was 
particularly important when cohort sizes were limited by availability of specimens.  
 
A further advantage was the ability to correlate gene expression profiling with 
DNA methylation profiles, thus providing a way to link the findings to the 
developing ‘molecular era’ of paediatric brain tumour research (Mack and Taylor, 
2017). 
 
One of the challenges presented by this design was the generation of extremely 
large datasets. Whilst the analysis aimed to focus on the changes that were most 
consistent across multiple tumour subtypes and tissue cohorts, there are still 
likely to be more conclusions that can be drawn from further analysis of this 
dataset.  
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6.4.3 Summary of key findings 
Analysis of molecular subgroups proved more informative than analysis of the 
combined dataset. PF1 tumours were associated with downregulation of the 
innate immune and inflammatory responses at first recurrence, whilst PF2 and ST 
tumours developed adaptive immune responses. All groups exhibited changes in 
the type I IFN pathway in at least one dataset. There was some evidence that 
radiotherapy may be associated with upregulated immune responses at 
recurrence. Immunophenoscores varied between PF and ST tumours, but cytolytic 
activity and CTA expression were low throughout (Table 6-20). 
 
 PF1 tumours PF2 tumours ST tumours 
FFPE Samples 13 3 8 (5 EPN_RELA) 
FF Samples 9 11 0 
Upregulated 
ontologies 
Radiotherapy – 
Type I IFN pathway 
including IFN 
related DNA 
damage signature 
(IRDS) genes. 
No radiotherapy – 
None 
Adaptive immune 
(T and B cell 
functions). 
Extracellular 
matrix and 
adhesion. 
IFN pathways. 
Adaptive immune 
response including 
T and B cells 
related functions. 
Type I IFN 
pathway. 
Downregulated 
ontologies 
Innate immune and 
inflammatory. 
Chemokines and 
chemotaxis. 
None Glycolytic and 
metabolic. 
Key (immune) 
mediators 
Up (in radiotherapy 
treated FF 
tumours): OAS1, 
OAS2, OAS3, BST2, 
RSAD2, MX1, 
CXCL12, IFI44, 
IFI44L, CX3CR1. 
Down in all: IL1R1, 
IL1R2, IL11RA, 
CXCL1, CXCL3, 
CXCL8, CCL2.   
Up: OAS1, OAS2, 
OAS3, BST2, 
RSAD2, MX1, 
CXCL12. 
Up: Interleukins 
1,2,4,6,8,10,12. 
NF-kB pathway. 
Immune Response Innate Adaptive Adaptive 
Immunophenoscore Highest 
MHC enriched 
EC enriched 
Intermediate 
SC enriched 
Lowest 
MHC depleted 
Cytolytic Activity Low Low Low 
CTA Expression CTNNA2, ANKRD45 Nil Nil 
Table 6-20: Summary of the key up and down regulated ontologies and mediators 
mediators associated with change at recurrence in the different molecular subgroups 
investigated with paired differential expression analyses. 
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6.4.4 Overall and location based analyses 
Differential expression analysis of all tumour pairs, irrespective of location or 
molecular classification, identified few shared differentially expressed genes at 
first recurrence (EMILIN3, ASIC4 and LHFPL3). EMILIN3 is an extracellular matrix 
molecule which plays a role in skin development in mammals (Corallo et al., 
2017) and has been associated with notochord development in zebrafish (Corallo 
et al., 2013). ASIC4 encodes for an acid sensing ion-channel involved in synaptic 
signalling, nociception and mechanoperception (Brown et al., 2015). LHFPL3 
encodes for a tetraspan transmembrane protein associated with lipoma and 
deafness (Brown et al., 2015). Individually these genes provided little insight into 
functional changes at relapse; recurrence is likely to result from the interaction of 
multiple functions or pathways rather than single genes. However, the 
identification of a change in EMILIN3 is consistent with changes in extracellular 
matrix ontologies, which were identified as being altered at first recurrence across 
all tumour types. 
 
Interestingly, when examining shared gene ontologies, immune and inflammatory 
responses were upregulated at first recurrence across all tumours. It was difficult 
to discern further details about the nature of these responses, as these terms 
were later identified to be associated with the various molecular subgroups. This 
global overview was therefore unlikely to be helpful in devising future research 
and treatment strategies. 
 
Tumours with ST location were associated with the upregulation of a number of 
immune related ontologies and downregulation of genes associated with 
metabolic pathways. Unfortunately, due to lack of FF ST tumours, it was not 
possible to examine a comparison cohort for the FFPE ST tumours. It was 
therefore unclear whether these results were representative of all ST 
ependymomas, especially given that this group contained a number of molecular 
diagnoses. The genes differentially expressed were largely distinct from the only 
other study which analysed relapse in ST tumours (Peyre et al., 2010). However, 
the study by Peyre and colleagues provided supplementary data which identified 
‘immune response’ and ‘immunological disease’ as significantly enriched 
ontologies.  
 
Three terms related to the Type I IFN response were upregulated in the ST 
GOrilla analysis; GO:0032481 – ‘Positive regulation of type I interferon 
production’ (FDR=0.008), GO:0032479 – ‘Regulation of type I interferon 
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production’ (FDR=0.012) and GO:0060337 – ‘Type I interferon signalling 
pathway’ (FDR=0.012). In addition to this, GO:0032727 – ‘Positive regulation of 
interferon alpha production’ was upregulated in the GSEA analysis (FDR=0.037). 
IFN alpha forms part of the type I IFN signalling pathway and consequently the 
results from these two separate analyses were consistent.  
 
Multiple interleukin related ontologies were upregulated at first recurrence in the 
FFPE ST cohort. Interleukins are cytokines involved in modulating the immune 
system. They are able to act upon T- and B-cells, encouraging their development 
and contributing to both adaptive immune responses and inflammation (Brocker 
et al., 2010). They have been shown to be associated with the activation of NF-
kB and MAPK pathways in GBM, with a consequent increase in tumour growth and 
proliferation (Yeung et al., 2013). Therefore, it was important to note that a 
number of NF-kB related ontologies were also upregulated at ST tumour 
recurrence. Further areas of investigation include whether targeting downstream 
pathways of interleukin and NF-kB signalling may have a role in therapy. This is 
particularly important in light of the association between ST ependymomas with 
the C11orf95-RelA fusion gene and NF-kB signalling (Parker et al., 2014; Pietsch 
et al., 2014). 
 
Ontologies associated with energy metabolism, particularly glycolysis, were 
downregulated at first recurrence in the ST tumours. It has long been suggested 
that cancer cells are able to modulate their metabolic activity to provide a 
survival advantage in energy restricted surroundings (Warburg, 1956). In fact, 
‘Reprogramming Energy Metabolism’ has been added as an emerging ‘Hallmark of 
Cancer’ alongside ‘Evading immune destruction’ (Hanahan and Weinberg, 2011). 
Given the small sample size, further validation is needed in an independent 
dataset regarding metabolic changes at recurrence. 
 
The FFPE and FF posterior fossa location cohorts produced disparate results. The 
FFPE posterior fossa dataset was associated with a significant downregulation of 
immune ontologies and the FF posterior fossa dataset was associated with 
upregulation of immune and inflammatory ontologies. As there was a difference 
in the proportion receiving radiotherapy between these two groups (patients were 
more likely to have received radiotherapy in the FF cohort, p=0.037), it would be 
tempting to conclude that radiotherapy was the factor responsible. Indeed, this 
would be a biologically plausible explanation; radiotherapy has been associated 
with the ability to stimulate an immune response by exposing tumour antigens to 
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antigen presenting cells (Park et al., 2014). However, when the molecular 
composition of the PF location cohort was analysed in more depth, it became 
apparent that there was a difference between FF and FFPE cohorts. Whilst both 
datasets contained predominantly EPN_PFA tumours by DNA methylation profiling 
(FF 100%, FFPE 93%), the FF dataset had a greater proportion of tumours in the 
PF2 gene expression subgroup (FF 55%, FFPE 18%, p=0.041). PF1 and PF2 
subgroups also demonstrated contrasting immune responses at recurrence. It is, 
therefore, probable that the difference in expression patterns for the FFPE and FF 
posterior fossa location cohorts was due to the different composition of molecular 
diagnoses. This finding supports two conclusions. Firstly, the use of tumour 
location alone to predict clinical behaviour, including recurrence pattern, is 
inadequate. Secondly, not all EPN_PFA tumours, predicted by DNA methylation 
classification, exhibit the same biological behaviour at primary presentation and 
first recurrence. 
6.4.5 Molecular subgroup analyses 
This is believed to be the first study to profile paired primary and recurrent 
tumours with known EPN_RELA DNA methylation class predictions. However, the 
analysis was based on a limited dataset of just five tumours, so findings must be 
interpreted with caution and validated in other studies. EPN_RELA tumours 
demonstrated similar changes in gene ontology to those seen in the PF2 tumours; 
namely the upregulation of T- and B-cell related functions, indicating the 
presence of an adaptive immune response. This may suggest shared mechanisms 
between these tumour classifications at recurrence. It is not clear whether this 
adaptive response is pro- or anti-tumour and further investigation is required. 
 
Unsurprisingly, given that EPN_RELA made up 5/8 (63%) of the ST tumours, 
there was a significant overlap with the ontologies expressed in the overall ST 
location cohort, particularly related to immune functioning. However, the 
association with terms related to NF-kB signalling was not seen in this cohort, 
which was unexpected given the link between NF-kB and EPN_RELA tumours in 
the published literature (Parker et al., 2014; Pietsch et al., 2014).  
 
A number of downregulated terms exclusive to EPN_RELA tumours were related 
to transport of organic acids, phospholipids and lipids. These may link to changes 
associated with metabolic pathways seen at recurrence in the ST location cohort, 
but again need further confirmation. 
 
 198 
Downregulation of immune and inflammatory ontologies at recurrence were seen 
in PF1 tumours in both FFPE and FF cohorts, irrespective of treatment with 
radiotherapy. This indicates that therapeutic intervention may have minimal 
impact on tumour biology. The multicentre origin of samples in these cohorts 
suggests that this finding can be generalised. Whilst this immune and 
inflammatory downregulation has been described in a small, single centre, cohort 
of seven patients (Hoffman et al., 2014a), this is the first time that this 
phenomenon has been confirmed by an alternative technique (RNA-seq). This 
approach also added more detailed information about the nature of the 
downregulated ontologies, including specific changes in cell taxis and cytokine 
release.  
 
Cytokines are proteins with a role in cell signalling. It was evident from the gene 
expression analysis that there were differences in cytokine distribution between 
primary and matched recurrence within molecular subgroups.  
 
CCL2, CXCL1, CXCL3, CXCL6 and CXCL8 were chemokines representative of the 
PF1 subgroup downregulated in GSEA at first recurrence. Additionally, CXCL1 and 
CXCL6 were both differentially expressed at the FDR<0.05 level in the RNA-seq 
meta-analysis of the PF1 subgroups. These are all inflammatory chemokines and 
are associated with innate immunity and have chemoattractant properties for 
neutrophils and monocytes (Esche et al., 2005). Therefore, their decrease at first 
recurrence is consistent with a fall in the innate immune response.  
 
Chemokine release is stimulated by Pattern Recognition Receptors (PRRs) which 
are able to detect specific Pathogen Associated Molecular Patterns (PAMPs) and 
Damage Associated Molecular Patterns (DAMPs). The presence of PAMPs in the 
ependymoma samples in this study, was supported by changes in gene ontology 
terms such as GO:0009617 – ‘Response to bacterium’. PAMPs can take a variety 
of formats, including bacterial products and hypomethylated DNA containing CpG 
motifs (Esche et al., 2005). This is interesting given that, in addition to reports of 
large areas of hypermethylated CpG islands (Mack et al., 2014), EPN_PFA has 
also been reported to be globally hypomethylated (Bayliss et al., 2016). A 
hypothesis is that hypomethylated DNA may act as a PAMP in ependymoma. 
Numerous cancer associated molecules can serve as DAMPs including: heat shock 
proteins (HSPs); high-mobility group box-1 protein (HMGB1); adenosine 
triphosphate (ATP); and extracellular matrix danger molecules such as the S100 
proteins, hyaluronan, heparan sulfate proteins and fibronectin (Liu and Zeng, 
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2012; Schaefer, 2010). One explanation for the fall in chemokine response is that 
PAMPs and DAMPs are less evident in PF1 tumours at recurrence. A protein level 
analysis would be important to investigate this theory. 
 
A further hypothesis for the downregulated immune and inflammatory response, 
in the PF1 cohort is that the tumours have undergone an immunoselection 
process resulting in tumour immune escape (Zitvogel et al., 2006). Mechanisms 
of immune escape can vary depending on the level of T-cell infiltration into the 
tumour. Tumours with high levels of infiltration can suppress antigen expression 
and upregulate immune checkpoint markers; tumours with low levels of 
infiltration can alter the tumour microenvironment to prevent further T-cell 
recruitment (Spranger, 2016). Therefore, it would be important to establish the 
level of T-cell involvement in ependymoma, in order to interpret the potential of 
immune escape further. This is addressed in Chapter 7. 
 
There was an association between radiotherapy and upregulation of the adaptive 
immune response at first recurrence in the PF1 groups. The FF dataset, in which 
patients were more likely to have been treated with radiotherapy, exhibited an 
upregulation of the type I IFN pathway. The FFPE PF1 tumours treated with 
radiotherapy showed evidence of an adaptive immune response, however, 
specific terms related to type I IFN were not seen. Possible reasons for this 
include: type I IFN being genuinely unaffected in the FFPE cohort; the FFPE 
sample set being underpowered to detect a difference; or an artefactual result in 
the FF cohort. A technical validation of this finding was therefore performed in the 
FF samples. Although statistical analysis was precluded due to low sample 
numbers, this technical validation was supportive of the type I IFN changes given 
the fold change increases seen in matched RNA-seq and RT-qPCR results. The 
retrospective nature of this study meant that a causative role should not be 
assigned to radiotherapy. However, the findings in the PF1 groups add weight to 
the hypothesis that irradiation following primary disease contributes to the 
development of an adaptive immune response, which may be associated with 
type I IFN. Radiotherapy is known to augment the type I IFN response in other 
cancers (Woo et al., 2015; Zitvogel et al., 2015) so this merits further 
consideration.  
 
PF2 tumours demonstrated an increase in terms related to IFN signalling and 
adaptive immunity at first recurrence. In particular there was enrichment of T- 
and B-cell activation related terms, suggestive of an immunogenic tumour 
 200 
response. As recurrence still occurred, it is possible that this represented either 
an incomplete anti-tumour response or a driver of progression. As almost all the 
PF2 patients were treated with radiotherapy, it was not possible to assess 
whether radiotherapy may have contributed to this response.  
 
The type I IFN pathway was seen, to some extent, in ST, PF1 and PF2 tumours, 
suggesting that this may be a shared mechanism at recurrence. The type I IFN 
response can act as a ‘bridge’ between an innate immune response and the 
development of adaptive immunity by priming CD8+ T-cells. Additionally, there is 
evidence that modulation of the type I IFN pathway is a potential therapeutic 
approach in cancer (Medrano et al., 2017). To know whether this would be an 
option in ependymoma, a better understanding of its functional role is required. 
 
In the FF PF1 subgroup the type I IFN response was seen, but with no associated 
change in B- and T-cell ontologies. This may suggest that, whilst IFN was 
released, possibly in response to radiotherapy or chemotherapy, the adaptive 
immune effector cells were either not present or were unable to respond. A lack 
of T-cell responsiveness has previously been suggested in EPN_PFA ependymoma 
(Hoffman et al., 2014a; Griesinger et al., 2015).  
 
Upregulation of type I IFN has also been associated with the ability to modulate 
the host immune response and augment the efficacy of chemotherapy and 
radiotherapy (Bracci et al., 2017). Whilst a type I IFN response was seen in the 
PF2, ST and some radiotherapy treated PF1 ependymomas, the fact that all of 
these tumours still recurred suggests that this response was not fully protective. 
It may be that the type I IFN response and development of adaptive immunity 
alone was insufficient to prevent recurrence or may actually have contributed to 
further tumour progression or therapeutic resistance mechanisms (Dunn et al., 
2005). Interestingly, the clinical data analysed in Chapter 3 suggested that 
treatment with radiotherapy was associated with delayed time to progression but 
not OS. One possible explanation for this is a therapy induced immunological 
response which is eventually overwhelmed by the tumour.  
 
There is emerging evidence that, in some situations, the IFN response may be 
immunosuppressive (Bracci et al., 2017; Medrano et al., 2017; Minn, 2015). A 
recent study in GBM indicated that constitutive type I IFN signalling may 
contribute to immune escape mechanisms (Silginer et al., 2017). Additionally, 
constitutive type I IFN signalling has been associated with the development of 
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resistance to chemotherapy and radiotherapy (Bracci et al., 2017). In a breast 
cancer study, a set of seven IFN stimulated genes associated with resistance 
were described; the ‘Interferon Related DNA-Damage Signature’ (IRDS) (STAT1, 
MX1, ISG15, OAS1, IFIT1, IFIT3 and IFI44) (Weichselbaum et al., 2008). On 
review of the PF1 FF dataset, all seven IRDS genes were upregulated at first 
recurrence, six of them reaching statistical significance, with STAT1 having an 
increased fold change but not reaching significance. These genes were also 
upregulated at first recurrence in the PF2 and ST datasets; however, fewer 
reached statistical significance. The role of type I IFN in ependymoma, therefore, 
remains undefined and further molecular subgroup specific research is required. 
 
Whilst numerous terms relating to the immune and inflammatory responses, 
chemotaxis and cell signalling at recurrence were identified, a proportion of terms 
were also related to changes in the extracellular matrix (ECM). ECM components 
are able to signal through pattern recognition receptors to induce innate immune 
responses (Jiang et al., 2005). The ECM can bind cellular adhesion molecules and 
change the ability of leucocytes to freely migrate through a tissue, thus playing a 
role in immune cell recruitment and immune evasion (Morwood and Nicholson, 
2006). The ECM can also play a role in polarisation of T-cells towards a Th1 or 
Th2 phenotype, thereby affecting immune function (Morwood and Nicholson, 
2006). Modulators within the ECM are also able to contribute to the 
downregulation of inflammation, for example by exerting control over the 
complement cascade by binding to, and inactivating, elements of the pathway 
(Groeneveld et al., 2005). Therefore, it is interesting that elements of C1q, a 
recognition molecule for the complement cascade, were downregulated at first 
recurrence in the PF1 ependymomas. 
 
Other molecules of interest which occurred in both ECM gene ontology sets for 
the PF1 tumours included CD44, ITGA5, COL6A2, TGFBI, FERMT1, MMP16, 
THBS1, ABI3BP, ADAM12, SERPINE1, COL11A1 and COL27A1. Downregulation of 
CD44 molecules has been associated with a decrease in neutrophilic infiltrate in a 
kidney model (Rouschop, 2005). Therefore, a hypothesis for the decreased innate 
immune response in PF1 tumours is that ECM modifications contribute to immune 
evasion.  
 
The follow up of the gene expression data was not primarily focussed on ECM 
changes, but they are mentioned to highlight a potential role for the ECM in 
recurrent ependymoma. 
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6.4.6 Ependymoma immunophenoscores and cytolytic activity 
High immunophenoscores are associated with increased immunogenicity and 
neoantigen load (Charoentong et al., 2017). Tumours with high scores have also 
been associated with improved responses to CTLA-4 and PD1 checkpoint 
blockade. Clinical benefit to CTLA-4 blockade was only seen in tumours with an 
immunophenoscore greater than six, and to PD1 blockade with a score greater 
than five (Charoentong et al., 2017). The current study identified extremely low 
levels of expression of these potential therapeutic targets, suggesting that CTLA-
4 or PD1 blockade may not be an appropriate strategy for ependymoma. This 
finding is consistent with another report on ependymoma, examining PD1 and 
PDL1 at the protein level, which identified very low levels of expression (Dumont 
et al., 2017). 
 
After investigating the checkpoint blockade component of the 
immunophenoscore, all checkpoint molecules, identified in a review of markers 
associated with T-cell anergy, were examined (Catakovic et al., 2017). Consistent 
with the PD1 and CTLA-4 findings, almost all of the checkpoint receptors were 
present at levels too low to be considered expressed. The only exception to this 
was TIM3 and its ligand GAL9 which were expressed at a median of 2.8 
log2(TPM+1) and 2.00 log2(TPM+1). TIM3 has been suggested as a potential 
alternative target for checkpoint inhibition therapy (Anderson, 2014; Cheng and 
Ruan, 2015). 
 
Whilst the results of this gene expression analysis suggested that levels of 
checkpoint molecules in ependymoma may be too low to target with checkpoint 
blockade, further research is required to confirm the TIM3/GAL9 findings. This 
should include IHC staining, to confirm protein expression levels, and 
investigation into the functional role of TIM3 in suppression of the immune 
response.  
 
A recent study has suggested that levels of PDL1 are increased in EPN_RELA 
tumours compared to other subtypes, making EPN_RELA a potential target for 
checkpoint blockade (Witt et al., 2018). This was not the experience in this study. 
In fact, the only checkpoint molecules that showed differences between locations 
or DNA methylation groups were upregulated in the EPN_PFA tumours (TIM3 and 
CD112). There could be a number of reasons for this difference, including the 
specific selection of a cohort of children who recurred as opposed to a cohort of 
patients with mixed outcomes. However, given this conflicting finding, further 
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research is warranted. The results from this study did not support the conclusion 
that one subtype of disease may be more amenable to checkpoint blockade than 
another. 
 
Although changes in immune genes were present between primary and matched 
recurrences, the immunophenoscore failed to identify any differences. This may 
relate to the fact that the immunophenoscore measures specific parameters of 
the immune response which were not reflected in the primary and recurrent 
pairs. 
 
An alternative explanation for the lack of difference in immunophenoscore is the 
possibility that the changes seen in the paired gene expression analyses are a 
result of immunosuppressive actions of the tumour itself. Work by one research 
group has suggested that in EPN_PFA tumours, T-cells are anergic and therefore 
unable to function effectively (Hoffman et al., 2014a; Griesinger et al., 2015). 
Genes representative of anergic T-cells have been described in an in-vivo mouse 
model (Zheng et al., 2013). Interestingly, a number of these (LAG-3, CRABP2, 
NRGN, SEMA7A) overlapped with enriched genes in the PF1 groups. However, this 
result was not exclusive to PF1 tumours (EPN_PFA like) as the FFPE PF2 dataset 
was also enriched for a number of other genes associated with T-cell anergy 
(CRTAM and NRN1). This could either represent an artefact of the unsupervised 
clustering process or evidence of T-cell exhaustion in both tumour subtypes. 
There was no significant change in gene markers of T-cell anergy at recurrence in 
either of the PF datasets.  
 
The immunophenoscore data provided a novel insight into the ST tumours, which 
appeared to be even less immunogenic than the PF tumours. ST tumours were 
depleted for the MHC apparatus category, suggesting that one way in which the 
ST tumours had lower immunogenicity may be in downregulation of their ability 
to present tumour antigen. These results need to be taken into consideration 
when planning immunotherapy studies in these patients. 
 
Cytolytic activity (CYT) was found to be very low. This suggests that, across all 
molecular subtypes and recurrence statuses, cytotoxic T-cells (CTL) and Natural 
Killer (NK) cells are not undergoing activation to conduct active cell killing. Low 
CYT has been associated with a lack of neoantigen expression and poorer clinical 
outcomes, and has been used as a proxy marker for immunogenicity 
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(Charoentong et al., 2017). The findings are therefore consistent with those for 
the immunophenoscore. 
 
When comparing the CYT scores for the current ependymoma cohort with CYT 
scores generated for other cancer types, it was apparent that ependymoma had 
scores consistent with the least immunogenic tumours. The levels for 
ependymoma were close to the levels described in 499 glioma samples, obtained 
from the cancer genome atlas. The levels were also below those described for 
GBM, which was the tumour with the second lowest CYT scores of any cancer 
type (Rooney et al., 2015). 
 
The level of ependymoma immunogenicity was assessed using two different, but 
complementary and previously validated, approaches. This demonstrated that, 
despite immune gene expression changes at recurrence, there was little change 
in the already low levels of tumour immunogenicity. On the basis of these 
findings, interventions targeting immune modulation alone, particularly 
checkpoint blockade, are unlikely to be successful at either primary presentation 
or recurrence. Whilst changes in the type I IFN pathway were seen, the end point 
for any anti-tumour immune effect of this pathway would be the CD8+ mediated 
destruction of tumour cells. In this dataset, there was no discernible effect on 
cytolytic activity at the gene expression level to suggest efficacy of the type I IFN 
response.  
6.4.7 Tumour antigens: neoantigens and CT-antigens 
One way in which the immune system recognises cancer is via identification of 
tumour neoantigens. Higher immunophenoscores are associated with increased 
neoantigen burden (Charoentong et al., 2017). The nature of RNA sequencing 
meant that it was not possible to perform a direct assessment of the level of 
tumour neoantigens in these ependymoma samples. RNA-seq can identify single 
nucleotide polymorphisms (SNPs) that may form the basis of neoantigens. 
However, this analysis would only provide details about a very biased (coding) 
region of the genome. 
 
It could be inferred that the relatively low immunophenoscores and lack of 
significant changes in the score at recurrence suggest that the neoantigen burden 
is low. This was supported by the lack of detection of recurrent mutations in 
paediatric ependymomas and the very low mutational burden identified in whole 
genome and whole exome sequencing of a cohort of 47 PF ependymomas (Mack 
et al., 2014). However, in order to conclusively evidence any lack of change in 
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neoantigen burden at first recurrence, a study to perform whole genome 
sequencing of matched primary and recurrent paediatric ependymoma pairs is 
required.  
 
CTAs are immunogenic proteins that exhibit a restricted pattern of expression and 
can be re-expressed in cancer (Almeida et al., 2009). Whilst there was a different 
pattern of expression between the PF1 and PF2 subgroups, there was very little 
change in CTA expression at first recurrence for any molecular subgroup. It 
therefore seems unlikely that this is responsible for the change in immune 
profiles at recurrence. 
6.4.8 Potential implications for future therapies 
There has been a great deal of focus on the adaptive immune response in cancer, 
for example by the use of checkpoint blockade and chimeric antigen receptor 
(CAR) T-cell therapy. A greater understanding of the innate immune response to 
cancer is also developing and may lead to other innovative therapeutic 
approaches (Liu and Zeng, 2012; Woo et al., 2015). Whilst type I IFN signalling 
appears to be implicated in some way in each of the molecular subgroups, a 
better understanding of its role and impact on tumour development is needed, 
given its identification as a bridge between the innate and adaptive immune 
system (Woo et al., 2015). A recent study began to elucidate the role of type I 
IFN signalling in glioblastoma (Silginer et al., 2017), but such a specific approach 
is also required in primary and recurrent ependymoma. Without a better 
knowledge of how these pathways behave in this particular tumour type, clinical 
approaches to modulate IFN I signalling, for example by use of Toll Like Receptor 
ligands or oncolytic viruses (Woo et al., 2015) in patients could be ineffective, 
and in the worst case, dangerous, by stimulating an unexpected response. Of 
particular concern for this approach would be the significant increase in IRDS 
genes in the FF PF1 dataset. Alternatively, a better understanding of IFN type I 
signalling in ependymoma may suggest that this pathway would be a good target 
for therapeutic interventions at recurrence. 
6.4.9  Conclusions 
Through the use of two independent tumour cohorts, this chapter has 
demonstrated that analysis based on tumour location is unreliable in determining 
molecular outcomes. The analysis of groups based on gene expression and DNA 
methylation patterns was more informative. PF1 ependymomas were associated 
with a downregulation of innate immune and inflammatory responses, associated 
with possible immune escape. PF2 and ST tumours were associated with the 
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upregulation of the adaptive immune response but the impact of this was unclear 
given that these tumours still recurred. Irrespective of the ontological changes at 
recurrence, immunophenoscores and cytolytic activity were low for all groups, 
suggesting that ependymoma has low immunogenicity and may not be 
responsive to immune checkpoint blockade therapies. The type I IFN pathway 
may represent a potential therapeutic target in recurrent paediatric 
ependymoma, however further research is required to determine its role.
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7 A Study of Infiltrating Immune Cell Populations 
in Primary and Recurrent Ependymoma 
7.1 Introduction 
The spatial distribution and levels of immune cells within tumours may be 
important in aiding the understanding of tumour biology and outcomes. 
Researchers have described different tumour phenotypes in other cancer types: 
T-cell inflamed; immune excluded; and immune desert tumours (Chen and 
Mellman, 2017; Herbst et al., 2014; Kim and Chen, 2016) (Figure 7-1). T-cell 
inflamed tumours are associated with substantial T-cell infiltration of the tumour 
parenchyma; immune excluded tumours are associated with the accumulation of 
cells in the stroma but not the parenchyma; and immune desert tumours have 
minimal evidence of T-cells in the tumour environment overall. It has been 
suggested that these phenotypes are associated with various host characteristics, 
including age and environment, as well as tumour characteristics such as tumour 
type, chemokine profile and neoantigen burden (Chen and Mellman, 2017). The 
phenotypes have also been associated with different outcomes, including survival 
and response to immunotherapy. Different levels of immune cell infiltration may 
also be associated with different patterns of immune escape, contributing to 
tumour recurrence (Spranger, 2016). Knowledge of the level of immune and 
inflammatory cell infiltration and spatial distribution may help to ascertain 
whether ependymoma fits any of these phenotypes. This may lead to more 
informed approaches to new therapies and a better understanding of clinical 
outcomes. 
 
Cell types relevant to a basic understanding of tumour immunity include: CD4+ 
and CD8+ cells relating to T-cell infiltration; CD20+ cells relating to B-cell 
infiltration; and CD45+ cells related to infiltration with inflammatory cells. CD4+, 
CD8+ and CD20+ cells represent the adaptive immune response, whilst CD45+ 
cells represent the role of the inflammatory and innate immune responses. 
Details of the function of these cells were reviewed in section 1.5.2. 
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Figure 7-1: Immune phenotypes in cancer. Reproduced with permission from Chen and 
Mellman, 2017. 
 
Three studies have investigated immune infiltration in ependymoma. One 
contained nine primary tumours that recurred and ten non-recurrent primary 
tumours, from a mixture of intracranial locations (Donson et al., 2009). The 
second contained 13 PF tumours with matched recurrences (Hoffman et al., 
2014a). A third, recent study, included a greater number of samples but 
examined the levels of PDL1 infiltration in ependymoma specimens, postulating a 
DNA methylation group based difference (Witt et al., 2018). The samples included 
in these studies were not independent of one another. The first study found a 
significant association between CD4+ cell infiltration and recurrence in univariate 
analysis, but did not comment on the spatial distribution of the immune cells. The 
second found that tumours in the group equivalent to PF2 had slightly increased 
levels of CD4+ cells at first recurrence. Associations were not found with CD8+ 
cells in either study. The third study suggested that EPN_RELA tumours, 
compared to other molecular subtypes, were enriched for PDL1 and that more 
CD4+ and CD8+ cell infiltration was seen in EPN_RELA compared to the PF 
molecular diagnoses. The study did not specifically look at differences between 
primary and recurrent disease. 
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This chapter aimed to describe ependymoma immune cell infiltration in a larger 
cohort than previous works. Given the RNA sequencing findings in Chapter 6, it 
was also important to establish whether immune and inflammatory changes were 
seen at the protein, in addition to the gene, level.  
 
Whilst the samples included in the RNA sequencing analysis were selected to 
minimise non-tumour cells, they were not laser dissected or subject to cell 
sorting. Consequently, the gene expression changes may not have been isolated 
to tumour parenchyma. It was not possible to discern the spatial distribution of 
immune cells within the tumours from the gene expression data, but this can be 
established using immunohistochemistry (IHC). 
 
The specific aims of this chapter were to: 
(1) Investigate the spatial distribution of immune and inflammatory cells 
(CD4+, CD8+, CD20+ and CD45+) in all ependymoma types at 
primary and recurrence using IHC; 
(2) Investigate whether tumour location and grade were associated with 
altered quantities and distribution of immune and inflammatory cells; 
(3) Identify whether there were changes in the levels of immune and 
inflammatory markers within the parenchymal areas at recurrence, 
compared with paired primary disease; 
(4) Assess whether infiltration with immune or inflammatory cells was 
associated with TTP or OS, in univariate and multivariate analyses, in 
recurrent paediatric ependymoma. 
7.2 Materials and methods 
Samples from all tumour locations at both primary and recurrence were used to 
investigate tumour infiltration with CD8+, CD4+, CD20+ and CD45+ cells. The 
methods were designed in discussion with the authors of the two aforementioned 
studies in order to co-ordinate future collaborations in this area, however, the 
samples were new (Donson et al., 2009; Hoffman et al., 2014a). 
7.2.1 Tissue sections 
A cohort of 59 primary tumours, 55 with matched recurrences, was established 
(Appendix 1). The optimal approach for IHC projects of this size is to use tissue 
microarrays consisting of multiple cores of tumour on one microscope slide. This 
approach was attempted with the cluster of differentiation (CD) marker 
antibodies, but immune cells were present in insufficient quantities for reliable 
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identification. Consequently, IHC was performed across whole tumour sections to 
gain a more representative view. To ameliorate run to run variability, paired 
primary and recurrent tumours were stained within the same IHC run. 
7.2.2 Immunohistochemistry 
The details of the antibodies used to identify cellular infiltrates within the 
specimens are included in Table 7-1. The IHC reagents were from the EnVision 
Detection System, Peroxidase/DAB, Rabbit/Mouse (DAKO, UK). 
 
Marker Clone Manufacturer Concentration Function 
CD45 2B11+PD7/26 DAKO (M0701) 1/100 Common 
leucocyte antigen. 
Inflammatory 
marker. 
CD20 L26 DAKO (M0755) 1/200 Humoral 
immunity. 
Adaptive 
immunity. 
CD8 C8/144B DAKO (M7103) 1/100 Cell killing. 
Adaptive 
immunity. 
CD4 SP35 Cell Marque (104R-
18) 
Pre-diluted T-helper cells. 
Adaptive 
immunity. 
Table 7-1: List of antibodies used in the IHC analysis along with functional properties of 
the cells they represent. 
5 µm tissue sections were placed in a rack and rehydrated through xylene (15 
minutes), 100% ethanol (10 minutes) and 95% ethanol (10 minutes) before 
being washed with tap water. Antigen retrieval involved placing the rack in a pre-
heated steamer, in a sodium citrate buffer (Table 7-2), at pH six for 40 minutes.  
 
Reagent Amount 
Water 5 L 
Sodium Citrate Monohydrate 10.5 g 
2M Hydrochloric Acid 65 ml 
Table 7-2: Reagents for the sodium citrate buffer used in antigen retrieval. 
Following antigen retrieval, slides were cooled in the steamer for 10 minutes 
before a two minute wash in Phosphate Buffered Saline (PBS). 
 
Slides were wiped with a tissue before a hydrophobic pen was used to draw 
around each section to contain the liquid used in subsequent steps. Peroxidase 
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blocking solution was then added for five minutes before a further five minute 
PBS wash. After blotting with a tissue, diluted primary antibody was added in a 
sufficient quantity to cover the tissue section before being incubated for one hour 
at room temperature in a humidified chamber. Slides were washed again in PBS 
for five minutes before further blotting with a tissue and the addition of 
secondary antibody. Sections were incubated for a further 30 minutes at room 
temperature before another five minute PBS wash. 3,3’-diaminobenzidine (DAB) 
solution (1 part DAB to 49 parts substrate buffer) was added to the slides and 
incubated for five minutes before being washed off with tap water. Slides were 
then de-hydrated through 95% ethanol, 100% ethanol and finally xylene before 
mounting with DPX (Sigma-Aldrich, UK). 
 
Optimal primary antibody concentrations were determined by testing a range of 
dilutions on positive control tissue, to identify the concentration giving the most 
specific staining and least background. Positive controls were selected by 
consulting the Human Protein Atlas database (www.proteinatlas.org). The opinion 
of a neuropathologist (Dr Simon Paine) was also sought. 
7.2.3 Scoring tumour sections 
Photographs of 20 high power fields (HPFs), at 400x magnification, were selected 
at random from each section for CD4, CD8 and CD20 (Olympus, UK). 10 HPFs 
were selected for CD45. Attention was given to ensuring fields were taken from 
areas of tumour parenchyma, as opposed to surrounding stroma. For all markers, 
10 HPFs of non-parenchymal areas were taken in order to compare with tumour 
parenchyma. Positive cells exhibited circumferential brown staining around a cell 
nucleus and cytoplasm (Figure 7-2). To ascertain levels of cellular infiltrate, HPFs 
were scored by the author counting all positive cells, and a subset were double 
scored independently by another individual (SLB, FF), to ensure inter-scorer 
reliability. The IHC, photography and scoring were performed blind to clinical 
parameters. The order of scoring was determined by randomly selecting 
photographs of HPFs. 
7.2.4  Data analysis 
Data was analysed within the R statistical environment (R Core Team, 2014). 
Matched primary and recurrent pairs and parenchymal versus non-parenchymal 
tumour areas were compared using the Wilcoxon signed-rank test. Associations 
between immune cell infiltration of the primary tumour and survival outcomes 
were analysed using the approaches to survival analysis described in Chapter 3.2. 
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7.3  Results 
7.3.1 IHC cohort clinical features 
The IHC cohort contained 55 patients with primary and matched recurrent 
specimens. An additional four relapsed patients had primary tissue available and 
were included in survival analyses. DNA methylation group was unavailable for 13 
(22%) patients. 30 (51%) primary tumours were EPN_PFA, 11 (19%) EPN_RELA, 
1 (2%) EPN_PFB and 2 (3%) EPN_YAP. Other diagnoses accounted for 2 (3%) of 
the primary tumours (1 EPN_MPE, 1 HGNET_MN1). Other than the IHC cohort 
being less likely to have been treated with radiotherapy (p=0.022), there were no 
differences to the clinical cohort described in Chapter 3 (Table 7-3). 
 
Parameter 
Clinical Cohort 
(n=188) 
IHC Cohort 
(n=59) P Value 
Number % Number % 
Age 
<3 years 94 51 27 47 
0.762 3+ years 91 49 30 53 
NK 3 - 2 - 
Gender 
Male 105 58 30 56 
0.876 Female 77 42 24 44 
NK 6 - 5 - 
Extent of 
Resection 
GTR 76 45 25 46 
0.877 STR 93 55 29 54 
NK 19 - 5 - 
Location 
PF 136 73 39 66 
0.233 
ST 44 23 19 32 
SP 7 4 1 2 
NK 1 - - - 
Grade 
WHO II 85 52 27 47 
0.541 WHO III 78 48 31 53 
NK 25 - 1 - 
Radiotherapy 
at diagnosis 
Yes 104 59 23 41 
0.022 No 73 41 33 59 
NK 11 - 3 - 
Median age 35 months 40 months 0.574 
Median TTP 17 months 17 months 0.561 
Median OS 61 months 80 months 0.267 
Table 7-3: Clinical features of the IHC cohort compared to the overall clinical cohort 
described in Chapter 3. The only significant difference identified was an increased 
likelihood of treatment with radiotherapy in the IHC cohort. 
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7.3.2 Visual appearances of cellular markers and initial observations 
For all markers, positive cells were indicated by a ‘ring’ of brown staining around an 
unstained, blue centre. For all markers, infiltration into the tumour parenchyma appeared 
subjectively less than infiltration into the non-parenchymal and stromal areas. In 
particular, many samples showed increased evidence of infiltration within and around 
tumour vasculature, but very little positivity elsewhere in the specimen. For CD4, CD8 and 
CD20 markers, there were large areas of absent staining within parenchymal areas; 
infiltrating immune cells were sparse. CD45 appeared to have greater levels of infiltration 
in parenchymal areas. This pattern appeared to be consistent in both primary and 
recurrent tumours. Examples of positive staining, negative staining and staining in 
different tumour areas are provided in Figure 7-2 (A)–(H).   
 
 
 
 
 
 
 
 
 
Figure 7-2: (On next page) Representative images of IHC results. Positive cells were 
delineated by brown circumferential staining around a blue nucleus and cytoplasm. 
Examples within tumour parenchyma are given for CD20 (A) and CD8 (B) but CD4 and 
CD45 positive cells had identical appearances. Negative parenchymal areas demonstrated 
blue cell nuclei and cytoplasm with no brown markings (C) and (D). Assessment of spatial 
distribution of all markers indicated increased numbers of positive cells around blood 
vessels, here demonstrated for CD20 (E) and in stromal and other non-parenchymal areas 
compared to tumour parenchyma, here demonstrated for CD45 (F). Higher numbers of 
positive cells were also seen in areas of blood and necrosis. Examples provided for CD8 
(G) and CD4 (H). (A-E), (G) and (H) at 400x magnification, (F) at 100x magnification. 
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7.3.3 Average levels of expression in tumour parenchyma 
Numbers of CD20+, CD8+ and CD4+ cells were low in the primary tumour 
parenchyma with medians of zero (range 0-20), one (range 0-105) and zero 
(range 0-11) respectively. Numbers of CD45+ cells were higher, with a median of 
19 (range 0-119) (Figure 7-3). 
7.3.4 Spatial distribution of immune cells 
There were significantly lower numbers of all cell markers in the parenchymal 
areas compared to the non-parenchymal areas across all primaries and first 
recurrences (Figure 7-3).  
 
For the primary tumours, the median number of cells infiltrating parenchymal 
areas compared to non-parenchymal areas was 19 versus 70 for CD45+ 
(p<0.001), 0 versus 30 for CD20+ (p<0.001), 1 versus 16 for CD8+ (p<0.001) 
and 0 versus 13 for CD4+ (p<0.001). For the first recurrent tumours, the median 
number of cells infiltrating parenchymal areas compared to non-parenchymal 
areas was 10 versus 57 for CD45+ (p<0.001), 0 versus 21 for CD20+ (p<0.001), 
1 versus 16 for CD8+ (p<0.001) and 0 versus 8 for CD4+ (p<0.001). 
 
When subdivided based on location (PF and ST) and then DNA methylation 
subgroup (EPN_PFA and EPN_RELA), there remained statistically significantly 
more immune cells in the non-parenchymal areas than parenchymal areas for 
every cell marker in every location or DNA methylation defined subgroup, 
suggesting a generalisable effect across ependymoma subtypes. 
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Figure 7-3: Graphical illustration of distribution of immune and inflammatory cells between 
parenchymal and non-parenchymal tumour areas. For all cellular markers, there were 
more cells in the tumour non-parenchymal regions than in the tumour parenchyma. Per 20 
HPFs for CD4, CD8 and CD20 and 10 for CD45. P=Primary. R=Recurrence. 
7.3.5 Clinical features and parenchymal infiltration 
In view of the low numbers of CD20+, CD4+ and CD8+ cells in the parenchyma, 
OS and TTP were analysed based on comparing samples with no expression to 
samples with any expression. For CD45+ cells, values above and below the 
median were compared. 
 
Intracranial tumour location, tumour grade, extent of resection and DNA 
methylation classification (EPN_PFA versus EPN_RELA tumours) were compared 
with expression of CD4, CD8 or CD20 and CD45 in the parenchyma (Table 7-4). 
The only statistically significant association found was between positive CD20 
expression and higher tumour grade (p=0.041). 
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Location WHO Grade Resection DNA Methylation 
PF ST p II III p GTR STR p PFA RELA p 
CD45: 
High 
20 7 
0.333 
12 15 
1.000 
14 11 
0.473 
17 4 
0.706 
CD45: 
Low 
15 11 11 14 10 14 13 5 
CD20: 
Pos 
18 9 
1.000 
8 19 
0.041 
10 16 
0.404 
15 3 
0.465 
CD20: 
Neg 
19 10 17 11 14 12 15 7 
CD8: 
Pos 
22 12 
1.000 
17 17 
0.560 
15 17 
1.000 
18 7 
0.715 
CD8: 
Neg 
15 7 8 13 9 11 12 3 
CD4: 
Pos 
19 6 
0.224 
9 16 
0.376 
11 11 
0.934 
17 3 
0.273 
CD4: 
Neg 
17 13 15 14 13 16 13 7 
Table 7-4: Associations between location, grade, resection status and DNA methylation 
group for positive and negative expression of CD20, CD4 and CD8 and high or low 
expression levels for CD45. Numbers in boxes indicate number of samples that were either 
positive or negative. There was a significant association between CD20 expression and 
grade III tumours. Primary tumours only. No other associations were identified. Chi-square 
test used for comparisons.  
7.3.6 Cellular infiltration at recurrence 
All locations (Figure 7-4A and D) 
Paired analysis identified a significant decrease in the level of parenchymal 
infiltration with CD45+ cells at first recurrence. The median cell count at primary 
presentation was 19 cells per 10 HPFs compared to 10 at recurrence (1.9 fold 
decrease, p=0.002). No change was seen in the non-parenchymal areas (69.5 
cells at primary and 57 at recurrence, p=0.703).  
 
CD20+ infiltration in the parenchyma was not associated with a significant 
change at recurrence (median 0 at primary and recurrence, p=0.408). However, 
there was a significant fall in CD20+ cells in the non-parenchymal areas (median 
28 cells at primary and 21 at recurrence, p=0.034).  
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CD8+ and CD4+ cells showed no differences at primary versus first recurrence in 
both parenchyma and non-parenchyma (CD8+ parenchyma 1 at primary and 
recurrence p=0.525, non-parenchyma 15 at primary and 16 at recurrence 
p=0.556. CD4+ parenchyma 0 at primary and recurrence p=0.879, non-
parenchyma 10 at primary and 8 at recurrence p=0.632). 
 
Posterior fossa (Figure 7-4B and E) 
When examining the PF tumours as a separate group, there remained a fall in 
parenchymal CD45+ cells from primary tumour to first recurrence (median 24 to 
12 cells, p=0.009). There were no changes in any of the other cell markers in 
parenchymal or non-parenchymal regions. When examined by DNA methylation 
classification, there was a significant decrease in CD45+ cells from a median of 
26 at primary to 10 at recurrence for the EPN_PFA tumours (p=0.0194). 
 
Supratentorial (Figure 7-4C and F) 
When examining the ST tumours as a separate group, there was a fall in non-
parenchymal CD20+ cells from primary tumour to first recurrence (median 28 to 
20 cells, p=0.035). There were no changes in any other cell markers in 
parenchymal or non-parenchymal regions. When examined by DNA methylation 
classification, no differences were identified for the EPN_RELA tumours. 
 
As a potential association between radiotherapy and immune response was 
identified in Chapter 6, the immune markers were re-examined after stratification 
by treatment with radiotherapy. A fall in CD45 levels from primary to recurrence 
was identified in the parenchyma in the irradiated PF group (p=0.008), but no 
other significant differences were found between primary tumour and recurrence 
in irradiated and non-irradiated cohorts for CD4+, CD8+ or CD20+ cells. 
 
Figure 7-4: (On next page). Boxplots illustrating changes in parenchymal immune cell 
infiltrate of CD20, CD45, CD4 and CD8 at primary (P) and first recurrence (R) across (A) 
all tumour locations, (B) PF samples and (c) ST samples. Alongside boxplots illustrating 
changes in non-parenchymal immune cell infiltrate of the same markers at primary and 
first recurrence across (D) all tumours locations, (E) PF samples, and (F) ST samples. 
Significant decreases in CD45 were identified at first recurrence in the parenchyma for all 
and PF tumours. Significant decreases in CD20 were seen at first recurrence in the non-
parenchymal areas for all and the ST tumours. Numbers between indicate P-values. 
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7.3.7 Parenchymal infiltration and clinical outcomes 
In univariate analysis of all tumour types, a significant association was found 
between the presence of CD20+ or CD8+ cells in the parenchyma and poorer OS 
(p=0.007, p=0.009 respectively). No association was found between CD45+ or 
CD4+ cells and OS (p=0.939, p=0.788) (Figure 7-5). When examining time to 
first relapse, tumours with more CD20+ cells in the parenchyma recurred more 
rapidly (p=0.046) but no association was found with any other cellular infiltrate 
(CD45+ p= 0.947, CD8+ p= 0.797, CD4+=0.086) (Figure 7-6).  
 
To assess whether CD20+ or CD8+ cells maintained their association with poorer 
OS in multivariate analysis, the clinical parameters tested in Chapter 3 were first 
tested to assess their significance in this reduced cohort. Out of extent of 
resection, tumour location, treatment with radiotherapy and tumour grade, only 
higher tumour grade was associated with significantly poorer OS (Grade II 
median 152 versus Grade III 47 months, p=0.044). Therefore, CD20+ and CD8+ 
survival analysis was combined with tumour grade data. The Schoenfeld test was 
non-significant (p=0.096), suggesting that the CPH test assumptions were met. 
The only factor which remained significantly associated with poorer OS after this 
multivariate analysis was infiltration with CD8+ cells. CD20 expression lost its 
significance, probably because it had a significant association with tumour grade 
(chi-square test, p=0.041) (Table 7-5). 
 
Factor Hazard Ratio 95% CI P-value 
Tumour grade 
II 1.000 
0.853-3.760 0.124 
III 1.790 
CD20 Expression 
Yes 1.744 
0.823-3.700 0.147 
No 1.000 
CD8 Expression 
Yes 2.490 
1.087-5.704 0.031 
No 1.000 
Table 7-5: Multivariate analysis of features reaching significance in univariate analysis 
combined with CD8 and CD20 expression. Only CD8 expression remained significantly 
associated with poorer OS in this model (p=0.031). 53 were patients included in this 
analysis. 
When assessing time to progression, no clinical factors were significant in the 
univariate analysis for this cohort. Only CD20+ cells were associated with time in 
the univariate analysis of the IHC data, therefore no multivariate analysis was 
performed. 
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  Figure 7-5: Univariate analyses of overall survival for patients with 
expression of (A) CD4, (B) CD8, (C) CD20 and (D) CD45. Significant 
associations were identified for CD20 and CD8, both of which were 
associated with poorer OS. 
A 
B 
C 
D 
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 Figure 7-6: Univariate analyses of time to progression for patients with 
expression of (A) CD4, (B) CD8, (C) CD20 and (D) CD45. CD20 was 
associated with significantly more rapid progression. 
A 
B 
C 
D 
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7.4 Discussion 
This chapter presented the results of an IHC and clinical analysis of immune cell 
infiltrate in a cohort of 55 paediatric ependymomas which recurred. The primary 
aims were to investigate: 
(1) The spatial distribution of immune infiltrates; 
(2) Whether there was an association between clinical factors and immune 
cell infiltration; 
(3) Whether there was evidence of a change in the level of infiltration at 
recurrence compared to paired primary tumour; 
(4) Whether there was an association between immune cell infiltration of 
the primary tumour and survival outcomes. 
 
Spatial distribution of cellular infiltrates 
Attention was paid to ensure that the counted cellular infiltrate represented 
regions of tumour parenchyma rather than surrounding stromal, haemorrhagic or 
necrotic areas. This contrasted with previous studies where this approach was not 
specified (Donson et al., 2009; Hoffman et al., 2014a). An understanding of how 
immune cells are distributed across tumour sections is important to be able to 
interpret how recurrent ependymoma correlates with previously described tumour 
immune phenotypes (Chen and Mellman, 2017).  
 
For all immune cell markers, levels of tumour parenchymal infiltration were 
significantly lower than levels in the surrounding non-parenchymal areas. In fact, 
there were surprisingly few parenchymal CD20+, CD4+ or CD8+ cells, with 
medians of 0 or 1 cell per 20 HPFs. This suggested that levels of adaptive 
immune activity within these tumours may be low. This finding was consistent 
with the data presented regarding cytolytic activity and immunophenoscores in 
section 6.3. However, it was difficult to compare these results to previous studies 
in paediatric ependymoma because of the different approaches used in assessing 
expression levels (Donson et al., 2009; Hoffman et al., 2014a).  
 
In line with a small study investigating PD-L1 expression in ependymoma 
(Dumont et al., 2017), observation of whole tumour specimens identified 
infiltrates around tumour vasculature, but minimal infiltration into the tumour 
itself. The presence of significantly more markers of the immune response outside 
of, compared to within, the tumour parenchyma, provided evidence to suggest 
that ependymoma is not a T-cell inflamed tumour, and is more likely to be 
immune excluded. Given that this pattern was still seen when tumours were 
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stratified by location and DNA methylation profile, this finding can be extended 
across the most common intracranial molecular subgroups.  
 
Some may argue that the lack of immune cell markers within the ependymoma 
specimens is related to a lack of access for immune cells due to the immune 
privilege of the brain. This is contributed to by the impermeability of the blood 
brain barrier, lack of lymphatic supply to the parenchyma and lower levels of 
antigen presenting apparatus (Muldoon et al., 2013). However, this hypothesis is 
weakened by evidence that in gliomas this immune privilege is disrupted by 
remodelling of the ECM and vasculature, allowing immune cells to invade (Lee et 
al., 2009). Questions have also been raised about whether the brain 
microenvironment is really as immune privileged as previously thought (Carson et 
al., 2006). It would therefore be erroneous to assume that the lack of immune 
cell infiltration seen across this ependymoma cohort results from brain immune 
privilege. Future research questions must address other possible causes of 
immune cell exclusion from the tumour microenvironment, such as the 
composition of the ECM and chemokine profiles. There is also a possibility that 
this finding could represent immune suppression mediated tumour escape, rather 
than the effect of a competent blood brain barrier (Spranger, 2016); the change 
in cytokine profile at recurrence in the RNA-seq data may support this theory. 
 
A search of www.clinicaltrials.gov for ‘ependymoma’ and ‘immunotherapy’ 
highlighted eight trials investigating the role of various immunotherapy 
techniques in brain tumours, including ependymoma. In particular, one study was 
investigating the role of checkpoint blockade. In an era where immunotherapeutic 
approaches to ependymoma are being investigated, it is critical to develop a good 
understanding of the underlying tumour biology. Given that the data from the 
present study suggests a low number of T-cells within the parenchyma, in 
addition to low expression of checkpoint molecules and low immunophenoscores 
(Chapter 6), immune checkpoint blockade may not be beneficial. In fact, it has 
previously been suggested that lack of T-cell infiltration will result in a lack of 
effect for checkpoint blockade (Spranger, 2016). The risk of proceeding with 
checkpoint inhibition trials in ependymoma, without first considering the level of 
T-cell infiltrate, is that it could be concluded that checkpoint blockade is 
ineffective, when actually it needs synergy with another treatment to obtain 
optimal efficacy. One approach to this problem is the use of immunogenic 
chemotherapy which is being investigated in an attempt to increase levels of T-
cell infiltration into tumours (Pfirschke et al., 2016). Also, as this study has only 
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investigated tumours that go on to recur, it would be important to know more 
about the infiltration of tumours that do not recur. As many novel therapies are 
trialled at recurrence, if these non-recurrent tumours were more susceptible to 
checkpoint blockade, an important treatment opportunity would be missed. 
 
Association between immune infiltrate and clinical factors 
It was also important to consider whether baseline characteristics related to 
tumour grade, location and molecular subgroup were associated with differing 
levels of parenchymal immune cell infiltrate. The only significant association 
identified was between tumour grade and CD20+ cell infiltration (p=0.041). This 
must be interpreted with caution given the known difficulty in reaching consensus 
on designation of grade (Ellison et al., 2011). However, one strength of this study 
was that most samples underwent central pathology review in addition to local 
review at the originating centre. Assuming that all of the grade assignments were 
correct, a possible explanation for the finding is that B-cells may be stimulated by 
the increased levels of necrosis and inflammation in grade III tumours, resulting 
in cytokine release and chemotaxis to the affected area. However, if this 
hypothesis is true, one might expect to see an increase in other adaptive immune 
and inflammatory cells in grade III tumours, of which there was no evidence in 
this study. 
 
Given that there were no associations between tumour location and immune cell 
infiltration, it was unsurprising that the two main, location based, DNA 
methylation subgroups, EPN_PFA and EPN_RELA, also demonstrated no 
significant differences in immune cell infiltration. This finding contrasted with a 
recent study into PDL1 expression on T-cells in ependymoma, which suggested 
that EPN_RELA is enriched for this checkpoint marker and also associated with 
greater levels of CD4+ and CD8+ cells (Witt et al., 2018). However, the approach 
for determining which tumours had EPN_RELA versus other designations differed; 
the present study used DNA methylation profiling, whereas the study by Witt and 
colleagues used gene expression and other molecular profiles, so they are not 
directly comparable. Therefore, it remains difficult to conclude whether there are 
differences in the immune environment between intracranial locations and 
molecular subtypes in ependymoma. Further investigation is warranted to 
comprehensively delineate the immune environment in the different subgroups of 
the disease; some research groups have already begun to work towards this aim 
(Griesinger et al., 2015, 2017; Witt et al., 2018). 
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Paired analysis of immune infiltration at first recurrence 
It was important to assess whether the gene expression changes at recurrence, 
identified in Chapter 6, were also evident at the protein level. In the PF1 group 
this may have been indicated by a fall in the level of immune and inflammatory 
cells. In the PF2, ST and radiotherapy treated groups this may have been 
indicated by an increase in adaptive immune cell recruitment at recurrence.  
 
The majority of the PF location tumours that had RNA-seq data fell into the PF1 
group. In this group, CD45+ cells were significantly reduced at recurrence. This 
provided initial validation of the changes seen in the RNA-seq data in PF1 
tumours; however, it did not provide an explanation as to why this 
downregulation occurred.  
 
One possibility for this downregulation is a process of tumour immune escape, 
resulting in the presence of less cellular infiltrate. A number of different immune 
escape mechanisms have been described in both T-cell inflamed and non T-cell 
inflamed tumours. Given that the results of this study suggest that ependymoma 
is not T-cell inflamed, this narrows down potential mechanisms to: a lack of 
innate immune sensing; failure to recruit effector T-cells; and alterations to the 
tumour microenvironment (Spranger, 2016). The change in inflammatory 
chemokine profiles at recurrence, in the PF1 subgroup in the RNA-seq data, 
provides supportive evidence that microenvironmental changes may be an 
important mechanism in this response. Additionally, the identification of ECM 
changes may result in both a lack of innate immune sensing and a failure to 
recruit effector T-cells. The knowledge about immune cell spatial distribution, 
combined with gene expression profiling, has therefore helped to narrow down 
possible avenues of further research into immune escape in ependymoma.    
 
Unfortunately, there were too few PF2 tumours with RNA-seq classifications to 
perform a full subgroup analysis. This may explain why there were no significant 
increases at recurrence in the levels of CD20+, CD4+ or CD8+ cells in the PF 
tumours. However, there was also no evidence that ST tumours or tumours in 
patients who had received radiotherapy were associated with increased levels of 
immune infiltration at first recurrence. 
 
It would have been advantageous to be able to include expanded cohorts of PF2 
and ST tumours to validate the gene expression results with greater power. It is 
also possible that the statistical tests were not as reliable in these cohorts 
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because of the inherent variability in counting low numbers of cells. Although, if a 
genuine change was missed because of a small effect size between primary and 
recurrence, one would have to question whether it would be biologically plausible 
that this could impact overall patient outcomes. An alternative explanation for the 
lack of change seen is that, whilst the gene expression changes identified via the 
RNA sequencing were genuine, there was no resultant impact on an effective 
adaptive immune response. This theory would tend to be supported by the 
findings of the CYT data which indicated that immune effector activity remained 
low at recurrence in all tumour subtypes, despite an apparent upregulation of the 
adaptive immune response in some. 
 
Association between immune infiltrate, survival and tumour progression 
Univariate survival analyses associated the presence of CD20+ and CD8+ cells 
with worse OS in primary ependymomas which recurred. Survival analyses also 
identified CD20+ cells as being associated with a more rapid first progression. 
Multivariate analyses resulted in only the presence of CD8+ cells being associated 
with poorer OS. This finding is perhaps surprising given that CD8+ T-cell 
infiltration has previously been associated with improved outcomes in a number 
of meta-analyses in other malignancies (de Ruiter et al., 2017; Mao et al., 2016). 
However, these analyses did not all indicate whether they were based on multi- 
or univariate findings and were therefore at risk of confounding.  
 
By excluding patients who did not recur, the present study selected for 
particularly poor outcomes. Therefore, it is possible that the CD8+ T-cell 
infiltration in this group of patients, represented a fundamentally different 
population of cells to those identified in the studies linking them with good 
prognosis. Immune cells, other than CD8+ cytotoxic T-cells, express CD8; in 
particular macrophages (Baba et al., 2006) and dendritic cells (Shortman, 2000). 
There are also a group of CD8+ suppressor cells, which have been linked with 
poor outcomes. They are associated with a CD8+CD27/CD28- phenotype and 
have been suggested to suppress anti-tumour responses (Filaci & Suciu-foca 
2002, Maybruck et al. 2017). The association between CD8+ cells and poorer 
outcomes in recurrent ependymoma is a novel finding and as such requires 
confirmation in independent, prospective studies. Further assessment of 
molecular markers, including CD27 and CD28, present on the CD8+ cells is also 
required to establish any evidence of an immunosuppressive, and therefore pro-
tumour, function. 
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Further work is also needed in order to correlate the outcomes of a non-recurrent 
dataset with the recurrent dataset to assess whether the clinical correlates 
remain the same. 
 
Conclusions 
This chapter has provided evidence that paediatric ependymomas that recur are 
immune excluded tumours with low levels of T- and B-cell infiltrates at both 
primary and recurrence. There were few associations with clinical factors other 
than a significant association between B-cells and tumour grade, which may 
potentially be explained by higher levels of necrosis. The downregulation of the 
inflammatory response identified in PF1 tumours in previous chapters was 
supported by the findings of the IHC analysis. There was no evidence of an 
upregulated immune response in recurrent ST tumours or those treated with 
radiotherapy which may relate to a small sample size. There was an apparent 
association between CD8+ cell infiltration and poorer OS; further investigation is 
required to assess for additional markers of CD8+ suppressor cells. 
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8 Final Discussion and Conclusions 
This study aimed to undertake molecular profiling of recurrent ependymoma, 
combined with contemporary clinical data, to better understand recurrence 
biology and potential therapies. The specific aims were to: 
(1) Collate and analyse a cohort of recurrent paediatric ependymoma cases to 
determine: 
a. Patterns of recurrence in the overall cohort and location determined 
subgroups; 
b. Factors impacting upon time to first recurrence and overall 
survival; 
c. Factors impacting upon progression and survival after first 
recurrence; 
d. Factors affecting risk of recurrence. 
(2) Describe the clinical features of a cohort of DNA methylation defined 
cases which recurred; 
(3) Support the results of the clinical analysis and RNA-seq analysis by 
generating DNA methylation profiles for samples with tissue 
availability; 
(4) Undertake RNA sequencing of FFPE tumour specimens in order to 
expand the cohort for primary and recurrence analysis and validate 
the use of this technique against a cohort of FF specimens, in order to 
make recommendations for future research; 
(5) Perform gene expression analysis of matched primary and recurrent 
pairs to determine changes in expression patterns at recurrence and 
correlate with molecular classifications where DNA methylation data 
available; 
(6) Validate key expression changes using qPCR and IHC. 
 
This study included a number of novel elements. The large clinical data analysis, 
supported by DNA methylation results, allowed for the stratification of cohorts of 
children with recurrence by clinical and molecular profiles. This is believed to be 
the largest series of children with exclusively recurrent disease presented to date. 
The gene expression study into matched primary and recurrent ependymoma 
built on previous findings showing a role for the immune system in this disease 
(Donson et al., 2009; Hoffman et al., 2014a). However, the use of RNA-seq 
allowed for a greater depth of analysis and potentially better understanding of 
how the underlying ontological terms related to tumour function. The use of 
independent FFPE and FF cohorts increased the statistical power and made the 
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results more generalisable across molecular cohorts. Combining the gene 
expression data with DNA methylation profiles enabled a better insight into the 
molecular subgroups and provided evidence that EPN_PFB expression profiles are 
not exclusive to EPN_PFB. Data from the DNA methylation profiling also 
contributed to a larger study delineating new subgroups of EPN_PFA 
ependymoma (Pajtler et al., 2017). Validation of RNA sequencing from FFPE 
material was successful; an approach not previously reported in ependymoma 
and only to a very limited extent in brain tissue (Esteve-Codina et al., 2017). For 
the first time, this study has indicated that recurrent ependymoma appears to 
have low immunogenic potential and the use of IHC analyses indicated that it is 
an immune-excluded tumour. The implications of this for studies into 
immunotherapy have been considered. 
 
Clinical Features 
The clinical analysis highlighted the abysmal medium to long term outcomes for 
children with recurrent ependymoma. Whilst there had been improvement over 
the decades, prognosis remained very poor. The research emphasised the clear 
and pressing need for the development of new and effective therapies for this 
illness. 
 
The collation of a large, contemporaneous, cohort of clinical data from children 
with recurrent ependymoma permitted an up-to-date assessment of the clinical 
features associated with outcome in this devastating disease. The importance of 
preventing relapse was highlighted by a comparison with a cohort of data from 
children with isolated primary disease, which clearly demonstrated that 
recurrence was the most significant known indicator of poor outcomes. Patients 
with STR compared to GTR were at greater risk of recurrence but crucially, GTR 
did not prevent some children from recurring. It was evident that in patients who 
went on to relapse, previously identified prognostic factors at primary diagnosis, 
such as extent of resection and radiotherapy, did not impact upon OS. There was, 
however, a transient impact on progression if these interventions were delivered 
between first and second recurrence, but in the long-term this was lost. This 
study confirmed a previous suggestion that for some, ependymoma becomes a 
chronically relapsing disease (Zacharoulis et al., 2010). 
 
The inclusion of 188 patients in the recurrent cohort increased the statistical 
power over other studies (Antony et al., 2014; Goldwein et al., 1990; Messahel et 
al., 2009; Zacharoulis et al., 2010). One of the advantages of these greater 
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numbers was the ability to subdivide the cohort based on intracranial tumour 
location. This was important as previous authors have indicated that 
ependymomas in different locations are likely to arise from different progenitor 
cells (Taylor et al., 2005) and exhibit different driver mutations (Johnson et al., 
2010). Interestingly, it emerged that despite different origins, the clinical pattern 
of behaviour at recurrence was similar for PF and ST tumours, with the exception 
of statistically significant, but small, differences in time to progression. The 
exception to this was the spinal tumours which were associated with better 
outcomes, however the numbers in this analysis were small. The homogeneity of 
clinical outcomes in this study, despite location based stratification and the 
different clinical outcomes that have been previously attributed to different 
molecular subgroups (Pajtler et al., 2015), suggested that molecular classification 
might be more informative than location based classification. 
 
Combining DNA methylation data with the clinical cohort 
The dawning of the ‘molecular era’ of brain tumour research (Mack and Taylor, 
2017) meant that an analysis of clinical data needed to be placed into context 
with a molecular definition. One of the strengths of this study was that it is one of 
the first to provide molecular annotations to a cohort specifically designed to 
analyse recurrent disease.  
 
The findings seen in the PF and ST location clinical analyses were consistent with 
those for EPN_PFA and EPN_RELA subgroups. EPN_RELA tumours were associated 
with a more rapid time to first relapse than the EPN_PFA tumours. However, 
because EPN_PFA formed the majority of the PF cohort and EPN_RELA formed the 
majority of the ST cohort, it became difficult to discern the behaviour of the 
smaller molecular subgroups. Contrary to reports of EPN_PFB, EPN_MPE and 
EPN_YAP being less aggressive and therefore candidates for more conservative 
therapy (Pajtler et al., 2015; Ramaswamy et al., 2016), this study showed that 
they did relapse, but numbers were too low to draw robust conclusions regarding 
further implications for management. Larger collaborative efforts are needed to 
investigate the behaviour of EPN_PFB, EPN_YAP and EPN_MPE at both primary 
presentation and recurrence in childhood. 
 
DNA methylation subgroup assignment almost never changed between primary 
and first recurrence. This confirmed the findings of the original study delineating 
nine subgroups in ependymoma (Pajtler et al., 2015). The two exceptions were: 
one tumour which switched from EPN_PFA to DNET; and one which switched from 
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DNET to EPN_PFA. Unfortunately, sufficient tissue was not available for re-review 
of these cases, but discussion with collaborators in Heidelberg indicated that this 
pattern could reflect contamination of the sample with normal brain tissue 
(Personal communication, Kristian Pajtler, 2017). It was therefore unclear 
whether the two cases that did switch represented a genuine change in subgroup. 
The fact that tumours did not change DNA methylation groups at recurrence 
shows that when patients developed a further tumour, it almost always appeared 
to be an ependymoma recurrence, rather than a treatment induced malignancy. 
This was evident even in those cases of very late relapse.  
 
Expanding the role for nucleic acids extracted from FFPE 
One of the challenges of this study was obtaining sufficient samples to include in 
the analysis of paired primary and recurrent disease. Collaboration with other 
investigators was an obvious way to improve this, but strategies were also 
employed to make use of an extensive archive of FFPE tissue. Whilst DNA studies, 
such as methylation arrays, have advanced the use of FFPE tissue (Pajtler et al., 
2017, 2015; Ramaswamy et al., 2016), this has not been the same for RNA. By 
demonstrating that FFPE RNA sequencing is feasible in paediatric ependymoma, 
the potential for future gene expression work using this technique has increased.  
 
Whilst it was clear that the FFPE cohort reflected the clustering and gene 
expression patterns expected from the dataset, there were still some limitations 
as demonstrated by increased variability between the FFPE and FF samples. The 
main areas for improvement were: to minimise the impact of bacterial 
contamination of blocks, stored for long periods in non-sterile environments; to 
optimise protocols to minimise the impact of over sequencing short RNA 
fragments; and to develop a better understanding of acceptable quality control 
cut-offs for FFPE RNA-seq data. 
 
This study identified an attrition rate of approximately 20% of samples, largely 
due to over representation of bacterial reads. It could be argued that using RNA-
seq on these blocks creates the potential to yield a great deal of new data, 
particularly for rare diseases where samples are hard to obtain. This must be 
balanced against the risk of sample loss which may be financially costly.  
 
Compared to the FF tissue, the FFPE tissue was associated with shorter fragments 
of RNA and cDNA for sequencing. This resulted in some over-sequencing, with the 
presence of adapter content, and nucleotide bases that could not be called. 
 233 
Future researchers must set their initial sequencing parameters with this in mind; 
reads of 100 bases are not needed for FFPE blocks. 
 
A further difficulty with interpreting the FFPE RNA-seq data was a lack of 
information about what constitutes acceptable quality. Based on the results of the 
bioinformatic pipeline, many of the FFPE samples had quality control values below 
what was seen in the FF samples. However, as the final analysis still reflected FF 
and published data findings, a better understanding of acceptable quality control 
levels is needed. Until data quality metrics are standardised for FFPE tissue, 
confirmation of the findings of FFPE RNA-seq, with either a validation RNA-seq 
cohort or an orthogonal technique, is essential. 
 
Ensuring the correct molecular classification of tumours 
An important lesson learned from the combined analysis of DNA methylation and 
gene expression profiles, was that molecular subgroups of ependymoma should 
not be defined on the basis of gene expression profiling alone. Whilst previous 
authors have delineated EPN_PFA and EPN_PFB groups on the basis of gene 
expression (A. Griesinger et al., 2015; Hoffman et al., 2014a; Wani et al., 2012; 
Witt et al., 2011a), the profiles generated from this study have provided evidence 
that the EPN_PFB gene expression phenotype is not restricted to DNA 
methylation confirmed EPN_PFB. Whilst almost all of the tumours with EPN_PFA 
gene expression were EPN_PFA by DNA methylation profiling, the group 
consistent with EPN_PFB gene expression contained a mixture of molecular 
diagnoses, including EPN_PFA, EPN_PFB, EPN_MPE and EPN_YAP.  
 
Hoffman and colleagues (2014) used gene expression profiling alone to delineate 
two distinct PF groups, and concluded that they were EPN_PFA and EPN_PFB 
ependymomas. As part of this study’s collaboration with Hoffman and colleagues, 
additional DNA methylation classifications were obtained for a number of their PF 
tumours. All of the tumours in their EPN_PFB group, with available DNA 
methylation predictions, were in fact found to be EPN_PFA. This supported the 
findings from the FF and FFPE cohorts in the present study. This has shown that 
future research must, where possible, back up molecular subgroup information 
with the gold standard diagnostic approach of DNA methylation analysis. If this is 
not achieved, there is a danger that conclusions are reached based on incorrect 
subgrouping that may adversely influence clinical trial planning and future 
treatment decisions.  
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The evidence for multiple EPN_PFA gene expression groups in Chapter 6, 
alongside the clustering of the DNA methylation samples in Chapter 4, provided 
support for the existence of multiple EPN_PFA molecular subgroups. This data has 
contributed to further research in this area (Pajtler et al., 2017). 
 
Gene expression changes at primary and recurrence 
When stratified by molecular subgroup, the results of the matched primary and 
recurrent analyses showed strong overlaps between the FFPE and FF cohorts and 
provided further insight into the importance of molecular subgrouping. The 
differential expression results based on PF location in the two cohorts conflicted 
with one another. When analysed in more depth, it became apparent that the 
probable reason for this conflict was the different molecular composition of the 
posterior fossa location based subgroups. PF1 was the predominant cluster in the 
FFPE samples, whilst PF1 and PF2 were more balanced in the FF samples. 
 
PF2 and ST samples demonstrated similar patterns of recurrence to one another. 
There was an upregulation of genes and ontology terms related to the adaptive 
immune response, and evidence of induction of the type I IFN pathway. The 
results from the PF1 group differed to this, demonstrating a downregulation of 
the innate immune and inflammatory responses characteristic of this subgroup at 
primary presentation. Importantly, in the PF1 subgroup, these downregulated 
changes appeared irrespective of treatment with radiotherapy. 
 
The fact that the gene expression defined subgroups showed the most consistent 
changes at recurrence, when compared to location defined subgroups, suggested 
that recurrence pattern may actually be dependent on the original gene 
expression phenotype at primary diagnosis. Even though the PF2 subgroup 
contained several different DNA methylation predictions, the behaviour of this 
group was still the same across two independent cohorts.  
 
RNA sequencing was performed on whole tumour samples rather than selected 
tumour cells. Therefore, the gene expression pattern would to some extent be 
influenced by the tumour microenvironment. The PF1 group in particular, was 
associated with terms related to the microenvironment, including the extracellular 
matrix, immune response, wound healing and inflammatory response. This, along 
with immune related changes at recurrence, raises the question as to whether 
there is a role for the tumour microenvironment in the mechanisms of recurrence.  
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Role of the immune system 
In line with previous authors (Hoffman et al., 2014a; Donson et al., 2009) this 
study implicated the immune system in recurrent paediatric ependymoma. 
However, the use of: RNA sequencing; DNA methylation subgroup assignment; a 
wider sample set; and threshold free gene set enrichment, provided a greater 
resolution to the analysis. 
 
PF1 tumours showed downregulation of innate immune response ontologies. This 
was supported by the fact that CYT activity and immunophenoscores did not 
change, as they represent markers of an adaptive response in an immunogenic 
environment. There was a significant downregulation of a number of ontologies 
related to inflammatory chemokines and immune cell taxis. This raised the 
possibility that the PF1 tumours exhibited some sort of tumour immune escape 
mechanism (Spranger, 2016). This provides a plausible explanation for how these 
PF1 tumours might recur. The finding of a fall in the inflammatory marker CD45 
in the posterior fossa IHC validation cohort, also strongly supported the theory 
that the changes in gene expression in the PF1 subgroup were translated to a 
response at the protein level. 
 
It was less clear how recurrence occurred in PF2 and ST tumours, which 
demonstrated an upregulation of the adaptive immune response. If this immune 
response was anti-tumour, one might expect to identify either an increase in 
tumour immunogenicity, stimulating an immune response; or an increase in cell 
killing, as the final step in an effective immune response. Additionally, via IHC, 
one might expect to see an increase in the number of adaptive immune cells in 
the tumour parenchyma at recurrence. However, these tumours showed no 
evidence of an associated increase in the immunophenoscore, cytolytic activity or 
immune cell infiltration at recurrence. This could be explained by at least three 
possible hypotheses. Firstly, the adaptive response seen was somehow pro-
tumour in nature and stimulated further tumour growth. Secondly, the tumour 
overcame an anti-tumour response. Thirdly, there was an anti-tumour immune 
response, but the effector immune cells were unable to access tumour cells due 
to the nature of the ECM or BBB, thus confining the response to the surrounding 
stroma. This last hypothesis was supported by previous research on tumour 
immunophenotypes including immune excluded and immune desert tumours 
(Chen and Mellman, 2017). The IHC data was highly suggestive of adaptive 
immune cell exclusion, with significantly more cells seen in non-parenchymal 
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areas, such as resection cavities and necrosis, than parenchymal areas. Further 
work to investigate these hypotheses is warranted.  
 
Changes at recurrence largely occurred irrespective of whether radiotherapy was 
delivered after primary treatment. However, in the PF1 group there was evidence 
of an association between upregulation of the type I IFN pathway and 
radiotherapy. A technical validation by qPCR demonstrated that this change was 
not artefactual. Radiotherapy is known to invoke a type I IFN response in other 
cancers (Lim et al., 2014) and the IFN pathway has been suggested to have both 
positive and negative impacts upon cancer survival (Bracci et al., 2017; Minn, 
2015; Parker et al., 2016; Weichselbaum et al., 2008; Zitvogel et al., 2015). 
Consequently, this needs more extensive investigation to confirm whether 
radiotherapy was responsible for this change. If this association is confirmed then 
consideration of how this may impact patient management is required.  
 
A further important observation was the low level of expression of immune 
checkpoint molecules across FF and FFPE datasets. Given that there is increasing 
interest in immune checkpoint blockade and other immune modulating 
treatments as therapies for cancer (Anderson, 2014; Charoentong et al., 2017; 
Connolly et al., 2016; Liu and Zeng, 2012), a better understanding of their 
presence in ependymoma was warranted. Despite ongoing clinical trials into 
checkpoint blockade in ependymoma, remarkably, evidence was only found of 
two conflicting studies investigating whether these molecules are expressed at 
the protein level (Dumont et al. 2017, Witt et al. 2018). The current study 
supported the findings of Dumont, by demonstrating that at the gene expression 
level, checkpoint markers were lowly expressed. This raises questions over the 
potential efficacy of checkpoint blockade therapy in ependymoma. However, 
there may still be a role for other immunotherapies in this disease. Modalities 
such as Chimeric Antigen Receptor (CAR) T-cell therapy might be considered, 
particularly in light of some emerging evidence about its potential effectiveness in 
GBM (O’Rourke et al., 2017). A better understanding of the underlying 
ependymoma immune environment is therefore critical in considering different 
treatment modalities, and preventing both unanticipated negative consequences 
for patients, and the unnecessary use of finite resources. 
 
Immunohistochemistry 
The IHC cohort provided an initial insight into the relationship between immune 
cell infiltrate and survival in the recurrent cohort. It was surprising that CD8+ cell 
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infiltration appeared to be associated with worse outcomes in multivariate 
analysis and contradicted findings of studies of CD8+ cell infiltration in other 
tumours (Mao et al., 2016). This finding needs confirmation in an independent 
cohort. Further IHC is also needed to identify whether these CD8+ cells are 
indeed CD8+ effector cells capable of cell killing, or whether they represent 
another CD8+ subset which could be associated with suppressor activity. CD20+ 
cells were found to be associated with worse outcomes in a univariate analysis 
but this was lost in a multivariate approach. 
 
The spatial distribution of the immune cells was highly suggestive that all 
subtypes of ependymoma are T-cell excluded tumours. Possible mechanisms for 
this include: the chemokine profile of the tumour; properties of the tumour’s 
ECM; or functioning of the BBB (Muldoon et al., 2013). The changes in 
chemokines between primary and recurrence, and between molecular subgroups 
in the RNA sequencing dataset, may begin to provide some explanation for the 
mechanisms of immune exclusion in these tumours. The findings of the immune 
cell spatial distribution needs validation in another dataset, as this appears to be 
the first time this finding has been described in the literature in paediatric 
ependymoma. However, if the spatial distribution and behaviour as an immune 
excluded tumour are confirmed, this would provide supporting evidence as to how 
immune escape mechanisms indicated by the gene expression analysis may 
operate.  
 
Recommendations for future work 
Clinical Data 
Whilst the behaviour of the more common DNA methylation subgroups is 
becoming better understood at primary diagnosis (Pajtler et al., 2015; 
Ramaswamy et al., 2016), and now at recurrence; further understanding is 
needed of the behaviour of the less frequently occurring subgroups such as 
EPN_PFB and EPN_YAP. The fact that both of these groups appeared in the 
recurrent dataset suggested that outcomes may not be as good as previously 
suggested. Large, international, collaborative efforts are required to generate 
sufficiently sized cohorts with these molecular subgroups, in order to evaluate the 
true natural history of these diseases, before any decisions are made on altering 
their therapeutic burden. 
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DNA Methylation Profiling 
Whilst molecular subgroups remained largely unchanged at recurrence, there was 
evidence that correlation scores were lower in the relapsed tumours. Further 
investigation of the DNA methylation cohort is therefore required to analyse 
whether there are significantly differentially methylated probes at recurrence and 
whether they are related to the immune response.  
 
Immune studies 
Whilst associations between recurrent disease and changes in the immune 
response have been identified in this retrospective study, confirmation of these 
findings are needed in a prospective trial. The BIOMarkers of Ependymoma in 
Children and Adolescents (BIOMECA) arm of the current European ependymoma 
clinical trial (SIOP Ependymoma II) may provide an opportunity to investigate 
this further. A prospective design would also be able to specifically ask questions 
about the association between therapeutic interventions, such as radiotherapy, 
and underlying biological changes.  
 
Patient based studies may be limited to observational approaches. Therefore, it 
would be beneficial to demonstrate any therapeutic associations in a suitable 
animal model, for example a mouse model of ependymoma. Cell culture work is 
often used for follow up of biological findings. However, this is limited by the lack 
of tumour microenvironment and immune infiltrate. In spite of this, work has 
begun to identify whether secretion of the chemokines identified in the RNA-seq 
analysis is derived from tumour or immune cells. Additionally, it may be 
interesting to investigate the response of ependymoma cell lines to inflammatory 
chemokines. 
 
A further question relates to whether there is a change in neoantigen load in 
recurrent ependymoma compared to matched primary disease. Increased 
neoantigen expression has been associated with an increased host immune 
response to tumour (Charoentong et al., 2017; Rooney et al., 2015). RNA 
sequencing data cannot provide detail about the overall level of neoantigen load 
because it does not sequence across the entire genome. Therefore, whole 
genome or exome sequencing of matched primary and recurrent tumours are 
needed to estimate changes in the neoantigen burden, and to infer whether it 
may be responsible for driving an immune response in the PF2 and ST samples. 
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Non-recurrent tumours 
It is unclear whether non-recurrent ependymomas represent different entities to 
recurrent ependymomas. This study has focussed on the biology of a cohort of 
recurrent tumours; a biological comparison with a cohort of non-recurrent 
tumours is required. Work is underway to identify this cohort in order to 
undertake RNA sequencing to compare gene expression patterns. IHC is also 
being undertaken to identify whether the immune infiltrate of the non-recurrent 
tumours differs to that of the recurrent tumours. Work by previous authors 
(Donson et al., 2009) has found some weak associations between immune 
infiltrate and recurrence status, but was probably underpowered to detect 
significant differences. 
 
Final Conclusions 
The key strengths of this study were the size and follow up duration of the clinical 
data, coupled with molecular analysis using both gene expression and DNA 
methylation profiles. The use of RNA-Seq from FFPE in a paediatric brain tumour 
cohort was novel. This allowed the inclusion of more samples and validated the 
approach for future work. The combination of these entities meant that the study 
was able to robustly reflect the recent molecular developments in ependymoma 
research. No other studies were found during the literature search which linked 
these elements in an analysis of paired primary and recurrent disease.  
 
Clinical behaviour of recurrent disease was similar across intracranial molecular 
subtypes. Standard therapy did not reliably prevent recurrence and only provided 
transient benefits after first relapse. The main factor determining overall survival 
in this disease was recurrence status.  
 
Molecular analyses confirmed a strong association between recurrence and the 
immune system, but raised new questions about the ability of immune cells to 
interact directly with ependymoma cells in view of their spatial distribution. 
Furthermore, protein level analyses indicated that ependymoma is an immune 
excluded tumour. 
 
Therapy appeared to have minimal impact on tumours with an inflammatory 
phenotype at primary presentation (PF1) and there was some evidence that these 
tumours may undergo immune escape. It was possible that radiotherapy had 
some impact on the type I IFN pathway in this subgroup, but this needs further 
confirmation.  
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Development of an adaptive immune response in PF2 and ST molecular 
subgroups did not prevent recurrence and the origin and implications of this 
response require further investigation.   
 
Further research is warranted to fully understand the underlying tumour biology, 
and to investigate the role of the immune system in ependymoma. This is vital to 
guide further treatment interventions, including whether tumour modulating 
immunotherapy may be a viable option in this devastating disease.  
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Appendix 1: Samples used in biological analyses 
Appendix 1, Table 1: Summary of all clinical cases including in any of the biological analyses (RNA-seq and/or DNA methylation and/or 
IHC).  
Study ID Paired RNA-Seq Paired Methylation Paired IHC RNA-Seq Group Methylation (Classifier score) Gender Location P R1 
Epend003 FFPE YES YES PF1 PFA (1) PFA (1) M PF 
Epend018 NO NO YES    M ST 
Epend022 NO NO YES  PFA (1)  M PF 
Epend029 NO YES YES  RELA (1) RELA (1) M ST 
Epend030 NO NO YES  PFA (1)  M PF 
Epend033 FFPE NO YES PF1  PFA (1) M PF 
Epend034 NO NO YES  PFA (1)  F PF 
Epend050 NO YES NO  DNET (1) RELA (1) M ST 
Epend051 FFPE NO NO PF1 PFA (1)  F PF 
Epend078 NO YES NO  PFA (0.5) PFA (0.96) M PF 
Epend085 FFPE NO YES PF2 PFA (0.98)  F PF 
Epend092 FF NO YES PF1   F ST 
Epend095 FFPE YES YES PF1 PFA (0.76) PFA (0.84) F PF 
Epend096 NO NO YES   SPINE (0.51) M ST 
Epend097 FF YES YES PF2 PFA (1) PFA (0.95) F PF 
Epend098 NO YES YES  PFA (0.89) PFA (0.91) F PF 
Epend101 NO YES NO  PFA (0.98) PFA (0.57) M PF 
Epend103 NO YES YES  YAP (1) YAP (1) F ST 
Epend114 FF NO YES ST   M ST 
Epend115 NO NO YES   PFA (1) F PF 
Epend118 FFPE YES YES ST RELA (1) RELA (1) M ST 
Epend121 FF YES NO PF1 PFA (0.97) PFA (1) M PF 
Epend122 FF/FFPE YES NO PF1 PFA (1) PFA (1) F PF 
Epend123 FF YES NO PF2 HGNET_MN1 (1) HGNET_MN1 (1) M SP 
Epend124 FF/FFPE YES YES PF2 YAP (1) YAP (1) F ST 
Epend129 FF YES YES PF2 MPE (1) MPE (1) F SP 
Epend136 NO YES YES  PFA (1) PFA (0.99) F ST 
Epend138 NO NO YES   PFA (0.99) M PF 
Epend140 FF NO YES ST   F ST 
Epend147 NO NO YES  PFA (0.71)  F PF 
Epend161 FF YES NO PF2 PFA (1) PFA (1) F PF 
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Study ID Paired RNA-Seq Paired Methylation Paired IHC RNA-Seq Group Methylation (Classifier score) Gender Location 
Epend162 FF YES NO ST PFA (1) PFA (0.99) F PF 
Epend163 NO YES NO  PFA (1) PFA (1) M PF 
Epend176 NO YES NO  PFA (1) PFA (0.87) M PF 
Epend182 NO YES NO  RELA (1) RELA (1) F ST 
Epend183 NO NO YES  PFA (1)  M PF 
Epend185 NO NO YES    F ST 
Epend186 NO YES YES  PFA (1) PFA (1) M PF 
Epend190 NO NO YES   PFA (1) M PF 
Epend193 FF YES YES PF2 PFA (1) PFA (0.95) M PF 
Epend195 FFPE YES YES PF1 PFA (1) PFA (0.99) M PF 
Epend196 NO YES YES  PFA (0.99) PFA (1) F PF 
Epend197 FFPE YES YES PF1 PFA (1) PFA (1) M PF 
Epend203 FFPE YES YES PF1 PFA (0.98) PFA (0.97) F PF 
Epend205 FFPE YES YES PF1 PFA (0.93) PFA (0.98) M PF 
Epend207 NO NO YES  PFA (0.99)  F PF 
Epend208 FF NO NO PF1   M PF 
Epend209 NO YES YES  RELA (1) RELA (1) F ST 
Epend211 FFPE YES NO PF1 PFA (0.95) PFA (0.97) M PF 
Epend213 FFPE YES YES PF1 PFA (0.97) PFA (1) F PF 
Epend224 NO YES YES  RELA (1) RELA (1) M ST 
Epend230 FFPE YES YES PF1 PFA (1) PFA (0.94) M PF 
Epend234 FFPE YES YES PF2 PFA (0.99) PFA (0.95) M PF 
Epend244 NO YES NO  PFA (1) PFA (0.88) M PF 
Epend245 NO NO YES  PFA (0.99)  M PF 
Epend256 NO YES YES  PFA (0.98) PFA (0.94) M PF 
Epend258 FFPE YES YES ST RELA (1) RELA (1) M ST 
Epend277 NO YES NO  PFA (1) PFA (1) F PF 
Epend279 NO NO YES     PF 
Epend280 NO YES YES  RELA (1) RELA (1)  ST 
Epend281 NO NO YES     PF 
Epend287 FFPE NO YES PF1 PFA (0.58)  M PF 
Epend289 FF YES NO PF2 PFA (1) PFA (1) M ST 
Epend293 FFPE YES YES ST HGNET_MN1 (1) HGNET_MN1 (1) M PF 
Epend300 NO NO YES    F PF 
Epend305 FFPE YES YES PF1 PFA (0.84) PFA (0.9) M ST 
Epend306 FFPE YES YES ST RELA (0.98) RELA (0.84) F ST 
Epend316 FFPE YES YES PF2 PFB (0.79) PFB (0.78) M PF 
Epend330 FFPE YES NO ST RELA (1) RELA (1) F ST 
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Study ID Paired RNA-Seq Paired Methylation Paired IHC RNA-Seq Group Methylation (Classifier score) Gender Location 
Epend331 FFPE YES NO PF1 PFA (1) PFA (1) F PF 
Epend332 NO YES NO  PFA (1) DNET (0.76) M PF 
Epend333 FFPE NO NO ST HGNET_BCOR (1)  M PF 
Epend334 NO YES NO  PFA (0.75) PFA (0.66) F PF 
Epend335 FF NO NO PF2   M PF 
Epend336 FF NO NO PF1  PFA (0.51) F PF 
Epend337 FF YES NO PF1 PFA (0.68) PFA (0.74) F PF 
Epend338 FF NO NO PF2 PFA (0.74)  M PF 
Epend339 FF NO NO PF1   M PF 
Epend340 FF YES NO PF1 PFA (0.75) PFA (0.59) M PF 
Epend341 FF NO NO PF2    PF 
Epend342 FF NO NO PF2   M PF 
Epend343 FF YES NO PF1 PFA (0.52) PFA (0.80) M PF 
Epend344 FF NO NO PF1   M PF 
Epend345 NO YES NO  PFA (0.97) PFA (1) F PF 
Epend346 FF NO NO PF2   M PF 
Epend347 FF YES NO PF1 PFA (1) PFA (1) M PF 
Epend348 FF YES NO PF2 PFA (0.78) PFA (0.58) F PF 
Epend357 NO NO YES    F ST 
Epend371 NO YES NO  PFA (0.99) PFA (1) F PF 
Epend372 NO YES NO  RELA (1) RELA (1) F ST 
Epend381 NO YES YES  RELA (0.99) RELA (1)  ST 
Epend400 NO YES YES  PFA (1) PFA (1) F PF 
Epend401 NO NO YES      
Epend402 NO NO YES      
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Appendix 1, Table 2, Page 1: Clinical features of the cases included in any of the biological analyses (RNA=Seq and/or DNA Methylation 
and/or IHC). RT: Radiotherapy. S: Surgery. CT: Chemotherapy. F/U: Follow-up. 
Study ID Relapses Age TTP Status F/U Duration Grade RT S CT Resection Mets P R1 P R1 P R1 P R1 P R1 P R1 
Epend003 2 22 31 A 131 II III N Y Y Y Y  GTR GTR Y  
Epend018 1 68 124 A 162 III  Y Y Y Y N N GTR GTR N N 
Epend022 5 34 4 A 245 II II N Y Y Y Y  STR STR   
Epend029 4 115 2 D 68 III III Y Y Y Y N  GTR   Y 
Epend030 3 35 27 D 80 III III N Y Y Y Y  GTR GTR   
Epend033 3 25 2 D 19 III III N Y Y Y Y  STR  Y  
Epend034 2 30 8 A 83 II  N Y Y Y Y  GTR STR   
Epend050 1 152 4 A 155 III III N Y Y Y Y N STR    
Epend051 2 30 27 D 36 III III Y Y Y Y Y  STR GTR   
Epend078 3 104 35 D 68 II II Y  Y Y Y  GTR STR   
Epend085 2 39 17 A 31 III  Y  Y Y N  STR    
Epend092 2 46 26 A 338 II II Y  Y  Y  STR  N  
Epend095 1 24 104 D 113 III III N Y Y Y Y  GTR  N N 
Epend096 1 67 9 D 12 III  Y  Y  Y  STR   Y 
Epend097 2 145 26 A 158 III  Y  Y Y Y  STR STR N N 
Epend098 2 68 149 D 173 III III N Y Y Y Y N STR GTR N N 
Epend101 4 54 17 D 68 II  N Y Y Y Y  STR STR Y  
Epend103 1 17 4 A 260 III III N N Y Y Y  STR    
Epend114 1 50 32 D 41 III III N N Y Y Y  STR    
Epend115 1 72 4 D 17 II  N N Y Y Y  STR   N 
Epend118 3 162 23 D 110 II II N Y Y Y Y Y STR    
Epend121 1 13 16 A 84 III II N Y Y Y Y  GTR STR N N 
Epend122 1 39 2 A 69 III II N Y Y Y Y  STR STR N N 
Epend123 3 50 11 D 63 III III Y Y Y Y N Y GTR STR N Y 
Epend124 2 3 15 A 62 III III N N Y Y Y N STR STR N N 
Epend129 3 72 9 D 63 II II N Y Y Y N Y GTR  N N 
Epend136 5 17  D 154 II III Y Y Y Y Y  STR    
Epend138 1 65 27 A 51 III III Y  Y Y N      
Epend140 3 84 17 D 67 III  Y  Y Y N  GTR    
Epend147 4 178 17 D 30 III  Y  Y Y   GTR    
Epend161 3 23 19 A 95 II II N Y Y Y Y N GTR GTR   
Epend162 1 35 8 D 29 II III N Y Y Y Y Y GTR STR N N 
Epend163 2 42 27 D 48 II II Y N Y Y N Y STR STR N N 
Epend176 4 21 13 D 43 III  N Y Y Y Y  STR GTR N N 
 267 
Study ID Relapses Age TTP Status F/U Duration Grade RT S CT Resection Mets 
Epend182 8 74 23 D 61 III  Y N Y Y N N GTR GTR N N 
Epend183 1 23 29 A 259 II III N Y Y Y Y  STR GTR N N 
Epend185 5 13 46 A 241 II  N N Y Y Y  STR STR   
Epend186 4 15 40 D 106 III III N Y Y Y Y  STR STR   
Epend190 1 22 16 A 225 II II N Y Y Y Y  STR GTR N N 
Epend193 2 26 67 D 77 II III N Y Y Y Y Y GTR GTR N N 
Epend195 2 17 4 D 6 III III N N Y Y Y  GTR    
Epend196 5 24 27 D 71 II III N Y Y Y Y  GTR GTR N N 
Epend197 4 16 16 D 34 II II N Y Y Y Y  GTR STR N Y 
Epend203 1 62 0 A 152 II  Y Y Y Y N  STR    
Epend205 3 52 21 D 42 III III Y Y Y Y N Y GTR  N Y 
Epend207 4 77 13 D 37 III  Y  Y Y N  STR GTR N N 
Epend208 1 16 1 A 68             
Epend209 7 75 4 D 152 II  Y  Y Y Y  STR STR   
Epend211 1 18 122 A 134 II  N Y Y Y Y  GTR    
Epend213 1 26 68 A 126 II  N Y Y Y Y  GTR    
Epend224 2 40 12 D 22 III III N Y Y Y Y  STR STR   
Epend230 4 24 17 D 45 III  N Y Y Y Y N GTR GTR   
Epend234 2 27 109 D 114 II  N N Y Y Y  GTR STR   
Epend244 2 16 54 D 71 II  N Y Y Y Y  GTR    
Epend245 2 18 18 D 28 II  N Y Y Y Y  GTR    
Epend256 2 24 9 D 28 II  N Y Y Y Y  STR    
Epend258 3 10 5 A 99 III III N N Y Y Y  STR  Y  
Epend277 4 20 24 A 151   N N Y Y       
Epend279 2 187 17 D 40 III  Y  Y  Y  STR    
Epend280 2 120 15 D 30 III  Y  Y Y N  STR    
Epend281 2 106 77 A 110 II  Y  Y Y N  GTR    
Epend287 1 30 34 A 54 III III Y Y Y Y N Y GTR STR N Y 
Epend289 1 28 16               
Epend293 7 101 47 D 153 II III Y Y Y Y N Y GTR    
Epend300 4 152 27 D 64 II  Y N Y Y Y  STR STR   
Epend305 2 78 31 D 47 III III Y Y Y Y Y  STR STR   
Epend306 2 123 19 D 28 II  Y N Y Y N Y GTR STR   
Epend316 1 199 6 A 145 II II Y N Y Y Y Y STR GTR N N 
Epend330 5 73 16 A 92 III III N N Y Y  Y GTR    
Epend331 1 18 36 D 37 II II N N Y Y   GTR GTR   
Epend332 4 73 16 D 32 II  Y Y Y Y   GTR GTR N Y 
Epend333 3 24 17 D 27 III III N N Y Y Y  GTR STR   
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Study ID Relapses Age TTP Status F/U Duration Grade RT S CT Resection Mets 
Epend334 1 57 31 A 135 II II Y Y Y Y N N GTR GTR N N 
Epend335 1 160 35 D 68 II II Y Y Y Y N N GTR GTR N N 
Epend336 3 79 19 A 117 II II Y Y Y Y N N GTR GTR N Y 
Epend337 3 20 50 D 82 III III Y Y Y Y Y Y STR STR N N 
Epend338 2 89 23 D 47 III III Y Y Y Y N N GTR GTR N N 
Epend339 2 71 5 D 16 III III Y  Y Y N Y GTR STR N Y 
Epend340 3 43 8 D 24   Y Y Y Y N N   N Y 
Epend341 1 24 51 A 70   Y Y Y Y N N     
Epend342 5 46 9 A 54   Y Y Y Y N N STR STR   
Epend343 2 32 6 A 53 III III Y  Y Y Y Y STR GTR N N 
Epend344 2 8 4 D 56    Y Y Y Y N     
Epend345 1 7 14 D 41   Y Y Y Y Y N    Y 
Epend346 2 33 20 D 54   Y Y Y Y Y N     
Epend347 2 46 44 A 89   Y Y Y Y Y N     
Epend348 1 40 9 A 55    Y Y Y Y N     
Epend357 3 158 7 A 67  III Y N Y Y Y  GTR GTR   
Epend371 1 119 35 A 35 II          N N 
Epend372 1     II            
Epend381 2     III III           
Epend400 1   D  III    Y N   STR  N Y 
Epend401                  
Epend402                  
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Appendix 2: File formats 
A brief summary of the file formats encountered in the RNA sequencing analysis 
is outlined below. 
 
File formats: Fastq 
Biological data generated from high throughput sequencing reads can be stored 
as a plain text file in the fastq format. Fastq consists of 4 lines for each Illumina 
sequencing read arranged as follows: 
(1) The @ character followed by the Sequence ID or another title (this 
follows a structured format for Illumina reads); 
(2) Raw sequence letters (e.g. AGTGATAGA…); 
(3) + character followed optionally by a repeat of line (1); 
(4) Symbols which encode the quality of the reads, this must be equal in 
length to line (2) (Cock et al., 2010). 
In addition to the above, the fastq file can contain a sequence ID in the Illumina 
format which takes on the following form: 
 
@SequenceID: @ABCDE_1234:17:3:2:27:851:1832#0/1 
 
This encodes the following: 
• ABCDE_1234: ID of the sequencer; 
• 17: Run number on sequencer; 
• 3: Flow cell ID; 
• 2: Flow cell lane; 
• 27: Tile number within the flow cell lane; 
• 851: X co-ordinate of cluster within the tile; 
• 1832: Y co-ordinate of cluster within the tile; 
• #0: Index number for multiplex sequencing; 
• /1: Membership of a pair of reads (/1 for the first read, /2 for the second 
read) (Illumina, 2014). 
 
File Format: SAM/BAM 
The output of aligning high throughput sequencing data to the transcriptome 
and/or genome is a BAM or SAM file. These abbreviations stand for Binary 
Alignment/Map format or Sequence Alignment/Map format respectively. These 
are text files made up of an optional header followed by an alignment section 
(The SAM/BAM Format Specification Working Group, 2016). The header section 
can contain information about the format of the file, the reference sequence and 
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read groups. The alignment section contains 11 mandatory fields as described in 
the working group documentation: 
• QNAME: Query template name – usually the read name; 
• FLAG: Encodes specific properties of the read such as whether it is 
correctly mapped or whether it is part of a pair. This type of annotation 
uses a combination of bitwise flags; 
• RNAME: Name of the reference sequence which may include the 
chromosome name; 
• POS: The left most mapping position of the first matching base. If the 
sequence is unmapped POS is set as 0. For SAM files the reference starts 
at 1 and for BAM files the reference starts at 0; 
• MAPQ: The mapping quality; 
• CIGAR: The CIGAR string indicates how the bases in the aligned sequence 
correspond with the reference. Base lengths are combined with an 
operation (M=alignment match, I=insertion to reference, D=deletion from 
reference). When interpreted in combination with the POS column the 
exact details of the alignment can be understood; 
• RNEXT: The reference sequence of the next alignment (i.e. the pair of the 
read if paired reads); 
• TLEN: Observed template length. If all segments mapped to the same 
reference the template length is the number of bases from the left-most 
mapped base to the right-most mapped base; 
• SEQ: The sequence itself; 
• QUAL: The quality score for each base in SEQ. This uses the same code as 
for the .fastq format. 
The alignment section also contains a number of optional fields with tags 
encoding specific parameters. These tags may contain information such as the 
strand details from the library preparation process or quality data form the 
sequencing machine itself (The SAM/BAM Format Specification Working Group, 
2016). 
 
BAM files are compressed using the BGZF compression format which allows for 
rapid access to the data. They are binary versions of SAM files and are not human 
readable. 
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Appendix 3: Scripts used for bioinformatic analyses 
Code was executed in either the R statistical environment or via the HPC interface 
if other programmes used (e.g. Trimmomatic, Tophat 2, Bowtie, Picard tools). 
 
#Adapter and quality trim (Trimmomatic) 
java -jar Trimmomatic-0.35.jar PE -threads 16 4589FFPE-xxx.R1.fastq.gz 
4589FFPE-xxx.R2.fastq.gz output_forward_pairedxxxFFPE.fq.gz 
output_forward_unpairedxxxFFPE.fq.gz output_reverse_pairedxxxFFPE.fq.gz 
output_reverse_unpairedxxxFFPE.fq.gz ILLUMINACLIP:TruSeq3-PE-
2.fa:2:30:10:8:TRUE LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:30 
 
#Filter mapping to rRNA, tRNA & MTrna (Tophat 2 and Bowtie) 
tophat -o "./tophatoutxxxFFPErrna19" -g 1 -p 16 -r -45 --no-mixed rRNA4 
output_forward_pairedxxxFFPE.fq.gz output_reverse_pairedxxxFFPE.fq.gz 
 
#Convert unmapped BAM file back to fastq file for mapping to reference 
genome and transcriptome (Tophat 2) 
bam2fastx -A -o xxxFFPEfiltered19.fq.gz -P 
"./tophatoutxxxFFPErrna19/unmapped.bam" 
 
#Map filtered fastq files to reference genome and transcriptome (Tophat 
2) 
tophat -o "./tophatoutxxxFFPEgenomemap19strandspecific" -g 1 -p 16 -r -45 --
library-type fr-firststrand -G gencodev11.gtf hg19 xxxFFPEfiltered19.1.fq.gz 
xxxFFPEfiltered19.2.fq.gz 
 
#Calculate insert sizes (Picard Tools) 
java -jar picard.jar CollectInsertSizeMetrics 
I=./bamfiles/accepted_hitsFFR001.bam O=./insertsize/insertFFR001.txt 
H=./insertsize/insertFFR001.pdf M=0.5 
 
#Count reads mapped to the genome (FeatureCounts/RSubRead) 
library("Rsubread") 
 
setwd("~/files") 
 
#Import files and set up list of BAM files for processing: 
csvfile <- "Sample Sheet" 
(sampletable <- read.csv("ffpesamplesheet.csv",row.names=1)) 
dir <- "." 
filenames <- file.path(dir, sampletable$bam_file) 
file.exists(filenames) 
 
#Generate counts matrix using Rsubread: 
exonfeatures <- featureCounts(files=filenames, isPairedEnd=TRUE, 
requireBothEndsMapped=TRUE, countChimericFragments=FALSE, minMQS=10, 
strandSpecific=2, annot.ext="gencodev11.gtf", isGTFAnnotationFile=TRUE, 
GTF.featureType="exon", GTF.attrType="gene_id", nthreads=16) 
 
#View parameters of count assay: 
sum(exonfeatures$counts) 
write.csv(exonfeatures$counts, "hg19exoncountstrandFFPE.csv") 
summary(exonfeatures) 
exonstats <- exonfeatures$stat 
write.csv(exonstats, file="exonstatsstrandFFPE.csv") 
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#Generate counts matrix using Rsubread: 
genefeatures <- featureCounts(files=filenames, isPairedEnd=TRUE, 
requireBothEndsMapped=TRUE, countChimericFragments=FALSE, minMQS=10, 
strandSpecific=2, annot.ext="gencodev11.gtf", isGTFAnnotationFile=TRUE, 
GTF.featureType="gene", GTF.attrType="gene_id", nthreads=16) 
 
#View parameters of count assay: 
sum(genefeatures$counts) 
write.csv(genefeatures$counts, "hg19genecountstrandFFPE.csv") 
summary(genefeatures) 
genestats <- genefeatures$stat 
write.csv(genestats, file="genestatsstrandFFPE.csv") 
 
#Extract gene lengths for FPKM calculations 
library(GenomicFeatures) 
txdb <- makeTxDbFromGFF("gencodev11.gtf", format="gtf") 
exons.list.per.gene <- exonsBy(txdb,by="gene") 
exonic.gene.sizes <- 
lapply(exons.list.per.gene,function(x){sum(width(reduce(x)))}) 
 
#Calculate TPM Matrix: 
library(GenomicFeatures) 
library("org.Hs.eg.db") 
library("AnnotationDbi") 
 
rawdata <- read.csv("~/Documents/Analysis/RNA-seq Analysis/2016 Re-
analysis/FeatureCounts Output/hg19exoncountstrandredo.csv") 
X2 <- gsub("\\.[0-9]*$", '', rawdata$X) 
rawdata$X <- NULL 
row.names(rawdata) <- X2 
rawdata$X <- NULL 
 
coldata <- read.csv("~/Documents/Analysis/RNA-seq Analysis/Data 
outputs/Sample Sheets/ffsamplesheet.csv") 
row.names(coldata) <- coldata$rnaseq_id 
 
b <- as.character(coldata$rnaseq_id) 
colnames(rawdata) <- b 
 
genelength <- read.csv("~/Documents/Analysis/RNA-seq Analysis/Data 
outputs/genelength.csv") 
ma_fpkm <- data.frame(rawdata) 
ma_fpkm$gene <- row.names(ma_fpkm) 
genelength$kblength <- genelength$V1/1000 
ma_fpkm <- ma_fpkm[with(ma_fpkm, order(gene)), ] 
ma_fpkm$gene <- NULL 
ma_fpkm <- (ma_fpkm/genelength$kblength) 
rawdata <- as.data.frame(ma_fpkm) 
 
fpm <- function(x) { 
  result <- c(x/((sum(x))/1000000)) 
  return(result) 
} 
 
rawdata$`sample name/column name` <- fpm(rawdata$`sample name/column 
name`) 
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ma_tpm <- rawdata 
tpmlog <- (ma_tpm+1) 
tpmlog <- log2(tpmlog) 
 
tpmlog$entrez <- mapIds(org.Hs.eg.db, 
                        keys=row.names(tpmlog), 
                        column="ENTREZID", 
                        keytype="ENSEMBL", 
                        multiVals="first") 
tpmlog$symbol <- mapIds(org.Hs.eg.db, 
                        keys=row.names(tpmlog), 
                        column="SYMBOL", 
                        keytype="ENSEMBL", 
                        multiVals="first") 
 
 
col_idx <- grep("entrez", names(tpmlog)) 
tpmlog <- tpmlog[, c(col_idx, (1:ncol(tpmlog))[-col_idx])] 
 
col_idx <- grep("symbol", names(tpmlog)) 
tpmlog <- tpmlog[, c(col_idx, (1:ncol(tpmlog))[-col_idx])] 
 
#EdgeR for Differential Expression between primary and recurrence 
library("org.Hs.eg.db") 
library("AnnotationDbi") 
library("GenomicFeatures") 
library("edgeR") 
 
countdata <- read.csv("Raw counts matrix") 
coldata <- read.csv(“Sample sheet") 
 
 
b <- as.character(coldata$rnaseq_id) 
colnames(countdata) <- b 
 
countdata <- cbind(X2, countdata) 
 
 
rownames(countdata) <- countdata$X2 
countdata$X2 <- NULL 
countdata$entrez <- mapIds(org.Hs.eg.db, 
                           keys=row.names(countdata), 
                           column="ENTREZID", 
                           keytype="ENSEMBL", 
                           multiVals="first") 
countdata$symbol <- mapIds(org.Hs.eg.db, 
                           keys=row.names(countdata), 
                           column="SYMBOL", 
                           keytype="ENSEMBL", 
                           multiVals="first") 
 
col_idx <- grep("entrez", names(countdata)) 
countdata <- countdata[, c(col_idx, (1:ncol(countdata))[-col_idx])] 
 
col_idx <- grep("symbol", names(countdata)) 
countdata <- countdata[, c(col_idx, (1:ncol(countdata))[-col_idx])] 
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countdata <- na.omit(countdata) 
 
 
y <- DGEList(counts=countdata[,3:34], genes=countdata[,1:2]) 
y$samples 
 
#Remove duplicated symbols 
o <- order(rowSums(y$counts), decreasing=TRUE) 
y <- y[o,] 
d <- duplicated(y$genes$symbol) 
y <- y[!d,] 
nrow(y) 
 
#Remove lowly expressed transcripts 
keep <- rowSums(cpm(y)>1) >(50% of samples) 
 
y <- y[keep, , keep.lib.sizes=FALSE] 
nrow(y) 
 
#Recompute library sizes 
y$samples$lib.size <- colSums(y$counts) 
y$samples 
#Use entrez gene IDs as row names 
rownames(y$counts) <- rownames(y$genes) <- y$genes$X 
 
y <- calcNormFactors(y) 
y$samples 
 
patient <- factor(coldata$paired) 
recurrence <- factor(coldata$primrecc) 
location <- factor(coldata$location) 
data.frame(Sample=colnames(y),patient,recurrence) 
design1 <- model.matrix(~patient+recurrence) 
rownames(design1) <- colnames(y) 
design1 
 
y <- estimateGLMCommonDisp(y, design=design1) 
y <- estimateGLMTrendedDisp(y, design=design1) 
y <- estimateGLMTagwiseDisp(y, design=design1) 
 
plotBCV(y) 
fit <- glmFit(y, design=design1) 
lrt <- glmLRT(fit, coef=(position in dataframe for comparison)) 
 
#Code for ChAMP DNA Methylation Data 
testDir <- “Directory containing DNA methylation .IDAT files” 
myLoad <- champ.load(testDir, arraytype = “450k”) 
champ.QC() 
Normalisation <- champ.norm(resultsDir = “results directory”) 
mdsPlot(Normalisation, numpositions=1000
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Appendix 4: Basic RNA sequencing outcomes 
Appendix 4, Table 1: Basic RNA sequencing outcomes for the FFPE tissue. Age refers to the age of the tissue block at the time of 
sequencing. Nanodrop (spectrophotometer) concentration is measured in ng/µl. 260/280 and 260/230 are the purity scores from the 
spectrophotometer. Genes indicates the number of genes detected at >1 count in the sample. 
RNA-
Seq ID ID Raw reads 
% 
Trimmed 
% 
rRNA 
% Human 
Alignment 
% 
Bacterial 
Alignment 
Age Nanodrop Conc 260/280 260/230 Tissue Genes 
11A Epend003.P 58050650 2.9 2.1 70.6 10.4 15.4 104.5 1.98 1.05 Core 22917 
11B Epend003.R1 60613568 3.0 3.1 71.8 6.4 12.7 136.6 1.99 0.32 Core 21974 
5B Epend022.R1 45085860 3.3 7.5 74.0 5.8 18.4 116.5 1.99 1.06 Core 27111 
5C Epend022.R2 44823694 2.6 1.5 82.1 4.7 18.1 65.6 2.01 0.1 Core 25861 
36B Epend029.R1 50716789 2.8 14.9 70.7 1.0 11.3 91.1 1.95 0.61 Core 27251 
14A Epend030.P 55774570 2.0 3.6 72.5 3.5 13.8 42.1 2.02 0.34 Core 27093 
14B Epend030.R1 43329931 4.6 0.5 4.4 82.6 11.5 69.4 1.44 0.91 Core 5293 
3A Epend033.P 52190563 8.8 2.2 59.1 11.2 19.3 44.9 1.61 0.58 Core 20489 
3B Epend033.R1 54941100 2.8 2.6 77.5 2.8 19.0 215.7 1.98 1.03 Core 24864 
10A Epend034.P 2201032 8.5 8.5 1.3 77.8 17.2 36.4 1.73 0.73 Core 1651 
10B Epend034.R1 27984209 3.5 71.7 0.8 21.2 12.8 27.4 2.06 0.72 Core 6379 
35A Epend051.P 42779742 3.2 8.2 41.6 35.5 18.4 192.4 1.91 1.33 Core 22852 
35B Epend051.R1 30225114 6.1 3.2 2.2 76.3 16.1 100.5 1.71 0.8 Core 6372 
20A Epend085.P 47849106 2.3 2.3 85.0 1.4 9.0 40.1 1.87 0.73 Core 27958 
20B Epend085.R1 59121375 2.6 2.3 83.0 1.2 7.6 29.8 1.96 0.54 Core 29649 
1A Epend092.P 65231524 2.6 3.9 76.8 3.5 27.9 72.3 0.94 0.51 Core 26864 
1C Epend092.R2 49473715 2.3 4.1 78.0 4.8 24.8 110.8 1.89 0.43 Core 25988 
6A Epend095.P 53661997 2.7 2.5 61.4 21.1 24.2 117.4 1.87 0.47 Core 18292 
6B Epend095.R1 28126061 2.4 6.0 77.2 5.3 15.5 72.3 1.88 0.52 Core 25173 
18B Epend097.R1 38586050 6.0 2.6 39.9 41.4 9.4 45.3 1.86 0.14 Core 21933 
32A Epend098.P 55086293 2.8 1.9 78.3 2.7 20.4 131.3 1.99 0.29 Core 27018 
32B Epend098.R1 30381194 22.1 1.2 2.9 67.9 7.9 34 1.91 0.05 Core 7570 
4B Epend114.R1 41515099 1.9 2.7 78.1 5.9 18.3 310.4 1.94 1.81 Core 24943 
2A Epend118.P 42851384 3.2 2.0 37.2 49.4 22.1 75.9 1.64 0.56 Core 16424 
2B Epend118.R1 55213594 2.4 3.2 78.3 3.4 20.1 78.4 2.25 0.36 Core 24986 
2C Epend118.R2 42161486 6.1 6.7 38.3 22.0 15.5 54.4 0.73 0.89 Core 20888 
2D Epend118.R3 39230674 10.0 2.9 47.3 30.9 13.2 50.1 1.77 1.09 Core 22673 
23A Epend121.P 43235763 2.4 4.4 83.5 0.9 5.4 517.6 1.94 0.77 Core 27106 
26A Epend122.P 46208949 2.6 7.8 77.3 1.9 4.1 142.1 1.97 0.26 Core 26589 
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RNA-
Seq ID ID Raw reads 
% 
Trimmed 
% 
rRNA 
% Human 
Alignment 
% 
Bacterial 
Alignment 
Age Nanodrop Conc 260/280 260/230 Tissue Genes 
26B Epend122.R1 47356510 2.3 4.3 79.9 1.4 3.9 40.8 1.77 0.39 Core 26706 
24A Epend123.P 56059694 2.3 1.8 81.3 0.5 4.1 90.5 1.78 0.66 Core 28129 
25A Epend124.P 45256088 3.1 13.5 71.2 2.5 3.6 194.7 2.01 0.38 Core 24491 
25B Epend124.R1 4673675 5.4 9.1 54.3 25.5 2.3 26.3 2.03 0.11 Core 14905 
39A Epend129.P 51479763 2.5 4.9 81.0 0.6 4.0 175.5 2.01 0.36 Core 27052 
54A Epend183.P 50845798 5.4 4.1 30.1 49.8 20.8 55.1 1.67 0.17 Scroll 14145 
54B Epend183.R1 37928669 4.8 2.8 0.5 86.4 18.3 229.8 1.89 1.4 Scroll 4568 
55C Epend185.R2 61268582 6.5 5.1 49.0 26.1 14.9 54 1.8 0.65 Scroll 21417 
55D Epend185.R3 51359965 4.8 1.4 1.3 88.3 12.8 68.5 1.78 0.85 Scroll 8463 
55E Epend185.R4 42073846 2.6 7.5 50.7 31.1 11.7 251.4 1.93 1.74 Scroll 23063 
53A Epend186.P 49510679 22.4 0.9 11.1 60.0 19.2 34 1.72 0.21 Scroll 11525 
53B Epend186.R1 36602606 7.9 4.6 15.5 58.6 15.8 55.4 2.03 0.15 Scroll 14088 
53C Epend186.R2 20248984 11.6 8.1 11.6 63.4 12.1 80.2 1.87 0.32 Scroll 12987 
53D Epend186.R3 29629888 5.8 3.1 10.1 69.9 10.9 53.1 1.67 0.35 Scroll 13075 
56B Epend190.R1 43750296 10.7 2.9 0.4 80.1 16.6 216.6 1.94 0.49 Scroll 1847 
16B Epend193.R1 45878755 3.6 8.0 71.7 5.7 9.7 397.8 2.02 0.61 Scroll 27308 
16C Epend193.R2 37715959 2.5 2.9 10.5 78.9 9.4 23 1.96 0.07 Scroll 13986 
57A Epend195.P 40159692 3.7 8.9 45.5 29.3 13.4 212.2 1.93 0.93 Scroll 21581 
57B Epend195.R1 93162604 4.0 3.4 58.8 20.3 13.0 94.3 1.94 0.24 Scroll 23778 
52B Epend196.R1 49460284 8.4 9.3 35.7 33.1 9.8 247.2 1.99 0.46 Scroll 21857 
52C Epend196.R2 55546665 1.9 22.7 62.9 0.7 8.2 84.5 1.8 0.44 Scroll 28425 
58A Epend197.P 51880018 4.3 6.2 73.9 8.1 11.4 228.3 1.95 1.02 Scroll 26859 
58B Epend197.R1 36378455 8.7 10.8 33.3 36.3 10.0 256.5 1.95 1.48 Scroll 20469 
62A Epend203.P 68577710 3.0 3.6 81.2 0.8 11.9 371.1 2 1.14 Scroll 29798 
62B Epend203.R1 28787935 2.2 1.3 50.9 33.9 11.8 105.2 1.9 0.87 Scroll 20310 
61A Epend205.P 62385098 2.0 2.6 84.0 0.9 11.5 129.1 1.9 1.3 Scroll 28383 
61B Epend205.R1 56117115 4.4 10.7 38.0 35.7 9.7 168.2 1.99 1.43 Scroll 18963 
61C Epend205.R2 55199448 2.7 1.7 83.3 0.6 8.6 566.2 2.01 1.72 Scroll 28306 
17A Epend207.P 47155929 2.0 4.4 33.2 50.5 10.8 150.1 1.94 0.54 Scroll 15999 
48A Epend211.P 45077666 2.1 6.3 68.4 12.0 21.9 230.4 2 0.61 Core 21369 
48B Epend211.R1 39972715 2.0 2.7 77.1 7.7 11.7 46.9 1.77 0.29 Core 25664 
47A Epend213.P 50975838 10.0 6.9 12.3 58.7 16.8 59.5 1.81 0.11 Core 16839 
47B Epend213.R1 44876648 3.1 5.5 80.6 1.1 11.1 481.7 1.99 1.2 Core 28116 
43A Epend230.P 45545750 6.8 15.4 1.6 69.7 19.6 104.1 1.88 0.58 Core 7750 
43B Epend230.R1 39969723 5.3 2.7 65.3 14.4 18.1 142.8 1.94 0.31 Core 24460 
43C Epend230.R2 54464174 7.6 7.9 33.1 40.0 16.3 169 1.97 0.39 Core 15855 
 277 
RNA-
Seq ID ID Raw reads 
% 
Trimmed 
% 
rRNA 
% Human 
Alignment 
% 
Bacterial 
Alignment 
Age Nanodrop Conc 260/280 260/230 Tissue Genes 
59A Epend234.P 57635915 1.9 6.8 78.3 1.5 19.6 110.1 2.01 0.3 Scroll 28617 
59B Epend234.R1 40816548 2.7 4.6 74.8 6.7 10.5 148 1.92 0.59 Scroll 24586 
59C Epend234.R2 46342992 3.8 4.9 73.6 8.4 10.2 55.5 1.92 0.52 Scroll 27145 
51A Epend256.P 47198389 2.0 4.6 78.9 2.2 13.3 192.2 1.96 1.25 Core 27223 
51C Epend256.R2 57076886 2.0 5.5 79.7 1.1 11.6 74.2 1.98 1.2 Core 26249 
29A Epend258.P 42812480 2.5 5.9 77.4 1.0 12.7 488 1.95 1.65 Core 25187 
29B Epend258.R1 58373414 2.9 2.3 77.3 3.2 12.3 216.3 1.99 1.65 Core 24770 
30A Epend280.P 50325106 2.2 4.4 83.2 1.6 11.0 158.6 1.74 0.36 Core 27546 
30B Epend280.R1 11354416 4.1 63.0 4.2 25.8 9.2 21.3 2.12 0.09 Core 9584 
46A Epend287.P 47857070 2.6 6.3 78.7 1.8 3.5 251.2 1.94 1.05 Core 28219 
46B Epend287.R1 45116953 2.2 19.5 54.8 11.9 0.5 58.6 1.93 0.9 Core 23259 
65A Epend288.P 45599658 3.1 6.0 77.6 3.3 7.0 201.4 2.03 0.03 Scroll 27584 
65D Epend288.R3 81189859 3.4 2.4 75.8 6.0 5.0 80.4 1.91 0.26 Scroll 25738 
65E Epend288.R4 47478221 1.9 1.3 82.6 1.9 4.6 156.7 1.93 0.88 Scroll 27132 
28A Epend293.P 35646871 3.7 3.8 81.9 1.9 15.3 287.9 1.94 1.63 Core 26985 
28B Epend293.R1 48154168 2.3 1.4 82.0 2.9 11.3 78.9 1.79 1.11 Core 26018 
28E Epend293.R4 55614306 2.5 4.4 81.6 0.8  234.2 2.03 0.71 Core 27424 
28F Epend293.R5 48844876 1.9 6.7 82.3 1.1  83.4 1.97 0.28 Core 27786 
28G Epend293.R6 25632770 3.2 8.8 66.9 12.7  215.9 1.99 1.17 Core 21274 
28H Epend293.R7 40792024 3.6 2.7 82.0 2.1  70.5 1.96 0.33 Core 27079 
27A Epend305.P 34495433 31.4 1.9 34.3 45.5 13.6 53.6 1.97 0.11 Core 17708 
27B Epend305.R1 15146602 2.4 2.9 83.0 1.2 11.0 140.7 1.94 0.78 Core 24434 
44A Epend306.P 68494371 2.4 2.3 77.1 6.3 13.3 182.2 1.92 0.47 Core 26262 
44B Epend306.R1 58156554 3.0 3.5 79.9 3.1 11.6 138.4 1.93 0.87 Core 28024 
45A Epend316.P 48730352 2.2 2.4 85.5 2.1 11.6 136.2 1.93 0.83 Core 26808 
45B Epend316.R1 39011090 2.1 1.7 85.9 1.9 11.0 107.9 1.95 0.4 Core 27030 
38A Epend329.P 78967281 2.6 8.9 80.2 0.4 2.7 319.8 1.54 0.18 Core 31269 
63A Epend330.P 10613332 5.3 1.6 8.7 77.8 6.9 74 1.72 0.29 Scroll 10791 
63B Epend330.R1 31841825 14.1 3.3 8.7 64.3 5.5 37.7 1.84 0.43 Scroll 15305 
63C Epend330.R2 10126681 4.6 11.4 0.5 79.7 5.3 38.7 1.76 0.4 Scroll 2492 
63E Epend330.R4 49844622 2.7 6.6 60.1 22.7 2.3 95.3 1.94 0.24 Scroll 24067 
64A Epend331.P 53254189 2.4 7.0 76.2 3.2 7.6 39.4 2 1.25 Scroll 26775 
64B Epend331.R1 73119157 2.0 13.1 73.3 0.9 4.6 134.6 1.91 0.26 Scroll 28228 
67A Epend333.P 39293572 7.0 11.9 38.3 17.4 14.8 877.5 2.04 1.84 Scroll 20933 
67B Epend333.R1 53541840 3.7 4.3 72.2 4.2 13.3 24.2 2.01 0.28 Scroll 23866 
83B Epend349.R1 37298100 4.5 1.0 0.6 86.0  35.9 1.67 0.14 Scroll 1835 
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83C Epend349.R2 18498813 6.2 0.8 1.2 85.6  59.8 1.81 0.06 Scroll 3336 
84A Epend371.P 42095259 2.9 2.0 5.0 85.0 5.8 89.5 1.83 0.86 Scroll 10118 
84B Epend371.R1 93187157 1.8 6.2 83.2 0.6  151.9 2 1.46 Scroll 29944 
85A Epend372.P 39646334 2.3 0.9 1.0 91.4  26.2 1.86 0.33 Scroll 5061 
85B Epend372.R1 48135029 3.2 3.7 21.5 58.8  42.4 1.75 0.92 Scroll 15709 
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Appendix 4, Table 2: Basic RNA sequencing outcomes for the FF tissue.  
 
RNA-Seq ID Raw reads % Trimmed %rRNA 
% Human 
Alignment 
1A 38011142 7.2 3.9 78.0 
1B 50740785 5.1 3.6 83.2 
1C 52748458 2.1 2.3 89.5 
4A 51488585 5.5 47.9 40.5 
4B 60754916 4.7 1.4 85.4 
12A 49232540 3.2 4.7 86.4 
12C 68920610 4.5 3.2 83.8 
15A 53359467 3.3 4.1 86.7 
15B 49033158 5.7 1.6 84.9 
16A 37422006 3.5 4.7 85.6 
16B 40520519 3.3 1.1 88.9 
17A 54173568 4.1 1.5 86.8 
18A 54211377 5.1 3.2 83.5 
18B 50265356 7.6 0.9 79.9 
18C 43108985 6.6 1.8 81.6 
20A 52575726 3.3 0.8 89.6 
20C 72302943 4.8 1.1 88.1 
21A 60844655 6.6 0.7 82.9 
21B 64208203 4.7 28.4 59.9 
23A 58463112 5.4 0.9 85.2 
23B 50293092 5.2 4.2 80.8 
24A 57208160 3.7 6.4 84.5 
24B 57115152 5.0 2.5 85.8 
25A 61900222 4.7 7.5 80.9 
25B 62055449 3.3 0.7 89.9 
25C 66678612 3.7 12.0 77.3 
26A 52015796 5.7 0.7 86.1 
26B 61519898 2.9 1.8 88.2 
34A 42802524 2.7 0.8 89.4 
34B 49183057 7.1 2.9 82.1 
39A 58093772 5.0 6.8 81.0 
39B 78527974 3.6 61.6 29.7 
40A 47664372 4.0 7.1 80.3 
40B 47682890 6.9 3.4 80.0 
41A 57855608 4.6 4.5 83.2 
41B 48069317 6.1 2.8 81.0 
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69A 58502970 2.3 1.7 90.0 
69B 55011425 4.5 8.3 81.1 
70A 49651561 6.8 5.9 79.5 
70B 22035684 5.6 1.5 83.9 
71A 56465234 3.0 1.6 88.5 
71B 63250400 3.8 4.2 84.8 
72A 55770800 5.2 8.4 79.1 
72B 66149159 4.4 5.0 83.0 
73A 46803002 6.9 68.1 16.3 
73B 63635666 3.7 5.4 84.0 
74A 58567648 3.2 6.2 84.0 
74B 45609693 4.7 2.8 85.4 
74C 52999899 4.4 1.0 87.2 
75A 52329878 4.8 3.9 83.9 
75B 39869320 7.7 3.1 78.6 
76A 51814823 5.5 2.9 83.9 
76B 57030618 2.1 2.7 88.8 
76C 71129009 3.4 1.9 88.4 
76D 54412895 4.8 31.2 56.1 
76E 58318558 3.9 4.4 85.1 
77A 42510039 5.2 3.4 83.8 
77B 54017210 5.2 5.3 84.2 
78A 51256068 4.4 1.2 86.8 
78B 59336838 5.4 6.7 81.8 
78C 49572507 8.0 2.2 78.4 
80A 46134028 5.1 1.7 85.4 
80B 62867765 4.1 16.9 72.1 
81A 59738410 4.9 3.2 84.3 
81B 49351093 3.9 7.9 81.7 
82A 49812270 6.6 6.0 77.8 
82B 49480393 5.8 2.0 85.5 
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Appendix 5: Lists of enriched ontologies derived 
from primary and recurrent pair comparisons 
Gene Ontology Results (GOrilla) for primary and recurrent comparisons. Contains 
lists of ontologies up and downregulated at first recurrence in both FFPE and FF 
datasets. The only exception is the ST and EPN_RELA datasets where only FFPE 
comparisons were made. 
 
ALL TUMOURS: UPREGULATED AT FIRST RECURRENCE (All Terms) 
 
GO term Description 
FFPE 
FDR 
FF 
FDR 
GO:0043062 extracellular structure organization 2.19E-04 1.81E-15 
GO:0030198 extracellular matrix organization 3.29E-04 1.77E-15 
GO:0032101 regulation of response to external stimulus 6.44E-04 6.00E-11 
GO:0006955 immune response 2.08E-03 2.27E-11 
GO:0006954 inflammatory response 2.69E-03 4.10E-11 
GO:0032501 multicellular organismal process 2.58E-03 1.24E-10 
GO:0044243 multicellular organismal catabolic process 9.49E-05 6.51E-08 
GO:0030574 collagen catabolic process 2.48E-04 3.50E-08 
GO:0044236 multicellular organism metabolic process 4.06E-03 4.94E-07 
GO:0032963 collagen metabolic process 3.82E-03 1.85E-06 
GO:0044259 
multicellular organismal macromolecule metabolic 
process 2.86E-03 5.57E-06 
GO:0006811 ion transport 6.39E-03 2.73E-06 
GO:0033993 response to lipid 2.82E-02 4.10E-06 
GO:0032944 regulation of mononuclear cell proliferation 3.44E-02 5.52E-06 
GO:0050670 regulation of lymphocyte proliferation 2.96E-02 1.17E-05 
GO:0070663 regulation of leukocyte proliferation 2.97E-02 1.32E-05 
GO:0022617 extracellular matrix disassembly 3.16E-02 1.30E-04 
GO:0015671 oxygen transport 2.92E-03 2.48E-03 
GO:0050710 negative regulation of cytokine secretion 4.03E-02 6.85E-03 
GO:0015669 gas transport 1.82E-02 1.53E-02 
GO:0003013 circulatory system process 4.08E-02 7.73E-03 
GO:0050954 sensory perception of mechanical stimulus 4.67E-02 2.98E-02 
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ALL TUMOURS: DOWNREGULATED AT FIRST RECURRENCE (Top 100 Terms Only) 
 
GO term Description FFPE FDR 
FF 
FDR 
GO:0048731 system development 3.06E-10 2.34E-09 
GO:0023052 signaling 7.99E-08 2.34E-11 
GO:0007267 cell-cell signaling 6.61E-08 7.50E-10 
GO:0032502 developmental process 3.87E-05 1.52E-12 
GO:0003008 system process 2.10E-05 5.10E-12 
GO:0051960 regulation of nervous system development 9.00E-07 1.38E-10 
GO:0048856 anatomical structure development 8.19E-06 2.11E-11 
GO:0050877 nervous system process 6.47E-07 3.31E-09 
GO:0060284 regulation of cell development 9.03E-07 2.99E-09 
GO:0007610 behavior 6.69E-08 1.24E-07 
GO:0050767 regulation of neurogenesis 9.73E-06 8.77E-10 
GO:0050804 modulation of chemical synaptic transmission 1.67E-07 1.50E-07 
GO:0007186 G-protein coupled receptor signaling pathway 8.89E-06 5.18E-09 
GO:0051239 regulation of multicellular organismal process 1.06E-03 6.16E-11 
GO:0007399 nervous system development 1.74E-07 5.05E-07 
GO:0045664 regulation of neuron differentiation 5.30E-05 2.32E-09 
GO:0099537 trans-synaptic signaling 1.02E-04 1.99E-09 
GO:0099536 synaptic signaling 1.05E-04 2.11E-09 
GO:0032501 multicellular organismal process 2.49E-04 9.06E-10 
GO:0030001 metal ion transport 2.50E-04 2.59E-09 
GO:0006811 ion transport 1.46E-02 1.30E-10 
GO:0043269 regulation of ion transport 4.11E-03 8.25E-10 
GO:0048869 cellular developmental process 1.16E-02 3.32E-10 
GO:0042391 regulation of membrane potential 2.32E-03 1.70E-09 
GO:2000026 regulation of multicellular organismal development 1.07E-03 4.71E-09 
GO:0044057 regulation of system process 4.39E-02 1.18E-10 
GO:0007154 cell communication 8.92E-06 1.08E-06 
GO:0007268 chemical synaptic transmission 5.42E-04 2.57E-08 
GO:0098916 anterograde trans-synaptic signaling 5.57E-04 2.65E-08 
GO:0007611 learning or memory 2.33E-06 1.39E-05 
GO:0034220 ion transmembrane transport 3.61E-02 9.30E-10 
GO:1903522 regulation of blood circulation 1.28E-02 3.39E-09 
GO:0006812 cation transport 2.24E-02 5.25E-09 
GO:0050890 cognition 2.12E-06 1.10E-04 
GO:0045665 negative regulation of neuron differentiation 3.89E-04 1.06E-06 
GO:0050793 regulation of developmental process 8.23E-03 6.96E-08 
GO:0007155 cell adhesion 2.29E-06 2.99E-04 
GO:0009653 anatomical structure morphogenesis 2.14E-02 3.59E-08 
GO:0008016 regulation of heart contraction 3.52E-02 2.43E-08 
GO:0022610 biological adhesion 2.78E-06 3.65E-04 
GO:0050768 negative regulation of neurogenesis 3.69E-04 2.82E-06 
GO:0051094 positive regulation of developmental process 5.36E-05 2.56E-05 
GO:0051962 positive regulation of nervous system development 2.16E-04 7.10E-06 
GO:0060078 regulation of postsynaptic membrane potential 1.03E-04 1.86E-05 
GO:0007626 locomotory behavior 2.88E-05 6.89E-05 
GO:0034762 regulation of transmembrane transport 1.92E-02 1.28E-07 
GO:0007612 Learning 3.00E-05 1.10E-04 
GO:0098660 inorganic ion transmembrane transport 1.52E-02 2.77E-07 
GO:0034765 regulation of ion transmembrane transport 1.57E-02 3.93E-07 
GO:0051961 negative regulation of nervous system development 7.51E-04 8.97E-06 
GO:0010469 regulation of receptor activity 2.37E-03 7.50E-06 
GO:0010721 negative regulation of cell development 1.20E-03 1.64E-05 
GO:0051241 negative regulation of multicellular organismal process 4.93E-02 4.13E-07 
GO:0098662 inorganic cation transmembrane transport 1.90E-02 1.10E-06 
GO:0010975 regulation of neuron projection development 2.02E-03 1.09E-05 
GO:0045595 regulation of cell differentiation 2.39E-03 1.10E-05 
GO:0006814 sodium ion transport 2.70E-03 3.51E-05 
GO:0030182 neuron differentiation 3.74E-03 3.09E-05 
GO:0050770 regulation of axonogenesis 2.63E-02 5.72E-06 
GO:0050808 synapse organization 5.60E-05 3.33E-03 
GO:0050806 positive regulation of synaptic transmission 3.45E-05 5.46E-03 
GO:0072503 cellular divalent inorganic cation homeostasis 1.73E-03 1.09E-04 
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FF 
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GO:0010769 regulation of cell morphogenesis involved in differentiation 2.08E-02 9.96E-06 
GO:0007215 glutamate receptor signaling pathway 1.87E-02 1.35E-05 
GO:0060079 excitatory postsynaptic potential 8.81E-03 6.29E-05 
GO:0072507 divalent inorganic cation homeostasis 2.05E-03 2.71E-04 
GO:0045596 negative regulation of cell differentiation 3.11E-02 1.89E-05 
GO:0051240 positive regulation of multicellular organismal process 8.23E-03 9.24E-05 
GO:0045165 cell fate commitment 2.35E-02 3.78E-05 
GO:0035725 sodium ion transmembrane transport 3.54E-03 3.02E-04 
GO:2001257 regulation of cation channel activity 2.35E-03 5.38E-04 
GO:0051480 regulation of cytosolic calcium ion concentration 2.01E-02 6.66E-05 
GO:0006874 cellular calcium ion homeostasis 2.88E-03 4.91E-04 
GO:0055074 calcium ion homeostasis 4.10E-03 3.75E-04 
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger 1.22E-04 1.39E-02 
GO:0023051 regulation of signaling 4.06E-03 4.95E-04 
GO:0022898 regulation of transmembrane transporter activity 2.06E-02 1.10E-04 
GO:0035235 ionotropic glutamate receptor signaling pathway 4.54E-03 5.42E-04 
GO:0032412 regulation of ion transmembrane transporter activity 1.91E-02 1.73E-04 
GO:0048812 neuron projection morphogenesis 8.24E-03 6.78E-04 
GO:0048167 regulation of synaptic plasticity 2.79E-02 2.13E-04 
GO:0051966 regulation of synaptic transmission, glutamatergic 3.50E-03 1.93E-03 
GO:0120039 plasma membrane bounded cell projection morphogenesis 1.39E-02 4.91E-04 
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway 2.56E-04 3.14E-02 
GO:0050771 negative regulation of axonogenesis 3.52E-02 2.37E-04 
GO:0032409 regulation of transporter activity 3.12E-02 2.78E-04 
GO:1900449 regulation of glutamate receptor signaling pathway 1.55E-02 7.52E-04 
GO:0048858 cell projection morphogenesis 1.74E-02 6.73E-04 
GO:0051965 positive regulation of synapse assembly 2.09E-03 8.94E-03 
GO:2000463 positive regulation of excitatory postsynaptic potential 2.85E-03 7.82E-03 
GO:0055065 metal ion homeostasis 4.34E-03 5.29E-03 
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules 8.43E-04 2.77E-02 
GO:0007204 positive regulation of cytosolic calcium ion concentration 3.98E-02 6.23E-04 
GO:0050807 regulation of synapse organization 2.42E-02 1.05E-03 
GO:0120035 regulation of plasma membrane bounded cell projection organization 1.35E-02 1.93E-03 
GO:0010646 regulation of cell communication 1.01E-02 2.59E-03 
GO:0010720 positive regulation of cell development 3.69E-02 8.62E-04 
GO:0031344 regulation of cell projection organization 1.85E-02 1.72E-03 
GO:0031345 negative regulation of cell projection organization 1.84E-02 1.88E-03 
GO:0006875 cellular metal ion homeostasis 1.32E-02 2.64E-03 
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ST TUMOURS: UPREGULATED AT FIRST RECURRENCE (Top 100 Terms Only) 
 
GO Term Description FFPE FDR 
GO:0006955 immune response 1.62E-26 
GO:0002376 immune system process 3.03E-21 
GO:0006952 defense response 3.70E-21 
GO:0002682 regulation of immune system process 3.20E-15 
GO:0050776 regulation of immune response 1.10E-13 
GO:0002684 positive regulation of immune system process 3.46E-13 
GO:0070665 positive regulation of leukocyte proliferation 6.80E-13 
GO:0042102 positive regulation of T cell proliferation 3.37E-12 
GO:0001817 regulation of cytokine production 3.61E-12 
GO:0043207 response to external biotic stimulus 3.90E-12 
GO:0050671 positive regulation of lymphocyte proliferation 4.89E-12 
GO:0006954 inflammatory response 6.17E-12 
GO:0032946 positive regulation of mononuclear cell proliferation 6.37E-12 
GO:0098542 defense response to other organism 6.39E-12 
GO:0070663 regulation of leukocyte proliferation 7.39E-12 
GO:0009607 response to biotic stimulus 1.60E-11 
GO:0050863 regulation of T cell activation 1.83E-11 
GO:0007165 signal transduction 2.00E-11 
GO:0050867 positive regulation of cell activation 2.38E-11 
GO:0051251 positive regulation of lymphocyte activation 2.43E-11 
GO:0002694 regulation of leukocyte activation 2.57E-11 
GO:0050670 regulation of lymphocyte proliferation 2.60E-11 
GO:0007166 cell surface receptor signaling pathway 3.09E-11 
GO:0050865 regulation of cell activation 3.11E-11 
GO:0045785 positive regulation of cell adhesion 3.13E-11 
GO:0002696 positive regulation of leukocyte activation 3.17E-11 
GO:0032944 regulation of mononuclear cell proliferation 3.18E-11 
GO:0050870 positive regulation of T cell activation 3.18E-11 
GO:1903039 positive regulation of leukocyte cell-cell adhesion 3.19E-11 
GO:0001775 cell activation 3.19E-11 
GO:0045321 leukocyte activation 3.19E-11 
GO:1903037 regulation of leukocyte cell-cell adhesion 4.85E-11 
GO:0051707 response to other organism 4.86E-11 
GO:0050778 positive regulation of immune response 4.97E-11 
GO:0031347 regulation of defense response 5.51E-11 
GO:0002253 activation of immune response 6.27E-11 
GO:0022407 regulation of cell-cell adhesion 6.70E-11 
GO:0050707 regulation of cytokine secretion 7.84E-11 
GO:0001819 positive regulation of cytokine production 8.05E-11 
GO:0051249 regulation of lymphocyte activation 9.01E-11 
GO:0048584 positive regulation of response to stimulus 1.90E-10 
GO:0022409 positive regulation of cell-cell adhesion 3.12E-10 
GO:0032101 regulation of response to external stimulus 3.12E-10 
GO:0002757 immune response-activating signal transduction 3.17E-10 
GO:0050896 response to stimulus 3.54E-10 
GO:0045087 innate immune response 3.64E-10 
GO:0051239 regulation of multicellular organismal process 3.84E-10 
GO:0002250 adaptive immune response 4.27E-10 
GO:0002764 immune response-regulating signaling pathway 4.31E-10 
GO:0050900 leukocyte migration 5.65E-10 
GO:0030155 regulation of cell adhesion 1.51E-09 
GO:0048583 regulation of response to stimulus 1.71E-09 
GO:0009605 response to external stimulus 1.82E-09 
GO:0002252 immune effector process 3.38E-09 
GO:0050727 regulation of inflammatory response 3.57E-09 
GO:0002697 regulation of immune effector process 5.72E-09 
GO:0009617 response to bacterium 6.23E-09 
GO:0042742 defense response to bacterium 1.20E-08 
GO:0042129 regulation of T cell proliferation 2.65E-08 
GO:0032501 multicellular organismal process 4.51E-08 
GO:0046641 positive regulation of alpha-beta T cell proliferation 1.63E-07 
GO:0050715 positive regulation of cytokine secretion 2.44E-07 
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GO:0002237 response to molecule of bacterial origin 3.18E-07 
GO:0046634 regulation of alpha-beta T cell activation 7.55E-07 
GO:0048518 positive regulation of biological process 9.54E-07 
GO:0002791 regulation of peptide secretion 1.10E-06 
GO:0019221 cytokine-mediated signaling pathway 1.21E-06 
GO:0001818 negative regulation of cytokine production 1.27E-06 
GO:0030334 regulation of cell migration 1.41E-06 
GO:0051240 positive regulation of multicellular organismal process 1.57E-06 
GO:0007155 cell adhesion 2.37E-06 
GO:0050777 negative regulation of immune response 2.68E-06 
GO:0022610 biological adhesion 2.69E-06 
GO:0002768 immune response-regulating cell surface receptor signaling pathway 2.76E-06 
GO:0050708 regulation of protein secretion 2.79E-06 
GO:0046635 positive regulation of alpha-beta T cell activation 3.19E-06 
GO:0046649 lymphocyte activation 4.40E-06 
GO:0045088 regulation of innate immune response 5.00E-06 
GO:0002793 positive regulation of peptide secretion 5.60E-06 
GO:0032496 response to lipopolysaccharide 6.03E-06 
GO:2000145 regulation of cell motility 1.08E-05 
GO:0002429 immune response-activating cell surface receptor signaling pathway 1.14E-05 
GO:0002274 myeloid leukocyte activation 1.20E-05 
GO:0042108 positive regulation of cytokine biosynthetic process 1.50E-05 
GO:0032675 regulation of interleukin-6 production 1.91E-05 
GO:0042127 regulation of cell proliferation 2.18E-05 
GO:0050710 negative regulation of cytokine secretion 2.24E-05 
GO:0002683 negative regulation of immune system process 2.25E-05 
GO:0016477 cell migration 2.38E-05 
GO:0032940 secretion by cell 2.66E-05 
GO:0050714 positive regulation of protein secretion 2.69E-05 
GO:0033993 response to lipid 2.78E-05 
GO:0070372 regulation of ERK1 and ERK2 cascade 3.02E-05 
GO:0046903 secretion 3.10E-05 
GO:0002703 regulation of leukocyte mediated immunity 3.23E-05 
GO:0046640 regulation of alpha-beta T cell proliferation 3.25E-05 
GO:0002263 cell activation involved in immune response 3.33E-05 
GO:0042035 regulation of cytokine biosynthetic process 3.40E-05 
GO:0051270 regulation of cellular component movement 3.46E-05 
GO:0006887 exocytosis 3.47E-05 
 
 
 
 
 
 
 
 
 
 286 
ST TUMOURS: DOWNREGULATED AT FIRST RECURRENCE (All Terms) 
 
GO Term Description FFPE FDR 
GO:0048856 anatomical structure development 6.82E-10 
GO:0032502 developmental process 1.66E-06 
GO:0007610 behavior 3.70E-04 
GO:0051960 regulation of nervous system development 3.46E-03 
GO:0045664 regulation of neuron differentiation 3.81E-03 
GO:0007399 nervous system development 3.87E-03 
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules 3.92E-03 
GO:0061621 canonical glycolysis 4.44E-03 
GO:0061718 glucose catabolic process to pyruvate 4.93E-03 
GO:0007420 brain development 5.07E-03 
GO:0048731 system development 5.23E-03 
GO:0061615 glycolytic process through fructose-6-phosphate 5.36E-03 
GO:0006735 NADH regeneration 5.54E-03 
GO:0061620 glycolytic process through glucose-6-phosphate 5.77E-03 
GO:0098609 cell-cell adhesion 6.47E-03 
GO:0023052 signaling 6.56E-03 
GO:0050767 regulation of neurogenesis 6.59E-03 
GO:0009887 animal organ morphogenesis 6.83E-03 
GO:0030182 neuron differentiation 1.19E-02 
GO:0048513 animal organ development 1.22E-02 
GO:0006007 glucose catabolic process 1.45E-02 
GO:0007154 cell communication 1.69E-02 
GO:0006096 glycolytic process 1.79E-02 
GO:0006757 ATP generation from ADP 2.43E-02 
GO:0007267 cell-cell signaling 2.59E-02 
GO:0032501 multicellular organismal process 3.03E-02 
GO:0009653 anatomical structure morphogenesis 3.73E-02 
GO:0051966 regulation of synaptic transmission, glutamatergic 4.08E-02 
GO:0099643 signal release from synapse 4.38E-02 
GO:0019320 hexose catabolic process 4.41E-02 
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EPN_RELA TUMOURS: UPREGULATED AT FIRST RECURRENCE (Top 100 Terms 
Only) 
 
GO Term Description FFPE FDR 
GO:0051239 regulation of multicellular organismal process 1.34E-07 
GO:0022610 biological adhesion 7.25E-07 
GO:0007155 cell adhesion 8.08E-07 
GO:0032501 multicellular organismal process 2.01E-06 
GO:0032101 regulation of response to external stimulus 5.42E-06 
GO:0043547 positive regulation of GTPase activity 6.13E-06 
GO:0006952 defense response 6.53E-06 
GO:0006955 immune response 9.55E-06 
GO:0007165 signal transduction 3.30E-05 
GO:0043087 regulation of GTPase activity 5.30E-05 
GO:0001817 regulation of cytokine production 1.13E-04 
GO:0051345 positive regulation of hydrolase activity 1.34E-04 
GO:0030198 extracellular matrix organization 3.83E-04 
GO:0043062 extracellular structure organization 3.84E-04 
GO:0002376 immune system process 4.03E-04 
GO:0050727 regulation of inflammatory response 4.20E-04 
GO:0002730 regulation of dendritic cell cytokine production 4.65E-04 
GO:0045765 regulation of angiogenesis 5.21E-04 
GO:1901342 regulation of vasculature development 5.83E-04 
GO:0007166 cell surface receptor signaling pathway 5.85E-04 
GO:0009605 response to external stimulus 7.83E-04 
GO:0022603 regulation of anatomical structure morphogenesis 8.26E-04 
GO:0050793 regulation of developmental process 8.83E-04 
GO:0051336 regulation of hydrolase activity 9.36E-04 
GO:0050878 regulation of body fluid levels 9.42E-04 
GO:1904018 positive regulation of vasculature development 1.15E-03 
GO:0030155 regulation of cell adhesion 1.31E-03 
GO:0008360 regulation of cell shape 1.38E-03 
GO:0070372 regulation of ERK1 and ERK2 cascade 1.42E-03 
GO:0006954 inflammatory response 1.77E-03 
GO:0030334 regulation of cell migration 1.79E-03 
GO:0051240 positive regulation of multicellular organismal process 1.79E-03 
GO:0045766 positive regulation of angiogenesis 1.81E-03 
GO:0032651 regulation of interleukin-1 beta production 1.84E-03 
GO:0009653 anatomical structure morphogenesis 1.84E-03 
GO:0001775 cell activation 1.84E-03 
GO:0050707 regulation of cytokine secretion 1.85E-03 
GO:0070374 positive regulation of ERK1 and ERK2 cascade 1.87E-03 
GO:0002697 regulation of immune effector process 1.92E-03 
GO:0098542 defense response to other organism 2.03E-03 
GO:0050715 positive regulation of cytokine secretion 2.06E-03 
GO:0050706 regulation of interleukin-1 beta secretion 2.09E-03 
GO:0050718 positive regulation of interleukin-1 beta secretion 2.32E-03 
GO:0050716 positive regulation of interleukin-1 secretion 2.37E-03 
GO:0002250 adaptive immune response 2.38E-03 
GO:0002252 immune effector process 2.38E-03 
GO:0033993 response to lipid 2.39E-03 
GO:2000026 regulation of multicellular organismal development 2.40E-03 
GO:0048583 regulation of response to stimulus 2.43E-03 
GO:0006869 lipid transport 2.59E-03 
GO:0072376 protein activation cascade 2.62E-03 
GO:0040011 locomotion 2.81E-03 
GO:0050704 regulation of interleukin-1 secretion 4.00E-03 
GO:0031347 regulation of defense response 4.00E-03 
GO:1901700 response to oxygen-containing compound 4.73E-03 
GO:0044093 positive regulation of molecular function 4.82E-03 
GO:0038001 paracrine signaling 4.87E-03 
GO:0045785 positive regulation of cell adhesion 4.90E-03 
GO:0032652 regulation of interleukin-1 production 4.91E-03 
GO:0032675 regulation of interleukin-6 production 4.94E-03 
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GO:0032715 negative regulation of interleukin-6 production 4.99E-03 
GO:0045087 innate immune response 5.00E-03 
GO:0002793 positive regulation of peptide secretion 5.00E-03 
GO:0048646 anatomical structure formation involved in morphogenesis 5.07E-03 
GO:0001525 angiogenesis 5.07E-03 
GO:0043085 positive regulation of catalytic activity 5.24E-03 
GO:0050790 regulation of catalytic activity 5.29E-03 
GO:2000145 regulation of cell motility 5.32E-03 
GO:0065008 regulation of biological quality 5.46E-03 
GO:0003073 regulation of systemic arterial blood pressure 5.50E-03 
GO:0032731 positive regulation of interleukin-1 beta production 5.54E-03 
GO:0065009 regulation of molecular function 5.70E-03 
GO:0043207 response to external biotic stimulus 5.72E-03 
GO:0014070 response to organic cyclic compound 5.82E-03 
GO:0045321 leukocyte activation 5.97E-03 
GO:0051056 regulation of small GTPase mediated signal transduction 6.47E-03 
GO:0016477 cell migration 6.82E-03 
GO:0015711 organic anion transport 7.06E-03 
GO:0051270 regulation of cellular component movement 7.43E-03 
GO:0023052 signaling 8.19E-03 
GO:0009607 response to biotic stimulus 8.92E-03 
GO:0001818 negative regulation of cytokine production 8.92E-03 
GO:0014910 regulation of smooth muscle cell migration 8.95E-03 
GO:0050714 positive regulation of protein secretion 9.21E-03 
GO:0006820 anion transport 9.26E-03 
GO:0032732 positive regulation of interleukin-1 production 9.35E-03 
GO:0048870 cell motility 1.09E-02 
GO:0002366 leukocyte activation involved in immune response 1.10E-02 
GO:0032502 developmental process 1.11E-02 
GO:0035023 regulation of Rho protein signal transduction 1.17E-02 
GO:0032655 regulation of interleukin-12 production 1.17E-02 
GO:0098609 cell-cell adhesion 1.17E-02 
GO:0003008 system process 1.20E-02 
GO:0031348 negative regulation of defense response 1.24E-02 
GO:0006811 ion transport 1.29E-02 
GO:0051707 response to other organism 1.29E-02 
GO:0007015 actin filament organization 1.30E-02 
GO:0046903 secretion 1.30E-02 
GO:0002263 cell activation involved in immune response 1.30E-02 
GO:0040012 regulation of locomotion 1.31E-02 
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PF LOCATION TUMOURS: OVERLAPPING FFPE DOWNREGULATED AND FF 
UPREGULATED TERMS (All Terms) 
 
GO Term Description 
FFPE 
(DOWN) 
FDR 
FF (UP) 
FDR 
GO:0002376 immune system process 1.02E-05 2.88E-28 
GO:0006952 defense response 1.49E-09 4.65E-23 
GO:0006955 immune response 1.10E-08 3.30E-23 
GO:0032101 regulation of response to external stimulus 5.58E-08 3.76E-14 
GO:0019221 cytokine-mediated signaling pathway 2.69E-10 1.66E-11 
GO:0002682 regulation of immune system process 1.34E-03 2.00E-17 
GO:0002684 positive regulation of immune system process 2.99E-03 5.03E-17 
GO:0001775 cell activation 1.88E-02 2.24E-17 
GO:0007166 cell surface receptor signaling pathway 2.79E-08 8.70E-11 
GO:0002252 immune effector process 1.39E-02 2.09E-16 
GO:0048584 positive regulation of response to stimulus 2.49E-07 1.85E-11 
GO:0006954 inflammatory response 3.37E-05 9.14E-13 
GO:0007165 signal transduction 1.18E-04 5.12E-12 
GO:0051239 regulation of multicellular organismal process 8.63E-06 1.12E-10 
GO:0045321 leukocyte activation 3.82E-02 3.82E-14 
GO:0050776 regulation of immune response 4.13E-03 4.34E-13 
GO:0048583 regulation of response to stimulus 1.05E-05 4.40E-10 
GO:0001817 regulation of cytokine production 3.87E-02 1.73E-13 
GO:0045087 innate immune response 2.20E-04 3.85E-11 
GO:0040011 locomotion 1.21E-04 2.18E-10 
GO:0060337 type I interferon signaling pathway 9.85E-03 7.48E-12 
GO:0030155 regulation of cell adhesion 1.36E-03 1.10E-10 
GO:0032103 positive regulation of response to external stimulus 4.44E-05 4.02E-09 
GO:0050900 leukocyte migration 3.15E-02 1.03E-11 
GO:0050778 positive regulation of immune response 3.52E-02 2.47E-11 
GO:0045785 positive regulation of cell adhesion 1.87E-02 7.54E-11 
GO:0016477 cell migration 2.61E-05 8.84E-08 
GO:0050727 regulation of inflammatory response 3.20E-05 8.84E-08 
GO:0042330 taxis 1.89E-02 2.83E-10 
GO:0006935 chemotaxis 1.90E-02 2.89E-10 
GO:0031347 regulation of defense response 2.14E-02 3.68E-10 
GO:0048870 cell motility 4.87E-04 1.75E-08 
GO:0046649 lymphocyte activation 2.36E-03 9.09E-09 
GO:0007155 cell adhesion 3.48E-03 8.81E-09 
GO:0022610 biological adhesion 4.20E-03 1.08E-08 
GO:0051240 positive regulation of multicellular organismal process 2.35E-03 3.23E-08 
GO:2000145 regulation of cell motility 1.38E-02 6.05E-09 
GO:0030334 regulation of cell migration 8.10E-03 1.05E-08 
GO:0002253 activation of immune response 1.97E-02 7.08E-09 
GO:0051241 negative regulation of multicellular organismal process 5.21E-06 2.88E-05 
GO:0002683 negative regulation of immune system process 2.12E-02 2.82E-08 
GO:0040012 regulation of locomotion 2.32E-02 2.79E-08 
GO:0050896 response to stimulus 1.98E-02 3.49E-08 
GO:0023052 signaling 1.13E-02 7.95E-08 
GO:0007267 cell-cell signaling 5.74E-03 2.87E-07 
GO:0051270 regulation of cellular component movement 1.14E-02 2.24E-07 
GO:0030335 positive regulation of cell migration 1.13E-02 2.94E-07 
GO:0060333 interferon-gamma-mediated signaling pathway 5.37E-03 7.08E-07 
GO:2000147 positive regulation of cell motility 1.48E-02 4.98E-07 
GO:0051272 positive regulation of cellular component movement 1.04E-02 1.36E-06 
GO:0040017 positive regulation of locomotion 2.28E-02 8.22E-07 
GO:0023051 regulation of signaling 9.52E-04 2.59E-05 
GO:0002521 leukocyte differentiation 3.83E-02 7.14E-07 
GO:0050920 regulation of chemotaxis 4.71E-02 6.61E-07 
GO:0010646 regulation of cell communication 5.00E-04 8.84E-05 
GO:0042127 regulation of cell proliferation 3.51E-04 1.68E-04 
GO:0048518 positive regulation of biological process 4.91E-03 1.99E-05 
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(DOWN) 
FDR 
FF (UP) 
FDR 
GO:0032501 multicellular organismal process 1.12E-02 1.04E-05 
GO:0010466 negative regulation of peptidase activity 3.54E-04 4.00E-04 
GO:0060326 cell chemotaxis 1.28E-03 1.15E-04 
GO:0048522 positive regulation of cellular process 6.44E-03 3.14E-05 
GO:0030595 leukocyte chemotaxis 2.02E-03 1.06E-04 
GO:0030593 neutrophil chemotaxis 1.32E-04 2.43E-03 
GO:2000026 regulation of multicellular organismal development 7.09E-05 5.78E-03 
GO:0006928 movement of cell or subcellular component 3.55E-02 1.85E-05 
GO:0034341 response to interferon-gamma 2.98E-02 2.25E-05 
GO:0009966 regulation of signal transduction 1.13E-03 7.26E-04 
GO:0050793 regulation of developmental process 7.30E-05 1.38E-02 
GO:0010647 positive regulation of cell communication 9.87E-03 1.16E-04 
GO:0010951 negative regulation of endopeptidase activity 1.36E-03 8.94E-04 
GO:0071621 granulocyte chemotaxis 1.54E-04 8.48E-03 
GO:0023056 positive regulation of signaling 9.56E-03 1.59E-04 
GO:0050921 positive regulation of chemotaxis 3.08E-03 6.13E-04 
GO:0065009 regulation of molecular function 3.48E-02 7.48E-05 
GO:0009967 positive regulation of signal transduction 5.75E-03 4.97E-04 
GO:0030198 extracellular matrix organization 2.54E-02 1.32E-04 
GO:0002673 regulation of acute inflammatory response 3.91E-03 8.91E-04 
GO:0043062 extracellular structure organization 2.90E-02 1.31E-04 
GO:0008284 positive regulation of cell proliferation 1.89E-02 2.10E-04 
GO:1902531 regulation of intracellular signal transduction 3.90E-02 1.08E-04 
GO:1902533 positive regulation of intracellular signal transduction 1.40E-02 3.24E-04 
GO:0052547 regulation of peptidase activity 7.29E-03 6.27E-04 
GO:0052548 regulation of endopeptidase activity 1.14E-02 5.91E-04 
GO:1990266 neutrophil migration 8.35E-04 8.45E-03 
GO:0018212 peptidyl-tyrosine modification 4.18E-02 2.95E-04 
GO:0070098 chemokine-mediated signaling pathway 4.25E-03 3.69E-03 
GO:0097530 granulocyte migration 7.94E-04 2.18E-02 
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation 4.60E-02 1.41E-03 
GO:0045937 positive regulation of phosphate metabolic process 2.30E-02 3.11E-03 
GO:0010562 positive regulation of phosphorus metabolic process 2.32E-02 3.12E-03 
GO:0002920 regulation of humoral immune response 5.75E-03 1.53E-02 
GO:0048585 negative regulation of response to stimulus 4.09E-03 2.54E-02 
GO:0042327 positive regulation of phosphorylation 1.92E-02 6.13E-03 
GO:0001934 positive regulation of protein phosphorylation 2.17E-02 5.86E-03 
GO:0045861 negative regulation of proteolysis 7.35E-03 2.02E-02 
GO:0043410 positive regulation of MAPK cascade 1.36E-02 1.33E-02 
GO:0032102 negative regulation of response to external stimulus 2.35E-02 7.96E-03 
GO:0022603 regulation of anatomical structure morphogenesis 2.30E-02 2.11E-02 
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PF1 DOWNREGULATED TERMS IN BOTH FFPE AND FF COHORTS (Top 100 Terms 
Only) 
 
GO term Description FFPE FDR 
FF 
FDR 
GO:0006952 defense response 1.83E-22 1.74E-08 
GO:0032501 multicellular organismal process 3.85E-05 8.19E-23 
GO:0006954 inflammatory response 6.99E-14 7.64E-11 
GO:0006955 immune response 7.39E-18 4.98E-04 
GO:0032502 developmental process 4.12E-06 1.21E-15 
GO:0019221 cytokine-mediated signaling pathway 2.98E-17 4.33E-04 
GO:0051239 regulation of multicellular organismal process 2.56E-10 8.31E-11 
GO:0007186 G-protein coupled receptor signaling pathway 5.34E-13 1.65E-07 
GO:0032101 regulation of response to external stimulus 3.20E-11 1.66E-07 
GO:0048584 positive regulation of response to stimulus 2.70E-10 6.95E-08 
GO:0048856 anatomical structure development 2.68E-03 2.54E-14 
GO:0007166 cell surface receptor signaling pathway 1.01E-10 3.19E-06 
GO:0051240 positive regulation of multicellular organismal process 8.76E-11 4.59E-06 
GO:0002376 immune system process 5.63E-13 2.32E-03 
GO:0050896 response to stimulus 7.59E-06 1.88E-10 
GO:0048869 cellular developmental process 4.93E-05 3.28E-11 
GO:0048583 regulation of response to stimulus 1.06E-09 1.61E-06 
GO:0023052 signaling 1.49E-10 2.19E-05 
GO:0050727 regulation of inflammatory response 3.42E-09 1.39E-06 
GO:0045937 positive regulation of phosphate metabolic process 3.80E-06 1.26E-09 
GO:0010562 positive regulation of phosphorus metabolic process 3.86E-06 1.29E-09 
GO:0007267 cell-cell signaling 3.19E-11 1.78E-04 
GO:0003008 system process 4.16E-05 1.38E-10 
GO:0010646 regulation of cell communication 3.85E-06 2.72E-09 
GO:0042330 taxis 1.39E-07 8.32E-08 
GO:0006935 chemotaxis 1.44E-07 8.43E-08 
GO:0060326 cell chemotaxis 1.49E-07 1.08E-07 
GO:0023051 regulation of signaling 9.47E-06 2.73E-09 
GO:0043410 positive regulation of MAPK cascade 2.22E-07 1.47E-07 
GO:0042127 regulation of cell proliferation 3.16E-04 1.34E-10 
GO:0001934 positive regulation of protein phosphorylation 2.93E-06 3.34E-08 
GO:0032103 positive regulation of response to external stimulus 2.57E-08 4.32E-06 
GO:0043408 regulation of MAPK cascade 1.29E-06 1.07E-07 
GO:0048518 positive regulation of biological process 1.94E-03 8.58E-11 
GO:0006959 humoral immune response 3.47E-09 5.37E-05 
GO:0002526 acute inflammatory response 2.23E-05 1.19E-08 
GO:0050877 nervous system process 2.33E-08 1.25E-05 
GO:0051174 regulation of phosphorus metabolic process 2.89E-05 1.76E-08 
GO:0030154 cell differentiation 3.47E-03 1.65E-10 
GO:0019220 regulation of phosphate metabolic process 2.62E-05 2.56E-08 
GO:0007165 signal transduction 1.31E-06 5.59E-07 
GO:0030198 extracellular matrix organization 2.78E-05 3.38E-08 
GO:0043062 extracellular structure organization 2.75E-05 3.84E-08 
GO:0042327 positive regulation of phosphorylation 4.48E-06 2.55E-07 
GO:2000026 regulation of multicellular organismal development 1.55E-06 8.03E-07 
GO:0030595 leukocyte chemotaxis 1.43E-06 1.05E-06 
GO:0007154 cell communication 1.88E-07 8.07E-06 
GO:0001932 regulation of protein phosphorylation 9.04E-06 1.69E-07 
GO:0023056 positive regulation of signaling 3.24E-05 5.02E-08 
GO:0050900 leukocyte migration 4.89E-06 4.31E-07 
GO:0010647 positive regulation of cell communication 2.27E-05 9.50E-08 
GO:0051241 negative regulation of multicellular organismal process 6.83E-08 5.56E-05 
GO:0001525 angiogenesis 1.67E-02 2.36E-10 
GO:0048646 anatomical structure formation involved in morphogenesis 7.37E-03 8.76E-10 
GO:0046903 secretion 5.02E-07 1.30E-05 
GO:0008284 positive regulation of cell proliferation 1.25E-03 8.77E-09 
GO:0009653 anatomical structure morphogenesis 1.05E-03 1.34E-08 
GO:0048522 positive regulation of cellular process 6.44E-03 2.47E-09 
GO:0051094 positive regulation of developmental process 1.85E-07 9.80E-05 
GO:0009967 positive regulation of signal transduction 1.54E-04 1.46E-07 
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GO term Description FFPE FDR 
FF 
FDR 
GO:0050793 regulation of developmental process 1.20E-04 3.03E-07 
GO:0040011 locomotion 1.69E-06 2.55E-05 
GO:0006953 acute-phase response 8.86E-05 5.40E-07 
GO:0033993 response to lipid 3.74E-03 2.47E-08 
GO:1902533 positive regulation of intracellular signal transduction 3.46E-04 3.11E-07 
GO:0065008 regulation of biological quality 8.05E-03 1.37E-08 
GO:0030593 neutrophil chemotaxis 4.60E-06 2.80E-05 
GO:0071621 granulocyte chemotaxis 5.78E-06 2.39E-05 
GO:2000147 positive regulation of cell motility 2.72E-03 5.17E-08 
GO:0045765 regulation of angiogenesis 5.67E-05 2.90E-06 
GO:0030335 positive regulation of cell migration 2.04E-03 8.76E-08 
GO:0070098 chemokine-mediated signaling pathway 4.10E-07 6.08E-04 
GO:0007610 behavior 1.53E-08 1.64E-02 
GO:0009966 regulation of signal transduction 2.30E-04 1.10E-06 
GO:0009888 tissue development 1.07E-02 2.44E-08 
GO:0051272 positive regulation of cellular component movement 2.63E-03 1.19E-07 
GO:0016477 cell migration 2.79E-06 1.24E-04 
GO:0009605 response to external stimulus 2.82E-04 1.76E-06 
GO:0042325 regulation of phosphorylation 6.43E-05 7.78E-06 
GO:0097529 myeloid leukocyte migration 7.68E-06 7.03E-05 
GO:1990266 neutrophil migration 5.84E-06 1.04E-04 
GO:0001817 regulation of cytokine production 6.47E-08 1.25E-02 
GO:0097530 granulocyte migration 1.04E-05 8.38E-05 
GO:0002687 positive regulation of leukocyte migration 8.54E-05 1.04E-05 
GO:0002682 regulation of immune system process 8.84E-07 1.20E-03 
GO:0022603 regulation of anatomical structure morphogenesis 5.67E-03 2.74E-07 
GO:0043207 response to external biotic stimulus 6.18E-06 3.79E-04 
GO:0050920 regulation of chemotaxis 2.64E-03 1.17E-06 
GO:1901342 regulation of vasculature development 5.99E-04 5.18E-06 
GO:0002690 positive regulation of leukocyte chemotaxis 1.43E-04 2.35E-05 
GO:0001819 positive regulation of cytokine production 6.47E-06 6.74E-04 
GO:0040017 positive regulation of locomotion 1.06E-02 4.20E-07 
GO:0030334 regulation of cell migration 6.02E-04 9.80E-06 
GO:0009607 response to biotic stimulus 1.34E-05 6.54E-04 
GO:0050921 positive regulation of chemotaxis 3.87E-04 2.56E-05 
GO:0048870 cell motility 2.11E-05 5.03E-04 
GO:0009617 response to bacterium 4.21E-04 2.91E-05 
GO:0030155 regulation of cell adhesion 2.99E-06 5.35E-03 
GO:0050804 modulation of chemical synaptic transmission 1.02E-06 1.73E-02 
GO:0050729 positive regulation of inflammatory response 3.84E-05 5.01E-04 
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PF2 UPREGULATED TERMS IN BOTH FFPE AND FF COHORTS (All Terms) 
 
GO Term Description FFPE FDR 
FF 
FDR 
GO:0002376 immune system process 1.36E-02 3.10E-37 
GO:0006952 defense response 6.41E-05 4.02E-24 
GO:0030198 extracellular matrix organization 1.01E-02 5.60E-26 
GO:0043062 extracellular structure organization 1.07E-02 5.77E-26 
GO:0007165 signal transduction 1.03E-02 1.02E-25 
GO:0007155 cell adhesion 4.18E-09 9.40E-16 
GO:0022610 biological adhesion 4.93E-09 1.46E-15 
GO:0006955 immune response 6.44E-07 1.38E-17 
GO:0001775 cell activation 1.87E-02 2.43E-21 
GO:0032940 secretion by cell 3.48E-05 1.95E-15 
GO:0046903 secretion 1.73E-04 1.66E-15 
GO:0006954 inflammatory response 1.13E-02 5.82E-17 
GO:0006887 exocytosis 1.67E-03 4.89E-16 
GO:0045055 regulated exocytosis 2.23E-03 1.95E-15 
GO:0030334 regulation of cell migration 3.65E-02 1.50E-14 
GO:0050900 leukocyte migration 1.78E-03 3.39E-13 
GO:0030155 regulation of cell adhesion 9.18E-03 2.24E-13 
GO:0032101 regulation of response to external stimulus 7.39E-04 4.11E-12 
GO:2000145 regulation of cell motility 1.51E-02 2.26E-13 
GO:0051270 regulation of cellular component movement 2.97E-02 1.29E-13 
GO:0051239 regulation of multicellular organismal process 1.69E-03 3.01E-12 
GO:0098609 cell-cell adhesion 1.12E-08 1.15E-06 
GO:0032501 multicellular organismal process 6.58E-04 3.40E-11 
GO:0040012 regulation of locomotion 3.66E-02 1.08E-12 
GO:0032502 developmental process 2.89E-02 1.50E-12 
GO:0051240 positive regulation of multicellular organismal process 3.88E-03 1.93E-11 
GO:0032879 regulation of localization 1.07E-05 2.12E-08 
GO:0040011 locomotion 3.39E-02 3.15E-10 
GO:0007154 cell communication 2.66E-09 6.94E-03 
GO:0050865 regulation of cell activation 2.90E-02 2.29E-09 
GO:0042330 taxis 1.67E-03 5.34E-08 
GO:0006935 chemotaxis 1.70E-03 5.39E-08 
GO:0001817 regulation of cytokine production 3.52E-03 2.79E-08 
GO:0003008 system process 5.19E-06 4.86E-05 
GO:0001819 positive regulation of cytokine production 1.13E-03 3.69E-06 
GO:0045087 innate immune response 1.55E-02 4.37E-07 
GO:0043270 positive regulation of ion transport 8.23E-06 8.26E-04 
GO:0002697 regulation of immune effector process 4.96E-02 7.25E-07 
GO:0060326 cell chemotaxis 3.48E-02 1.72E-05 
GO:0010959 regulation of metal ion transport 2.18E-04 2.75E-03 
GO:0006898 receptor-mediated endocytosis 1.96E-02 2.75E-04 
GO:0051050 positive regulation of transport 3.31E-03 1.69E-03 
GO:1903522 regulation of blood circulation 9.00E-03 9.14E-04 
GO:0010035 response to inorganic substance 3.67E-02 6.37E-04 
GO:0051234 establishment of localization 8.94E-03 3.59E-03 
GO:0006022 aminoglycan metabolic process 2.42E-02 1.46E-03 
GO:0050707 regulation of cytokine secretion 4.76E-02 9.35E-04 
GO:0007162 negative regulation of cell adhesion 4.94E-02 1.01E-03 
GO:0030203 glycosaminoglycan metabolic process 3.40E-02 1.95E-03 
GO:0008016 regulation of heart contraction 7.59E-03 1.90E-02 
GO:1903510 mucopolysaccharide metabolic process 2.26E-02 8.97E-03 
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